PRIMER ON THE AUTONOMIC NERVOUS SYSTEM THIRD EDITION
PRIMER ON THE AUTONOMIC NERVOUS SYSTEM THIRD EDITION Editor In Chief
David Robertson Vanderbilt University
Editors
Italo Biaggioni Vanderbilt University
Geoffrey Burnstock
University College Medical School
Phillip A. Low
Mayo College of Medicine
Julian F.R. Paton University of Bristol
AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier
Academic Press is an imprint of Elsevier 32 Jamestown Road, London NW1 7BY, UK 225 Wyman Street, Waltham, MA 02451, USA 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA First edition 1996 Second edition 2004 Third edition 2012 Copyright © 2012 Elsevier Inc. All rights reserved Except the figures of chapter 76 for which the author retains copyright Cover Image: The human autonomic nervous system, which in large part lies deep within the body, is readily accessible through biopsies of the skin. In the cover image, using the cholinergic marker, vasoactive intestinal peptide (shown in red), there is clear visualization of the sympathetic cholinergic innervation running between the endothelial and basal lamina layers of cutaneous blood vessels in a skin biopsy of the distal thigh. The blood vessels are visualized with the endothelial vascular marker CD31 (an endothelial vascular marker that highlights blood vessels – shown in green) and the vascular basal lamina with collagen type IV (a marker that highlights the basal lamina layer of the extracellular matrix – shown in blue). Image courtesy of Ningshan Wang, Christopher Gibbons and Roy Freeman. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone (44) (0) 1865 843830; fax (44) (0) 1865 853333; email:
[email protected]. Alternatively, visit the Science and Technology Books website at www.elsevierdirect.com/rights for further information Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made British Library Cataloguing-in-Publication Data A catalogue record for this book is available from the British Library Library of Congress Cataloging-in-Publication Data A catalog record for this book is available from the Library of Congress ISBN : 978-0-12-386525-0 For information on all Academic Press publications visit our website at elsevierdirect.com Typeset by MPS Limited, a Macmillan Company, Chennai, India www.macmillansolutions.com Printed and bound in United States of America 12
13
14
15
10
9
8
7
6
5
4
3
2
1
Hub
Home
Browse
My settings
Scopus
My alerts
All fields
Articles Images
Search
ScienceDirect
Applications
Register
Go to SciVal Suite
Shopping cart
Help
Author
Journal/Book title --This Journal/Book--
Login
Volume
Advanced search Issue
Page
Search
Search tips
Primer on the Autonomic Nervous System (Third Edition) Copyright © 2012 Elsevier Inc. All rights reserved ISBN: 978-0-12-386525-0 About this Book | Shortcut link to this Title Add to Favorites
Font Size: = Full-text available
= Abstract only
Table of Contents Front-matter, Pages i,iii Show preview |
PDF (187 K) | Related articles | Related reference work articles
Copyright, Page iv Show preview |
PDF (54 K) | Related articles | Related reference work articles
Preface, Page xix, David Robertson, Italo Biaggioni, Geoffrey Burnstock, Phillip A. Low, Julian F.R. Paton Show preview |
PDF (33 K) | Related articles | Related reference work articles
List of Contributors, Pages xxi-xxv, Ana P.L. Abdala, David H. Adams, Marlies Alvarenga, Amy C. Arnold, Felicia B. Axelrod, Franca Barbic, Peter J. Barnes, Deborah Bauer, Christopher Bell, Eduardo E. Benarroch, Elizabeth M. Berry-Kravis, Luciano Bernardi, Italo Biaggioni, Lori Birder, Virginia L. Brooks, Joan Heller Brown, Geoffrey Burnstock, Michael Camilleri, J.Preston Campbell, Robert M. Carey, et al. Show preview |
PDF (80 K) | Related articles | Related reference work articles
Part I: Introduction Part II: Biochemical and Pharmacological Mechanisms Part III: Autonomic Physiology Part IV: Stress Part V: Pathophysiological Mechanisms Part VI: Cardiovascular Disorders Part VII: Catecholamine Disorders Part VIII: Autonomic Synucleinopathies Part IX: Peripheral Autonomic Disorders Part X: Autonomic Disorders Part XI: Orthostatic Intolerance Part XII: Special Clinical Conditions Part XIII: Management of Autonomic Disorders Part XIV: Experimental Autonomic Neuroscience Index, Pages 693-703 Show preview |
PDF (817 K) | Related articles | Related reference work articles
Hub
Home
Browse
Search
My settings
Scopus
My alerts
All fields
Articles Images
ScienceDirect
Applications
Register
Login
Shopping cart
Help
Author
Journal/Book title --This Journal/Book--
Go to SciVal Suite
Volume
Advanced search Issue
Page
Search
Search tips
Primer on the Autonomic Nervous System (Third Edition) Copyright © 2012 Elsevier Inc. All rights reserved ISBN: 978-0-12-386525-0 About this Book | Shortcut link to this Title Add to Favorites
Font Size: = Full-text available
= Abstract only
Table of Contents Front-matter, Pages i,iii Show preview |
PDF (187 K) | Related articles | Related reference work articles
Copyright, Page iv Show preview |
PDF (54 K) | Related articles | Related reference work articles
Preface, Page xix, David Robertson, Italo Biaggioni, Geoffrey Burnstock, Phillip A. Low, Julian F.R. Paton Show preview |
PDF (33 K) | Related articles | Related reference work articles
List of Contributors, Pages xxi-xxv, Ana P.L. Abdala, David H. Adams, Marlies Alvarenga, Amy C. Arnold, Felicia B. Axelrod, Franca Barbic, Peter J. Barnes, Deborah Bauer, Christopher Bell, Eduardo E. Benarroch, Elizabeth M. Berry-Kravis, Luciano Bernardi, Italo Biaggioni, Lori Birder, Virginia L. Brooks, Joan Heller Brown, Geoffrey Burnstock, Michael Camilleri, J.Preston Campbell, Robert M. Carey, et al. Show preview |
PDF (80 K) | Related articles | Related reference work articles
Part I: Introduction Chapter 1 - Development and Differentiation of Autonomic Neurons, Pages 3-8, Chun-Hyung Kim, Kwang-Soo Kim Show preview |
PDF (534 K) | Related articles | Related reference work articles
Chapter 2 - Central Autonomic Control, Pages 9-12, Eduardo E. Benarroch Show preview |
PDF (286 K) | Related articles | Related reference work articles
Chapter 3 - Imaging of Brainstem Sites Involved in Cardiovascular Control, Pages 13-16, Vaughan G. Macefield, Luke A. Henderson Show preview |
PDF (494 K) | Related articles | Related reference work articles
Chapter 4 - Peripheral Autonomic Nervous System, Pages 17-26, Robert W. Hamill, Robert E. Shapiro, Margaret A. Vizzard Show preview |
PDF (591 K) | Related articles | Related reference work articles
Chapter 5 - Cotransmission, Pages 27-33, Geoffrey Burnstock Show preview |
PDF (319 K) | Related articles | Related reference work articles
Part II: Biochemical and Pharmacological Mechanisms Chapter 6 - Noradrenergic Neurotransmission, Pages 37-43, David S. Goldstein Show preview |
PDF (304 K) | Related articles | Related reference work articles
Chapter 7 - Tyrosine Hydroxylase, Pages 45-47, Kazuto Kobayashi, Toshiharu Nagatsu Show preview |
PDF (232 K) | Related articles | Related reference work articles
Chapter 8 - Antidepressant-Sensitive Norepinephrine Transporters: Structure and Regulation, Pages 49-50, Maureen K. Hahn Show preview |
PDF (314 K) | Related articles | Related reference work articles
Chapter 9 - α -Adrenergic Receptors, Pages 51-54, Marion C. Mohl, Robert M. Graham 1 Show preview |
PDF (525 K) | Related articles | Related reference work articles
Chapter 10 - α -Adrenergic Receptors, Pages 55-58, Qin Wang 2 Show preview |
PDF (169 K) | Related articles | Related reference work articles
Chapter 11 - β-Adrenergic Receptors, Pages 59-61, C.Michael Stein Show preview |
PDF (183 K) | Related articles | Related reference work articles
Chapter 12 - Dopaminergic Neurotransmission, Pages 63-65, Graeme Eisenhofer, Heinz Reichmann Show preview |
PDF (393 K) | Related articles | Related reference work articles
Chapter 13 - Dopamine Receptors, Pages 67-70, Sean M. Peterson, Nikhil Urs, Marc G. Caron Show preview |
PDF (278 K) | Related articles | Related reference work articles
Chapter 14 - Cholinergic Neurotransmission, Pages 71-74, Brett A. English, Carrie K. Jones Show preview |
PDF (142 K) | Related articles | Related reference work articles
Chapter 15 - Acetylcholine and Muscarinic Receptors, Pages 75-78, Joan Heller Brown, Nora Laiken Show preview |
PDF (120 K) | Related articles | Related reference work articles
Chapter 16 - Nicotinic Receptors, Pages 79-82, Palmer Taylor Show preview |
PDF (655 K) | Related articles | Related reference work articles
Chapter 17 - Serotonin Receptors and Neurotransmission, Pages 83-86, Elaine Sanders-Bush, Charles D. Nichols Show preview |
PDF (406 K) | Related articles | Related reference work articles
Chapter 18 - Purinergic Neurotransmission and Nucleotide Receptors, Pages 87-93, Geoffrey Burnstock Show preview |
PDF (439 K) | Related articles | Related reference work articles
Chapter 19 - Adenosine Receptors and Autonomic Regulation, Pages 95-97, Italo Biaggioni Show preview |
PDF (184 K) | Related articles | Related reference work articles
Chapter 20 - Nitric Oxide and Autonomic Regulation, Pages 99-101, Alfredo Gamboa Show preview |
PDF (280 K) | Related articles | Related reference work articles
Chapter 21 - Glutamatergic Neurotransmission, Pages 103-107, Deborah Bauer, Michael Robinson Show preview |
PDF (282 K) | Related articles | Related reference work articles
Chapter 22 - GABAergic Neurotransmission, Pages 109-111, Andre H. Lagrange, Mark D. Grier Show preview |
PDF (212 K) | Related articles | Related reference work articles
Chapter 23 - Renin-Angiotensin, Pages 113-116, Amy C. Arnold, Debra I. Diz Show preview |
PDF (347 K) | Related articles | Related reference work articles
Chapter 24 - Aldosterone and the Mineralocorticoid Receptor, Pages 117-119, J. Howard Pratt Show preview |
PDF (342 K) | Related articles | Related reference work articles
Chapter 25 - Vasopressin and Disorders of Water Homeostasis, Pages 121-125, Joseph G. Verbalis Show preview |
PDF (92 K) | Related articles | Related reference work articles
Chapter 26 - Calcitonin Gene-Related Peptide and Adrenomedullin, Pages 127-129, Donald J. DiPette, Scott C. Supowit Show preview |
PDF (61 K) | Related articles | Related reference work articles
Chapter 27 - Leptin Signaling and Energy Homeostasis, Pages 131-134, Kamal Rahmouni Show preview |
PDF (427 K) | Related articles | Related reference work articles
Chapter 28 - The Endothelin System, Pages 135-139, Ernesto L. Schiffrin Show preview |
PDF (288 K) | Related articles | Related reference work articles
Chapter 29 - Pharmacology of the Nucleous Tractus Solitarii, Pages 141-144, Ching-Jiunn Tseng, Pei-Wen Cheng, Che-Se Tung Show preview |
PDF (200 K) | Related articles | Related reference work articles
Part III: Autonomic Physiology Chapter 30 - Entrainment of Sympathetic Rhythms, Pages 147-149, Michael P. Gilbey Show preview |
PDF (66 K) | Related articles | Related reference work articles
Chapter 31 - Cross-talk Between Body Systems: Respiratory-Cardiovascular Coupling in Health and Disease, Pages 151-155, Julian F.R. Paton, Anthony E. Pickering Show preview |
PDF (507 K) | Related articles | Related reference work articles
Chapter 32 - Circadian Rhythms and Autonomic Function, Pages 157-159, Diego A. Golombek Show preview |
PDF (182 K) | Related articles | Related reference work articles
Chapter 33 - Baroreceptor Reflexes, Pages 161-165, Mark W. Chapleau Show preview |
PDF (301 K) | Related articles | Related reference work articles
Chapter 34 - Genetic Determinants of Baroreflex Function, Pages 167-169, Italo Biaggioni Show preview |
PDF (63 K) | Related articles | Related reference work articles
Chapter 35 - Cardiac and Other Visceral Afferents, Pages 171-176, John C. Longhurst, Liang-Wu Fu Show preview |
PDF (746 K) | Related articles | Related reference work articles
Chapter 36 - Autonomic Control of the Heart, Pages 177-180, Rachel C. Drew, Lawrence I. Sinoway Show preview |
PDF (525 K) | Related articles | Related reference work articles
Chapter 37 - Cardiac Vagal Ganglia, Pages 181-185, Javier G. Castillo, David H. Adams Show preview |
PDF (626 K) | Related articles | Related reference work articles
Chapter 38 - Neural Control of Blood Vessels, Pages 187-191, Julian H. Lombard, Allen W. Cowley Jr. Show preview |
PDF (585 K) | Related articles | Related reference work articles
Chapter 39 - Physiology of Upright Posture, Pages 193-195, Wouter Wieling, Jan T. Groothuis Show preview |
PDF (182 K) | Related articles | Related reference work articles
Chapter 40 - Cerebral Circulation, Pages 197-200, Ronald Schondorf Show preview |
PDF (372 K) | Related articles | Related reference work articles
Chapter 41 - Autonomic Control of the Lower Airways, Pages 201-204, Peter J. Barnes Show preview |
PDF (804 K) | Related articles | Related reference work articles
Chapter 42 - Gastrointestinal Function, Pages 205-209, Michael Camilleri Show preview |
PDF (1064 K) | Related articles | Related reference work articles
Chapter 43 - The Splanchnic Circulation, Pages 211-213, Gregory D. Fink, John W. Osborn Show preview |
PDF (65 K) | Related articles | Related reference work articles
Chapter 44 - Autonomic Control of the Kidney, Pages 215-220, Edwin K. Jackson Show preview |
PDF (567 K) | Related articles | Related reference work articles
Chapter 45 - Dopamine Mechanisms in the Kidney, Pages 221-223, Robert M. Carey Show preview |
PDF (261 K) | Related articles | Related reference work articles
Chapter 46 - Autonomic Control of the Lower Urinary Tract, Pages 225-228, Lori Birder, William C. de Groat Show preview |
PDF (273 K) | Related articles | Related reference work articles
Chapter 47 - Bladder Function in Health and Disease, Pages 229-233, Marcus J. Drake, Brian A. Parsons Show preview |
PDF (716 K) | Related articles | Related reference work articles
Chapter 48 - Physiology and Pathophysiology of Female Sexual Function, Pages 235-238, Max J. Hilz Show preview |
PDF (300 K) | Related articles | Related reference work articles
Chapter 49 - Control of the Pupil, Pages 239-242, Karen M. Joos, Mark R. Melson Show preview |
PDF (390 K) | Related articles | Related reference work articles
Chapter 50 - Central Thermoregulation, Pages 243-247, Shaun F. Morrison Show preview |
PDF (472 K) | Related articles | Related reference work articles
Chapter 51 - Sweating, Pages 249-251, Phillip A. Low Show preview |
PDF (161 K) | Related articles | Related reference work articles
Chapter 52 - Regulation of Metabolism, Pages 253-255, Christopher Bell Show preview |
PDF (252 K) | Related articles | Related reference work articles
Chapter 53 - Autonomic Innervation of the Skeleton, Pages 257-259, Florent Elefteriou, J.Preston Campbell Show preview |
PDF (299 K) | Related articles | Related reference work articles
Chapter 54 - Sex Differences in Autonomic Function, Pages 261-264, Emma C. Hart, Nisha Charkoudian, Michael J. Joyner Show preview |
PDF (206 K) | Related articles | Related reference work articles
Chapter 55 - Autonomic Control During Pregnancy, Pages 265-268, Virginia L. Brooks, Belinda H. McCully, Priscila A. Cassaglia Show preview |
PDF (358 K) | Related articles | Related reference work articles
Part IV: Stress Chapter 56 - Aging and the Autonomic Nervous System, Pages 271-273, Lewis A. Lipsitz, Vera Novak Show preview |
PDF (67 K) | Related articles | Related reference work articles
Chapter 57 - Exercise, Pages 275-279, Qi Fu, Benjamin D. Levine Show preview |
PDF (509 K) | Related articles | Related reference work articles
Chapter 58 - Effects of High Altitude, Pages 281-282, Luciano Bernardi Show preview |
PDF (93 K) | Related articles | Related reference work articles
Chapter 59 - Space Physiology, Pages 283-285, Gilles Clément, Scott Wood Show preview |
PDF (132 K) | Related articles | Related reference work articles
Chapter 60 - Hypothermia and Hyperthermia, Pages 287-289, Nisha Charkoudian Show preview |
PDF (144 K) | Related articles | Related reference work articles
Chapter 61 - Psychological Stress and the Autonomic Nervous System, Pages 291-293, Michael G. Ziegler Show preview |
PDF (66 K) | Related articles | Related reference work articles
Chapter 62 - Mind–Body Interactions, Pages 295-299, Calvin Carter, Daniel Tranel Show preview |
PDF (398 K) | Related articles | Related reference work articles
Part V: Pathophysiological Mechanisms Chapter 63 - Alpha-Synuclein and Neurodegeneration, Pages 303-305, Kiren Ubhi, Leslie Crews, Eliezer Masliah Show preview |
PDF (383 K) | Related articles | Related reference work articles
Chapter 64 - Insulin Resistance and the Autonomic Nervous System, Pages 307-312, Megan S. Johnson, Vincent G. DeMarco, Adam WhaleyConnell, James R. Sowers Show preview |
PDF (786 K) | Related articles | Related reference work articles
Chapter 65 - Salt Sensitivity of Blood Pressure, Pages 313-318, Cheryl L. Laffer, Fernando Elijovich Show preview |
PDF (279 K) | Related articles | Related reference work articles
Chapter 66 - Endothelial Dysfunction, Pages 319-324, Julian P.J. Halcox Show preview |
PDF (331 K) | Related articles | Related reference work articles
Chapter 67 - Inflammation, Immunity and the Autonomic Nervous System, Pages 325-329, Paul J. Marvar, David G. Harrison Show preview |
PDF (366 K) | Related articles | Related reference work articles
Chapter 68 - Oxygen Sensing, Pages 331-333, Nanduri R. Prabhakar Show preview |
PDF (146 K) | Related articles | Related reference work articles
Chapter 69 - Reactive Oxygen Species and Oxidative Stress, Pages 335-338, Rhian M. Touyz Show preview |
PDF (245 K) | Related articles | Related reference work articles
Part VI: Cardiovascular Disorders Chapter 70 - Neurally Mediated Syncope, Pages 341-343, Satish R. Raj Show preview |
PDF (146 K) | Related articles | Related reference work articles
Chapter 71 - Sympatho-Vagal Imbalance in Hypertension, Pages 345-348, Guido Grassi, Gino Seravalle Show preview |
PDF (214 K) | Related articles | Related reference work articles
Chapter 72 - Baroreflex Failure, Pages 349-353, Jens Jordan Show preview |
PDF (464 K) | Related articles | Related reference work articles
Chapter 73 - Blood Pressure Variability, Pages 355-357, Stanley Fernandez, Sirisha Srikakarlapudi, Joseph L. Izzo Show preview |
PDF (65 K) | Related articles | Related reference work articles
Chapter 74 - Obesity-Associated Hypertension, Pages 359-361, Cyndya Shibao Show preview |
PDF (267 K) | Related articles | Related reference work articles
Chapter 75 - Orthostatic Hypertension, Pages 363-365, David Robertson Show preview |
PDF (58 K) | Related articles | Related reference work articles
Chapter 76 - Heart Failure, Pages 367-370, John S. Floras Show preview |
PDF (321 K) | Related articles | Related reference work articles
Chapter 77 - Stress Cardiomyopathy and Takotsubo Syndrome, Pages 371-375, David Robertson, Kyoko Sato Show preview |
PDF (951 K) | Related articles | Related reference work articles
Chapter 78 - Clinical Evaluation of Autonomic Disorders, Pages 377-382, Paola Sandroni Show preview |
PDF (233 K) | Related articles | Related reference work articles
Chapter 79 - Tilt Table Studies, Pages 383-387, Satish R. Raj Show preview |
PDF (444 K) | Related articles | Related reference work articles
Chapter 80 - Sympathetic Microneurography, Pages 389-392, B. Gunnar Wallin Show preview |
PDF (601 K) | Related articles | Related reference work articles
Chapter 81 - Clinical Applications of Microneurography, Pages 393-397, Tadaaki Mano Show preview |
PDF (310 K) | Related articles | Related reference work articles
Chapter 82 - Clinical Sympathetic Imaging, Pages 399-403, David S. Goldstein Show preview |
PDF (530 K) | Related articles | Related reference work articles
Chapter 83 - Assessment of the Autonomic Control of the Cardiovascular System by a Frequency Domain Approach, Pages 405-408, Raffaello Furlan, Franca Barbic Show preview |
PDF (311 K) | Related articles | Related reference work articles
Chapter 84 - Assessment of Sudomotor Function, Pages 409-411, Ronald Schondorf Show preview |
PDF (259 K) | Related articles | Related reference work articles
Chapter 85 - Cutaneous Autonomic Innervation: Assessment by Skin Biopsy, Pages 413-417, Christopher H. Gibbons, Roy Freeman Show preview |
PDF (1450 K) | Related articles | Related reference work articles
Part VII: Catecholamine Disorders Chapter 86 - Pheochromocytoma, Pages 421-425, Graeme Eisenhofer, Jacques W.M. Lenders, William M. Manger Show preview |
PDF (454 K) | Related articles | Related reference work articles
Chapter 87 - Deficiencies of Tetrahydrobiopterin, Tyrosine Hydroxylase and Aromatic L-Amino Acid Decarboxylase, Pages 427-430, Keith Hyland, Lauren A. Hyland Show preview |
PDF (204 K) | Related articles | Related reference work articles
Chapter 88 - Dopamine β-Hydroxylase Deficiency, Pages 431-434, Emily M. Garland Show preview |
PDF (200 K) | Related articles | Related reference work articles
Chapter 89 - Menkes Disease and Other ATP7A-Related Phenotypes, Pages 435-437, Stephen G. Kaler Show preview |
PDF (265 K) | Related articles | Related reference work articles
Chapter 90 - Norepinephrine Transporter Deficiency, Pages 439-442, Maureen K. Hahn Show preview |
PDF (489 K) | Related articles | Related reference work articles
Chapter 91 - Monoamine Oxidase Deficiency, Pages 443-444, Jacques W.M. Lenders, Graeme Eisenhofer Show preview |
PDF (110 K) | Related articles | Related reference work articles
Chapter 92 - Congenital Central Hypoventilation Syndrome (CCHS) and PHOX2B Mutations, Pages 445-449, Debra E. Weese-Mayer, Pallavi P. Patwari, Casey M. Rand, André Diedrich, Nancy L. Kuntz, Elizabeth M. Berry-Kravis Show preview |
PDF (843 K) | Related articles | Related reference work articles
Part VIII: Autonomic Synucleinopathies Chapter 93 - Multiple System Atrophy, Pages 453-457, David Robertson, Sid Gilman Show preview |
PDF (88 K) | Related articles | Related reference work articles
Chapter 94 - Parkinson’s Disease, Pages 459-461, John Y. Fang, Thomas L. Davis Show preview |
PDF (66 K) | Related articles | Related reference work articles
Chapter 95 - Dementia with Lewy Bodies, Pages 463-466, Sylvia Stemberger, Michaela Stampfer, Gregor K. Wenning Show preview |
PDF (125 K) | Related articles | Related reference work articles
Chapter 96 - Pure Autonomic Failure, Pages 467-469, Horacio Kaufmann, Irwin J. Schatz Show preview |
PDF (61 K) | Related articles | Related reference work articles
Part IX: Peripheral Autonomic Disorders Chapter 97 - Diagnostic Workup of Peripheral Neuropathies with Dysautonomia, Pages 473-475, Amanda C. Peltier Show preview |
PDF (66 K) | Related articles | Related reference work articles
Chapter 98 - Diabetic Autonomic Dysfunction, Pages 477-481, Amanda C. Peltier, Stephen N. Davis Show preview |
PDF (299 K) | Related articles | Related reference work articles
Chapter 99 - Amyloidotic Autonomic Failure, Pages 483-487, Yadollah Harati, Cecile L. Phan Show preview |
PDF (312 K) | Related articles | Related reference work articles
Chapter 100 - Autoimmune Autonomic Ganglionopathy, Pages 489-492, Steven Vernino, Phillip A. Low Show preview |
PDF (160 K) | Related articles | Related reference work articles
Chapter 101 - Guillain–Barré Syndrome, Pages 493-494, Phillip A. Low, James G. McLeod Show preview |
PDF (90 K) | Related articles | Related reference work articles
Chapter 102 - Hereditary Autonomic Neuropathies, Pages 495-498, Yadollah Harati, Shahram Izadyar Show preview |
PDF (111 K) | Related articles | Related reference work articles
Chapter 103 - Familial Dysautonomia (Riley–Day Syndrome), Pages 499-502, Horacio Kaufmann, Lucy Norcliffe-Kaufmann, Felicia B. Axelrod Show preview |
PDF (389 K) | Related articles | Related reference work articles
Part X: Autonomic Disorders Chapter 104 - Autonomic Disturbances in Spinal Cord Injuries, Pages 505-509, Christopher J. Mathias, David A. Low Show preview |
PDF (310 K) | Related articles | Related reference work articles
Chapter 105 - Drug-Induced Autonomic Dysfunction, Pages 511-514, James M. Luther Show preview |
PDF (131 K) | Related articles | Related reference work articles
Part XI: Orthostatic Intolerance Chapter 106 - Postural Tachycardia Syndrome (POTS), Pages 517-519, Phillip A. Low, Paola Sandroni Show preview |
PDF (88 K) | Related articles | Related reference work articles
Chapter 107 - Mechanisms of Postural Tachycardia Syndrome, Pages 521-523, Satish R. Raj Show preview |
PDF (500 K) | Related articles | Related reference work articles
Chapter 108 - Symptoms and Signs of Postural Tachycardia Syndrome (POTS), Pages 525-528, Julian Stewart Show preview |
PDF (207 K) | Related articles | Related reference work articles
Chapter 109 - Delayed Orthostatic Hypotension, Pages 529-530, Christopher H. Gibbons, Roy Freeman Show preview |
PDF (434 K) | Related articles | Related reference work articles
Chapter 110 - Chronic Fatigue Syndrome and the Autonomic Nervous System, Pages 531-534, Luis E. Okamoto, Satish R. Raj, Italo Biaggioni Show preview |
PDF (129 K) | Related articles | Related reference work articles
Chapter 111 - Joint Hypermobility Syndrome and Dysautonomia, Pages 535-537, Giris Jacob, Blair P. Grubb Show preview |
PDF (71 K) | Related articles | Related reference work articles
Part XII: Special Clinical Conditions Chapter 112 - Neuroleptic Malignant Syndrome, Pages 541-544, Fenna T. Phibbs, P. David Charles Show preview |
PDF (79 K) | Related articles | Related reference work articles
Chapter 113 - Migraine and the Autonomic Nervous System, Pages 545-547, Pietro Cortelli Show preview |
PDF (172 K) | Related articles | Related reference work articles
Chapter 114 - Epilepsy and Autonomic Regulation, Pages 549-552, Matthias Dütsch, Max J. Hilz Show preview |
PDF (431 K) | Related articles | Related reference work articles
Chapter 115 - Disorders of Sweating, Pages 553-559, Robert D. Fealey Show preview |
PDF (391 K) | Related articles | Related reference work articles
Chapter 116 - Male Erectile Dysfunction, Pages 561-564, Douglas F. Milam Show preview |
PDF (200 K) | Related articles | Related reference work articles
Chapter 117 - Sleep Apnea, Pages 565-569, Tomas Konecny, Virend K. Somers Show preview |
PDF (732 K) | Related articles | Related reference work articles
Chapter 118 - Altered Adrenal Function and the Autonomic Nervous System, Pages 571-574, Subbulaxmi Trikudanathan, Gordon H. Williams Show preview |
PDF (108 K) | Related articles | Related reference work articles
Chapter 119 - Mastocytosis, Pages 575-576, L. Jackson Roberts II Show preview |
PDF (79 K) | Related articles | Related reference work articles
Chapter 120 - Cocaine Overdose, Pages 577-581, Andrew Kontak, Wanpen Vongpatanasin, Ronald G. Victor Show preview |
PDF (566 K) | Related articles | Related reference work articles
Chapter 121 - Complex Regional Pain Syndrome, Pages 583-587, Wilfrid Jänig Show preview |
PDF (266 K) | Related articles | Related reference work articles
Chapter 122 - Carcinoid Tumors, Pages 589-591, Kenneth R. Hande Show preview |
PDF (109 K) | Related articles | Related reference work articles
Chapter 123 - Paraneoplastic Autonomic Dysfunction, Pages 593-596, Ramesh K. Khurana Show preview |
PDF (121 K) | Related articles | Related reference work articles
Chapter 124 - Abdominal Pain and Cyclic Vomiting, Pages 597-600, Gisela Chelimsky, Thomas Chelimsky Show preview |
PDF (131 K) | Related articles | Related reference work articles
Chapter 125 - Fecal Incontinence, Pages 601-602, James F.X. Jones Show preview |
PDF (135 K) | Related articles | Related reference work articles
Part XIII: Management of Autonomic Disorders Chapter 126 - Panic Disorder, Pages 605-608, Murray Esler, Marlies Alvarenga, David Kaye, Gavin Lambert, Jane Thompson, Jacqui Hastings, Rosemary Schwarz, Margaret Morris, Jeff Richards Show preview |
PDF (642 K) | Related articles | Related reference work articles
Chapter 127 - Physical Measures, Pages 609-612, Wouter Wieling, Roland D. Thijs Show preview |
PDF (368 K) | Related articles | Related reference work articles
Chapter 128 - Water and the Osmopressor Response, Pages 613-615, Jens Jordan Show preview |
PDF (231 K) | Related articles | Related reference work articles
Chapter 129 - Droxidopa (L-DOPS), Pages 617-620, Horacio Kaufmann Show preview |
PDF (262 K) | Related articles | Related reference work articles
Chapter 130 - Midodrine, Adrenergic Agonists and Antagonists, Pages 621-625, Janice L. Gilden Show preview |
PDF (160 K) | Related articles | Related reference work articles
Chapter 131 - Agents Potentiating Sympathetic Tone, Pages 627-630, Cyndya Shibao, Luis Okamoto Show preview |
PDF (422 K) | Related articles | Related reference work articles
Chapter 132 - Acetylcholinesterase and its Inhibitors, Pages 631-633, Brett A. English, Andrew A. Webster Show preview |
PDF (136 K) | Related articles | Related reference work articles
Chapter 133 - Fludrocortisone, Pages 635-637, David Robertson, Rose Marie Robertson Show preview |
PDF (117 K) | Related articles | Related reference work articles
Chapter 134 - Acarbose, Pages 639-641, Cyndya Shibao Show preview |
PDF (111 K) | Related articles | Related reference work articles
Chapter 135 - Erythropoietin in Autonomic Failure, Pages 643-644, Italo Biaggioni Show preview |
PDF (73 K) | Related articles | Related reference work articles
Chapter 136 - Somatostatin Agonists, Pages 645-648, Robert Hoeldtke Show preview |
PDF (333 K) | Related articles | Related reference work articles
Chapter 137 - Harnessing the Autonomic Nervous System for Therapeutic Intervention, Pages 649-652, Murray Esler Show preview |
PDF (579 K) | Related articles | Related reference work articles
Chapter 138 - Acupuncture Regulation of Cardiovascular Function, Pages 653-657, John C. Longhurst Show preview |
PDF (618 K) | Related articles | Related reference work articles
Chapter 139 - Bionic Baroreflex, Pages 659-662, Takayuki Sato, André Diedrich, Kenji Sunagawa Show preview |
PDF (330 K) | Related articles | Related reference work articles
Part XIV: Experimental Autonomic Neuroscience Chapter 140 - Anesthetic Management in Autonomic Disorders, Pages 665-668, Chih Cherng Lu, Shung Tai Ho, Che Se Tung Show preview |
PDF (158 K) | Related articles | Related reference work articles
Chapter 141 - Evolution of the Cardiovascular Autonomic Nervous System in Vertebrates, Pages 669-673, Tobias Wang Show preview |
PDF (748 K) | Related articles | Related reference work articles
Chapter 142 - Human Physiome, Pages 675-680, Peter Hunter Show preview |
PDF (1267 K) | Related articles | Related reference work articles
Chapter 143 - Modeling the Autonomic Nervous System, Pages 681-687, Ilya A. Rybak, Yaroslav I. Molkov, Julian F.R. Paton, Ana P.L. Abdala, Daniel B. Zoccal Show preview |
PDF (1018 K) | Related articles | Related reference work articles
Chapter 144 - Optogenetics, Pages 689-691, Sergey Kasparov Show preview |
PDF (292 K) | Related articles | Related reference work articles
Index, Pages 693-703 Show preview |
About ScienceDirect What is ScienceDirect Content details Set up How to use Subscriptions Developers
PDF (817 K) | Related articles | Related reference work articles
Contact and Support Contact and Support
About Elsevier About Elsevier About SciVerse About SciVal Terms and Conditions Privacy policy Information for advertisers
Copyright © 2012 Elsevier B.V. All rights reserved. SciVerse® is a registered trademark of Elsevier Properties S.A., used under license. ScienceDirect® is a registered trademark of Elsevier B.V.
Preface
The Primer on the Autonomic Nervous System aims to provide a concise and accessible overview of autonomic neuroscience for students, scientists, and clinicians. In spite of its compact size, its 144 chapters draw on the expertise of more than 250 scientists and clinicians. We thank the American Autonomic Society for its continued interest and moral support of this project. We especially express appreciation to our contributors, who, along with the editors, prepared their chapters without compensation in order to keep the cost of the Primer within the reach of students and trainees. We are delighted with the enthusiastic reception of the first and second English editions, and the Japanese edition of the Primer, which has sold more copies than any previous text on autonomic neuroscience. With this edition we welcome Julian F.R. Paton as a new editor. The third edition of the Primer would not have been possible without Mrs. Sonja Campbell, whose efficiency
and wisdom, combined with her mastery of lucid English prose, facilitated the preparation of this substantially enlarged edition. We also thank Mica Haley and Melissa Turner at Academic Press, who kept all of us on track and on schedule. In earlier editions, readers were encouraged to email their criticisms and advice for improving the text. We thank the many of you who took time to do just that. Several new sections and a number of clarifications based on these suggestions have been implemented. If you have comments or advice for improving future editions please send them to
[email protected].
xix
David Robertson Italo Biaggioni Geoffrey Burnstock Phillip A. Low Julian F.R. Paton
List of Contributors
Ana P.L. Abdala School of Physiology and Pharmacology, Bristol Heart Institute, University of Bristol, Bristol, UK David H. Adams Guggenheim Pavillion, New York, NY, USA Marlies Alvarenga Baker IDI Heart and Diabetes Institute, Melbourne, Australia Amy C. Arnold Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA Felicia B. Axelrod Professor, Pediatrics and Neurology, New York University School of Medicine, New York, NY 10016, USA Franca Barbic Neuroscience Research Association, Bolognini Hospital, Seriate (Bg), Italy Peter J. Barnes Department of Thoracic Medicine, National Heart and Lung Institute, London, UK Deborah Bauer Departments of Pediatrics and Pharmacology, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104, USA Christopher Bell Department of Health and Exercise Science, Colorado State University, Fort Collins, CO, USA Eduardo E. Benarroch Department of Neurology, Mayo Clinic, Rochester, MN, USA Elizabeth M. Berry-Kravis Professor of Pediatrics, Neurology, and Biochemistry at Rush University Medical Center, Chicago, IL 60612, USA Luciano Bernardi Clinica Medica 2 – Dipartimento Medicina Interna, IRCCS S. Matteo, Universita’ di Pavia, 27100 Pavia, Italy Italo Biaggioni Professor of Medicine and Pharmacology, Vanderbilt University, Nashville, TN 37212, USA Lori Birder University of Pittsburgh School of Medicine, Departments of Medicine and Pharmacology, Pittsburgh PA 15261, USA Virginia L. Brooks Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, OR 97239, USA Joan Heller Brown Department of Pharmacology, University of California, San Diego School of Medicine, La Jolla, CA, USA Geoffrey Burnstock Autonomic Neuroscience Centre, University College Medical School, London NW3 2PF, UK Michael Camilleri Mayo Clinic, Rochester, MN, USA J. Preston Campbell Vanderbilt University Medical Center, Nashville, TN 37232, USA Robert M. Carey Division of Endocrinology, University of Virginia Health Systems, Charlottesville, VA, USA Marc G. Caron Department of Cell Biology, Duke University Medical Center, Durham, NC 27710, USA Calvin Carter Department of Neurology, University of Iowa, College of Medicine, Iowa City, IA, USA Priscila A. Cassaglia Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, OR 97239, USA Javier G. Castillo Resident Physician, Department of Cardiothoracic Surgery, The Mount Sinai School of Medicine, New York, NY, USA
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00149-9
Mark W. Chapleau Departments of Internal Medicine, and Molecular Physiology and Biophysics, University of Iowa and Veterans Affairs Medical Center, Iowa City, IA, USA Nisha Charkoudian Department of Anesthesiology and Department of Physiology, and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA P. David Charles Movement Disorders Clinic, Medical Center South, Vanderbilt University, Nashville, TN, USA Gisela Chelimsky Department of Pediatrics, Rainbow Babies and Children’s Hospital, and University Hospitals Case Medical Center, Cleveland, OH 44106, USA Thomas Chelimsky Department of Neurology, University Hospitals Case Medical Center, Cleveland, OH 44106, USA Pei-Wen Cheng Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC Gilles Clément International Space University, Strasbourg, France Pietro Cortelli Department of Neurological Sciences, Alma Mater Studiorum, University of Bologna, 40123 Bologna, Italy Allen W. Cowley Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA Leslie Crews Department of Pathology, University of California, San Diego/La Jolla, CA, USA Stephen N. Davis Chair, Internal Medicine, University of Maryland, Baltimore, MD, USA Thomas L. Davis Clinical Research Center, Vanderbilt University, Nashville, TN, USA William C. de Groat University of Pittsburgh School of Medicine, Departments of Medicine and Pharmacology, Pittsburgh, PA 15261, USA Vincent G. DeMarco University of Missouri, Diabetes and Cardiovascular Center, and the Harry S. Truman VA Medical Center, Columbia, MO, USA André Diedrich Autonomic Dysfunction Center, Department of Medicine and Department of Biomedical Engineering, Vanderbilt University School of Medicine, Nashville, TN, USA Donald J. DiPette Departments of Medicine (DJD), and Cell Biology and Anatomy (SCS), University of South Carolina School of Medicine, Columbia, SC 29208, USA Debra I. Diz Professor and Director, Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1032, USA Marcus J. Drake FRCS(Urol)Bristol Urological Institute, Bristol, UK Rachel C. Drew Heart and Vascular Institute, Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, USA Matthias Dütsch Department of Neurology, University of Erlangen-Nuremberg, D-91054 Erlangen, Germany, and Department of Neurology, Rummelsberg Hospital, D-90592 Schwarzenbruck, Germany Graeme Eisenhofer Department of Medicine, and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Dresden, Dresden, Germany
xxi
© 2012 Elsevier Inc. All rights reserved.
xxii
LIst of ContrIbutors
Florent Elefteriou Assistant Professor and Director Elect, Vanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA Fernando Elijovich Professor of Medicine, Texas A&M HSC, College of Medicine and Center for Neuroscience, USA Brett A. English Division of Allergy, Pulmonary and Critical Care Medicine, Drug Discovery, Vanderbilt University Medical Center, Nashville, TN, USA Murray Esler Baker IDI Heart and Diabetes Institute, Melbourne, Australia John Y. Fang Assistant Professor, Department of Neurology, Vanderbilt University, Nashville, TN, USA and Staff Physician, Neurology Service, Tennessee Valley Healthcare System, Nashville, TN, USA Robert D. Fealey Department of Neurology, Mayo Clinic, Rochester, MN, USA Stanley Fernandez Department of Medicine, State University of New York at Buffalo, Buffalo, NY 14215, USA Gregory D. Fink Michigan State University, Department of Pharmacology and Toxicology, East Lansing, MI 48840, USA John S. Floras University Health Network and Mount Sinai Hospital Department of Medicine, University of Toronto, Toronto, Ont., Canada Roy Freeman Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA Qi Fu Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, The University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, USA Liang-Wu Fu Department of Medicine, School of Medicine, University of California, Irvine, Irvine, CA 92697-4075, USA Raffaello Furlan Internal Medicine, Bolognini Hospital, Seriate (Bg), University of Milan, Milan, Italy Alfredo Gamboa Autonomic Dysfunction Center, Vanderbilt University, Nashville, TN, USA Emily M. Garland Division of Clinical Pharmacology, Medical Center North, Vanderbilt University, Nashville, TN, USA Christopher H. Gibbons Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center, Boston MA 02215, USA Michael P. Gilbey Department of Physiology, University College London, London, UK Janice L. Gilden Professor of Medicine, Rosalind Franklin University of Medicine and Science, James A. Lovell Federal Health Care Center, North Chicago, and Saints Mary and Elizabeth Medical Center, Chicago, IL, USA Sid Gilman Department of Neurology, 300 N. Ingalls St. 3D15, Ann Arbor, MI, USA David S. Goldstein National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA Diego A. Golombek Universidad Nacional de Quilmes/ CONICET, Buenos Aires, Argentina Robert M. Graham Victor Chang Cardiac Research Institute, Darlinghurst, Sydney, NSW 2010, Australia Guido Grassi Università Milano-Bicocca, Ospedale San Gerardo, Monza (Milan), Milan, Italy, andIstituto Auxologico Italiano, Milan, Italy
Mark D. Grier Department of Pharmacology, Vanderbilt University, Nashville, TN, USA Jan T. Groothuis Department of Physiology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands, and, Department of Rehabilitation, St Maartenskliniek, 6500 GM Nijmegen, The Netherlands Blair P. Grubb Recanati Autonomic Dysfunction Center, Tel Aviv University, Faculty of Medicine, Tel-Aviv 64239, Israel Maureen K. Hahn Department of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA Julian P.J. Halcox Professor of Cardiology, Cardiff University School of Medicine, Wales Heart Research Institute, Cardiff, CF14 4XN, UK Robert W. Hamill Department of Neurology, University of Vermont, College of Medicine, Burlington, VT, USA Kenneth R. Hande Division of Medical Oncology, Preston Research Building, Nashville, TN, USA Yadollah Harati Department of Neurology, Baylor College of Medicine, Houston, TX, USA David G. Harrison Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA Emma C. Hart Department of Anesthesiology, Mayo Clinic, Rochester, MN, USA Jacqui Hastings Baker IDI Heart and Diabetes Institute, Melbourne, Australia Luke A. Henderson Department of Anatomy and Histology, University of Sydney, Sydney, Australia Max J. Hilz Department of Neurology, University of ErlangenNuremberg, D-91054 Erlangen, Germany, and Departments of Neurology, Medicine, Psychiatry, New York University School of Medicine, New York, NY 10016, USA Robert Hoeldtke Division of Endocrinology, West Virginia University, Morgantown, WV, USA Shung Tai Ho Graduate Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan, ROC Peter Hunter Auckland Bioengineering Institute, University of Auckland, New Zealand Keith Hyland Department of Neurochemistry, Medical Neurogenetics, Atlanta, GA, USA Lauren Hyland Department of Neurochemistry, Medical Neurogenetics, Atlanta, GA, USA Shahram Izadyar Department of Neurology, Baylor College of Medicine, Houston, TX, USA Joseph L. Izzo Department of Medicine, State University of New York at Buffalo, Buffalo, NY 14215, USA Edwin K. Jackson University of Pittsburgh School of Medicine, Department of Pharmacology and Chemical Biology, Pittsburgh, PA 15219, USA Giris Jacob Head of Medicine F, Recanati Autonomic Dysfunction Center, Tel Aviv (Sourasky) Medical Center, Tel Aviv University, Faculty of Medicine, Tel-Aviv 64239, Israel Wilfrid Jänig Physiologisches Institut, Christian-AlbrechtsUniversität zu Kiel, Kiel, Germany Megan S. Johnson University of Missouri, Diabetes and Cardiovascular Center, Columbia, MO, USA Carrie K. Jones Department of Pharmacology, and Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN, USA James F.X. Jones School of Medicine and Medical Sciences, University College Dublin, Ireland
I. INTRODUCTION
LIst of ContrIbutors
Karen M. Joos Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, USA Jens Jordan Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany Jens Jordan Institute of Clinical Pharmacology, Hannover Medical School, 30625 Hannover, Germany Michael J. Joyner Department of Anesthesiology, Mayo Clinic, Rochester, MN, USA Stephen G. Kaler Program in Molecular Medicine, NICHD, Bethesda, Maryland 20892-1853, USA Sergey Kasparov Professor of Molecular Physiology, University of Bristol, Bristol, BS8 1TD, UK Horacio Kaufmann Professor, Neurology, Pediatrics and Medicine, New York University School of Medicine, New York, NY 10016, USA Horacio Kaufmann New York University School of Medicine, New York, NY 10016, USA David Kaye Baker IDI Heart and Diabetes Institute, Melbourne, Australia Ramesh K. Khurana Division of Neurology, Union Memorial Hospital, Baltimore, MD, USA Chun-Hyung Kim Department of Psychiatry, Harvard Medical School, Boston, MA, USA Kwang-Soo Kim Department of Psychiatry, Harvard Medical School, Boston, MA, USA Kazuto Kobayashi Department of Molecular Genetics, Institute of Biomedical Sciences, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan Nancy L. Kuntz Associate Professor of Pediatrics, Northwestern University Feinberg School of Medicine, Center for Autonomic Medicine in Pediatrics at CMH, Chicago, IL 60614, USA Tomas Konecny Assistant Professor of Medicine, Department of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, MN, USA, and ICRC – Department of Cardiovascular Diseases, St Anne’s University Hospital Brno, Brno, Czech Republic Andrew Kontak Division of Cardiology/Hypertension Section, University of Texas Southwestern Medical Center, Dallas, TX, USA Cheryl L. Laffer Associate Professor of Medicine, Texas A&M HSC College of Medicine, USA Andre H. Lagrange Assistant Professor of Neurology, Epilepsy Division, Vanderbilt University, Nashville, TN, USA Nora Laiken Department of Pharmacology, University of California, San Diego School of Medicine, La Jolla, CA, USA Gavin Lambert Baker IDI Heart and Diabetes Institute, Melbourne, Australia Jacques W.M. Lenders Department of Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, and Department of Medicine, University Hospital Carl Gustav Carus Dresden, Dresden, Germany Benjamin D. Levine Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, The University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, USA Lewis A. Lipsitz Institute for Aging Research, Hebrew Senior Life; Division of Gerontology, Beth Israel Deaconess Medical Center; Harvard Medical School, Boston, MA, USA Julian H. Lombard Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
xxiii
John C. Longhurst Departments of Medicine, Physiology and Biophysics, Pharmacology and Biomedical Engineering, University of California, Irvine, Irvine, CA 92697-4075, USA David A. Low Autonomic and Neurovascular Medicine Unit, Faculty of Medicine, Imperial College London at St Mary’s Hospital London, WZ1NY, UK Phillip A. Low Department of Neurology, Mayo Foundation, Rochester, MN 55905, USA Chih Cherng Lu, MD,MS Department of Anaesthesiology, Departments of Tri-Service General Hospital/National Defense Medical Center, Taipei, Taiwan, ROC James M. Luther Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University, Nashville, TN, USA Vaughan G. Macefield Professor of Integrative Physiology, School of Medicine, University of Western Sydney, NSW 1797, Australia Belinda H. McCully Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, OR 97239, USA James G. McLeod Department of Medicine, University of Sydney, Sydney, Australia William M. Manger New York University Medical Center, and National Hypertension Association, New York, NY, USA Tadaaki Mano Tokai Central Hospital, Kakamigahara, Gifu, Japan Paul J. Marvar Department of Psychiatry, and Center of Behavioral Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA Eliezer Masliah University of California-San Diego, La Jolla, CA 92093-0624, USA Christopher J. Mathias Autonomic and Neurovascular Medicine Unit, Faculty of Medicine, Imperial College London at St Mary’s Hospital London, WZ1NY, UK and Autonomic Unit, National Hospital for Neurology and Neurosurgery, Queen Square/Institute of Neurology, University College London, London, UK Mark R. Melson Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, USA Douglas F. Milam Department of Urologic Surgery, Vanderbilt University, Nashville, TN, USA Marion C. Mohl Victor Chang Cardiac Research Institute, Darlinghurst, Sydney, NSW, 2010, Australia Yaroslav I. Molkov Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, PA, USA Margaret Morris Baker IDI Heart and Diabetes Institute, Melbourne, Australia Shaun F. Morrison Department of Neurological Surgery, Oregon Health and Science University, Portland, OR 97239, USA Toshiharu Nagatsu Department of Pharmacology, School of Medicine, Fujita Health University, Toyoake 470-1192, Japan Charles D. Nichols Department of Pharmacology, LSU Health Sciences Center, New Orleans, LA, USA Lucy Norcliffe-Kaufmann Instructor, Physiology and Neuroscience, New York University School of Medicine, New York, NY 10016, USA Vera Novak Division of Gerontology, Beth Israel Deaconess Medical Center;, Harvard Medical School, Boston, MA, USA Luis E. Okamoto Department of Medicine, Division of Clinical Pharmacology, and the Autonomic Dysfunction Center, Vanderbilt University School of Medicine, Nashville, TN, USA
I. INTRODUCTION
xxiv
LIst of ContrIbutors
John W. Osborn University of Minnesota, Department of Integrative Biology and Physiology, Minneapolis, MN 55455, USA Brian A. Parsons Bristol Urological Institute, Southmead Hospital, Bristol, UK Julian F.R. Paton School of Physiology and Pharmacology, Bristol Heart Institute, University of Bristol, Bristol, BS8 1TD, UK Pallavi P. Patwari Assistant Professor of Pediatrics, Northwestern University Feinberg School of Medicine, and Assistant Director, Center for Autonomic Medicine in Pediatrics at CMH, Chicago, IL 60614, USA Cecile L. Phan Department of Neurology, Baylor College of Medicine, Houston, TX, USA Fenna T. Phibbs Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA Nanduri R. Prabhakar Institute for Integrative Physiology, and Center for Systems Biology of O2 Sensing, Biological Sciences Division, University of Chicago, IL, USA Amanda C. Peltier Department of Neurology, Division of Neuromuscular, Vanderbilt University, Nashville, TN, USA Sean M. Peterson Department of Cell Biology, Duke University Medical Center, Durham, NC 27710, USA Anthony E Pickering School of Physiology and Pharmacology, Bristol Heart Institute, University of Bristol, Bristol, BS8 1TD, UK J. Howard Pratt Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA Kamal Rahmouni University of Iowa, Cardiovascular Center, Iowa City, IA, USA Satish R. Raj Autonomic Dysfunction Unit, Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University, Nashville, TN, USA Casey M. Rand Center for Autonomic Medicine in Pediatrics at CMH, Chicago, IL 60614, USA Heinz Reichmann Department of Neurology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany Jeff Richards Baker IDI Heart and Diabetes Institute, Melbourne, Australia L.Jackson Roberts Division of Clinical Pharmacology, Robinson Research Building, Vanderbilt University, Nashville, TN, USA David W. Robertson Vanderbilt University, Nashville, TN, USA Rose Marie Robertson Vanderbilt University, Nashville, TN, USA Michael Robinson Departments of Pediatrics and Pharmacology, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104, USA Ilya A. Rybak Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, PA, USA Elaine Sanders-Bush Department of Pharmacology, Vanderbilt University, Nashville, TN, USA Paola Sandroni Deptartment of Neurology, Mayo Clinic, Rochester, MN, USA Kyoko Sato Department of Cardiovascular Control, Kochi Medical School, Nankoku, Japan Takayuki Sato Department of Cardiovascular Control, Kochi Medical School, Japan Irwin J. Schatz John A. Burns School of Medicine, University of Hawaii at Manoa, Department of Medicine, Honolulu, HI, USA
Ernesto L. Schiffrin Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, and Lady Davis Institute for Medical Research, McGill University, Montreal, Que., Canada. Ronald Schondorf Department of Neurology, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada Rosemary Schwarz Baker IDI Heart and Diabetes Institute, Melbourne, Australia Gino Seravalle Istituto Auxologico Italiano, Milan, Italy. Robert E. Shapiro Department of Neurology, University of Vermont College of Medicine, Burlington, VT, USA Cyndya Shibao Department of Medicine, Division of Clinical Pharmacology, and the Autonomic Dysfunction Center,Vanderbilt University School of Medicine, Nashville, TN, USA Virend Somers Professor of Medicine, Department of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, MN, USA Michaela Stampfer Movement Disorders Section, Department of Neurology, University Hospital, Innsbruck, Austria C.Michael Stein Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA Sylvia Stemberger Division of Clinical Neurobiology, Innsbruck Medical University, Innsbruck, Austria Julian Stewart New York Medical College, Hawthorne, NY, USA Lawrence I. Sinoway Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, USA James R. Sowers University of Missouri, Diabetes and Cardiovascular Center, and the Harry S. Truman VA Medical Center, Columbia, MO, USA Sirisha Srikakarlapudi Department of Medicine, State University of New York at Buffalo, Buffalo, NY 14215, USA Kenji Sunagawa Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Japan Scott C. Supowit Departments of Medicine (DJD), and Cell Biology and Anatomy (SCS), University of South Carolina School of Medicine, Columbia, SC 29208, USA Palmer Taylor Department of Pharmacology, University of California, La Jolla, CA, USA Jane Thompson Baker IDI Heart and Diabetes Institute, Melbourne, Australia Roland D. Thijs Department of Neurology and Clinical Neurophysiology, Leiden University Medical Centre, 2300 RC Leiden, The Netherlands and Department of Neurology, Dutch Epilepsy Clinics Foundation, 2300 RC Hoofddorp, the Netherlands Rhian M Touyz Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ont., Canada Daniel Tranel Department of Neurology, University of Iowa, College of Medicine, Iowa City, IA, USA Subbulaxmi Trikudanathan Endocrinology, Diabetes and Hypertension Division, Brigham and Women’s Hospital, and, Harvard Medical School, Boston, MA, USA Ching-Jiunn Tseng Department of Medical Education and Research, Kaohsiung Veterans’ General Hospital, Kaohsiung, Taiwan, ROC Che-Se Tung Department of Physiology, National Defense Medical Center, Taipei, Taiwan, ROC Kiren Ubhi Department of Neurosciences, University of California, San Diego/La Jolla, CA, USA
I. INTRODUCTION
LIst of ContrIbutors
Nikhil Urs Department of Cell Biology, Duke University, Durham, NC 27710, USA Joseph G. Verbalis Georgetown University, Washington, DC 20007, USA Steven Vernino Department of Neurology, UT Southwestern Medical Center, Dallas, TX 75390-9036, USA Ronald G. Victor Hypertension Center, The Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA Margaret A. Vizzard University of Vermont College of Medicine, Burlington, VT, USA Wanpen Vongpatanasin Division of Cardiology/Hypertension Section, University of Texas Southwestern Medical Center, Dallas, TX, USA B. Gunnar Wallin Institute of Neuroscience and Physiology, Sahlgrenska Academy at Göteborg University, S-41345 Göteborg, Sweden Tobias Wang Zoophysiology, Department of Biological Sciences, Aarhus University, Denmark Qin Wang Department of Physiology and Biophysics, University of Alabama at Birmingham, Birmingham, AL, USA Andrew A. Webster Professor and Chair, Department of Pharmaceutical Sciences, Belmont University School of Pharmacy, Nashville, TN, USA
xxv
Debra E. Weese-Mayer Professor of Pediatrics, Northwestern University Feinberg School of Medicine, and Director, Center for Autonomic Medicine in Pediatrics, at Children’s Memorial Hospital (CMH), Chicago, IL 60614, USA Gregor K. Wenning Movement Disorders Section, Department of Neurology, University Hospital, Innsbruck, Austria Adam Whaley-Connell University of Missouri, Diabetes and Cardiovascular Center, and the Harry S. Truman VA Medical Center, Columbia, MO, USA Wouter Wieling Department of Internal Medicine, Academic Medical Centre, 1105 AZ Amsterdam, The Netherlands Gordon H. Williams Endocrinology, Diabetes and Hypertension Division, Brigham and Women’s Hospital, and, Harvard Medical School, Boston, MA, USA Scott Wood Universities Space Research Association, Houston, TX, USA Michael G. Ziegler UCSD Medical Center, San Diego, CA, USA Daniel B. Zoccal Department of Physiological Sciences, Center of Biological Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil
I. INTRODUCTION
PA R T I
INTRODUCTION
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00001-9
© 2012 Elsevier Inc. All rights reserved.
C H A P T E R
1 Development and Differentiation of Autonomic Neurons Chun-Hyung Kim, Kwang-Soo Kim increasing the sympathetic outflow to the heart and other viscera, the parasympathetic system is responsible for the basal autonomic functions such as heart rate and respiration under normal conditions. The enteric system regulates peristalsis of the gut wall and modulates the activity of the secretary glands. During the last decade, exciting progress has been made with regard to the molecular mechanisms underlying the development of the ANS. Among many different aspects, this review will focus primarily on the transcriptional regulatory code underlying the development and neurotransmitter identity determination of the ANS.
An intricate network of extracellular signals and nuclear transcription factors orchestrates the specification of numerous neuronal phenotypes during development of the vertebrate nervous system. During the last decade or so, impressive progress has been achieved in identifying the extracellular signaling molecules and key transcription factors that critically govern the development and fate determination of the autonomic nervous system (ANS). In particular, the so-called “transcriptional regulatory code” underlying the development and differentiation of the ANS has been elucidated; several key fatedetermining transcription factors such as Mash1, Phox2, AP2 and GATA3, have been identified to be responsible for development of the autonomic nervous system and the neurotransmitter identity specification. One important emerging feature is that those key transcription factors regulate not only development, but also final properties of differentiated neurons such as neurotransmitter identity. In line with this concept, those factors directly or indirectly regulate the expression of both cell type-specific markers as well as pan-neuronal markers. Second, these transcription factors function in an intricate regulatory cascade, starting from key signaling molecules such as bone morphogenic proteins. Finally, as evidenced by the study of dopamine β-hydroxylase gene regulation, multitudes of cell type-specific factors (e.g., Phox2a and 2b) and general transcription factors (e.g., CREB and Sp1) co-operatively regulate the expression of cell type-specific marker genes. This new molecular information will facilitate our understanding of the function of the autonomic nervous system in the normal, as well as in the diseased brain.
THE ANS IS DERIVED FROM NEURAL CREST CELLS During the early developmental period of vertebrate embryo, the neural tube and notochord are formed from the ectodermal and mesodermal layers, respectively. At this time, neural crest cells originate from the dorsolateral edge of the neural plate, and are generated at the junction of the neural tube and the ectoderm (Fig. 1.1). Interactions between the non-neural ectodermal layer and the neural plate critically influence the formation of neural crest cells at their interface [1]. Upon formation, neural crest cells migrate along specific routes to diverse destinations and differentiate into a variety of cell types that include all neurons and glial cells of the peripheral nervous system and the neurons of the gastric mucosal plexi. In addition, some other cell types such as smooth muscle cells, pigment cells, and chromatophores are known to arise from neural crest cells. Much progress has recently been achieved in the identification of signaling molecules and downstream transcription factors that control lineage determination and differentiation of neural crest cells [2,3].
INTRODUCTION The autonomic nervous system (ANS; also called the autonomic division or the autonomic motor system) is one of two major divisions of the peripheral nervous system. The ANS has three major subdivisions that are spatially segregated: the sympathetic, the parasympathetic, and the enteric nervous systems. While the sympathetic system controls the fight-or-flight reactions during emergencies by
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00001-9
SIGNALING MOLECULES REGULATE THE DEVELOPMENTAL PROCESSES OF THE ANS Recent studies have demonstrated that various signaling molecules, e.g., members of the bone morphogenic
3
© 2012 Elsevier Inc. All rights reserved.
4
1. DEvElOPmENT AND DIffERENTIATION Of AUTONOmIC NEURONs
development, while its robust activation opposes, even in the presence of BMP-2, SA cell development and the expression of SA lineage-determining genes [9]. Finally, during the last decade, numerous studies demonstrated that different neurotrophic factors such as NGF, GDNF, NT3, and/or their receptor signaling, critically regulate the survival and development of all three divisions of the ANS [10,11].
Neural plate Ectodermis Mesoderm
TRANSCRIPTIONAL REGULATORY CODE UNDERLYING THE DEVELOPMENT AND PHENOTYPIC SPECIFICATION OF THE ANS Notochord
Neural crest
Neural tube
Somite Dorsal aorta
FIGURE 1.1 All cell types of the ANS are derived from neural crest cells. Neural crest cells are formed at the dorsal neural tube and migrate along diverse routes. Depending on their specific routes and interactions with the target tissues, they differentiate into a variety of cell types including pigment cells, different types of neurons and glia of the ANS, and parts of the adrenal gland.
protein (BMP) family, Wnt, sonic hedgehog, and fibroblast growth factor, play critical roles in the early formation of neural crest cells as well as for final determination of neuronal identity [1–5]. These signals are often provided from neighboring tissues during migration of neural crest cells. For instance, grafting and ablation experiments in chick embryos demonstrate that the notochord is necessary but not sufficient to induce adrenergic phenotypes of neural crest-derived sympathetic ganglia [6,7]. A possible candidate for notochord-derived molecule(s) is sonic hedgehog [7]. In addition, a series of elegant experiments established that BMP family members, expressed from the dorsal aorta, play a crucial role in the differentiation and fate determination of the sympathetic nervous system [8 and references therein]. It is of note that these extracellular signaling molecules seem to work in concert with intracellular signals such as cAMP. Consistent with this, using neural crest cell culture, induction of differentiation and neurotransmitter phenotypes by BMP is enhanced by cAMP-elevating agents [4,9]. Interestingly, it appears that cAMP signaling acts as a bimodal regulator of sympathoadrenal (SA) cell development in neural crest cultures because its moderate activation promotes SA cell
Various transcription factors are thought to trigger a regulatory cascade by inducing the expression of downstream transcription factors, which eventually activate or repress the final target genes [4,12]. The regulatory cascade controlling the ANS’s noradrenergic neurotransmitter phenotype has been extensively studied, leading to the identification and functional characterization of critical transcription factors (Fig. 1.2). For example, the basic helix-loop-helix (bHLH) factor, Mammalian achaete-scute homolog-1 (Mash1, and the chicken homolog Cash1) induced by BMPs is the first transcription factor shown to be essential for noradrenergic neuron development. Downstream of Mash1 lies the homeodomain transcription factor Phox2a which is a critical regulator of noradrenergic cell lineage development. A closely related transcription factor Phox2b is also induced by BMPs independently of Mash1 and is another essential regulator of noradrenergic neuron development. In addition, GATA2/3 and dHand play critical roles for noradrenergic neuron development. Recent work from our laboratory showed that AP2β may critically regulate NA neuron development in the ANS. Specific functional roles of these key transcription factors in the development of the ANS have been identified as shown below (Fig. 1.2).
Mash1 (also called Cash1) Mash1, a basic helix-loop-helix (bHLH) protein, is the first transcription factor shown to be essential for development of the ANS. In Mash1/ mice, virtually all noradrenaline (NA) neurons of the nervous system are affected, suggesting that Mash1 is a critical factor for determining the NA fate. Mash1 appears to relay BMP molecules’ signals for sympathetic development. Consistent with this idea, Mash1 expression was induced by BMPs in neural crest cultures and it was largely diminished in sympathetic ganglia following inhibition of BMPs function [13]. In Mash1-inactivated mouse embryos, neural crest cells migrated to the vicinity of the dorsal aorta, but did not develop into mature sympathetic neurons, as evidenced by the lack of expression of tyrosine hydroxylase (TH) and dopamine β-hydroxylase (DBH), as well as the absence of pan-neuronal markers [14]. In addition,
I. INTRODUCTION
TRANsCRIPTIONAl REgUlATORy CODE UNDERlyINg THE DEvElOPmENT AND PHENOTyPIC sPECIfICATION Of THE ANs
cAMP
whereas Phox2a expression is regulated by both Mash1 and Phox2b (Fig. 1.2). Recent promoter studies showed that Phox2a and 2b are able to directly activate the DBH promoter by interacting with multiple sequence motifs residing in the 5 flanking region (see below). Collectively, Phox2a and 2b appear to regulate both the development and neurotransmitter identity of sympathetic neurons and of other noradrenergic neurons.
BMPs
? Phox2b MASH1/CASH1
PKA
AP2 β
PNMT
CREB
GATA3
TH Neurotransmitter identity
Phox2a
DBH
5
c-Ret
GATA3
Survival
FIGURE 1.2 Diagrams depicting the regulatory network of the NA phenotype determination and maintenance. The diagram shows the possible regulatory interactions in the cascade of development and NA phenotype expression of ANS neurons. Thick arrows indicate likely direct regulation and thin arrows indicate direct or indirect regulation. BMPs are secreted from the dorsal aorta and activate the expression of MASH1/CASH1 and Phox2b. Phox2b then activates the expression of Phox2a. Phox2a and/or Phox2b in turn activate neurotransmitterspecifying genes TH and DBH. Direct action of Phox2a/2b on DBH transcription has been demonstrated. The transcription factor CREB has been shown to interact with the 5 promoter and directly activates transcription of the TH and DBH genes. The cAMP signaling pathway appears to regulate NA phenotype determination in concert with Phox2a/2b. The zinc finger factor GATA3, presumably downstream of Phox2b, also appears to be required for expression of NA-specific genes. Phox2a and 2b also regulate the expression of pan-neuronal genes including the GDNF receptor c-Ret, which may relate to their role in formation and/or survival of ANS neurons.
Mash1 directly or indirectly affects the expression of Phox2a, another key transcription factor important for DBH gene expression in a noradrenergic neuron-specific manner [15–17]. Thus, Mash1 is the first transcription factor known to control both differentiation and maintenance of noradrenergic neurons [18].
Phox2 Genes Phox2a and Phox2b are two closely related homeodomain transcription factors that are expressed in virtually all neurons that transiently or permanently express the noradrenergic neurotransmitter phenotype [19]. Gene inactivation studies have demonstrated that Phox2a and/or 2b are essential for proper development of all three divisions of the ANS and some noradrenergic containing structures of the CNS. For instance, in both Phox2a/ and 2b/ mouse brain, the major noradrenergic population in the locus coeruleus does not form, strongly suggesting that both genes are required for its development [20,21]. In contrast, only Phox2b seems to be required for the development of sympathetic neurons. In Phox2a/ mice, sympathetic neuron development is largely normal. Interestingly, however, both genes are able to induce sympathetic neuron-like phenotype when ectopically expressed in chick embryos [22]. During sympathetic development, Phox2b expression is induced by BMP molecules independently of Mash1,
The zinc finger transcription factor GATA-3 is a master regulator of type 2 T helper cell development. Interestingly, in GATA-3/ mice, noradrenaline deficiency is a proximal cause of embryonic lethality suggesting that GATA-3 is involved in the specification of noradrenergic neurotransmitter phenotype during noradrenergic neuron development [23]. Forced expression of GATA-3 in primary neural crest stem cell (NCSC) culture and developing chick embryos demonstrated that GATA-3 is able to increase the number of sympathoadrenergic neurons among NCSC culture, and induce ectopic expression of noradrenergic marker genes (TH and DBH) in developing chick embryos [24]. Furthermore, both TH and DBH promoters are robustly transactivated by GATA-3 via specific upstream subdomains encompassing binding motifs for transcription factors CREB, Sp1, and AP4. Protein–protein interaction assays showed that GATA-3 is able to physically interact with these transcription factors in vitro as well as in vivo [25]. Taken together, it is likely that GATA3 plays a critical role for specification of the NA phenotype via novel and distinct protein-protein interactions in both CNS and ANS development.
AP2(Activator Protein 2)β AP2 is a retinoic acid-inducible and developmentally regulated transcription factor with the basic helix-span-helix domain recognizing the palindromic 5-GCCNNNGGC-3 motif or its related GC-rich sequences. AP-2 family has 5 members, AP-2α, AP-2β, AP-2γ, AP-2δ, and AP-2, which show different spatiotemporal expression patterns during development. Based on its expression pattern in the neural crest, it was assumed that AP-2α regulates differentiation of neural crest-derived cells. However, our recent works demonstrated that AP2β is expressed in sympathetic ganglia of developing chick and mouse embryos and facilitates sympathoadrenergic differentiation in neural crest stem cells, while AP2α dramatically increases melanocytes at the expense of sympathoadrenergic cells [26,27]. Lossof-function studies of AP2β/ mouse revealed that DBH expression was significantly reduced in sympathetic ganglia as well as LC, indicating distinctive roles in neural crest differentiation and noradrenergic neurotransmitter specification in both central and peripheral nervous systems. Furthermore, these studies showed that AP2β directly controls the epinephrine phenotype by activating the
I. INTRODUCTION
6
1. DEvElOPmENT AND DIffERENTIATION Of AUTONOmIC NEURONs
phenylethanolamine-N-methyl-transferase (PNMT) gene expression (Fig. 1.2).
Other Transcription Factors Although the above transcription factors are the most promising candidates, additional factors are emerging as being important for the ANS’ development and phenotype specification. For instance, dHand is another bHLH transcription factor whose expression is induced by BMPs and is dependent on Mash1. Based on its specific expression in sympathetic neurons, dHand may directly contribute to the ANS development. However, analysis of dHand function was hampered because knockout mice die before sympathetic neuron development. It is worthwhile to note that transcriptional regulation of the ANS and phenotype identity may require the combinatorial action of cell type-specific factors (e.g., Phox2a and 2b) and general transcription factors. Such examples may include cAMP response element binding protein and Sp1, which are required for transcriptional activity of both the TH and DBH genes (see below).
NEUROTRANSMITTER PHENOTYPES OF THE ANS Among the various phenotypes of a particular neuron, neurotransmitter identity is an essential feature because it determines the nature of the chemical neurotransmission a given neuron will mediate, and influences its specific connectivity with target cells. For specification of neurotransmitter identity, given neurons should express relevant genes encoding the biosynthetic enzymes and cofactors, as well as the specific reuptake protein(s). In addition, expression of these genes needs to be matched with the appropriate receptors of the target tissues. Therefore, expression of particular neurotransmitter phenotypes should be coordinated with the differentiation and phenotype specification of the target tissues. Recently, molecular mechanisms underlying the specification of neurotransmitters in the nervous system have been investigated extensively and key signaling molecules and transcriptional factors have been identified. Among these, specification of the noradrenaline (NA) phenotype of the sympathetic nervous system and the CNS is well characterized. Therefore, we will focus our discussion on the molecular characterization of the NA phenotype determination and its phenotypic switch to the cholinergic phenotype.
NA Phenotype NA is a major neurotransmitter of the ANS, especially in sympathetic neurons, and fundamentally mediates the function of the ANS. Consistent with this, a rare human disease called the dopamine β-hydroxylase deficient disease, in which NA is undetectable, was identified to be associated with severe autonomic function failure [28].
NA is one of the catecholamine neurotransmitters that are synthesized from tyrosine by three consecutive enzymatic steps. While tyrosine hydroxylase is responsible for the first step of catecholamine biosynthesis, converting tyrosine to L-dopa, and is expressed in all catecholamine neurons, dopamine β-hydroxylase (DBH) is responsible for conversion of dopamine to NA and is specifically expressed in NA neurons. Thus, DBH is a hallmark protein of NA neurons and the control mechanism of its expression is an essential feature of the development of NA neurons.
Control Mechanism of DBH Gene Expression is Closely Related to the ANS Development Numerous investigators using both in vivo transgenic mouse approaches and in vitro cell culture systems have studied DBH gene regulation. As schematically summarized in Figure 1.3, the 5 1.1 kb region upstream of the DBH gene promoter has three functional domains that can drive reporter gene expression in a NA cell type-specific manner. More detailed deletional and sitedirected mutational analyses indicate that as little as 486 bp of the upstream sequence of the human DBH gene can direct expression of a reporter gene in a cell-specific manner [29]. While the distal region spanning 486 to 263 bp appears to have a cell-specific silencer function, the proximal part spanning 262 to 1 bp is essential for high-level and cell-specific DBH promoter activity. In this 262 bp proximal area, four protein-binding regions (domains I to IV), initially identified by DNase I footprinting analysis, were found to encompass functionally important, multiple cis-regulatory elements [29], including the cAMP response element (CRE), YY1, AP2, Sp1, and core motifs of homeodomain (HD) binding sites. Site-directed mutagenesis of each sequence motif has revealed that these multiple cis-acting elements synergistically and/ or co-operatively regulate the transcriptional activity of the DBH gene [16]. Among these, two ATTA-containing motifs in domain IV and another motif in domain II were identified to be NA-specific cis-acting motifs in that their mutation diminished the DBH promoter function only in NA cell lines. More recently, another NA-specific cisregulatory element was identified between domain II and III (Fig. 1.3). Interestingly, analysis of DNA-protein interactions on the DBH promoter demonstrated that all of these four NA-specific cis-regulatory elements are Phox2binding sites [15]. Taken together, this experimental evidence establishes that the DBH gene is an immediate downstream target of Phox2 proteins.
Mutations of DBH Gene are Closely Associated with the Autonomic Disorder, Orthostatic Hypotension DBH deficiency is a rare congenital disorder, first described in 1986 [28,30]. DBH deficiency is a severe autonomic disorder exhibiting sympathetic noradrenergic
I. INTRODUCTION
NEUROTRANsmITTER PHENOTyPEs Of THE ANs DBH deficiency
Normal
nucleus
nucleus
ER X
L-tyrosine
L-tyrosine
L-DOPA
L-DOPA
dopamine
dopamine
Golgi
LDCV
FIGURE 1.3 Effects of pathogenic mutations on DBH synthesis and trafficking. In normal, DBH enzymes (circle) are translated in the ER, transported to the Golgi, and then packaged into the LDCVs. In LDCV, DBH converts dopamine (triangle) to noradrenaline (rectangle). Noradrenaline are released by exocytosis upon stimulation of the nerve terminal and readily detectable in plasma. In DBH deficiency, DBH proteins (S-shape) encoded by missense mutations are retained in the ER and fail to be targeted to the LDCV due to their misfolding. As the result, noradrenaline is not synthesized in LDCV, leading to absence of noradrenaline in plasma. Instead, dopamine is dramatically increased.
failure and adrenomedullary failure but intact vagal and sympathetic cholinergic function [31]. DBH deficient patients exhibit severe deficits in autonomic regulation of cardiovascular function predisposing them to orthostatic hypotension. These patients display characteristic perturbations in the level of catecholamines: undetectable noradrenaline and its metabolites, and highly elevated dopamine and its metabolites. Given the fundamental role of noradrenaline in the nervous system, the report of adult patients with undetectable noradrenaline is both surprising and interesting. The report of frequent miscarriages and spontaneous abortions in mothers of known DBH deficiency cases suggests the interesting possibility that there could be many more undiagnosed fetal and neonatal deaths resulting from DBH deficiency and that those adult patients are lucky survivors [30]. In line with this, a DBH knock out mouse study showed less than 5% live births [32]. Mortality appeared to be due to cardiovascular failure caused by DBH deficiency in utero, which is reminiscent of tyrosine hydroxylase null mice. We, and others, have recently reported a mutation in the splice donor site of the first exon-intron junction and several missense mutations associated with the DBH deficiency syndrome in the DBH gene of these patients [33–35]. The mutation in the splice donor site (IVS1 2T→C) of DBH resulted in abnormal mRNA splicing and generated a transcript containing a premature stop codon as well as
7
a normal transcript. Interestingly, all missense mutations so far identified in DBH deficient patients are subtle amino acid substitutions resulting in defective protein trafficking and mislocation, probably due to protein misfolding (Fig. 1.3) [35]. One of the well-known chemical chaperones, glycerol, could partially rescue defective secretion of DBH mutant proteins, suggesting the possibility that DBH deficiency disease could be more fundamentally treated with pharmacological chaperones [35].
Cholinergic Phenotype and the Switch of Neurotransmitter Phenotypes by Target Cell Interactions Another major neurotransmitter of the ANS is acetylcholine, and neurons generating this neurotransmitter are designated cholinergic. Among sympathetic neurons, the number of cholinergic neurons is much less than NA neurons. While differentiation and cholinergic specification are extensively investigated in central motor neurons [4], development of cholinergic ANS neurons is not well characterized. Therefore, it is of great interest to understand if key transcription factors such as HB9 and MNR2, likewise play key roles in determining the cholinergic phenotype during development of the ANS. Interestingly, it is well described that upon contacting developing sweat glands, the NA phenotype of sympathetic axons switches to the cholinergic phenotype [10]. The putative cholinergic-inducing factor secreted from sweat glands remains to be defined although leukemia inhibitory factor and ciliary neurotrophic factor are candidates. Consistent with the observation that TH and DBH expression remains even after neurotransmitter switch from the NA to the cholinergic phenotype, a recent study reported that levels of the TH cofactor, tetrahydrobiopterin (BH4), dropped significantly during the switch [36]. Immunoreactivity for the BH4-synthesizing GTP cyclohydrolase became undetectable in sweat gland neurons during this phenotypic switch, suggesting that suppression of cofactor expression underlies the neurotransmitter switch during development.
Acknowledgements This work was supported by NIH grants (MH048866, MH087903, and NS070577).
References [1] Liem Jr KF, Tremml G, Roelink H, Jessell TM. Dorsal differentiation of neural plate cells induced by BMP-mediated signals from epidermal ectoderm. Cell 1995;82:969–79. [2] Sauka-Spengler T, Bronner-Fraser M. A gene regulatory network orchestrates neural crest formation. Nat Rev Mol Cell Biol 2008;9:557–68. [3] Christiansen JH, Coles EG, Wilkinson DG. Molecular control of neural crest formation, migration and differentiation. Curr Opin Cell Biol 2000;12:719–24.
I. INTRODUCTION
8
1. DEvElOPmENT AND DIffERENTIATION Of AUTONOmIC NEURONs
[4] Edlund T, Jessell TM. Progression from extrinsic to intrinsic signaling in cell fate specification: a view from the nervous system. Cell 1999;96:211–24. [5] Wilson SI, Rydstrom A, Trimborn T, Willert K, Nusse R, et al. The status of Wnt signalling regulates neural and epidermal fates in the chick embryo. Nature 2001;411:325–30. [6] Stern CD, Artinger KB, Bronner-Fraser M. Tissue interactions affecting the migration and differentiation of neural crest cells in the chick embryo. Development 1991;113:207–16. [7] Ernsberger U, Rohrer H. The development of the noradrenergic transmitter phenotype in postganglionic sympathetic neurons. Neurochem Res 1996;21:823–9. [8] Schneider C, Wicht H, Enderich J, Wegner M, Rohrer H. Bone morphogenetic proteins are required in vivo for the generation of sympathetic neurons. Neuron 1999;24:861–70. [9] Bilodeau ML, Boulineau T, Hullinger RL, Andrisani OM. Cyclic AMP signaling functions as a bimodal switch in sympathoadrenal cell development in cultured primary neural crest cells. Mol Cell Biol 2000;20:3004–14. [10] Francis NJ, Landis SC. Cellular and molecular determinants of sympathetic neuron development. Annu Rev Neurosci 1999;22:541–66. [11] Taraviras S, Pachnis V. Development of the mammalian enteric nervous system. Curr Opin Genet Dev 1999;9:321–7. [12] Goridis C, Brunet JF. Transcriptional control of neurotransmitter phenotype. Curr Opin Neurobiol 1999;9:47–53. [13] Goridis C, Rohrer H. Specification of catecholaminergic and serotonergic neurons. Nat Rev Neurosci 2002;3:531–41. [14] Guillemot F, Lo LC, Johnson JE, Auerbach A, Anderson DJ, et al. Mammalian achaete-scute homolog 1 is required for the early development of olfactory and autonomic neurons. Cell 1993;75:463–76. [15] Seo H, Hong SJ, Guo S, Kim HS, Kim CH, et al. A direct role of the homeodomain proteins Phox2a/2b in noradrenaline neurotransmitter identity determination. J Neurochem 2002;80:905–16. [16] Kim HS, Seo H, Yang C, Brunet JF, Kim KS. Noradrenergic-specific transcription of the dopamine beta-hydroxylase gene requires synergy of multiple cis-acting elements including at least two Phox2abinding sites. J Neurosci 1998;18:8247–60. [17] Yang C, Kim HS, Seo H, Kim CH, Brunet JF, et al. Paired-like homeodomain proteins, Phox2a and Phox2b, are responsible for noradrenergic cell-specific transcription of the dopamine betahydroxylase gene. J Neurochem 1998;71:1813–26. [18] Hirsch MR, Tiveron MC, Guillemot F, Brunet JF, Goridis C. Control of noradrenergic differentiation and Phox2a expression by MASH1 in the central and peripheral nervous system. Development 1998;125:599–608. [19] Brunet JF, Pattyn A. Phox2 genes - from patterning to connectivity. Curr Opin Genet Dev 2002;12:435–40. [20] Morin X, Cremer H, Hirsch MR, Kapur RP, Goridis C, et al. Defects in sensory and autonomic ganglia and absence of locus coeruleus in mice deficient for the homeobox gene Phox2a. Neuron 1997;18:411–23. [21] Pattyn A, Goridis C, Brunet JF. Specification of the central noradrenergic phenotype by the homeobox gene Phox2b. Mol Cell Neurosci 2000;15:235–43.
[22] Stanke M, Junghans D, Geissen M, Goridis C, Ernsberger U, et al. The Phox2 homeodomain proteins are sufficient to promote the development of sympathetic neurons. Development 1999;126:4087–94. [23] Lim KC, Lakshmanan G, Crawford SE, Gu Y, Grosveld F, et al. Gata3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system. Nat Genet 2000;25:209–12. [24] Hong SJ, Huh Y, Chae H, Hong S, Lardaro T, et al. GATA-3 regulates the transcriptional activity of tyrosine hydroxylase by interacting with CREB. J Neurochem 2006;98:773–81. [25] Hong SJ, Choi HJ, Hong S, Huh Y, Chae H, et al. Transcription factor GATA-3 regulates the transcriptional activity of dopamine betahydroxylase by interacting with Sp1 and AP4. Neurochem Res 2008;33:1821–31. [26] Hong SJ, Lardaro T, Oh MS, Huh Y, Ding Y, et al. Regulation of the noradrenaline neurotransmitter phenotype by the transcription factor AP-2beta. J Biol Chem 2008;283:16860–16867. [27] Hong SJ, Huh YH, Leung A, Choi HJ, Ding Y, et al. Transcription factor AP-2b regulates the neurotransmitter phenotype and maturation of chromaffin cells. Mol Cell Neurosci 2011;46:245–51. [28] Robertson D, Goldberg MR, Onrot J, Hollister AS, Wiley R, et al. Isolated failure of autonomic noradrenergic neurotransmission. Evidence for impaired beta-hydroxylation of dopamine. N Engl J Med 1986;314:1494–7. [29] Seo H, Yang C, Kim HS, Kim KS. Multiple protein factors interact with the cis-regulatory elements of the proximal promoter in a cellspecific manner and regulate transcription of the dopamine betahydroxylase gene. J Neurosci 1996;16:4102–12. [30] Man in’t Veld AJ,, Boomsma F, Moleman P, Schalekamp MA. Congenital dopamine-beta-hydroxylase deficiency. A novel orthostatic syndrome. Lancet 1987;1:183–8. [31] Biaggioni I, Goldstein DS, Atkinson T, Robertson D. Dopaminebeta-hydroxylase deficiency in humans. Neurology 1990;40:370–3. [32] Thomas SA, Matsumoto AM, Palmiter RD. Noradrenaline is essential for mouse fetal development. Nature 1995;374:643–6. [33] Kim CH, Zabetian CP, Cubells JF, Cho S, Biaggioni I, et al. Mutations in the dopamine beta-hydroxylase gene are associated with human norepinephrine deficiency. Am J Med Genet 2002;108:140–7. [34] Deinum J, Steenbergen-Spanjers GC, Jansen M, Boomsma F, Lenders JW, et al. DBH gene variants that cause low plasma dopamine beta hydroxylase with or without a severe orthostatic syndrome. J Med Genet 2004;41:e38. [35] Kim CH, Leung A, Huh YH, Yang E, Kim DJ, et al. Norepinephrine deficiency is caused by combined abnormal mRNA processing and defective protein trafficking of dopamine b-hydroxylase. J Biol Chem 2011;286:9196–9204. [36] Habecker BA, Klein MG, Sundgren NC, Li W, Woodward WR. Developmental regulation of neurotransmitter phenotype through tetrahydrobiopterin. J Neurosci 2002;22:9445–52.
I. INTRODUCTION
C H A P T E R
2 Central Autonomic Control Eduardo E. Benarroch Central control of the sympathetic and parasympathetic outputs involves several interconnected areas distributed throughout the neuraxis. This central autonomic network has a critical role in moment-to-moment control of visceral function, homeostasis, and adaptation to internal or external challenges. The functions of the central autonomic network are organized in four hierarchical levels that are closely interconnected: spinal, bulbopontine, pontomesencephalic and forebrain levels (Fig. 2.1). The spinal level mediates segmental sympathetic or sacral parasympathetic reflexes and is engaged in stimulus-specific patterned responses under the influence of the other levels. The bulbopontine (lower brainstem) level is involved in reflex control of circulation, respiration, gastrointestinal function, and micturition. The pontomesencephalic (upper brainstem) level integrates autonomic control with pain modulation and integrated behavioral responses to stress. The forebrain level includes the hypothalamus, which is involved in integrated control of autonomic and endocrine responses for homeostasis and adaptation, and components of the anterior limbic circuit, including the insula, anterior cingulate cortex, and amygdala, which are involved in integration of bodily sensation with emotional and goal-related autonomic responses.
sympathetic and parasympathetic outputs, primarily via a relay in the lateral hypothalamus [4,5].
Anterior Cingulate Cortex The anterior cingulate cortex is interconnected with the anterior insula and is subdivided into ventral (affective) and dorsal (cognitive) regions [6]. The ventral anterior cingulate is part of the brain “default mode network” whereas the dorsal anterior cingulate is a component of the frontoparietal attention networks. The ventral anterior cingulate cortex includes subcallosal and precallosal portions that have extensive connections with the insula, prefrontal cortex, amygdala, hypothalamus, and brain stem. Via these projections, the anterior cingulate cortex controls sympathetic and parasympathetic functions [7].
Amygdala The amygdala provides affective or emotional value to incoming sensory information [8] and has multiple downstream targets that participate in the autonomic and neuroendocrine response to stress [9]. The central nucleus of the amygdala (CeA), both directly and via the bed nucleus of the stria terminalis, has a major role in integration of the stress responses, particularly fear responses, via its widespread connections with the hypothalamus and brainstem, particularly the periaqueductal gray and the medullary reticular formation [10].
FOREBRAIN COMPONENTS The forebrain regions involved in the control of autonomic functions include the insular cortex, anterior cingulate cortex, amygdala, and several areas of the hypothalamus.
Hypothalamus The hypothalamus integrates autonomic and endocrine responses necessary for homeostasis and adaptation. It acts as a visceromotor pattern generator that initiates specific patterns of autonomic and endocrine responses according to the stimulus, such as hypoglycemia, changes in blood temperature or osmolarity, or external stressors [2,11]. The preoptic-hypothalamic area is functionally subdivided into three functional zones, periventricular, medial, and lateral [11]: The periventricular zone includes the suprachiasmatic nucleus (the circadian pacemaker), and several areas involved in neuroendocrine control via the pituitary gland. The medial zone includes the medial
Insular Cortex The insular cortex is the primary interoceptive cortex and integrates visceral, pain and temperature sensations [1,2]. The dorsal insula has a viscerotropic organization [3] and receives inputs from gustatory, visceral, muscle, and skin receptors via the thalamus. The dorsal insula projects to the right anterior insula, which, via its connections with neocortical association and limbic areas, integrates these interoceptive inputs with emotional and cognitive processing to conveys the conscious experience of bodily sensation [1]. The insula is also a visceromotor area controlling both the
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00002-0
9
© 2012 Elsevier Inc. All rights reserved.
10
2. CEnTRAl AuTonomIC ConTRol
FIGURE 2.1 Central autonomic control areas and levels of interaction of autonomic control.
preoptic area, paraventricular nucleus (PVN) and dorsomedial nucleus (DMH), which orchestrate coordinated autonomic and endocrine outputs for thermoregulation, osmoregulation, and stress responses [11–14]. The lateral zone includes nuclei that control sleep, arousal and motivated behavior [2]. The main autonomic outputs of the hypothalamus originate from the PVN, DMH, and lateral hypothalamic area [2]. The PVN contains different neuronal populations that are differentially activated during stress responses [12]. They include magnocellular neurons that release arginine-vasopressin (AVP) to the general circulation; neurons that release corticotropin releasing hormone and activate the adrenocortical axis, and neurons that project to autonomic nuclei of the brainstem and spinal cord [12]. Via these outputs, the PVN modulates stress responses, food and sodium intake, glucose metabolism, and cardiovascular, renal, gastrointestinal, and respiratory functions. The DMH participates in stress responses [13]; thermoregulation [14,15] and cardiovascular control [16].
Hypocretin/orexin neurons of the posterior lateral hypothalamus contribute to control autonomic output in the setting of arousal, feeding and reward driven behaviors [2].
BRAINSTEM COMPONENTS The brainstem areas controlling autonomic output include the periaqueductal gray matter of the midbrain (PAG), the parabrachial nucleus (PBN) and several medullary regions, including the nucleus of the solitary tract (NTS), ventrolateral reticular formation of the medulla, and medullary raphe (Fig. 2.1).
Periaqueductal Gray The PAG is the interface between the forebrain and the lower brain stem and has a major role in integrated autonomic and somatic responses to stress, pain modulation,
I. INTRODUCTION
AuTonomIC ouTPuT of THE CEnTRAl nERvous sysTEm
and other adaptive functions. It consists of different longitudinal columns that, via their different spinal, brainstem, and cortical connections, participate in cardiovascular responses associated with pain modulation [17]; coordination of the micturition reflex [18]; and control of respiration.
Parabrachial Complex and Adjacent Regions of the Pons The PBN is a major relay center that receives converging visceral, nociceptive and thermoreceptive inputs from the spinal cord and conveys this information to the hypothalamus, amygdala, and thalamus [2]. The PBN also participates in the control of respiratory, cardiovascular, and gastrointestinal functions. The dorsal pontine tegmentum also contains the pontine micturition center (PMC), also referred to as Barrington nucleus or M- (for medial) region, which is critical for the coordination of the micturition reflex and participates in the control of the function of the lower gastrointestinal tract and sexual organs [18].
Nucleus of the Solitary Tract The NTS is the first relay station of taste and visceral afferent information and includes several subnuclei with a viscerotropic organization. The rostral portion of the NTS receives taste inputs; the intermediate portion receives gastrointestinal afferents; and the caudal portion receives baroreceptor, cardiac, chemoreceptor, and pulmonary afferents [19]. The NTS relays this information, either directly or via the PBN, to rostral brainstem and forebrain areas [2,3]. The NTS is also the first central relay for all medullary reflexes controlling cardiovascular function (baroreflex and cardiac reflexes) [20], respiration (carotid chemoreflex and pulmonary mechanoreflexes), and gastrointestinal motility [21].
Rostral Ventrolateral Medulla The rostral ventrolateral medulla (RVLM), including the C1 group of epinephrine-containing neurons, is a key area for regulation of arterial blood pressure [20,21]. Glutamatergic neurons of the RVLM project directly and provide tonic excitation to sympathetic preganglionic neurons controlling cardiac output and total peripheral resistance [15]. The RVLM mediates all reflexes controlling arterial blood pressure, including the baroreflex, cardiopulmonary reflexes, and chemoreflexes [20,22]. The sympathoexcitatory RVLM neurons receive and integrate a large variety of inputs from the brainstem and forebrain [22]. These include inhibitory signals from baroreceptorsensitive neurons of the NTS and mediated via inhibitory gamma-aminobutyric acid (GABA) ergic neurons of the caudal ventrolateral medulla [22]. The RVLM also receives several inputs from the hypothalamus, including the PVN.
11
Caudal Ventrolateral Medulla The caudal ventrolateral medulla contains GABAergic neurons that maintain a tonic inhibitory control on the RVLM and relay the inhibitory inputs from the NTS mediating the sympathoinhibitory component of the arterial baroreflex. Electrical stimulation studies indicate that the caudal medulla also contains pressor regions [23]. The caudal ventrolateral medulla also contains the A1 group of neurons that provide noradrenergic innervation to the hypothalamus and are a component of a reflex pathway that triggers AVP release in response to hypovolemia or hypotension [24].
Ventromedial Medulla and Caudal Raphe The rostral ventromedial medulla including the caudal raphe nuclei, has an important role in thermoregulation [15] pain modulation [17], and control of automatic ventilation [25]. One group of medullary raphe neurons initiate sympathetic responses to cold via input to preganglionic sympathetic neurons that activate skin vasoconstriction and non-shivering thermogenesis in the brown adipose tissue [26].
AUTONOMIC OUTPUT OF THE CENTRAL NERVOUS SYSTEM Sympathetic Preganglionic Units The sympathetic output is critical for maintenance of arterial pressure, thermoregulation, and redistribution of regional blood flow during stress and exercise. The sympathetic output originates from sympathetic preganglionic neurons located in the thoracolumbar spinal cord at the T1 to -L2 segments, primarily in the intermediolateral cell column. These neurons are organized into functionally separate units that innervate selective subpopulations of sympathetic ganglion neurons and receive distinct segmental afferent inputs triggering segmental somato- and viscerosympathetic reflexes [27]. Different preganglionic sympathetic units are recruited in a coordinated fashion by premotor neurons in the brainstem and hypothalamus to initiate different patterns of responses to specific internal or external stressors, such as postural changes, exercise, hypoglycemia, dehydration, exposure to heat or cold, or stress [2]. The main sources of premotor sympathetic innervation are the RVLM, medullary raphe, A5 noradrenergic group of the pons; PVN, and lateral hypothalamic area [4,28].
Parasympathetic Outputs In contrast to the sympathetic system, which mediates stimulus-specific patterns of responses affecting multiple effectors; the parasympathetic system mediates reflexes activated in an organ-specific fashion.
I. INTRODUCTION
12
2. CEnTRAl AuTonomIC ConTRol
Vagal Output The vagal output originates from preganglionic neurons located in the dorsal motor nucleus of the vagus (DMV) and in the ventrolateral portion of the nucleus ambiguus (NAmb) in the medulla. The DMV contains most of the vagal preganglionic parasympathetic neurons that are organized in a viscerotropic fashion [29] and innervate the local ganglia in the respiratory tract, enteric nervous system (ENS), liver and pancreas. The DMV receives inputs from the NTS and mediates all vago-vagal reflexes controlling gastrointestinal motility and secretion [21]. Vagal preganglionic neurons located in the ventrolateral portion of the NAmb provide the primary control of the heart via the cardiac ganglia [30]. These cardiovagal outputs inhibit the automatism of the sinoatrial node exerting a beat-to-beat control of the heart rate. The cardiovagal NAMb neurons are activated by the NTS during the baroreflex and are inhibited during inspiration. Sacral Parasympathetic Output The sacral preganglionic output originates in neurons located in the lateral gray matter at the S2-S4 segments of the sacral spinal cord [31]. These neurons are critical for normal micturition, defecation, and sexual organs; this involves their coordinated interactions with both lumbar sympathetic neurons located at T12-L2 levels and somatic motor neurons of the Onuf nucleus at the S2-S4 levels innervating the external urinary sphincter and pelvic floor.
References [1] Craig AD. Interoception: the sense of the physiological condition of the body. Curr Opin Neurobiol 2003;13:500–5. [2] Saper CB. The central autonomic nervous system: conscious visceral perception and autonomic pattern generation. Annu Rev Neurosci 2002;25:433–69. [3] Cechetto DF. Central representation of visceral function. Fed Proc 1987;46:17–23. [4] Loewy AD. Descending pathways to the sympathetic preganglionic neurons. Prog Brain Res 1982;57:267–77. [5] Westerhaus MJ, Loewy AD. Central representation of the sympathetic nervous system. 2001 [6] Vogt BA, Vogt L, Farber NB, Bash E, et al. Architecture and neurocytology of monkey cingulate gyrus. J Comp Neurol 2005;485:218–39. [7] Verberne AJ, Owens NC. Cortical modulation of the cardiovascular system. Prog Neurobiol 1998;54:149–68. [8] LeDoux J. The amygdala. Curr Biol 2007;17:R868–874. [9] Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci 2009;10:397–409. [10] Davis M. The role of the amygdala in fear and anxiety. Annu Rev Neurosci 1992;15:353–75. [11] Thompson RH, Swanson LW. Structural characterization of a hypothalamic visceromotor pattern generator network. Brain Res Brain Res Rev 2003;41:153–202.
[12] Sawchenko PE, Li HY, Ericsson A. Circuits and mechanisms governing hypothalamic responses to stress: a tale of two paradigms. Prog Brain Res 2000;122:61–78. [13] Dimicco JA, Zaretsky DV. The dorsomedial hypothalamus: a new player in thermoregulation. Am. J Physiol Regul Integr Comp Physiol 2007;292:R47–63. [14] Yoshida K, Li X, Cano G, et al. Parallel preoptic pathways for thermoregulation. J Neurosci 2009;29:11954–11964. [15] Morrison SF. RVLM and raphe differentially regulate sympathetic outflows to splanchnic and brown adipose tissue. Am J Physiol 1999;276:R962–973. [16] Dampney RA, Horiuchi J, McDowall LM. Hypothalamic mechanisms coordinating cardiorespiratory function during exercise and defensive behavior. Auton Neurosci 2008. [17] Bandler R, Keay KA, Floyd N, et al. Central circuits mediating patterned autonomic activity during active vs. passive emotional coping. Brain Res Bull 2000;53:95–104. [18] Holstege G. Micturition and the soul. J Comp Neurol 2005;493:15–20. [19] Jean A. The nucleus tractus solitarius: neuroanatomic, neurochemical and functional aspects. Arch Int Physiol Biochim Biophys 1991;99:A3–52. [20] Dampney RA, Horiuchi J. Functional organisation of central cardiovascular pathways: studies using c-fos gene expression. Prog Neurobiol 2003;71:359–84. [21] Travagli RA, Hermann GE, Browning KN, Rogers C, et al. Brainstem circuits regulating gastric function. Annu Rev Physiol 2006;68:279–305. [22] Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci 2006;7:335–46. [23] Goodchild AK, Moon EA. Maps of cardiovascular and respiratory regions of rat ventral medulla: focus on the caudal medulla. J Chem Neuroanat 2009;38:209–21. [24] Lightman SL, Todd K, Everitt BJ. Ascending noradrenergic projections from the brainstem: evidence for a major role in the regulation of blood pressure and vasopressin secretion. Exp Brain Res 1984;55:145–51. [25] Corcoran AE, Hodges MR, Wu Y, Wang W, Wylie CJ, Deneris ES, Richerson S, et al. Medullary serotonin neurons and central CO2 chemoreception. Respir. Physiol Neurobiol 2009;168:49–58. [26] Morrison SF, Nakamura K, Madden CJ. Central control of thermogenesis in mammals. Exp Physiol 2008;93:773–97. [27] Janig W, Habler HJ. Neurophysiological analysis of target-related sympathetic pathways – from animal to human: similarities and differences. Acta Physiol Scand 2003;177:255–74. [28] Strack AM, Sawyer WB, Hughes JH, Platt KB, Lavey AD, et al. A general pattern of CNS innervation of the sympathetic outflow demonstrated by transneuronal pseudorabies viral infections. Brain Res. 1989;491:156–62. [29] Huang XF, Tork I, Paxinos G. Dorsal motor nucleus of the vagus nerve: a cyto- and chemoarchitectonic study in the human. J Comp Neurol 1993;330:158–82. [30] Hopkins DA, Armour JA. Brainstem cells of origin of physiologically identified cardiopulmonary nerves in the rhesus monkey (Macaca mulatta). J Auton Nerv Syst 1998;68:21–32. [31] Birder L, de Groat W, Mills I, Morrison J, Thor K, Drake M, et al. Neural control of the lower urinary tract: peripheral and spinal mechanisms. Neurourol Urodyn 29:128–39.
I. INTRODUCTION
C H A P T E R
3 Imaging of Brainstem Sites Involved in Cardiovascular Control Vaughan G. Macefield, Luke A. Henderson The medulla is phylogenetically the oldest structure of the brain, containing dense clusters of neurons (nuclei) that coordinate many homeostatically critical functions, such as respiration, heart rate and blood pressure. Much of what we know of the functions of the medulla we have learnt from experiments in anesthetized or decerebrate animals. And, although its small size makes it difficult to study its function in awake humans, it is possible to use non-invasive neuroimaging approaches to delineate some of its nuclei. We shall limit our discussion to the control of arterial pressure, in which most of the work has been carried out. The maintenance of blood pressure within a relatively narrow physiological range is essential to ensure adequate perfusion of vital organs such as the brain. A primary determinant of arterial pressure is the level of sympathetically-mediated vasoconstriction within skeletal muscle. Muscle sympathetic nerve activity (MSNA) occurs as pulse-synchronous bursts, the incidence and magnitude of which are inversely correlated to diastolic pressure. The beat-to-beat control of arterial pressure is governed by the baroreflex – a classic negative-feedback loop in which increases in blood pressure, detected by the arterial baroreceptors (located in the carotid sinus and aortic arch), are corrected by withdrawal of muscle vasoconstrictor drive as well as decreases in heart rate and stroke volume. This short-term regulation of blood pressure survives removal of structures rostral to the medulla yet is abolished by transection of the spinal cord immediately below the medulla, indicating that the medulla contains structures critical for the generation and maintenance of vasomotor tone.
produce increases in activity in cutaneous sympathetic neurons yet no increase in blood pressure [1]. It is known from intracellular recordings from RVLM neurons that they exhibit an irregular tonic firing that decreases with increases in blood pressure and increases with decreases in blood pressure; it is also known that this tonic activity is modified by excitatory and inhibitory inputs, but that in the absence of such inputs this tonic activity continues [2]. The current understanding of the baroreflex circuitry defined primarily in anesthetized animal preparations – is that primary afferent axons from the baroreceptors project to the caudal region of the nucleus tractus solitarius (NTS), where they synapse onto second-order neurons, which in turn send excitatory (glutamatergic) projections onto GABAregic neurons within the region of the caudal ventrolateral medulla (CVLM). These CVLM GABAergic neurons synapse directly onto excitatory neurons within the RVLM and serve to inhibit the spontaneous activity of RVLM premotor sympathetic neurons. Nucleus ambiguus and the dorsal motor nucleus of the vagus also receive glutamatergic projections from NTS [3], activating vagal cardiac efferents and slowing the heart. In addition to these components of the basic baroreflex arc, it is known that other brainstem regions, such as the caudal pressor area (CPA), located in the most caudal part of the ventrolateral medulla, can also influence baroreflex activity by altering the activity in these baroreflex medullary nuclei [2]. Studies in conscious animals, using c-fos expression as a marker of neuronal activation, have confirmed the operation of the NTS-CVLM-RVLM serial pathway during maneuvers that increase or decrease arterial pressure [4,5].
IDENTIFICATION OF MEDULLARY CARDIOVASCULAR NUCLEI IN EXPERIMENTAL ANIMALS
IDENTIFICATION OF MEDULLARY CARDIOVASCULAR NUCLEI IN HUMANS
The circuitry responsible for the baroreflex has been examined in detail in anesthetized experimental animals. Early work had shown that excitation within discrete regions of the rostral ventrolateral medulla (RVLM) could activate muscle vasoconstrictor neurons and increase blood pressure, while activation within other areas could
Non-invasive neuroimaging has become a powerful tool in defining the functions of various regions in the human brain, but relatively little work has been done in cardiovascular control (for review see [6]). Most of the recent studies in this area use functional magnetic resonance imaging (fMRI), in which changes in blood-oxygen
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00003-2
13
© 2012 Elsevier Inc. All rights reserved.
14
3. ImAgIng of BRAInSTEm SITES InvolvEd In CARdIovASCulAR ConTRol
FIGURE 3.1 Significant BOLD signal intensity changes in the medulla and cerebellum, obtained from the brainstem-specific scans (n 15) overlaid onto an average T2-weighted anatomical image set. Ventral is at the base of each image. The hot and cool color scales (coded for t-value) indicate regional signal increases and decreases, respectively. Slice positions (MNI space) are indicted in the top right of each image. To the right are three graphs showing the mean (SEM) percent changes in signal intensity (SI) over time for three significant clusters. Vertical grey boxes indicate each of the three inspiratory-capacity apnea periods. From Macefield et al. (2006) [8].
level dependent (BOLD) signal intensity are used as a proxy marker of neuronal activity: increases in signal intensity reflect increases in neuronal activity, while decreases reflect deactivations. Such approaches have been used in the anesthetized cat to identify changes in signal intensity within the medullary regions described above [7], but relatively few studies have applied fMRI to investigate the role of the brainstem in human cardiovascular control. One of the first investigations to do so used the Valsalva maneuver – a forced expiratory effort which evokes a stereotypical pattern of autonomic changes. The virtue in using this maneuver is that the changes in heart rate and arterial pressure are well known, with the increase in arterial pressure being brought about by an increase in muscle sympathetic nerve activity (MSNA). Significant changes in BOLD signal intensity occurred in the amygdala, hippocampus, insular and lateral frontal cortices, as well as in the dorsal pons, dorsal medulla, lentiform nucleus, and fastigial and dentate nuclei of the cerebellum [7]. This was one of the first studies to have attempted to identify the functional roles of the human brainstem in autonomic control, but the fact that the Valsalva maneuver is a complex, volitionally generated task makes it difficult to tease out elements related to motor planning, execution, sensory feedback and autonomic changes. A simpler maneuver, the inspiratory-capacity apnea – a maximal inspiratory
FIGURE 3.2 Left panel, axial sections of the brainstem during a series of inspiratory-capacity apneas, showing bilateral activation of the dorsolateral medulla. Data from Macefield et al. (2006) [8]. Right panel, axial sections of the human brainstem showing a high density of AngII binding in RVLM. Data reproduced with permission from Allen et al. (1988) [9]. See color plate at back of the book.
breath-hold – evokes a sustained increase in MSNA that is believed to be due primarily to unloading of the low-pressure baroreceptors. During the static phase of the maneuver, in which the inspiratory pump muscles are quiescent and only the laryngeal constrictors are active, intrathoracic pressure changes because of the elastic recoil of the lungs and chest wall against the closed glottis. This is different to the Valsalva maneuver, in which the diaphragm, abdominal and intercostal muscles are co-activated in a sustained effort that increases intra-abdominal and intrathoracic pressures. Like the Valsalva maneuver,
I. INTRODUCTION
IdEnTIfICATIon of mEdullARy CARdIovASCulAR nuClEI In HumAnS
15
FIGURE 3.3 Significant increases (warm color scale) and decreases (cool color scale) in BOL1D signal intensity within the brainstem correlated with MSNA total burst activity in the resting state; raw fMRI data from seven experiments. Equivalent histological sections are shown on the right. Figure from Macefield and Henderson (2010) [12].
the inspiratory-capacity apnea evokes discrete changes in BOLD signal intensity over multiple brain regions. Significant increases in BOLD signal intensity occur bilaterally in the lateral prefrontal cortex, anterior insular cortex, anterior cingulate cortex, dorsomedial hypothalamus and deep cerebellar nuclei; decreases in signal intensity occur in the hippocampus, posterior cingulate cortex and the cerebellar cortex [8]. As shown in the sagital and axial sections of the human brainstem in Figure 3.1, bilateral increases in activity also occur in the rostral lateral medulla, with decreases occurring in the dorsomedial and caudal lateral medulla. We believe the increases in the rostral lateral medulla reflect increases in activity of the RVLM. In humans, the RVLM and CVLM are displaced dorsally by the large inferior olivary nuclei [9]. The functional and anatomical localization of the human RVLM is illustrated in Figure 3.2: the left panel shows a bilateral increase in signal intensity during a maximal inspiratory breath-hold; the right panel shows the anatomical identification of the human RVLM, based on histochemical identification [9]. While McAllen and colleagues have functionally identified the medullary raphé nucleus during whole-body cooling [10], until recently no human fMRI studies had functionally identified NTS. As indicated in the right panel of Figure 3.2, the solitary tract nucleus is located dorsal and medial to the RVLM. We believe the decreases in signal intensity in the dorsomedial medulla reflect decreases in NTS, with the decreases in the caudal lateral medulla reflecting
decreases in neuronal activity in the CVLM. These responses can be explained by (i) the reduction of baroreceptor inputs to the NTS; (ii) a consequent reduction in activity of CVLM; and hence (iii) a reduction in inhibitory drive to the RVLM. The withdrawal of inhibitory drive to RVLM then allows this nucleus to increase its activity and thereby bring about an increase in MSNA. Sustained increases in MSNA can also be induced by static handgrip exercise and post-exercise ischemia: accumulation of the metabolites of contraction activates metaboreceptors within the muscle and induces a reflex increase in MSNA and arterial pressure. It is known that metaboreceptors project to the NTS, which sends excitatory projections to the RVLM without an intervening inhibitory synapse: increases in BOLD signal intensity occurred in discrete regions of the human medulla corresponding to the NTS and RVLM, but did not include CVLM [11]. A recent development has been concurrent microneurography and fMRI. By recording spontaneous bursts of MSNA and correlating these to spontaneous fluctuations in BOLD signal intensity it has been possible to functionally identify regions of the brainstem involved in the generation of spontaneous MSNA [12]. Analysis of the temporal coupling between BOLD signal intensity and nerve signal intensity revealed sites in which the two signals covaried, but these sites were limited to the medulla. The advantage of this approach is that maneuvers, with all of the associated confounds, need not be performed. As shown in Figure 3.3, increases in MSNA were associated
I. INTRODUCTION
16
3. ImAgIng of BRAInSTEm SITES InvolvEd In CARdIovASCulAR ConTRol
with bilateral increases in signal intensity in the rostral lateral medulla that corresponds to the human equivalent of the RVLM. There was also a unilateral (left) increase in activity in the area that corresponds to the caudal pressor area (CPA). Reciprocal decreases in signal intensity occurred in the dorsomedial region of NTS and in CVLM, though on average the latter appeared to be limited to the right side. Although not illustrated here, increases in signal intensity also occurred in the medullary raphé and in the region that includes the dorsal motor nucleus of the vagus. The use of this approach promises to increase our understanding of the functional organization of the medulla and changes in sympathetic outflow that are associated with many pathophysiological states.
References [1] McAllen RM, May CN, Shafton AD. Functional anatomy of sympathetic premotor cell groups in the medulla. Clin Exp Hypertens 1995;17:209–21. [2] Dampney RA, Polson JW, Potts PD, Hirooka Y, Horiuchi J. Functional organization of brain pathways subserving the baroreceptor reflex: studies in conscious animals using immediate early gene expression. Cell Mol Neurobiol 2003;23:597–616. [3] Wang J, Irnaten M, Neff RA, Venkatesan P, Evans C, Loewy AD, et al. Synaptic and neurotransmitter activation of cardiac vagal neurons in the nucleus ambiguus. Ann N Y Acad Sci 2001;940:237–46. [4] Minson JB, Llewellyn-Smith IJ, Arnolda LF, Pilowsky PM, Chalmers JP. C-fos expression in central neurons mediating the arterial baroreceptor reflex. Clin Exp Hypertens 1997;19:631–43.
[5] Horiuchi J, Killinger S, Dampney RA. Contribution to sympathetic vasomotor tone of tonic glutamatergic inputs to neurons in the RVLM. Am J Physiol 2004;287:R1335–43. [6] Critchley HD, Nagai Y, Gray MA, Mathias CJ. Dissecting axes of autonomic control in humans: insights from neuroimaging. Auton Neurosci. 2011;161:34–42. [7] Henderson LA, Richard CA, Macey PM, Runquist ML, Yu PL, Galons JP, et al. Functional magnetic resonance signal changes in neural structures to baroreceptor reflex activation. J Appl Physiol 2004;96:693–703. [8] Macefield VG, Gandevia SC, Henderson LA. Neural sites involved in the sustained increase in muscle sympathetic nerve activity induced by inspiratory-capacity apnea – a fMRI study. J Appl Physiol 2006;100:266–73. [9] Allen AM, Moeller I, Jenkins TA, Zhuo J, Aldred GP, Chai SY, Mendelsohn FA. Angiotensin receptors in the nervous system. Brain Res Bull 1998;47:17–28. [10] McAllen RM, Farrell M, Johnson JM, Trevaks D, Cole L, McKinley MJ, et al. Human medullary responses to cooling and rewarming the skin: a functional MRI study. Proc Nat Acad Sci USA 2006;103:809–13. [11] Sander M, Macefield VG, Henderson LA. Cortical and brainstem changes in neural activity during static handgrip and post-exercise ischemia in humans. J Appl Physiol 2010;108:1691–700. [12] Macefield VG, Henderson LA. Real-time imaging of the medullary circuitry involved in the generation of spontaneous muscle sympathetic nerve activity in awake subjects. Human Brain Mapp 2010;31:539–59.
I. INTRODUCTION
C H A P T E R
4 Peripheral Autonomic Nervous System Robert W. Hamill, Robert E. Shapiro, Margaret A. Vizzard are paired structures that are located bilaterally along the vertebral column. They extend from the superior cervical ganglia (SCG), located rostrally at the bifurcation of the internal carotid arteries, to ganglia located in the sacral region. All told, there are three cervical ganglia (the SCG, middle cervical ganglion, and inferior cervical ganglion, which is usually termed the cervicothoracic or stellate ganglion because it is a fused structure combining the inferior cervical and first thoracic paravertebral ganglia), eleven thoracic ganglia, four lumbar ganglia, and four to five sacral ganglia. More caudally, two paravertebral ganglia join to become the ganglion impar. Prevertebral ganglia are midline structures located anterior to the aorta and vertebral column, and are represented by the celiac ganglia, aortico-renal ganglia, and the superior and inferior mesenteric ganglia. Previsceral, or terminal ganglia, are small collections of sympathetic ganglia located close to target structures; they are also referred to as short noradrenergic neurons since their axons cover limited distances. Generally, the preganglionic fibers are relatively short and the postganglionic fibers are quite long in the SNS. The axons of these postsynaptic neurons are generally unmyelinated and of small diameter (5 μm). The target organs of sympathetic neurons include smooth muscle and cardiac muscle, glandular structures, and parenchymal organs (e.g., liver, kidney, bladder, reproductive organs, muscles, etc. (see Fig. 4.1)) as well as other cutaneous structures. The spinal cells of origin for the presynaptic input to sympathetic peripheral ganglia are located from the first thoracic to the second lumbar level of the cord, although minor variations exist. The principal neurons generally have been viewed as located in the lateral horn of the spinal gray matter (intermediolateral cell column-IML), but four major groups of autonomic neurons exist: intermediolateralis pars principalis (ILP), intermediolateralis pars funicularis (ILF), nucleus intercalatus spinalis (IC) and the central autonomic nucleus (CAN) or dorsal commissural nucleus (DCN) (anatomical nomenclature is nucleus intercalatus pars paraependymalis (ICPE)). For paravertebral ganglia, 85–90% of the presynaptic fibers originate from cell bodies in ILP or ILF. Prevertebral ganglia and terminal ganglia receive a larger proportion of preganglionic terminals from the CAN/DCN. The nucleus intercalatus also contributes preganglionic fibers, but the exact
The autonomic nervous system (ANS) is structurally and functionally positioned to interface between the internal and external milieu, coordinating bodily functions to ensure homeostasis (cardiovascular and respiratory control, thermal regulation, gastrointestinal motility, urinary and bowel excretory functions, reproduction, and metabolic and endocrine physiology), and adaptive responses to stress (flight or fight response). Thus, the ANS has the daunting task of ensuring the survival as well as the procreation of the species. These complex roles require complex responses, and depend upon the integration of behavioral and physiological responses that are coordinated centrally and peripherally. In 1898, Langley, a Cambridge University physiologist coined the term “autonomic nervous system” and identified three separate components (sympathetic, parasympathetic, and enteric). The following section of the Primer will focus on the first two aspects of the peripheral ANS: sympathetic nervous system (SNS) including the adrenal medulla; and parasympathetic nervous system (PNS). The following précis will address the neuroanatomy of the SNS, adrenal medulla, and PNS, and then present a more detailed, albeit brief, review of the functional neuroanatomy, physiology and pharmacology of the peripheral autonomic nervous system. Importantly, the ANS’s role at multiple interfaces in normal and abnormal physiology is emerging as a key mediator of pathophysiology in a range of complex disorders (anxiety and panic, chronic fatigue syndrome, regional pain syndromes, autonomic failure) and a critical substrate underpinning the field of neurocardiology. The following information will serve as a framework from which to view the complexity of the ANS as revealed in the more detailed descriptions that follow.
SYMPATHETIC NERVOUS SYSTEM (SEE FIG. 4.1) The SNS is organized at a spinal and peripheral level such that cell bodies within the thoracolumbar segments of the spinal cord provide preganglionic efferent innervation to sympathetic neurons that reside in ganglia dispersed in three arrangements: paravertebral, prevertebral, and previsceral or terminal ganglia. Paravertebral ganglia
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00004-4
17
© 2012 Elsevier Inc. All rights reserved.
18
4. PERIPHERAl AuToNomIC NERvouS SySTEm
Parasympathetic Division
Brainstem & Spinal Cord
Sympathetic Division
Target Organs
Trunk
Trunk
Target Organs
Oliary Ganglion
III
Nucleus Ambigours Superior Cervical Ganglion
Parotid Gland
Middle Cervical Ganglion Stellate
Heart
Ganglion
Respiratory Tract & Lungs
Small Intestine Adrenal Medulla Small Intestine
Celiac Ganglion
Greater Splanchnic Nerve Lesser Splanchnic Nerve Superior Mesenteric Ganglion
Colon Pelvin Colon & Rectum Genitourinary Tract
Interior Mesenteric Ganglion
C1 C2 C3 C4 C5 C6 C7 C8 T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 L1 L2 L3 L4 L5 S1 S2 S3 S4 S5
Submandibular Ganglion
Sweat Glands, Hair Follicles, Blood Vessels
Lacrimal & Submandibular Glands
Stomach
VII IX X X
Edinger-Westphal Nucleus Superior Salivatory Nucleus Inferior Salivatory Nucleus Dorsal Motor Nucleus
Eye
Pterygopalatine Ganglion
Otic Ganglion
Eye Lacrimal & Palatine Glands Submandibular & Sublingual Glands Parotid Gland
Respiratory Tract & Lungs Gastrointestinal Tract, Liver & Pancreas Heart Nasopharynx Esophagus
Pelvic Colon & Rectum Pelvic Nerve
Genitourinary Tract
Hypogastric Ganglion
FIGURE 4.1 Schematic diagram of the sympathetic and parasympathetic divisions of the peripheral autonomic nervous system. The paravertebral chain of the sympathetic division is illustrated on both sides of the spinal outflow in order to demonstrate the full range of target structures innervated. Although the innervation pattern is diagrammatically illustrated to be direct connects between preganglionic outflow and postganglionic neurons, there is overlap of innervation such that more than one spinal segment provides innervation to neurons within the ganglia.
extent of these is not fully understood and is probably limited. These spinal autonomic nuclei receive substantial supraspinal input from multiple transmitter systems located at multiple levels of the neuraxis; diencephalon (hypothalamus) and brainstem (raphe, locus coeruleus, reticular formation and ventral lateral medulla) provide the largest input and the pattern of innervation viewed in horizontal sections reveals a ladder like arrangement of the distribution of nerve terminals [1]. Without detailing the source or course of specific systems, it is important to point out that the following different neurotransmitter systems impinge on preganglionic neurons within this ladder like structure: monoamines – epinephrine, norepinephrine (NE), serotonin; neuropeptides – substance P, thyrotropin-release hormone (TRH), met-enkephalin, vasopressin, oxytocin, and neuropeptide Y (NPY); amino acids – glutamate, GABA, and glycine. Undoubtedly, others exist and more will be found. It is apparent that dysfunction of these supraspinal systems, or alterations of these
neurotransmitters by disease or pharmacological agents will alter the spinal control of peripheral ganglia and result in clinical dysfunction. The outflow from the spinal cord to peripheral ganglia is segmentally organized with some overlap. Retrograde tracing studies indicate that there is a rostral-caudal gradient: SCG receives innervation from spinal segments T1–T3; stellate ganglia – T1–T6; adrenal gland – T5–T11; celiac and superior mesenteric ganglia – T5–T12; inferior mesenteric and hypogastric ganglion from L1–L2. These presynaptic fibers, which are small in diameter (2–5 μm) and thinly myelinated, exit the ventral roots via the white rami communicantes to join the paravertebral chain either directly innervating their respective ganglion at the same level or traveling along the chain to innervate a target ganglion many levels away (Fig. 4.2). The distribution of postsynaptic fibers also follow a regional pattern with the head, face and neck receiving innervation from the cervical ganglia (spinal segments T1–4), the upper limb and
I. INTRODUCTION
19
SymPATHETIC NERvouS SySTEm
Parasympathetic Nervous System
Sympathetic Nervous System Thoracolumbar Spinal Cord
Sacral Spinal Cord
Spinal ganglion Afferent autonomic fiber Vasomotor Sudomotor Pilomotor fibers
Preganglionic fiber Postganglionic fiber
Gray communicating ramus (post ganglionic) White communicating ramus (preganglionic)
Paravertebral ganglion
Splanchnic nerve
Descending colon Rectum Urinary Bladder Sexual organs
Pelvic splanchnic nerve Prevertebral ganglion Pelvic ganglion
Postganglionic visceral nerves to smooth muscle of inner organs & visceral blood vessels
FIGURE 4.2 Schematic illustration of the segmental spinal arrangement of the sympathetic and parasympathetic nervous system. Although segmental interactions exist, they are polysynaptic operating via interneurons; the primary input to spinal preganglionic neurons is supraspinal originating from brainstem structures (not shown).
thorax from the stellate and upper thoracic ganglia (spinal segments T1–8); the lower trunk and abdomen from lower thoracic ganglia (spinal segments T4–12), and the pelvic region and lower limbs from lumbar and sacral ganglia (spinal segments T10–L2). More recently, with the introduction of trans-neuronal tracing techniques, using pseudorabies virus (PRV), it has been possible to inject ganglia in the periphery and examine the trans-synaptic passage of PRV. Thus, supraspinal neurons projecting to the specific sets of preganglionic neurons that innervate the peripheral ganglia injected may be examined. Interestingly, a surprisingly common set of central pathways influencing the thoracolumbar sympathetic outflow were labeled. For instance, following injections in either the SCG, stellate or celiac ganglia, or the adrenal gland, the following five brain areas are labeled: ventromedial and rostral ventrolateral medulla; caudal raphe nuclei; A5 noradrenergic cell group; and the paraventricular nucleus of the hypothalamus [2]. Apparently, these central loci must share regulatory functions that are coordinated through similar pathways of thoracolumbar outflow. These same studies indicate that other brain areas are only labeled from specific ganglia; thus, site specific central control exists as well. Of additional interest is that numerous, small interneurons in Rexed laminae VII and X of the spinal cord were labeled providing structural support
for the observation that spinal intersegmental and intrasegmental autonomic interactions (including autonomic reflexes) exist. It is apparent that the structural organizational of the sympathetic nervous system permits the integration and dissemination of responses depending on demand. Multiple supraspinal descending pathways provide a dense innervation of all four major autonomic cell groups in the spinal cord, but clearly specific topographic responses exist as well. In turn, each preganglionic neuron innervates anywhere from 4 to 20 postganglionic sites, and each spinal outflow level may reach multiple peripheral ganglia which in turn supply multiple targets, permitting additional dispersion of sympathetic responses when indicated. At each thoracic level there are an estimated 5000 preganglionic neurons (these counts have generally been limited to the cells located in the ILP). Since preganglionic output to prevertebral ganglia originates from more medially placed cell bodies, it is conceivable that a greater number of neurons at certain segmental levels contribute to the output. Thus, a given spinal segment has a powerful base to influence greater than 100,000 postganglionic neurons. Although original thinking suggested that responses were “all-or-none and widespread”, anatomical studies have continued to reveal subtleties of structural arrangements that indicate that the system is not only poised for
I. INTRODUCTION
20
4. PERIPHERAl AuToNomIC NERvouS SySTEm
generalized activation of the peripheral sympathetic nervous system, but is also able to exert control of relatively specific sites and functions. The postganglionic fibers in the SNS travel quite lengthy paths to arrive at target organs. For instance, fibers from the SCG traverse the extracranial and intracranial vasculature to reach such targets as the lacrimal glands, parotid glands, pineal gland, and pupils. Fibers from the stellate ganglia course through the brachial plexus to reach vascular and cutaneous targets in the upper limb and hand. Within the abdomen, axons originating from the paravertebral ganglia supply the viscera as well as the mesenteric vasculature. Lumbar and sacral paravertebral ganglia course distally along peripheral nerves and blood vessels to reach the distal vasculature and cutaneous structures in the feet. In humans, the innervation to the leg requires a sympathetic axon to be 50 cm long and with an estimated overall diameter of 1.2 μm the axonal volume is approximately 565,000 μm3. This axonal cytoskeleton and its metabolic requirements are supported by a perikaryon of about 30 μm with a somal volume of 14,000 μm3. With this structural architecture to maintain, these neurons are vulnerable to various metabolic and structural insults. Although most preganglionic fibers have a relatively short course to their ganglion targets, the upper thoracic preganglionic fibers travel relatively longer distances to reach the stellate and SCG, and preganglionic fibers to the adrenal medulla and prevertebral ganglia course through the paravertebral chain reaching these visceral targets as the splanchnic nerves. Along the course, fiber systems may be interrupted, resulting in local autonomic dysfunction. For example, the Horner’s syndrome results from lesion of either preganglionic fibers to the SCG or the postganglionic axons which leave the SCG to innervate Müller’s muscle of the upper eyelid, pupillodilator muscles, facial vasculature, and sudomotor structures of the face (see Fig. 4.1). The autonomic neuroeffector junction is generally a poorly defined synaptic structure lacking the pre- and postjunctional specializations that are observed in the central nervous system or skeletal muscle motor end plates. The unmyelinated, highly branched postganglionic fibers become beaded with varicosities as they approach their targets. The varicosities are not static; they move along as structures with a diameter of 0.5 to 2 μm, and a length of approximately 1.0 μm. The number of varicosities varies from 10,000/mm3 to over 2 million per mm3 depending on the target being innervated. The varicosities are packed with mitochondria and vesicles containing various transmitters, and are at varying distances from their target organs. For instance, for smooth muscle targets, this distance varies from 20 nm in the vas deferens to 1–2 μm in large arteries. In a sense the release of transmitter is accomplished en passage as the impulse travels along an autonomic axon. The lack of a restrictive synaptic arrangement permits the released NT to diffuse various distances along a target organ and activate multiple receptors,
again expanding the overall effect of sympathetic activation. Between 100 and 1000 vesicles exist in each varicosity in noradrenergic fibers. Traditional teaching suggests that vesicle characteristics indicate the transmitter system: small granular vesicles are noradrenergic; small agranular vesicles are cholinergic; large granular vesicles are peptidergic. However, exceptions to these correlations exist. The principal neuronal phenotype in peripheral sympathetic ganglia is the noradrenergic neuron which is generally multipolar in character with synapses mainly located more on dendrites than somata. Depending on which ganglia are examined, studies indicate that from 80–95% of ganglion cells will stain positively for tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis, or have positive catecholamine fluorescence. The remaining cells have a mixture of transmitters, or are postganglionic cholinergic cells (the sudomotor and periosteal components of sympathetic function). Within sympathetic ganglia there is a small group of small intensely fluorescent (SIF) neurons. The transmitters identified in SIF cells include dopamine, epinephrine, or serotonin. As will be described later, the original concept that preganglionic neurons in the SNS are cholinergic and postganglionic neurons are noradrenergic has given way to new information that a whole array of molecules (cholinergic, catecholaminergic, monoaminergic, peptidergic, “non-cholinergic, non-adrenergic”, and gaseous) appear to be involved in neurotransmission either as agents themselves or as neuromodulators (vide infra).
SYMPATHOADRENAL AXIS AND THE ADRENAL GLAND Interactions between the adrenal cortex and adrenal medulla constitute a critical link between the autonomic and endocrine systems. The adrenal cortex is largely regulated by the hypothalamic-pituitary-adrenocortical axis, whereas the adrenal medulla is primarily under neural control. Both adrenal cortex and medulla, respond to stress and metabolic aberrations. The coordinated response of elevated plasma cortisol and catecholamines during stress indicate that central limbic and hypothalamic centers exert combined influences to ensure the needed neurohumoral adaptations. The interdependence of these two components of the adrenal gland arise early in development: migrating sympathoblasts destined for the adrenal medulla require the presence of the cortical tissue to change their developmental fate from neurons to that of chromaffin cells. These cells, named because they exhibit brown color when treated with “chrome salts”, do not develop neural processes but instead serve an endocrine function by releasing their neurohumors (epinephrine, norepinephrine, and neuropeptides) into the blood stream. During adulthood, the presence of the cortex is critical for maintaining the levels of epinephrine since the induction of the enzyme
I. INTRODUCTION
PARASymPATHETIC NERvouS SySTEm
phenylethanolamine-n-methyltransferase is dependent on local levels of cortisol. Although traditional teaching emphasizes the preganglionic cholinergic splanchnic innervation of the adrenal medulla, there is also evidence that postganglionic sympathetic fibers, vagal afferents, and other sensory afferents are present. Tracing studies indicate that dye placed within the adrenal medulla is transported retrogradely within spinal preganglionic sympathetic neurons in a somewhat bell shaped distribution from approximately T2–L1 with the predominant innervation originating from T7–T10. Neuronal cell bodies are primarily within the nucleus intermediolateralis pars principalis (ILP) with the pars funicularis and pars intercalatus providing a relatively small portion of the innervation. The exiting nerve roots pass through the sympathetic chain, join to form the greater splanchnic nerve, and distribute themselves beneath the adrenal capsule and within the medulla. A small number of nerve cells are labeled in ganglia within the sympathetic chain suggesting that postganglionic sympathetic fibers innervate the gland. Whether these terminals are labeled as they pass along blood vessels within the gland or whether they innervate medullary or cortical cells is not fully resolved. Also, at least in the guinea pig, tracing studies indicate that the parasympathetic system may contribute a small efferent innervation to the gland since neurons in the dorsal motor nucleus of the vagus are labeled after injections in the medulla. Also, cell bodies within the dorsal root ganglia and vagal sensory ganglia (nodose) are also labeled after tracer studies of the adrenal medulla indicating an afferent innervation as well. Lastly, although not a prominent innervation pattern, there appears to be an intrinsic innervation that arises from ganglion cells sparsely populating the subcapsular, cortical and medullary regions of the gland. The innervation pattern of the adrenal medulla is thus more complex than the traditionally listed thoracolumbar preganglionic cholinergic outflow, although the major adaptive responses depend on the preganglionic cholinergic innervation since surgical section of these nerves, or pharmacological blockade with cholinergic antagonists preclude the induction of tyrosine hydroxylase and appropriate release of catecholamines following various stress paradigms. Morphological studies of the adrenal medulla have revealed the presence of two basic types of granules in chromaffin cells. A diffuse spherical granule contains the predominant monoamine secreted by medullary cells, epinephrine, whereas eccentrically located dense core granules contain norepinephrine. As indicated above for ganglion neurons, chromaffin cells of the adrenal medulla also cocontain other molecules. For instance, the opioid molecules are well represented: enkephalin is co-contained in vesicles with the monoamines. The signaling cascade responsible for enhancing the synthesis and release of these neurohormonal agents is complicated and includes preganglionic innervation, steroid hormones (e.g., glucocorticoids), and growth factors (e.g., nerve growth factor, NGF).
21
PARASYMPATHETIC NERVOUS SYSTEM (SEE FIG. 4.1) The craniosacral outflow is the source of central neuronal pathways providing the efferent innervation of peripheral ganglia of the parasympathetic nervous system (PNS). The cranial nerves involved include cranial nerves III, VII, IX, and X, and the sacral outflow is largely restricted to sacral cord levels 2, 3, and 4. As indicated for the SNS, the preganglionic innervation is largely cholinergic with these terminals releasing acetylcholine (ACh) at the ganglion synapses. In contrast to the SNS, the major transmitter postsynaptically is also ACh. These cholinergic neurons also co-contain other transmitter substances: preganglionic neurons contain enkephalins, and ganglionic cholinergic neurons frequently contain vasoactive intestinal peptide (VIP) and/or NPY. The parasympathetic fibers in cranial nerve III originate in the Edinger–Westphal nuclei of the midbrain and travel in the periphery of the nerve (where they are subject to dysfunction secondary to nerve compression), exiting along with the nerve to the inferior oblique to supply the ciliary ganglion. Second order postganglionic fibers exit in the ciliary nerves and supply the pupiloconstrictor fibers of the iris and the ciliary muscle where their combined action permits the near response, including accommodation. The salivatory nuclei, located near the pontomedullary junction, provide the preganglionic parasympathetic innervation for cranial nerves VII and IX. The superior salivatory nucleus sends preganglionic fibers, which leave the facial nerve at the level of the geniculate ganglion (non-parasympathetic sensory ganglion), to form the greater superficial petrosal nerve to the pterygopalatine (sphenopalatine) ganglia that provides postganglionic secretomotor and vasodilator fibers to the lacrimal glands via the maxillary nerve. Other preganglionic fibers in the facial nerve continue and subsequently leave via the chorda tympani to join the lingual nerve, eventually synapsing in the submandibular ganglion. Postsynaptic cholinergic fibers supply the sublingual and submandibular glands. Postganglionic fibers from the pterygopalatine and submandibular ganglia also supply glands and vasculature in the mucosa of the sinuses, palate, and nasopharynx. The inferior salivatory nucleus sends preganglionic fibers via the glossopharyngeal nerve (cranial nerve IX) to the otic ganglion that in turn relays postganglionic fibers to the parotid gland via the auriculotemporal nerve. The preganglionic fibers in cranial nerve IX branch from the nerve at the jugular foramen and contribute to the tympanic plexus and form the lesser superficial petrosal nerve. This nerve exits the intracranial compartment via the foramen ovale along with the third division of the trigeminal nerve to reach the otic ganglion. The most caudal cranial nerve participating in the preganglionic parasympathetic system is the vagus nerve (cranial nerve X). The dorsal motor nucleus of the vagus is located in the medulla and sends preganglionic fibers to innervate essentially all organ systems within the chest
I. INTRODUCTION
22
4. PERIPHERAl AuToNomIC NERvouS SySTEm
and abdomen including the gastrointestinal tract as far as the left colonic flexure (splenic flexure). Also, the nucleus ambiguus supplies preganglionic fibers to the vagus and these fibers are believed to be involved mostly with regulating visceral smooth muscle whereas the dorsal motor vagus neurons may be secretomotor in nature. The glossopharyngeal and vagus nerves also contain a substantial number of afferent fibers (in the vagus, afferent fibers may exceed the efferent fiber system by a ratio of 9 to 1) so that a sensory component related to autonomic control exists within cranial nerve IX and X. These afferents provide a critical component of the baroreceptor reflex arc relaying information regarding the systemic blood pressure to central cardiovascular areas in the nucleus tractus solitarii and other medullary centers involved in blood pressure and heart rate control. The parasympathetic cell bodies in the spinal cord are located in the sacral parasympathetic nucleus of second, third, and fourth sacral segments (see Fig. 4.2). These neurons send preganglionic nerve fibers via the pelvic nerve to ganglia located close to or within the pelvic viscera. Postganglionic fibers are relatively short, in contradistinction to their length in the SNS, and supply cholinergic terminals to structures involved in excretory (bladder and bowel) and reproductive (fallopian tubes and uterus, prostate, seminal vesicles, vas deferens, and erectile tissue) functions. Of interest, the pelvic ganglia involved in some of these functions appear to be mixed ganglia (especially in rodents) where sympathetic and parasympathetic neurons are components of the same pelvic ganglion. They appear to receive their traditional preganglionic input, but may have local interconnections that are not fully revealed by current studies. As indicated below, there is clear evidence that the cholinergic postganglionic neurons in the pelvic ganglion in the rodent co-contain vasoactive intestinal peptide and nitric oxide as two other neuroactive compounds. These neurons are believed to be integrally involved in sexual functions in the male, permitting the development and maintenance of potency. The exact regulatory factors controlling the synthesis and release of these transmitter molecules, and the specific receptor systems involved remain to be fully explored.
THE CONCEPT OF PLURICHEMICAL TRANSMISSION AND CHEMICAL CODING The notion of the presence of multiple transmitters and a chemical coding system of autonomic neurons is now firmly established. Originally it was posited that principal neurons were only noradrenergic (contained NE), but over the last two decades it has become clear that within a single neuron multiple transmitter systems may exist, and that within a given ganglion the variety and pattern of neurotransmitters may be quite extensive (see Table 4.1). Also, the composition of neurotransmitters (NT) may change depending on the location of the ganglia: paravertebral
TABLE 4.1 Neurotransmitter Phenotypes in Autonomic Neurons Autonomic Neurons Sympathetic neurons Paravertebral ganglia Prevertebral ganglia Terminal ganglia (previsceral ganglia) Parasympathetic neurons Major parasympathetic ganglia Ciliary Sphenopalatine Otic Submandibular/sublingual Pelvic ganglia Terminal parasympathetic ganglia (previsceral ganglia) Enteric neurons Myenteric plexus (Auerbach’s) Submucosal plexus (Meisner’s)
Transmitter Characteristics (not all inclusive) NE, CCK, somatostatin, SP, Enk, Ach VIP, 5-HT, NPY, DYN1-8, DYN1-17
ACh, VIP, SP, CAs-SIF, NPY, NO
GABA, ACh, VIP, 5-HT SP, Enk, SRIF, motilinlike peptide, bombesinlike peptide
Enteric ganglia Chromaffin cells of adrenal medulla Paraganglia-chromaffin
E, NE, Enk, NPY, APUD
SIF cells, ganglia
ganglia tend to have fewer transmitters whereas prevertebral and terminal ganglia may have various NT, although as noted for the guinea pig SGC (Fig. 4.3), some paravertebral ganglia have a broad array of transmitters. The exact co-location and functions of these multiple transmitters are not fully understood, but some general principles exist. Neuropeptide NPY is probably the most prominent peptide in sympathetic ganglia and is highly co-localized with NE. The sudomotor component of ganglia is dependent upon a population of cells, which are cholinergic in character [contain ACh as NT], and the most frequent peptide colocalized with ACh is vasoactive intestinal peptide (VIP). The distribution of these cholinergic cells varies: in paravertebral ganglia they may represent 10–15% of the neuronal population whereas they represent 1% of the neurons in prevertebral ganglia. NE NPY, and ACh VIP are believed to be released together, but some degree of activity associated-chemical coding exists. That is, at lower levels of activation NE is preferentially released, whereas higher levels of stimulation result in NPY being released. Both agents have vasoconstrictor properties and are integral in cardiovascular control, especially in the maintenance of blood pressure. Of course, the eventual action and effect of a transmitter rests with the receptor system that is activated (vide infra). Purinergic neurotransmission expands the co-transmission motif. Presynaptic and postsynaptic mechanisms exist: the purine nucleotide adenosine triphosphate (ATP) is in high concentration in sympathetic synaptic vesicles and following release ATP is catabolized to adenosine
I. INTRODUCTION
vISCERAl AffERENT NEuRoNS ANd AuToNomIC NERvouS SySTEm
23
FIGURE 4.3 Chemical coding and target organization. Chemical coding of sympathetic neurons projecting from the superior cervical ganglion to various targets in the head of guinea-pigs. Each population of neurons has a specific combination of neuropeptides. Note that all neurons containing a form of dynorphin A (DYN1-8 or DYN1-17) also contain dynorphin B and neo-endorphin. No neuropeptides have been found in neurons projecting to secretory tissue in the salivary or lacrimal glands. Neurons with similar peptide combinations also occur in other paravertebral ganglia of guinea-pigs, except that the salivary secretomotor neurons are absent. Conversely, the paravertebral ganglia have many non-noradrenergic vasodilatory neurons containing prodynorphin-derived peptides, VIP and NPY. AVAs, arterio-venous anastomoses; NA, noradrenaline; NPY, neuropeptide Y; ACh, acetylcholine; CGRP, calcitonin gene-related peptide; SP, substance P; VIP, vasoactive intestinal polypeptide (see Elfvin, Lindh and Hokfelt, 1993 [11]; Jänig, 2006 [12]).
moieties. There are at least eight receptors (four purinergic and four adenosinergic) that serve to translate purinergic and adenosinergic effects (vasoconstriction and vasodilatation) to vascular beds via endothelium-dependent and endothelium-independent mechanisms. Chemical coding also reveals that ganglion neurons with specific transmitter molecules innervate specific targets or receive specific afferent inputs. Apparently, anterograde and retrograde transsynaptic information appears to determine the transmitter phenotype of the neuron. Thus, studies of neuronal circuitry indicate that pathwayspecific combinations determine the presence and combinations of specific peptides within autonomic neurons. This is particularly so in the prevertebral ganglia, but studies in the guinea pig SCG demonstrate that the transmitter molecules will vary depending on the target organ supplied (see Fig. 4.3). Although all principal cells portrayed are noradrenergic in character (as indicated by NA), the neuropeptides co-contained in neurons vary depending on whether the targets are secretory (salivary and lacrimal glands), vascular (small vs. large arteries, arterioles vs. arterio-venous anastomoses), pupil or skin. Detailed pictures of these chemically coded circuits are beginning to emerge from studies of paravertebral (SCG), prevertebral (superior mesenteric), and previsceral (pelvic) ganglia. This phenomenon pertains to both the SNS and PNS. Preganglionic sympathetic neurons in the spinal cord have traditionally been viewed as cholinergic neurons.
More recently, it has been recognized that neuronal cell bodies in the cat ILP may contain a variety of transmitters including enkephalin, neurotensin, somatostatin, and substance P. In rodents, VIP and calcitonin gene-related pepitde (CGRP) containing neurons have also been localized to the ILP by immunocytochemistry. Also, preganglionic fibers in the sacral parasympathetic outflow co-contain enkephalin. It is apparent that neurotransmission is plurichemical in both preganglionic and postganglionic-fiber systems.
VISCERAL AFFERENT NEURONS AND AUTONOMIC NERVOUS SYSTEM Visceral afferent neurons are polymodal and are excited by physical (distention, contraction), chemical and thermal events. These stimuli are transmitted to the spinal cord and brainstem neurons resulting in target organ regulation, reflexes and sensation. In rats, vagal afferent neurons arising in the stomach may terminate within the medullary nucleus tractus solitarius in proximity to dendrites from dorsal motor nucleus efferent neurons sending axons back to the stomach [3]. Spinal primary afferent neurons that innervate viscera have multiple functions (afferent, efferent and trophic functions) [4] and contain a diverse assortment of neuropeptides including calcitonin generelated peptide (CGRP), substance P, vasoactive intestinal
I. INTRODUCTION
24
4. PERIPHERAl AuToNomIC NERvouS SySTEm
polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) [5]. For example, bladder afferent neurons travel in the hypogastric and pelvic nerves, and their cell bodies are located in dorsal root ganglia (DRG) at spinal segments T11–L2 and S2–S4 in humans and L1–L2 and L6–S1 in rats [5,6]. Bladder afferent fibers consist of lightly myelinated Aδ fibers and unmyelinated C-fibers. Sensation of bladder filling is conveyed by Aδ fibers, the most important mechanoreceptors of the bladder. C-fibers are normally “silent”, but they do respond to chemical or noxious stimuli, including extreme bladder pressure [5,6].
FUNCTIONAL NEUROANATOMY AND BIOCHEMICAL PHARMACOLOGY The peripheral ANS is well structured to provide the physiological responses critical for homeostasis and acute adaptations to stressful, perhaps life-threatening, circumstances. As outlined in Figure 4.1 and Table 4.2, multiple organ systems respond to neurotransmitters released from autonomic endings, and circulating catecholamines released from the adrenal medulla. Traditional teaching is that the effects of activation of the SNS and PNS are generally antagonistic; this is still largely the case. However, viewed more specifically, the relationships between these two major components of the ANS are far from simple. For instance, not all organs receive an equal number of both sets of fibers, and in some situations, both SNS and PNS effects are similar. It is important to remember that receptor systems, including the signal transduction components, on the target organs are the critical molecular proteins that determine the actual effects of ligand-receptor interactions on the cell membrane. Thus, when the SNS is stimulated with its capability to produce a widespread response, a host of receptor systems are activated to effect the necessary and desired change. An example of these responses includes the following aspects of SNS activation: dilatation of the pupil; slight increase in glandular secretions; bronchodilatation; increased heart rate and force of contraction; decreased gastrointestinal tract motility; decreased function of the reproductive organs; and mobilization of energy substrates to meet demands. The receptor systems mediating these responses include α1A, α1B,, α1D,, α2A, α2B, α2C, β1, β2 and β3 receptors. α1 receptors have subtypeselective distributions, second messenger systems and functions. Activation of these receptors occurs following interaction with NE and variously results in contraction of smooth muscle in the vasculature and iris, and relaxation of smooth muscle in the gut. α1 receptors exert a limited positive inotropic effect on the heart, as well as mediate salivary gland secretion and contraction of the prostate gland. α2 receptors also have discrete subtype-specific localizations and functions in brain, peripheral nerve, and target tissues. α2 receptors serve as autoreceptors on sympathetic nerve terminals and inhibit the release of NE as
TABLE 4.2 Autonomic Nervous System functions Organ
Sympathetic Nervous System
Parasympathetic Nervous System
Eye Pupil Ciliary muscle
Dilatation Relax (far vision)
Constriction Constrict (near vision)
Lacrimal gland
Slight secretion
Secretion
Parotid gland
Slight secretion
Secretion
Submandibular gland
Slight secretion
Secretion
Heart
Increased rate Positive inotropism
Slowed rate Negative inotropism
Lungs
Bronchodilation
Bronchodilation
Gastrointestinal tract
Decreased motility
Increased motility
Kidney
Decreased output
None
Bladder
Relax detrusor Contract sphincter
Contract detrusor Relax sphincter
Penis
Ejaculation
Erection
Sweat glands
Secretion
Palmar sweating
Piloerection muscles
Contraction
None
Blood vessels Arterioles
Constriction
None
Constriction or dilatation Glycogenolysis
None
Muscle Arterioles Metabolism
None
part of a negative feed back loop. α2 receptors also can act as constrictors of both arterial and venous vascular smooth muscle. Furthermore, these receptors play important roles in nociception and also mediate metabolic and endocrine changes such as inhibition of lipolysis in adipose tissue and reduction of insulin release from the pancreas. β receptors (β1) provide positive inotropic and chronotropic effects on the heart and stimulate renin release from the kidney. β2 receptors relax smooth muscle of the bronchi and pelvic organs as well as the vascular structures of the gut and skeletal muscle. β2 receptors located in liver and skeletal muscle elicit activation of glycogenolysis and gluconeogenesis. This receptor system is particularly activated by epinephrine rather than norepinephrine. The parasympathetic nervous system is poised for more focal responses, but some effects may be quite broad, particularly with the wide-ranging innervation of the vagus nerve. Activation of parasympathetic pathways lead to pupillary constriction, substantial secretion from lacrimal and salivary glands, slowed cardiac rate and negative inotropism, bronchoconstriction, enhanced gastrointestinal motility and contraction of the detrusor muscle of the bladder. In contrast to the SNS, the PNS does not appear to influence metabolic or endocrine processes in any major way. However, recent evidence indicates that preganglionic vagal fibers originating in the dorsal motor nucleus innervate postganglionic parasympathetic ganglia in the
I. INTRODUCTION
STRESS ANd AuToNomIC dySfuNCTIoN
pancreas, and appear to influence exocrine and endocrine function. Thus, as new data emerge, the integrated roles of the SNS and PNS will continue to expand. An understanding of the receptor systems mediating the responses to PNS activation is incomplete. Preganglionic cholinergic receptors, which exist in the SNS as well as PNS, are nicotinic in character whereas postganglionic cholinergic receptors are muscarinic. Recently, molecular cloning studies have revealed multiple subtypes of both sets of receptors. The subtypes of muscarinic receptors (mAChRs), M(1)-M(5), are more fully understood (at least for the first three subtypes): M1 receptors are excitatory to neurons in ganglia and lead to noradrenaline release in sympathetic neurons; M2 receptors mediate the bradycardia and decreased contractility of the heart following vagal activation; M3 stimulation leads to contraction of smooth muscle and enhanced secretion from glandular tissues. Nicotinic acetylcholine receptor subtypes (nAChRs) are widely expressed in the mammalian CNS and PNS, playing a central role in autonomic transmission. Neuronal nicotinic acetylcholine receptors (nAChR) are composed of 12 subunits (α2–α10, β2–β4) but very little was known, until recently, about their physiological roles. The repertoire of nicotinic subunits in autonomic ganglia includes α3, α5, α7, β2 and β4 subunits. In the periphery, nicotinic receptors mediate vital excitatory fast synaptic cholinergic transmission at both the neuromuscular junction and ganglia. However, there is only a limited understanding of subunit actions in the presynaptic and postsynaptic components of the peripheral ANS. Functional deletions of subunit by gene knockout in animals are beginning to overcome these limitations.
STRESS AND AUTONOMIC DYSFUNCTION A prominent role for stress in the pathophysiology of cardiovascular disease and presentation of clinical pain states, including functional gastrointestinal disorders have been well documented. In addition, anxiety and stress may generate and worsen urinary symptoms and functional urinary disorders [7], such as interstitial cystitis (IC)/bladder pain syndrome (BPS). The majority of IC/BPS patients report symptom exacerbation by stress, and clinical studies have shown that acute stress increases bladder pain and urgency in IC/BPS patients [7,8]. Clinical populations afflicted with bladder disorders have a greater incidence of comorbid anxiety disorders than populations without bladder dysfunction. Both anxiety and bladder dysfunction can be caused and/or exacerbated by exposure to environmental stressors in human clinical populations and animal models. A number of ongoing studies from various laboratories are evaluating whether autonomic nervous system pathology and stress/anxiety share overlapping neuronal circuitry. The complexity of autonomic control and the range of mechanisms available to peripheral sympathetic and
25
parasympathetic neurons and their targets are expanded by presynaptic gaseous molecules (nitric oxide [NO]) and postsynaptic endothelium released peptides. Also, central nervous system centers involved in autonomic control contain nitric oxide synthase and evidence suggests that NO may mediate sympatho-inhibition or sympathoexcitation depending on the nuclear groups involved. Peripherally, NO exerts tonic vasodilation and mediates acetylcholine-induced vasodilation, as well as mediating catecholamine release and action. Endothelins, released abluminally by endothelial cells, bind to endothelial and adrenoceptors on vascular smooth muscle and endothelial cells and appear to regulate sympathetic terminals as well. The recent discoveries that a number of neurotrophic factors (neurotrophins) and their receptors are part and parcel of the development and integrity of the SNS and PNS expand the horizons regarding how anatomical pathways are established and maintained, and adapt to intrinsic and extrinsic demands. Because of its relatively simple anatomical architecture, the peripheral ANS continues to serve as a model system to understand neuronal development, structural and functional linkages among neurons and their targets, and the integrative role(s) these “little brains” (6000–30,000 neurons) serve. More recently, observations of the clinical phenotype and neuropathology of Parkinson Disease (PD) suggest that the peripheral ANS may serve as a model to study human neurodegenerative disease since peripheral and preganglionic, including medullary preganglionic vagal (DMV) neurons, may be involved at the earliest stages of the disease [9], before the onset of the well-known motor system dysfunctions related to the basal ganglia. A neuropathological cascade that originates in peripheral autonomic nerves may gradually and progressively ‘spread’ to involve central nervous system structures with the eventual involvement of the classically described neurons of the locus, coeruleus, substantia nigra and more rostral structures. Recent investigations in animal models of PD have taken advantage of the relative simplicity of the peripheral ANS to explore pathophysiological mechanism of how α-synuclein might initiate the premotor clinical dysfunction and presumed underlying alteration is neurotransmitter biochemistry and neurophysiology of peripheral autonomic neurons [10]. As the structure-function relationships and molecular pharmacology of the peripheral ANS are clarified, and more understandings accrue regarding their involvement in disease processes, new approaches to understanding ANS functions in health and disease and treatments of its maladies will undoubtedly emerge. The following sections of this Primer will expand on these issues.
References [1] Romagnano MA, Hamill RW. Spinal sympathetic pathway: an enkephalin ladder. Science 1984;225:737–9. [2] Strack AM, Sawyer WG, Hughes JH, Platt KB, Loewy AD. A general pattern of CNS innervation of the sympathetic outflow
I. INTRODUCTION
26
[3] [4]
[5]
[6] [7]
[8] [9] [10]
[11] [12]
4. PERIPHERAl AuToNomIC NERvouS SySTEm
demonstrated by transneuronal pseudorabies viral infections. Brain Res 1989;491:156–62. Shapiro RE, Miselis RR. The central organization of the vagus nerve innervating the stomach of the rat. J Comp Neurol 1985;238:473–88. Jänig W, Habler HJ. Specificity in the organization of the autonomic nervous system: a basis for precise neural regulation of homeostatic and protective body functions. Prog Brain Res 2000;122:351–67. Arms L, Vizzard MA. Neuropeptides in lower urinary tract function. In: Urinary tract, handbook of experimental pharmacology 202. Berlin Heidelberg: Springer-Verlag; 2011. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 2008;9(6):453–66. Baldoni F, Ercolani M, Baldaro B, Trombini G. Stressful events and psychological symptoms in patients with functional urinary disorders. Percept Mot Skills 1995;80:605–6. Koziol JA, Clark DC, Gittes RF, Tan EM. The natural history of interstitial cystitis: a survey of 374 patients. J Urol 1993;149:465–9. Braak H, Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology 2008;70:1916–25. Hamill RW, Girard B, Tompkins JD, Galli JR, Parsons RL, Kershen RT, et al. Synucleinopathy model: Autonomic plasticity in the major pelvic ganglion (MPG) in mice with human alpha-synuclein overexpression. Developmental Neurobiol, in revision. Elfvin L-G, Lindh B, Hökfelt TJ. The chemical neuroanatomy of sympathetic ganglia. Ann Rev Neurosci 1993;16:471–507. Jänig W. The Integrative Action of the Autonomic Nervous System Neurobiology of homeostasis. Cambridge: Cambridge University Press; 2006.
Further Reading Baloh RH, Enomoto H, Johnson Jr. EM, Milbrandt J. The GDNF family ligands and receptors-implications for neural development. Curr Opin Neurobiol 2000;10:103–10. Burnstock G, Milner P. Structural and chemical organization of the autonomic nervous system with special reference to non-adrenergic, non-cholinergic transmission. In: Banister R, Mathias CJ, editors. Autonomic failure (4th edn.). New York: Oxford University Press; 1999. p. 63. Chowdhary S, Townend JN. Role of nitric oxide in the regulation of cardiovascular autonomic control. Clin Sci (Lond) 1999;97(July):5–17. Dinner DS, editor. The autonomic nervous system. (Review articles) J Clin Neurophysiol, 10; 1993 1–82 Gibbins I. Chemical neuroanatomy of sympathetic ganglia. In: McLachlan EM, editor. Autonomic ganglia. Luxembourg: Harwood Academic Publishers; 1995. p. 73–121. Goldstein DS. The autonomic nervous system in health and disease. New York: Marcel Dekker, Inc; 2001. 23–135 Schober A, Unsicker K. Growth and neurotrophic factors regulating development and maintenance of sympathetic preganglionic neurons. Int Rev Cytol 2001;205:37–76. Zansinger J. Role of nitric oxide in the neural control of cardiovascular function. Cardiovasc Res 1999;43:639–49.
I. INTRODUCTION
C H A P T E R
5 Cotransmission Geoffrey Burnstock
EARLY STUDIES
TABLE 5.1 Cotransmitters in the Peripheral and Central Nervous System
For many years, understanding of neurotransmission incorporated the concept that one neuron releases only a single transmitter, known as “Dale’s Principle”. This idea arose from a widely adopted misinterpretation of Dale’s suggestion in 1935 that the same neurotransmitter was stored in and released from all terminals of a single neuron, a suggestion which did not specifically preclude the possibility that more than one transmitter may be associated with the same neuron. Early hints that nerves might release more than one transmitter began in the 1950s with evidence for the involvement of both noradrenaline (NA) and acetylcholine (ACh) in sympathetic transmission. Koelle identified acetylcholinesterase in some adrenergic neurons in 1955, while Burn and Rand introduced the concept of a “cholinergic” link in adrenergic transmission in 1959. Another line of evidence provided by Hillarp concerned the coexistence of adenosine 5-triphosphate (ATP) with catecholamines, first in adrenal chromaffin cells and later in sympathetic nerves. Inconsistencies in the single transmitter hypothesis provided by these and other studies, including those concerned with invertebrate neurotransmission, from the early literature were rationalized in an article by Burnstock in 1976 [1] with the provocative title: “Do some nerve cells release more than one transmitter?” Today, it is widely accepted that cotransmission is an integral feature of neurotransmission. A role for ATP as a cotransmitter in sympathetic, parasympathetic, sensory-motor and enteric non-adrenergic, non-cholinergic (NANC) inhibitory nerves was supported by research from Burnstock and colleagues, while Hökfelt and colleagues focused on the colocalization, vesicular storage and release of peptides from both peripheral and central nerves (see [2–4]). Furness and Costa introduced the concept of “chemical coding” to describe the combination of potential neurotransmitters found in enteric nerves and this concept has since been applied to other nerve types, in both peripheral and central nervous systems (CNS) [5]. Colocalized substances are not necessarily cotransmitters, they can (especially peptides) act as pre- and/or postjunctional neuromodulators of the release and actions of the principal cotransmitters. The proportions of cotransmitters vary considerably between species and organs, and show
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00005-6
PERIPHERAL NERVOUS SYSTEM Sympathetic nerves
ATP NA NPY
Parasympathetic nerves
ATP ACh VIP
Sensory-motor
ATP CGRP SP
NANC enteric nerves
ATP NO VIP
Motor nerves (in early development)
ATP Ach
CENTRAL NERVOUS SYSTEM Cortex, caudate nucleus
ATP Ach
Hypothalamus, locus ceruleus
ATP NA
Hypothalamus, dorsal horn, retina
ATP GABA
Mesolimbic system
ATP DA
Hippocampus, dorsal horn
ATP glutamate
Compiled from [4]. ACh, acetylcholine; ATP, adenosine 5-triphosphate; CGRP, calcitonin gene-related peptide; DA, dopamine; GABA, γ-amino butyric acid; NA, noradrenaline; NO, nitric oxide; NPY, neuropeptide Y; SP, substance P; VIP, vasoactive intestinal peptide.
plasticity of expression during development and in pathological conditions. In general, classical transmitters are contained in small synaptic vesicles, whereas peptides are stored in large granular (dense-cored) vesicles (LGVs), although small molecule transmitters are sometimes stored together with peptides in LGVs. Pharmacological studies of pre- and postjunctional neuromodulation provide evidence, which is complementary to the concept of cotransmission. Evidence for ATP being a cotransmitter with established neurotransmitters in the CNS as well as in the periphery has been reported (see Table 5.1).
SYMPATHETIC NERVES There is substantial evidence to show that NA, ATP and neuropeptide Y (NPY) are cotransmitters in sympathetic nerves, having differentially important roles as transmitters and neuromodulators depending on the tissue, the species, and on the parameters of stimulation.
27
© 2012 Elsevier Inc. All rights reserved.
28
5. CoTRANSmISSIoN
The first indication that ATP might be released from sympathetic nerves was the demonstration that stimulation of sympathetic nerves by Su et al. in 1971 [6] led to release of tritium from taenia coli preincubated in [3H]adenosine (which is taken up and converted to [3H]ATP). Later Sol Langer and colleagues suggested that the substantial residual NANC response of the cat nictitating membrane observed after depletion of NA by reserpine was due to the release of ATP remaining in the sympathetic nerves. Most of the early studies establishing the model of cotransmission of NA and ATP were made by Dave Westfall and colleagues on the vas deferens, a tissue with a high density of sympathetic nerves. In retrospect, there was a good indication that the excitatory junction potentials (EJPs) recorded in the guinea pig vas deferens when the electrophysiology of sympathetic nerve smooth muscle transmission was first described by Burnstock and Holman in 1960, were due to ATP released as a cotransmitter from sympathetic nerves, rather than to NA. It was puzzling at the time that adrenoceptor antagonists failed to block the EJPs, although guanethidine, a drug that prevents the release of sympathetic transmitters, was effective. It was over 20 years later that NANC EJPs were shown to be blocked by desensitization of the ATP (P2) receptors by α,β-methylene ATP (α,β-meATP) and mimicked by ATP [7]. After destruction of sympathetic nerves with 6-hydroxydopamine, purinergic nerve-mediated responses were abolished. ATP is co-stored with NA in small and large vesicles. Differential prejunctional modulation of the release of NA and ATP by various agents has been shown in the vas deferens, perhaps indicating that NA and ATP are stored in different vesicles. Cotransmission of NA and ATP in perivascular sympathetic nerves supplying the rabbit aorta, portal vein and saphenous, pulmonary and mesenteric arteries, and the dog basilar artery has been demonstrated (see [8]). Electrophysiological studies have shown that in a number of vessels the electrical response to stimulation of perivascular sympathetic nerves is biphasic; an initial fast, transient depolarization or EJP of the vascular smooth muscle is followed by a slow, prolonged depolarization. The EJP and slow depolarization are mimicked by the effects of ATP and NA, respectively. Considerable variation exists in the proportions of NA and ATP utilized by sympathetic nerves. For example, in guinea pig submucosal arterioles both vasoconstriction and EJPs, evoked in response to electrical stimulation of sympathetic nerves, are mediated exclusively by ATP, with NA assuming the role of a neuromodulator, by acting through prejunctional α2-adrenoceptors to depress transmitter release. At the other extreme, in rat renal arteries the purinergic component is relatively small. It has also been noted that the purinergic component is optimal with short bursts of low frequency stimulation, whereas longer durations of higher frequency favor adrenergic transmission. NPY has been found to be present in LGV in most sympathetic nerves. The release of NPY, as well as NA and ATP, in response to electrical stimulation of sympathetic nerve terminals is prevented by guanethidine. The major role of
FIGURE 5.1 Schematic of sympathetic cotransmission. ATP and NA released from small granular vesicles (SGV) act on P2X and α1 receptors on smooth muscle, respectively. ATP acting on inotropic P2X receptors evokes excitatory junction potentials (EJPs), increase in intracellular calcium ([Ca2]i) and fast contraction; while occupation of metabotropic α1 adrenoceptors leads to production of inositol triphosphate (InsP3), increase in [Ca2]i and slow contraction. Neuropeptide Y (NPY) stored in large granular vesicles (LGV) acts on release both as a prejunctional inhibitory modulator of release of ATP and NA and as a postjunctional modulatory potentiator of the actions of ATP and NA. Nucleotidases are released from nerve varicosities, and are also present as ectonucleotidases. (Reproduced from [14] with permission from Elsevier.)
NPY in the vasculature, and in the vas deferens, appears to be that of a pre- and/or postjunctional modulator of sympathetic transmission, since it has little direct postjunctional action or causes contraction only at high concentrations (see Fig. 5.1). Direct vasoconstrictor actions of NPY have, however, been demonstrated in some vessels. At the prejunctional level, NPY has potent inhibitory effects, reducing the release of NA and ATP from sympathetic nerves. Postjunctionally, NPY generally acts to enhance the actions of sympathetic nerve stimulation, NA and ATP. Although 5-hydroxytryptamine (5-HT) immunofluorescent nerves have been localized in a number of vessels, for the most part 5-HT is not synthesized and stored in separate nerves, but is taken up, stored in, and released as a “false transmitter” from sympathetic nerves. Enkephalins have been shown to coexist with NA in cell bodies and fibers of some postganglionic sympathetic neurons. The functional significance of sympathetic coexistence of opioids is likely to be related to their prejunctional inhibitory effects on sympathetic transmission.
PARASYMPATHETIC NERVES The classical evidence for cotransmission of ACh and vasoactive intestinal polypeptide (VIP) in certain
I. INTRODUCTION
ENTERIC ANd CARdIAC NERvES
postganglionic parasympathetic neurons comes from pharmacological studies performed by Lundberg in 1981 on cat salivary glands (see [9]). ACh and VIP are released from the same parasympathetic nerve terminals in response to transmural nerve stimulation. During low frequency stimulation ACh is released to cause an increase in salivary secretion from acinar cells and also to elicit some minor dilatation of blood vessels in the gland. VIP is preferentially released at high frequencies to cause marked vasodilatation of blood vessels and, while it has no direct effect on acinar cells, it acts as a neuromodulator to enhance both the postjunctional effect of ACh on acinar cell secretion and the release of ACh from nerve varicosities via prejunctional receptors. Vasodilator nerves to the uterine arteries in the guinea pig contain immunoreactivity to VIP, which coexists with dynorphin, NPY and somatostatin. NPY-like immunoreactivity has been reported in some of the choline acetyltransferase-/VIP-containing neurons of the parasympathetic ciliary, sphenopalatine, otic and pterygopalatine ganglia with targets including the iris and cerebral vessels. Autonomic control of penile erection, involving relaxation of the smooth muscle of the corpus cavernosum as well as dilatation of other penile vascular beds, has traditionally been attributed to the vasodilator effects of ACh and VIP released from parasympathetic nerves. More recently, nitric oxide (NO) released from nerves arising from nerves in the pelvic ganglia, have been claimed to play a role in smooth muscle relaxation leading to penile erection. NO synthase (NOS)-containing fibers, shown by lesion studies to arise from parasympathetic cell bodies in the sphenopalatine ganglia, have been localized in the adventitia of cerebral arteries and many of these also contain VIP. A functional role for perivascular neuronal NO in cerebral arteries has been identified in studies showing that stimulation of adventitial nerve fibers causes vascular relaxation, which is attenuated by inhibitors of NOS. Parasympathetic nerves supplying the urinary bladder utilize ACh and ATP as cotransmitters, in variable proportions in different species, and by analogy with sympathetic nerves, ATP again acts through P2X ionotropic receptors to produce EJPs and fast contraction, while the slow component of the response is mediated by a metabotropic receptor, in this case muscarinic (see [10]). There is also evidence for parasympathetic, purinergic cotransmission to resistance vessels in the heart and airways.
SENSORY-MOTOR NERVES The neuropeptides substance P (SP) and calcitonin gene-related peptide (CGRP) are the principal transmitters of primary afferent nerves and have been shown to coexist in the same terminals. Furthermore, with the use of colloidal gold particles of different sizes, they have been shown to coexist in the same large granular vesicles. The motor (efferent) function of sensory nerves has been
29
demonstrated in rat mesenteric arteries where evidence exists for a role for CGRP as the mediator of vasodilatation following release from sensory motor nerves. In contrast, SP is not co-released with CGRP by electrical stimulation and SP has little or no vasodilator action on rat mesenteric arteries. While it is possible that SP released from nerves supplying the microvasculature could produce vasodilatation via SP receptors on endothelial cells, it is most unlikely to reach the endothelium without degradation in larger blood vessels. It may be that the role of the coexisting SP is either trophic or sensory (and not motor). Other peptide and non-peptide substances including neurokinin A, somatostatin, VIP and ATP have been described in capsaicin-sensitive sensory neurons. Unmyelinated sensory neurons containing cholecystokinin (CCK)/CGRP/dynorphin/SP have been shown to project to cutaneous arterioles in guinea pig skin. Neurons from the same ganglia which contain CCK/CGRP/SP, innovate arterioles of skeletal muscle, CGRP/dynorphin/ SP nerve fibers mostly supply the pelvic viscera, and CGRP/SP fibers run mainly to the heart, large arteries, and veins. There is also evidence for a sensory role for ATP and it has been proposed that ATP may coexist in sensory nerve terminals with SP and CGRP (Fig. 5.2).
ENTERIC AND CARDIAC NERVES Intrinsic neurons exist in most of the major organs of the body. Many of these are part of the parasympathetic nervous system, but certainly in the gut and perhaps also in the heart and airways, some of these intrinsic neurons are derived from neural crest tissue, which differs from that which forms the sympathetic and parasympathetic systems and appear to participate in local reflex actions independent of the CNS. The enteric nervous system contains several hundred million neurons located in the myenteric plexus between muscle coats and the submucous plexus. The chemical coding of these nerves has been examined in detail. A subpopulation of these intramural enteric nerves provides NANC inhibitory innervation of the gastrointestinal smooth muscle. It seems likely that three major cotransmitters are released from these nerves. ATP produces fast inhibitory junction potentials, NO also produces inhibitory potentials but with a slower time course, while VIP produces slow tonic relaxations. The proportions of these three transmitters varies considerably in different regions of the gut and in different species; for example, in some sphincters the NANC inhibitory nerves utilize largely VIP, in others largely NO, while in non-sphincteric regions of the intestine ATP is more prominent. In recent papers, evidence has suggested that ACh and ATP are fast excitatory cotransmitters to myenteric neurons and that there may be colocalization of ACh, ATP and 5-HT in enteric Dogiel Type I/S neurons. Detailed studies have allowed a very complete mapping of the complex neuronal markers and
I. INTRODUCTION
30
5. CoTRANSmISSIoN
FIGURE 5.2 Schematic hypotheses of the neurogenic basis of reflex vasodilatation of skin vessels. One suggestion is that substance P (a putative transmitter in sensory nerve endings in the spinal cord) is released from sensory nerve collaterals in the skin; another that ATP is the transmitter released from these collaterals. Both substances are powerful vasodilators and can release histamine from mast cells. ATP is also a potent inducer of prostaglandin synthesis. Another alternative, although less likely, is that a peripherally placed purinergic neuron is interposed between the sensory nerve collateral and the effector system. (This hypothesis incorporates early histologic reports of neurons in the skin and provides an alternative or additional explanation for the initiation of the vasodilator reflex by nicotine and its block by hexamethonium.) (Reproduced from [15], with permission.)
projections of enteric neurons. Several peptidergic substances, including NPY, VIP, enkephalin, somatostatin, peptide histidine isoleucine, galanin, SP and CGRP have been identified in enteric neurons, often coexisting (up to five peptides in the same neuron) with the neurotransmitters NA, ACh, 5-HT, NO and ATP (see Table 5.2). Studies of intrinsic cardiac neurons in culture have shown that subpopulations of intrinsic nerves in the atrial and intra-atrial septum contain and/or release cotransmitters, including ATP, NO, NPY, ACh and 5-HT. Many of these nerves project to the coronary microvasculature and produce potent vasomotor actions. NO together with ATP have been shown to be the mediators of NANC vasodilatation of the rabbit portal vein.
PHYSIOLOGICAL SIGNIFICANCE OF COTRANSMISSION In general, cotransmission offers greater physiological events by peripheral mechanisms rather than the all-ornone control by messages coming from the CNS, that has been the dominant view for many years (see [11]).
Cotransmitters with Different Firing Patterns Although single presynaptic action potentials release small molecule neurotransmitters, trains of impulses are
needed to release neuropeptides. For sympathetic and parasympathetic cotransmission, release of ATP is favored at low frequency stimulation, whereas NA and ACh are released at higher frequencies. There are instances where more than one fast cotransmitter is released (e.g. glutamate and ATP) together with one or more peptides.
Different Cotransmitters act on Different Postjunctional Cells Neurons using multiple transmitters may project to two or more targets. For example, ACh released at low frequency stimulation from parasympathetic nerves supplying salivary glands acts on acinar cells to produce secretion and a minor dilatation of vessels, whereas, at higher frequency stimulation, its cotransmitter VIP causes powerful vasodilatation of vessels in the glands and postjunctional enhancement of ACh-induced saliva secretion.
Neuromodulation A cotransmitter can feed back on presynaptic receptors that increase or decrease its own release or that of its cotransmitter(s). For example, ATP released as a cotransmitter with glutamate from primary afferent fibers in lamina II of the spinal cord can act on prejunctional P2X3 receptors to facilitate the release of its cotransmitter, glutamate,
I. INTRODUCTION
31
PHySIologICAl SIgNIfICANCE of CoTRANSmISSIoN
TABLE 5.2 Types of Neurons in the Enteric Nervous System Proportion
Chemical Coding
Function/Comments
Excitatory circular muscle motor neurons
12%
Short: ChAT/TK/ENK/GABA Long: ChAT/TK/ENK/NFP
To all regions, primary transmitter ACh, cotransmitter TK
Inhibitory circular muscle motor neurons
16%
Short: NOS/VIP/PACAP/ENK/ NPY/GABA Long: NOS/VIP/PACAP/ Dynorphin/BN/NFP
Several cotransmitters with varying prominence: NO, ATP, VIP, PACAP
Excitatory longitudinal muscle motor neurons
25%
ChAT/Calretinin/TK
Primary transmitter ACh, cotransmitter TK
Inhibitory longitudinal muscle motor neurons
~2%
NOS/VIP/GABA
Several cotransmitters with varying prominence: NO, ATP, VIP, PACAP
Ascending interneurons (local reflex)
5%
ChAT/Calretinin/TK
Primary transmitter ACh
Descending interneurons (local reflex)
5%
ChAT/NOS/VIP BN NPY
Primary transmitter ACh, ATP may be a cotransmitter
Descending interneurons (secretomotor reflex)
2%
ChAT/5-HT
Primary transmitter ACh, 5-HT (at NK3 receptors)
Descending interneurons (migrating myoelectric complex)
4%
ChAT/SOM
Primary transmitter ACh
Myenteric intrinsic primary afferent (primary sensory) neurons
26%
ChAT/Calbindin/TK/NK3 receptor
Primary transmitter TK
Intestinofugal neurons
1%
ChAT/BN/VIP/CCK/ENK
Primary transmitter ACh
Motor neurons to gut endocrine cells
N/A
N/A
For example, myenteric neurons innervating gastrin cells. Neurons of this type may be in submucosal ganglia
Non-cholinergic secretomotor/vasodilator neurons
45%
VIP/GAL
Primary transmitter VIP. A small proportion of these have cell bodies in myenteric ganglia
Cholinergic secretomotor/vasodilator neurons
15%
ChAT/Calretinin/Dynorphin
Primary transmitter ACh
MYENTERIC NEURONS
SUBMUCOSAL NEURONS
*Also listed are three types of motor neuron that are found in other parts of the tubular digestive tract, marked by asterisks. Reproduced from [13], with permission from Elsevier. ACh, acetylcholine; ATP, adenosine 5-triphosphate; BN, bombesin; CCK, cholecystokinin; CGRP, calcitonin gene-related peptide; ChAT, choline acetyltransferase; DA, dopamine; ENK, enkephalin; GABA, γ-amino butyric acid; GAL, galanin; 5-HT, 5-hydroxytryptamine; NA, noradrenaline; NFP, neurofilament protein; NK, neurokinin; NOS, nitric oxide synthase; NPY, neuropeptide Y; PACAP, pituitary adenylyl cyclase activating peptide; SOM, somatostatin; SP, substance P; TK, tachykinin; VIP, vasoactive intestinal peptide.
whereas adenosine resulting from ectoenzymatic breakdown of ATP acts on presynaptic P1 receptors to inhibit glutamate release. Both NA and ATP can prejunctionally modulate sympathetic transmission, NA via prejunctional α2-adrenoceptors and ATP via P1 receptors following breakdown to adenosine. Modulation of cotransmitter release and presynaptic action by other agents also occurs and might provide a new level of synaptic flexibility, in which individual neurons utilize more than one transmitter but retain independent control over their synaptic activity.
Synergism There are an increasing number of reports of the synergistic actions of cotransmitters. ATP and NA released from sympathetic nerves have synergistic actions on
smooth muscle of vas deferens and blood vessels, and ATP released with ACh from motoneurons facilitates the nicotinic actions of ACh at the skeletal neuromuscular junction. Co-operativity between receptors for ATP and N-methyl-D-aspartate (NMDA) in induction of long-term potentiation in hippocampal CA1 neurons has also been demonstrated. Thyrotropin-releasing hormone and 5-HT have been reported to have synergistic actions in spinal cord neurons. The mechanisms underlying cotransmitter synergism are not well understood. However, it has been suggested that postjunctional synergism between the responses of vas deferens to NA and ATP is caused by the ability of NA to potentiate the contractile responses to ATP by sensitizing smooth muscle cells to Ca2 via an inhibitory action on myosin light chain phosphatase, an action mediated by protein kinase C.
I. INTRODUCTION
32
5. CoTRANSmISSIoN
Negative Cross-Talk Co-application of nicotinic and P2X receptor agonists produces less than the additive responses predicted by independent receptor activation. Inhibitory interactions between 5-HT3 and P2X receptors have been described in submucosal and myenteric neurons.
Trophic Factors Some co-stored and co-released substances can act as long-term (trophic) factors, as well as neurotransmitters. For example, ATP can act on P2 receptors, or P1 (adenosine) receptors after ectoenzymatic breakdown, to promote vascular cell proliferation, motility, differentiation or death. NPY released from sympathetic nerves has cardiovascular trophic effects in end-stage renal disease. There is growing evidence that neurotrophic factors might be synthesized, stored and released from nerve terminals together with fast neurotransmitters.
Excitatory and Inhibitory Cotransmitters Although cotransmitters generally have similar actions on postjunctional cells, there are some examples of cotransmitters having opposite actions. For example, in the mammalian uterus, one or other cotransmitter dominates depending on the hormonal and/or tonic status of the postjunctional muscle cells. Brain-derived neurotrophic factor (BDNF) increases the release of ACh and reduces NA release from sympathetic nerves to cause a rapid shift from excitatory to inhibitory transmission.
False Cotransmitters For example, it has been known for some time that sympathetic nerves take up 5-HT, which can then be released as a “false transmitter”, rather than a genuine “cotransmitter”. A “false transmitter” is a substance actively taken up and subsequently released by a neuron that does not synthesize it.
Coexisting Peptides Acting as Neuromodulators In general, most neuropeptides act as neuromodulators rather than neurotransmitters. For example, NPY released from sympathetic nerves acts as a pre- and postjunctional modulator of ATP and NA release and postjunctional actions.
COTRANSMITTER PLASTICITY Cotransmitter plasticity occurs during development and ageing, following trauma or surgery and after chronic exposure to drugs, as well as in disease (see [12]). There were some outstanding early studies of the factors
influencing cotransmitter expression in sympathetic nerves. Evidence was presented that cholinergic differentiation in sympathetic neurons is promoted by neurotrophic factors from three different protein families (glial cell line-derived neurotrophic factor, neurotrophin 3 and ciliary neurotrophic factor), whereas noradrenergic differentiation is promoted by nerve growth factor. In another study, BDNF was claimed to switch sympathetic neurotransmission to the heart from an adrenergic excitation to cholinergic inhibition; it was also shown that the action of BDNF was mediated by the P75 neurotrophic receptor. Histamine, galanin and γ-aminobutyric acid (GABA) acting as cotransmitters in neurons of the tuberomammillary nucleus (hypothalamus) have independent control mechanisms. CGRP-like immunoreactivity was found earlier than SP-like immunoreactivity in cerebrovascular nerves during development, and increased in old age, while the density of SP-like immunoreactive fibers did not change. NA and NPY also show different expression in cerebrovascular nerves during development. Changes in chemical coding of myenteric neurons in ulcerative colitis have been reported, with a shift from cholinergic to more SP-mediated cotransmission. In interstitial cystitis and outflow obstruction, there is a substantial increase in ATP as the cotransmitter with ACh in parasympathetic nerves supplying the human bladder, and there is increase in ATP as a cotransmitter with NA in sympathetic nerves in spontaneous hypertensive rats (see [4]).
CONCLUDING COMMENTS It has been particularly difficult to establish cotransmitter roles for the many peptides found in nerves, partly because specific receptors and physiological roles have not been established for some of these and partly because of the lack of selective antagonists. In some enteric neurons, up to five neuropeptides have been identified. However, it is important to distinguish between neuromodulator, neurotransmitter and neurotrophic roles for released peptides or indeed as yet unrecognized roles. It is becoming clear that ATP is a primitive signalling molecule that has been retained as a cotransmitter in every nerve type in both the peripheral and central nervous systems, although the relative role of ATP varies considerably in different species and pathophysiological conditions. ATP appears to become a more prominent cotransmitter in stress and inflammatory conditions. Most nerves contain and release ATP as a fast cotransmitter together with classical transmitters such as ACh, NA, glutamate, GABA and one or more peptides. Now that cotransmission is recognized as a universal mechanism, it is recommended that the terms “adrenergic”, “cholinergic”, “peptidergic”, “purinergic”, “aminergic” and “nitrergic” should not be used when nerves are described, although adrenergic, cholinergic, peptidergic, purinergic, aminergic or nitrergic transmission is still meaningful.
I. INTRODUCTION
CoNCludINg CommENTS
References [1] Burnstock G. Do some nerve cells release more than one transmitter? Neuroscience 1976;1:239–48. [2] Kupfermann I. Functional studies of cotransmission. Physiol Rev 1991;71:683–732. [3] Merighi A. Costorage and coexistence of neuropeptides in the mammalian CNS. Prog Neurobiol 2002;66:161–90. [4] Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 2007;87:659–797. [5] Furness JB, Morris JL, Gibbins JL, Costa M. Chemical coding of neurons and plurichemical transmission. Ann Rev Pharmacol Toxicol 1989;29:289–306. [6] Su C, Bevan JA, Burnstock G. [3H]adenosine triphosphate: release during stimulation of enteric nerves. Science 1971;173:337–9. [7] Sneddon P, Burnstock G. Inhibition of excitatory junction potentials in guinea-pig vas deferens by α,β-methylene-ATP: further evidence for ATP and noradrenaline as cotransmitters. Eur J Pharmacol 1984;100:85–90. [8] Burnstock G. Noradrenaline and ATP as cotransmitters in sympathetic nerves. Neurochem Int 1990;17:357–68.
33
[9] Lundberg JM. Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Pharmacol Rev 1996;48:113–78. [10] Burnstock G. Cotransmission with particular emphasis on the involvement of ATP. In: Fuxe K, Hökfelt T, Olson L, Ottoson D, Dahlström A, Björklund A, editors. Molecular Mechanisms of Neuronal Communication. A Tribute to Nils-Ake Hillarp. Oxford: Pergamon Press; 1996. p. 67–87. [11] Burnstock G. Cotransmission. Curr Opin Pharmacol 2004;4:47–52. [12] Burnstock G. Co-transmission. The fifth Heymans memorial lecture – Ghent, February 17, 1990. Arch Int Pharmacodyn Ther 1990;304:7–33. [13] Furness JB. Types of neurons in the enteric nervous system. J Auton Nerv Syst 2000;81:87–96. [14] Burnstock G, Verkhratsky A. Vas deferens - a model used to establish sympathetic cotransmission. Trends Pharmacol Sci 2010;31:131–9. [15] Burnstock G. Autonomic neuroeffector junctions - reflex vasodilatation of the skin. J Invest Dermatol 1977;69:47–57.
I. INTRODUCTION
P A R T II
BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00001-9
© 2012 Elsevier Inc. All rights reserved.
C H A P T E R
6 Noradrenergic Neurotransmission David S. Goldstein The main chemical transmitter of the sympathetic nervous system mediating regulation of the circulation is the catecholamine norepinephrine (NE). Sympathetic stimulation releases NE, and binding of NE to adrenoceptors on cardiovascular smooth muscle cells causes the cells to contract. Sympathoneural NE therefore satisfies the main criteria defining a neurotransmitter – a chemical released from nerve terminals by electrical action potentials that interacts with specific receptors on nearby structures to produce specific physiological responses. Unlike most other neurotransmitters, NE can be measured in human plasma. This capability, coupled with the ability to assay simultaneously levels of NE and other compounds related to synthesis and disposition of NE, provides the bases for clinical neurochemical biomarkers of sympathetic innervation and function and for metabolomic approaches to diagnose several disorders. Such neurochemical measures often are more sensitive than physiological measures in clinical laboratory assessments of patients with autonomic dysfunction.
fibers in the ansae subclaviae pass along the dorsal surface of the pulmonary artery into the plexus that supplies the left main coronary artery. In primates, cardiac sympathetic nerves originate about equally from the superior, middle, and inferior cervical (stellate) ganglia. The right sympathetic chain generally projects to the anterior left ventricle and the left to the posterior left ventricle. Sympathetic innervation of the sinus and atrioventricular nodes also has a degree of sidedness, the right sympathetics projecting more to the sinus node and the left to the atrioventricular node. This sidedness means that left stellate stimulation produces relatively little sinus tachycardia. Epicardial sympathetic nerves provide the main source of noradrenergic terminals in the myocardium. Sympathetic nerves travel with the coronary arteries in the epicardium before penetrating into the myocardium, whereas vagal nerves penetrate the myocardium after crossing the atrioventricular groove and then course distally in the subendocardium. Post-ganglionic noradrenergic fibers reach all parts of the heart. The sinus and atrioventricular nodes and the atria receive the densest innervation, the ventricles less dense innervation, and the Purkinje fibers the least. Sympathetic and vagal afferents follow similar intracardiac routes to those of the efferents. The heart contains relatively high NE concentrations compared to other organs. In humans, the left ventricular myocardial NE concentration is roughly 10 pmoles per mg wet weight, with substantial inter-individual variability, corresponding to about 10 times the plasma concentration. The coronary arteries possess sympathetic noradrenergic innervation, but assessing the physiological role of this innervation has proven difficult, because several interacting factors complicate neural control of the coronary vasculature. Alterations in myocardial metabolism and systemic hemodynamics change coronary blood flow, coronary vasomotion in response to sympathetic stimulation depends on the functional integrity of the endothelium, and coronary arteries appear to possess less dense innervation than do other arteries. The body’s myriad arterioles largely determine total resistance to blood flow in the body and therefore contribute importantly to blood pressure. Sympathetic nerves enmesh blood vessels in lattice-like networks in the adventitial outer surface that extend inward to the adventitial-medial border. The concentration of sympathetic
CATECHOLAMINES, AND CATECHOLS The endogenous catecholamines are NE, dopamine (DA), and epinephrine (EPI, synonymous with adrenaline). Catecholamines are catechols, which are chemicals that have adjacent hydroxyl groups on a benzene ring. Catechol itself does not exist in the human body, but compounds that contain catechol as part of their molecular structure are called catechols. Human plasma normally contains six catechols – the catecholamines, L-DOPA (the amino acid precursor of the catecholamines), and two metabolites of the catecholamines, dihydroxyphenylglycol (DHPG, the main neuronal metabolite of NE), and dihydroxyphenylacetic acid (DOPAC, the main neuronal metabolite of DA). As will be seen, particular patterns of levels of catechols characterize different disorders of catecholamine systems.
NORADRENERGIC INNERVATION OF THE CARDIOVASCULAR SYSTEM Sympathetic nerves to the heart travel via the ansae subclaviae, branches of the left and right stellate ganglia. The
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00006-8
37
© 2012 Elsevier Inc. All rights reserved.
38
6. NORADRENERGIC NEuROTRANSMISSION
nerves increases as the arterial caliber decreases, so that small arteries and arterioles, the smallest nutrient vessels possessing smooth muscle cells, have the most intense innervation. The architectural association between sympathetic nerves and the vessels that determine peripheral resistance has enticed cardiovascular researchers particularly in the area of autonomic regulation for many years. Sympathetic vascular innervation varies widely among vascular beds, with dense innervation of resistance vessels in the gut, kidney, skeletal muscle, and skin. Sympathetic stimulation in these beds produces profound vasoconstriction, whereas stimulation in the coronary, cerebral, and bronchial beds elicits weaker constrictor responses, consistent teleologically with the “goal” of preserving blood flow to vital organs in emergencies.
NOREPINEPHRINE: THE MAIN SYMPATHETIC CARDIOVASCULAR NEUROTRANSMITTER Norepinephrine Synthesis Catecholamine biosynthesis begins with uptake of the amino acid tyrosine (TYR) into the cytoplasm of sympathetic neurons, adrenomedullary cells, possibly para-aortic enterochromaffin cells, and specific centers in the brain. Tyrosine hydroxylase (TH) catalyzes the conversion of TYR to DOPA. This is the enzymatic rate-limiting step in catecholamine synthesis. The enzyme is stereospecific, and tetrahydrobiopterin, ionized iron, and molecular oxygen regulate TH activity. Dihydropteridine reductase (DHPR) catalyzes the reduction of dihydropterin, produced during the hydroxylation of TYR. Since the reduced pteridine, tetrahydrobiopterin, is a key co-factor for TH, DHPR deficiency decreases the amount of TYR hydroxylation for a given amount of TH enzyme. Both phenylalanine hydroxylase and TH require tetrahydrobiopterin as a co-factor. DHPR deficiency therefore also inhibits phenylalanine metabolism and presents clinically as an atypical form of phenylketonuria. Multiple and complex mechanisms contribute to TH activation. Short-term mechanisms include feedback inhibition by DOPA and catecholamines and phosphorylation of the enzyme, the latter depending on membrane depolarization, contractile elements, and receptors. Long-term mechanisms include changes in TH synthesis. During stress-induced sympathetic stimulation, acceleration of catecholamine synthesis in sympathetic nerves helps to maintain tissue stores of NE. Even with diminished stores after prolonged sympathoneural activation, increased nerve traffic can maintain extracellular fluid levels of the transmitter. L-aromatic-amino-acid decarboxylase (LAAAD, also called DOPA decarboxylase) catalyzes conversion of DOPA to DA. Many types of tissues contain this enzyme – especially the kidneys, gut, liver, and brain. LAAAD activity depends on pyridoxal phosphate (vitamin B6).
Although LAAAD metabolizes most of the DOPA formed in catecholamine-synthesizing tissues, some of the DOPA enters the circulation unchanged. This provides the basis for using plasma DOPA levels to examine catecholamine synthesis. LAAAD inhibitors include carbidopa and benserazide. Both are catechols that do not readily penetrate the blood–brain barrier. By inhibiting conversion of DOPA to DA in the periphery, carbidopa and benserazide enhance the efficacy of L-DOPA and reduce its side effects in the treatment for Parkinson disease. LAAAD blockade increases DOPA levels and decreases levels of DOPAC, the deaminated metabolite of DA. Rates of increase in extracellular fluid DOPA levels and of decrease in DOPAC levels after acute LAAAD inhibition provide in vivo indices of TH activity. Dopamine-β-hydroxylase (DBH) catalyzes conversion of DA to NE. DBH is localized to vesicles in cells that synthesize catecholamines, such as noradrenergic neurons and chromaffin cells. Treatment with reserpine, which blocks translocation of amines from the axonal cytoplasm into vesicles, prevents conversion of DA to NE in sympathetic nerves. DBH contains – and its activity depends on – copper. Because of this dependence, children with Menkes disease, a rare, X-linked recessive inherited disorder of copper metabolism, have neurochemical evidence of concurrently increased catecholamine biosynthesis and decreased conversion of DA to NE, with high plasma ratios of DOPA:DHPG. Patients with congenital absence of DBH have virtually undetectable levels of both NE and DHPG and high levels of DA and DOPAC. DBH activity also requires ascorbic acid (vitamin C), which provides electrons for the hydroxylation. Phenylethanolamine-N-methyltransferase (PNMT) catalyzes the conversion of NE to EPI in the cytoplasm of chromaffin cells and some brainstem neurons.
Norepinephrine Storage Vesicles generated near the Golgi apparatus in cell bodies travel by axonal transport to the nerve terminals. Noradrenergic vesicles may also form by endocytosis within the axons. Since reserpine eliminates the electrondense cores of the small but not the large vesicles, the cores of the small vesicles may represent NE, whereas the electron-dense cores of the large vesicles may represent additional components. Cores of both types of vesicle contain adenosine triphosphate (ATP). The vesicles also contain at least three types of polypeptides: chromogranin A, an acidic glycoprotein; enkephalins; and neuropeptide Y (NPY). Extracellular fluid levels of each of these compounds have been considered as indices of exocytosis. Vesicles in sympathetic nerves actively remove and trap axoplasmic amines via the type 2 vesicular monoamine transporter (VMAT). Adrenomedullary chromaffin cells express both types of VMAT. Vesicular uptake favors l- over d-NE, Mg and ATP accelerate the uptake, and reserpine effectively and irreversibly blocks it. VMAT
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
NOREPINEPHRINE: THE MAIN SyMPATHETIC CARDIOvASCuLAR NEuROTRANSMITTER
proteins resemble the neuronal uptake carriers of the cell membrane. Neurotransmitter specificity appears to depend on different transporters in the cell membrane rather than on different vesicular transporters. Tissue NE stores are maintained by a balance of synthesis and loss. Under resting conditions, the main determinant of loss of NE from the tissue is net leakage of NE from the vesicles into the axoplasm, with subsequent enzymatic breakdown of the axoplasmic NE. This loss is balanced by ongoing synthesis of DA in the neuronal cytosol, vesicular uptake of cytosolic DA, and conversion of DA to NE catalyzed by DBH. Sympathetic neuroimaging using radio-iodinated metaiodobenzylguanidine, positron-emitting analogs of sympathomimetic amines, and 6-[18F]fluorodopamine depends on uptake of the imaging agents into the axoplasm via the cell membrane norepinephrine transporter (NET) and subsequent translocation into vesicles via the VMAT. Visualization of sympathetic innervation in organs such as the heart, therefore, results in radiolabeling of the vesicles in noradrenergic nerves.
Norepinephrine Release Adrenomedullary chromaffin cells, much easier to study than sympathetic nerves, have provided the most commonly used model for studying mechanisms of catecholamine release. Agonist occupation of nicotinic acetylcholine receptors releases catecholamines from the cells. Since nicotinic receptors mediate ganglionic neurotransmission, researchers have presumed that findings in adrenomedullary cells apply to post-ganglionic sympathetic noradrenergic neurons. Low plasma levels of NE in patients with autoimmune autonomic ganglionopathy from circulating antibodies to the neuronal nicotinic receptor support this view. According to the exocytotic theory of NE release, acetylcholine depolarizes terminal membranes by increasing membrane permeability to sodium. The increased intracellular sodium levels directly or indirectly enhance transmembrane influx of calcium, via voltage-gated calcium channels. The increased cytoplasmic calcium concentration evokes a cascade of biomechanical events resulting in fusion of the vesicular and axoplasmic membranes. Vesicle poration causes the interior of the vesicle to exchange with the extracellular compartment, and the soluble contents of the vesicles diffuse into the extracellular space. As predicted from this model, manipulations besides application of acetylcholine that depolarize the cell, such as electrical stimulation or increased K concentrations in the extracellular fluid, also activate voltage-gated calcium channels and trigger exocytosis. During cellular activation, simultaneous, stoichiometric release of soluble vesicular contents – ATP, enkephalins, chromogranins, and DBH – without similar release of cytoplasmic macromolecules, has provided biochemical support for the exocytosis theory.
39
At least two storage pools of NE seem to exist in sympathetic nerve terminals – a small, readily releasable pool of newly-synthesized NE and a large reserve pool in longterm storage. Because of conversion of DA to NE within vesicles, plasma DA responses during sympathetic stimulation may reflect release from the readily releasable pool. Sympathetic nerve endings can also release NE by calcium-independent, non-exocytotic mechanisms. One such mechanism is reverse transport through the neuronal uptake carrier. The indirectly acting sympathomimetic amine, tyramine, releases NE non-exocytotically, since tyramine releases NE independently of calcium and does not release DBH. Myocardial ischemic hypoxia also evokes calcium-independent release of NE. As noted above, sympathetic stimulation releases other compounds besides NE. Some of these compounds may function as co-transmitters. ATP, adenosine, NPY, acetylcholine, DA, and EPI have received the most attention. Pharmacological stimulation of a large variety of receptors on noradrenergic terminals affects the amount of NE released during cellular activation. Compounds inhibiting NE release include acetylcholine, gamma-aminobutyric acid (GABA), prostaglandins of the E series, opioids, adenosine, and NE itself. Compounds enhancing NE release include angiotensin II, acetylcholine (at nicotinic receptors), ACTH, GABA (at GABAA receptors), and EPI (via stimulation of pre-synaptic β2-adrenoceptors). In general, whether at physiological concentrations these compounds exert modulatory effects on endogenous NE release remains unproven, especially in humans. An exception, however, is inhibitory presynaptic modulation by NE itself, via autoreceptors on sympathetic nerves. This modulatory action appears to vary with the vascular bed under study, being prominent in skeletal muscle beds such as the forearm, relatively weak in the kidneys, and virtually absent in the adrenals. In addition to local feedback control of NE release, reflexive “long-distance” feedback pathways via high- and low-pressure baroreceptors elicit reflexive changes in sympathoneural impulse activity. Alterations in receptor numbers or of intracellular biomechanical events after receptor activation also affect responses to agonists. These factors may, therefore, regulate NE release by trans-synaptic local and reflexive long-distance mechanisms. NE released from sympathetic nerve terminals acts mainly locally, with only a small proportion of released NE reaching the bloodstream. One must, therefore, keep in mind the indirect and distant relationship between plasma NE levels and sympathetic nerve activity in interpreting plasma NE levels in response to stressors, pathophysiologic situations, and drugs.
Norepinephrine Disposition NE is inactivated mainly by uptake into cells, with subsequent intracellular metabolism or storage (Fig. 6.1). Reuptake into nerve terminals – Uptake-1 – via the cell
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
40
6. NORADRENERGIC NEuROTRANSMISSION Exo
VMA
Exo
DAv
DBH
LIVER
NEv
3-MT
VMA NET
3-MT
NET Leak
VMAT
COMT
ADH, ALDH
VMAT
DA DOPA TYR
TH
DOPA
LAAAD
NE
NEc
DAc MAO
COMT
COMT
3-OMeTyramine
NMN DOPAL
3-OMeTyramine
AR
HVA
DOPET
DOPEGAL
ALDH
DOPAC
AR
DHPG
COMT
NMN
ALDH
MHPG
DHMA COMT
HVA DOPAC
MHPG
DHPG
FIGURE 6.1 Diagram of steps in norepinephrine biosynthesis, release, cellular uptake, and metabolism. Abbreviations: ADH, alcohol dehydrogenase; ALDH, aldehyde dehydrogenase; AR, aldose/aldehyde reductase; COMT, catechol-O-methyltransferase; DA, dopamine; DBH, dopamine-β-hydroxylase; DHMA, dihydroxymandelic acid; DHPG, dihydroxyphenylglycol; DOPA, dihydroxyphenylalanine; DOPAC, dihydroxyphenylacetic acid; DOPEGAL, dihydroxyphenylglycolaldehdye; Exo, exocytosis; HVA, homovanillic acid; LAAAD, L-aromatic-amino-acid decarboxylase; MAO, monoamine oxidase; MHPG, methoxyhydroxyphenylglycol; 3-MT, 3-methoxytyrosine; 3-OMdTyramine, 3-methoxytyramine; NEc, cytoplasmic norepinephrine; NEv, vesicular norepinephrine; NET, cell membrane norepinephrine transporter; NMN, normetanephrine; TH, tyrosine hydroxylase; TYR, tyrosine; VMA, vanillylmandelic acid; VMAT, vesicular monoamine transporter.
membrane NET is the predominant means of terminating the actions of released NE. Uptake-1 is energy-requiring and can transport catecholamines against large concentration gradients. The only common structural feature of all known substrates for Uptake-1 is an aromatic amine, with the ionizable nitrogen moiety not incorporated in the aromatic system. Uptake-1 does not require a catechol nucleus. Alkylation of the primary amino group decreases the effectiveness of the transport, explaining why sympathetic nerves take up NE more efficiently than they do EPI and why they do not take up isoproterenol, an extensively alkylated catecholamine, at all. Methylation of the phenolic hydroxyl groups also markedly decreases susceptibility to Uptake-1, and so sympathetic nerves do not take up O-methylated catecholamine metabolites such as normetanephrine. Many drugs or in vitro conditions inhibit Uptake-1, including cocaine, tricyclics such as desipramine, NET blockers such as reboxetine, low extracellular Na concentrations, and Li(Fig. 6.2). Neuronal uptake absolutely requires intracellular K and extracellular Na. Transport does not directly require ATP; however, maintaining ionic gradients across cell membranes depends on ATP, and the carrier uses the energy expended in maintaining the transmembrane Na gradient to co-transport amines with Na.
There are distinct cell membrane transporters for NE and DA. The human NET protein includes 12–13 hydrophobic and therefore membrane-spanning domains, a structure that differs substantially from that of adrenoceptors and other receptors coupled with G-proteins but resembles that of transporters for DA, GABA, serotonin, and vesicular monoamines. Non-neuronal cells remove NE actively by a process called Uptake-2, which is characterized by the ability to transport isoproterenol, susceptibility to blockade by O-methylated catecholamines, corticosteroids, and β-haloalkylamines, and absence of susceptibility to blockade by cocaine and tricyclics. In contrast with Uptake-1, Uptake-2 functions independently of extracellular Na. The Uptake-2 carrier has little if any stereoselectivity and has low affinity and specificity for catecholamines. For instance, extraneuronal cells remove imidazolines such as clonidine by Uptake-2. Whereas reverse transport via the Uptake-1 carrier requires special experimental conditions, one can readily demonstrate reverse transport via the Uptake-2 carrier. Because of reverse transport, during infusion of a catecholamine at a high rate, the catecholamine can accumulate in extraneuronal cells, with re-entry of the catecholamine into the extracellular fluid via the Uptake-2 carrier after the infusion ends.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
NOREPINEPHRINE: THE MAIN SyMPATHETIC CARDIOvASCuLAR NEuROTRANSMITTER
SNS
Uptake-1
PLASMA
NE
FIGURE 6.2 Diagram of sympathoneural, hepatic, adrenomedullary, and gut contributions to plasma levels of norepinephrine and its metabolites. Additional abbreviations: DHPG-S, DHPG sulfate; MHPG-S, MHPG sulfate; MN-S, MN sulfate; mPST, monoamine-preferring phenolsulfotransferase; NMN-S, NMN sulfate.
NE NE
MAO
41
DHPG
MHPG
GUT CELL
DHPG
LIVER CELL
COMT MAO AD
VMA
VMA DHPG-S MHPG-S
COMT
EPI, NE NMN
DHPG-S MHPG-S
NMN-S
NMN-S
ADRENOMEDULLARY CELL
mPST
mPST
NMN
Norepinephrine Metabolism NE taken up into the axoplasm by the Uptake-1 transporter is subject to two fates, translocation into storage vesicles and deamination by monoamine oxidase (MAO). The combination of enzymatic breakdown and vesicular uptake constitute an intraneuronal “sink,” which keeps axoplasmic NE concentrations very low. Reserpine prevents the conservative recycling of NE and depletes NE stores. After reserpine injection, plasma DHPG levels increase rapidly, reflecting marked net leakage of NE from vesicular stores, and then decline to very low levels, reflecting decreased vesicular uptake of DA and decreased conversion of DA to NE. MAO catalyzes the oxidative deamination of DA to form DOPAC and of NE to form DHPG. Because of the efficient uptake and reuptake of catecholamines into the axoplasm of catecholamine neurons, and the rapid exchange of amines between the vesicles and axoplasm, the neuronal pool of MAO, located in the outer mitochondrial membrane, figures prominently in the overall functioning of catecholamine systems. Two isozymes of MAO, MAO-A and MAO-B, have been described. Clorgyline blocks MAO-A, and deprenyl and rasagiline block MAOB. MAO-A predominates in neural tissue, whereas both subtypes exist in non-neuronal tissue. Inhibitors of MAO-A potentiate pressor effects of tyramine, whereas inhibitors of MAO-B do not. NE and EPI are substrates for MAO-A, and DA is a substrate for both MAO-A and MAO-B. The immediate products of the deamination are short-lived aldehydes. For DA, the aldehyde intermediate,
dihydroxyphenylacetaldehyde (DOPAL) is converted rapidly to DOPAC by aldehyde dehydrogenase; for NE, the aldehyde intermediate is converted mainly to DHPG by an aldehyde/aldose reductase. The formation of the aldehydes reduces a flavine component of the enzyme. The reduced enzyme reacts with molecular oxygen, regenerating the enzyme but also producing hydrogen peroxide. Catechol-O-methyltransferase (COMT) in non-neuronal cells catalyzes the O-methylation of DHPG to form methoxyhydroxyphenylglycol (MHPG) and of DOPAC to form homovanillic acid (HVA). In the liver MHPG is converted vanillylmandelic acid (VMA), and in splanchnic organs catecholamines (especially DA) and their glycol metabolites are extensively sulfoconjugated. The main end-products of NE metabolism in plasma, therefore, are MHPG, conjugated MHPG, and VMA. Although MAO inhibitors are effective anti-depressants, a phenomenon known as the “cheese effect” limits their clinical use. In patients taking MAO inhibitors, administration of sympathomimetic amines such as in many nonprescription decongestants or ingestion of foods such as aged cheese, wine, or meat, which contain tyramine, can produce paroxysmal hypertension. Since tyramine and other sympathomimetic amines displace NE from sympathetic vesicles into the axoplasm, blockade of MAO in this setting causes non-exocytotic NE release, stimulating cardiovascular smooth muscle cells and producing intense vasoconstriction and hypertension. COMT catalyzes the conversion of NE to normetanephrine (NMN) and EPI to metanephrine (MN). Uptake-2 and COMT probably act in series to remove and degrade
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
42
6. NORADRENERGIC NEuROTRANSMISSION
circulating catecholamines. The methyl group donor for the reaction is S-adenosyl methionine. COMT is expressed by non-neuronal cells and adrenomedullary chromaffin cells but not by sympathetic neurons. Ongoing production of NMN and MN in such cells explains the high sensitivity of plasma levels of free (unconjugated) metanephrines in the diagnosis of pheochromocytomas, which are chromaffin cell tumors.
BIOMARKERS OF SYMPATHETIC NORADRENERGIC INNERVATION AND FUNCTION Simultaneous measurement of plasma levels of NE and its metabolites provides valuable information about sympathetic noradrenergic innervation and function. In general, sympathetic noradrenergic stimulation produces similar absolute increments in plasma NE and DHPG levels. In contrast, decreased Uptake-1 activity increases plasma levels of plasma NE more than of DHPG. Under resting conditions plasma DHPG is determined mainly by net leakage of NE from vesicles into the cytosol – an ongoing passive process. Thus, plasma DHPG is related indirectly to NE stores in sympathetic nerves. Because loss of sympathetic noradrenergic terminals can compensatorily increase nerve traffic, NE release and plasma NE levels may be maintained until denervation is advanced. Accordingly, plasma DHPG provides a more sensitive index of sympathetic noradrenergic denervation than does plasma NE. Assessments of effects of neuropharmacologic probes such as tyramine, desipramine, atomoxetine, yohimbine, clonidine, trimethaphan, and isoproterenol are often included in clinical studies of sympathetic noradrenergic function. In general, physiological measurements such as of blood pressure, heart rate, or local vascular resistances are not as sensitive as neurochemical measurements in detecting and characterizing sympathetic noradrenergic dysfunction. This is because patients with autonomic failure typically also have baroreflex failure, and patients with sympathetic noradrenergic denervation typically also have augmented cardiovascular responses to agonists at adrenoceptors, complicating the relationship between NE release and physiological dependent measures.
NE AND METABOLOMICS Patterns of plasma levels of catechols yield metabolomic information reflecting abnormal enzymatic activities that can be relevant to the diagnosis of several disorders. Because of the dependence of DBH on copper, all patients with Menkes disease, an X-linked recessive disorder of a copper-ATPase, have high plasma DOPAC:DHPG and DA:NE ratios. Familial dysautonomia and DBH deficiency also entail elevated ratios of DA metabolites to NE
metabolites. Due to the vesicular localization of DBH, the same abnormal pattern characterizes low VMAT-2 activity. Decreased TH activity, from reduced synthesis either of the enzyme itself or of the required co-factor tetrahydrobiopterin, results in low levels of all the endogenous catechols. LAAAD deficiency is associated with high DOPA:NE, DOPA:DHPG, and DOPA:DOPAC ratios. Decreased Uptake-1 activity, such as by hypofunctional mutation of the gene encoding the NET, results in relatively larger increments in plasma NE than in plasma DHPG during sympathetic noradrenergic stimulation. Decreased MAO-A activity from treatment with an MAO inhibitor or from mutation of the X-linked gene encoding MAO-A manifests as high NE:DHPG and DA:DOPAC ratios. Since DHPG exiting sympathetic noradrenergic neurons is extensively O-methylated by COMT, low COMT activity is associated with increased DHPG:MHPG ratios. Theoretically, decreased alcohol dehydrogenase activity should be associated with elevated MHPG:VMA ratios.
DIFFERENTIAL NORADRENERGIC VS. ADRENERGIC ACTIVATION IN STRESS Different stressors can elicit different patterns of sympathoneural outflows and therefore differential NE release in the various vascular beds. This patterning redistributes blood flows. Local sympathoneural release of NE also markedly affects cardiac function and glandular activity. The adjustments usually are not sensed, and the organism usually does not feel distressed. Examples of situations involving prominent changes in sympathoneural outflows include orthostasis, mild exercise, post-prandial hemodynamic changes, mild changes in environmental temperature, and performance of non-distressing locomotor tasks. In contrast, in response to perceived global threats whether from external physical or internal psychological or metabolic stimuli – especially when the organism senses an inability to cope with those stimuli – increased neural outflow to the adrenal medulla elicits catecholamine secretion into the adrenal venous drainage. In humans, the predominant catecholamine in the adrenal venous drainage is EPI. EPI rapidly reaches all cells of the body (with the exception of most of the brain), producing a wide variety of hormonal effects at low blood concentrations. One can comprehend all of the many effects of EPI in terms of countering acute threats to survival that mammals have faced throughout their evolution, such as sudden lack of metabolic fuels, trauma with hemorrhage, and antagonistic confrontations. Even mild hypoglycemia elicits marked increases in plasma levels of EPI, in contrast with relatively small increases in levels of NE. Distress accompanies all these situations, the experience undoubtedly fostering the long-term survival of the individual and the species by motivating avoidance learning and producing signs that are understood instinctively by other members of the species.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
DIffERENTIAL NORADRENERGIC vS. ADRENERGIC ACTIvATION IN STRESS
Across a variety of stressors, increases in adrenomedullary activity as indicated by elevated plasma EPI levels correlate more closely with increases in pituitaryadrenocortical activity as indicated by elevated plasma levels of corticotropin than with increases in sympathoneural activity as indicated by elevated plasma levels of NE. Thus, insulin-induced hypoglycemia produces large increases in plasma EPI and ACTH levels and rather mild NE responses, whereas cold exposure produces increases in plasma NE levels, with little or no increases in EPI or ACTH. These findings call into question the long held concept of a unitary sympathoadrenal system activated in a stereotypical manner during stress.
Further reading Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: A contemporary view with implications for physiology and medicine. Pharmacol Rev 2004;56:331–49.
43
Goldstein DS. The autonomic nervous system in health and disease. New York: Marcel Dekker, Inc. 2001. Goldstein DS. Adrenaline and the inner world: An introduction to scientific integrative medicine. Baltimore: The Johns Hopkins University Press; 2006. Goldstein DS. Catecholamines 101. Clin Autonomic Res 2010;20:331–52. Goldstein D.S. Neurocardiology: Therapeutic implications for cardiovascular disease. Cardiovasc Ther 2010 Nov 25. doi: 10.1111/j.17555922.2010.00244.x. [Epub ahead of print] Goldstein DS, Holmes C, Kaler SG. Relative efficiencies of plasma catechol levels and ratios for neonatal diagnosis of Menkes disease. Neurochem Res 2009;34:1464–8. Goldstein DS, Holmes C. Neuronal source of plasma dopamine. Clin Chem 2008;54:1864–71. Goldstein DS, Kopin IJ. Adrenomedullary, adrenocortical, and sympathoneural responses to stressors: A meta-analysis. Endocr Regul 2008;42:111–9. Lenders JWM, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002;287:1427–34.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
7 Tyrosine Hydroxylase Kazuto Kobayashi, Toshiharu Nagatsu INTRODUCTION
approximately 8.5 kb (GenBank Accession Number: BC104967). Alternative splicing from a single gene produces four kinds of mRNAs encoding TH isoforms (hTH1-4) that are different in amino acid sequences in the N-terminal region (see Fig. 7.1A) [see ref. 1 for detail]. The hTH1-4 isoforms are distinguishable by the combination of insertion/deletion of the 12-bp sequence (4 amino acids) in the 3-terminal portion of exon 1 and the 81-bp sequence (27 amino acids) corresponding to exon 2. The hTH1 isoform contains the shortest amino acid sequence (497 amino acids), and the hTH2, hTH3, and hTH4 isoforms contain additional sequences of 4, 27, and 31 amino acids, respectively, between the 30th and 31st amino acids in the hTH1 isoform. TH activity is regulated by phosphorylation mainly at serines 19, 31, and 40 in the N-terminal region (hTH1). In particular, the TH isoforms appear to be differentially modified by extracellular signal-regulated protein kinase (ERK) [3]. ERK phosphorylates serine 31 in the hTH1 isoform, whereas ERK phosphorylation of the corresponding site in the hTH2-4 isoforms is less efficient. The phosphorylation of serine 19 increases the rate of phosphorylation on serine 44 in the hTH2 isoform (corresponding to serine 40 in the hTH1) more greatly than phosphorylation of the site in the hTH1 isoform. Dumas et al. [4] subsequently demonstrated the generation of more isoforms encoding human TH through skipping exon 3 in the adrenal medulla (Fig. 7.1B). These isoform are overexpressed in the tissue of patients with progressive supranuclear palsy, a neurodegenerative disease mostly affecting the basal ganglia, cerebral cortex, and brain stem. The isoforms lack 74 amino acids containing the two major phosphorylation sites (serines 31 and 40). In addition, Ohye et al. [5] report a new splicing variant in the adrenal medulla that encodes TH isoform lacking exon 4 sequence, resulting in truncation of the C-terminal region of the protein. This splicing seems to cause inactivation of TH function. These recent data support that alternative splicing produces the functional diversity of TH isoforms, which may be involved in the complex mechanisms that regulate catecholamine metabolism. Altered metabolism related to TH gene expression may underlie the pathophysiology of some neurological and neurodegenerative diseases.
Tyrosine hydroxylase (TH; tyrosine 3-monooxygenase) (EC 1.14.16.2) catalyzes the conversion of L-tyrosine to L-3,4dihydroxyphenylalanine (L-DOPA), which is the initial and rate-limiting step in the biosynthetic pathway of catecholamines including dopamine, noradrenaline, and adrenaline [reviewed in ref. 1]. These catecholamines play important roles in a variety of physiological and behavioral functions in the nervous and endocrine systems. TH activity is regulated through different mechanisms at the levels of transcription of the gene and posttranslational modification of the protein. Gene targeting technique of the mouse genome reveals that TH function is essential for animal development and survival as well as brain function [reviewed in ref. 2]. Disruption of the TH gene (homozygous mutation) causes the lethality at the embryonic and neonatal stages because of alterations in the cardiovascular system. Reduction of TH activity in the mice heterozygous for the mutation impairs retention of long-term memory at the adult stage. Recent advances in molecular biological study of the human TH gene have shown that a number of TH isoforms are generated by alternative splicing from a single gene, suggesting a complex mechanism that generates the diversity of TH isoforms in the normal and pathological conditions. Human genetic studies have found mutations that lead to TH deficiency, showing an infantile onset, progressive hypokinetic-rigidity with dystonia or a complex encephalopathy with neonatal onset. In addition, the use of TH gene function has provided a useful approach for gene therapy trials of Parkinson’s disease. In the present chapter, we describe recent advances in molecular biological and genetic studies related to human TH gene. We recapitulate the mechanism that generates the diversity of human TH isoforms, the implication of TH mutations in congenital diseases, and the update of gene therapy trials for neurological disease by the use of TH gene.
DIVERSITY OF HUMAN TH GENE EXPRESSION The human TH gene is encoded on chromosome 11p15.5 and composed of 14 exons, spanning
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00007-X
45
© 2012 Elsevier Inc. All rights reserved.
46
7. TyRosInE HydRoxylAsE
FIGURE 7.1 Schematic illustration of alternative splicing from a single TH gene that generates the diversity of isoforms. (A) Alternative splicing events producing four kinds of mRNAs encoding TH isoforms (hTH1-4). These mRNAs are distinguishable by the combination of insertion/deletion of the 12-bp sequence in the 3-terminal portion of exon 1 and the 81-bp sequence corresponding to exon 2. (The data are cited from ref. 1.) (B) Splicing events producing the mRNAs lacking exon 3. These mRNAs correspond to hTH1, hTH3 and hTH4 mRNAs deleting exon 3. (The data are cited from ref. 4.)
CONGENITAL DISEASE ASSOCIATED WITH TH MUTATION
GENE THERAPY WITH TH GENE FUNCTION
TH deficiency is an autosomal recessive disorder associated with the mutations in the TH gene (see Fig. 7.2). The clinical phenotype of the disease shows an infantile onset, progressive L-DOPA-responsive dystonia or a progressive encephalopathy with L-DOPA-nonresponsive dystonia. This deficiency can be diagnosed by measuring the levels of catecholamine metabolites such as homovanillic acid and 3-methoxy-4-hydroxyphenylethylene glycol in cerebrospinal fluid and direct sequencing of the TH gene. So far, the deficiency is reported in fewer than 40 patients worldwide. TH mutations in the deficiency have been extensively studied, and the clinical, biochemical, and genetic data are summarized in ref. [6]. The majority of TH mutations (~95%) were missense mutations that lead to amino acid substitutions in the protein-coding region. Some of these mutations are clarified to result in partial loss of enzymatic activity in the bacterial expression system. In addition, deletion of a single nucleotide in the coding region is reported that generates a truncated form of TH protein. Single nucleotide substitutions in the cyclic AMP response element (CRE) in the promoter region of TH gene are also found in some cases. Since the CRE in the TH promoter is known to be important for both basal and inducible transcriptional activity, the mutations in the CRE may down-regulate the transcription of TH gene, affecting the TH expression level. The relationship between the mutation and clinical phenotype does not appear to be fully understood.
Parkinson’s disease is an age-related neurodegenerative disease caused by the progressive loss of dopamine neurons in the ventral midbrain and the consequent reduction of the dopamine level. The patients exhibit a range of clinical phenotypes with the most common motor deficits such as the resting tremor, rigidity, akinesia, and postural instability. The standard procedure to treat the disease is pharmacotherapy by oral administration of L-DOPA, but many patients gradually develop L-DOPA-induced dyskinesia and motor fluctuation. Gene therapy trials offer alternative, complementary approaches for clinical application of Parkinson’s disease [7]. One potential strategy for gene therapy is to produce dopamine in striatal cells through gene transfer of enzymes related to dopamine biosynthesis. Muramatsu et al. [8] report gene therapy trial of a non-human primate model for Parkinson’s disease by adeno-associated viral vectors that carry the genes encoding TH, GTP cyclohydrolase I (GCH1), and aromatic L-amino acid decarboxylase (AADC). GCH1 is the rate-limiting enzyme in the biosynthesis of the cofactor for TH, tetrahydrobiopterin (BH4), and AADC converts L-DOPA to dopamine. Ectopic expression of these three enzymes successfully achieves the increased production and release of dopamine, and thus improves behavioral deficits in the parkinsonian model. Gene therapy for continuous L-DOPA delivery is also a potentially useful therapeutic strategy for the disease. Björklund et al. [9] report that gene transfer of TH and GCH1 genes into striatal cells
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
ConClusIon
47
FIGURE 7.2 Overview of the mutations in TH deficiency. The exon/intron structure of the human TH gene is shown. The closed boxes indicate the protein-coding regions and the open boxes indicate 5- and 3-untranslated regions. Three mutations (71C T, 70G A, and 69T A) are located in the cyclic AMP response element in the TH promoter (the nucleotides 67 to 74 upstream of the initiation codon). The 295delC and 296delT mutations cause the frame shift in the protein-coding region. The 1198-24T A mutation in the putative branchpoint sequence in intron 11 results in alternative splicing that produces aberrant mRNAs. Other mutations generate amino acid substitutions in the protein-coding region. (The data are cited from ref. 6.)
of the parkinsonian model rats with adeno-associated viral vectors results in ectopic L-DOPA production, showing the optimal ratio of the amount of TH and GCH1 enzymes for the in vivo DOPA production. The elevated level in BH4 by GCH1 expression appears to contribute to the stabilization of TH protein. A subsequent study with positron emission tomography imaging demonstrates that the straital transfer with TH and GCH1 genes enables behavioral recovery correlated with correction of dopamine transmission in the striatum [10]. These gene therapy trials aiming at the delivery of dopamine or L-DOPA provide a reasonable, promising strategy for clinical application in the disease.
CONCLUSION In the present chapter, we presented a short review of recent advances of molecular biological and genetic studies of human TH gene. The functional diversity of TH isoforms is generated by alternative splicing from a single gene. This diversity appears to mainly affect the regulatory mechanism of TH activity through phosphorylation of the protein. The different regulatory mechanism may be implicated in the control of catecholamine metabolism. Mutations in the coding or promoter region of the human TH gene exist in congenital TH deficiency with the infantile onset, progressive hypokinetic-rigidity with dystonia or a complex encephalopathy with neonatal onset. Future genetic study will address the question whether mutations in the TH gene are involved in the neuropsychiatric diseases. Gene therapy trials with the use of TH gene function aiming at the in vivo delivery of dopamine or L-DOPA indeed show the recovery of behavior and brain dopamine metabolism in animal models for Parkinson’s disease. This strategy will generate a viable procedure for clinical application in the disease.
The progress on the TH gene studies provides a clearer understanding of catecholamine function in the pathophysiology in neurological and neurodegenerative diseases and a novel strategy for the management of these diseases.
References [1] Nagatsu T. The catecholamine system in health and diseases – Relation to tyrosine 3-monooxygenase and other catecholamine-synthesizing enzymes. Proc Jpn Acad Ser B Phys Biol Sci 2006;82:388–415. [2] Kobayashi K, Nagatsu T. Molecular genetics of tyrosine 3-monooxygenase and inherited diseases. Biochem Biophys Res Commun 2005;338:267–70. [3] Lehman IT, Bobrovskaya L, Gordon SL, Dunkley PR, Dickson PW. Differential regulation of the human tyrosine hydroxylase isoforms via hierarchical phosphorylation. J Biol Chem 2006;281:17644–17651. [4] Dumas S, Hir HL, Bodeau-Péan S, Hirsch E, Thermes C, Mallet J. New species of human tyrosine hydroxylase mRNA are produced in variable amounts in adrenal medulla and are overexpressed in progressive supranuclear palsy. J Neurochem 1996;67:19–25. [5] Ohye T, Ichinose H, Yoshizawa T, Kanazawa I, Nagatsu T. A new splicing variant for human tyrosine hydroxylase in the adrenal medulla. Neurosci Lett 2001;312:157–60. [6] Willemsen MA, Verbeek MM, Kamsteeg E-J, de Rijk-van Andel JF, et al. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 2010;133:1810–22. [7] Feng LR, Maguire-Zeiss KA. Gene therapy in Parkinson’s disease: rationale and current status. CNS Drugs 2010;24:177–92. [8] Muramatsu S, Fujimoto K, Ikeguchi K, Shizuma N, et al. Behavioral recovery in a primate model of Parkinson’s disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 2002;13:345–54. [9] Björklund T, Hall H, Breysse N, Soneson C, Carlsson T, Mandel RJ, et al. Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats. J Neurochem 2009;111:355–67. [10] Leriche L, Björklund T, Breysse N, Besret L, Grégoire M-C, Carlsson T, et al. Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy. J Neurosci 2009;29:1544–53.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
8 Antidepressant-Sensitive Norepinephrine Transporters: Structure and Regulation Maureen K. Hahn Chemical signaling at central and peripheral noradrenergic synapses is terminated through reuptake of released norepinephrine (NE) [1]. The protein executing this activity, the antidepressant-sensitive NE transporter (NET), has been cloned from multiple species including man [2]. The human NET (hNET) gene encodes a 617 amino acid polypeptide. A high resolution structure of a SLC6 bacterial family member, the leucine transporter (LeuTAa), from Aquifex aeolicus, was recently achieved, confirming the structure of this family as twelve transmembrane domain proteins with intracellular NH2 and COOH termini (Fig. 8.1) [3]. Expression of the original hNET isolate is sufficient to confer antidepressant-sensitive NE transport [4]. During biosynthesis, hNET protein is N-glycosylated at sites on a large extracellular loop between transmembrane domains (TMDs) 3 and 4, and the protein is subsequently trafficked to the plasma membrane [5]. Although hNET glycosylation is not known to be regulated, this modification enhances protein stability and transport activity [6]. Once inserted in the plasma membrane, hNET is exposed to the transmembrane sodium gradient that the transporter utilizes to bring about NE uptake. Extracellular chloride also facilitates uptake of NE
and intracellular potassium may offer further stimulation, though evidence that potassium is countertransported is lacking. Additionally, hNET supports NE-gated channel states that may allow NE to translocate hNET at high rates when synaptic concentrations are elevated [7]. To take advantage of this possibility, NETs would need to be enriched at synaptic sites of release. Consistent with this, studies with NET-specific antibodies reveal NET localized to the plasma membrane of synaptic boutons [8]. Additional hNET splice variants have been identified at the mRNA level, predicting additional NET species with altered COOH termini [9]. Whereas related, though not identical, mRNA variants have been identified in rat brain and bovine adrenal, evidence of splice variant protein expression is currently lacking [10,11]. Recent heterologous expression studies incorporating these variants reveal significantly disrupted maturation and surface trafficking, raising doubt as to their functional relevance, at least as monomers [12]. In this regard, although a single hNET cDNA can confer NE transport activity, multiple hNET proteins may assemble together as an oligomeric complex. Indeed, dimer or higher order complexes have been documented for the closely related dopamine transporter (DAT) and serotonin transporter (SERT) and the presence of oligomers of hNET would offer an explanation for genetic NET deficiency exhibited by subjects with a mutation in one of two hNET alleles [13–15]. Mouse models of genetic NET deficiency support a contribution of transporter expression to presynaptic NE homeostasis, extracellular NE clearance and psychostimulant action [16]. Studies conducted over the past few years have revealed that NET and related transporters are subject to rapid regulation including changes in transporter surface expression as well as intrinsic transport activity [17,18]. This regulatory potential is believed to involve both transporter phosphorylation and the regulated associations of accessory proteins. Thus, NET has been found to complex with the catalytic subunit of protein phosphatase 2A (PP2Ac), the SNARE protein syntaxin 1A as well as the scaffolding protein PICK1 [18–20]. The NH2 terminus of hNET supports syntaxin 1A associations whereas the transporter’s COOH terminal PDZ domain is required for PICK1 binding. Protein kinase C activators disrupt Syntaxin and PP2Ac associations,
NE, Na+, Cl–
Extracellular
Intracellular P P
FIGURE 8.1 Norepinephrine transporters. Depicted is the 12transmembrane topology predicted for the NET protein, bearing three N-glysosylated residues on the second extracellular loop. The cytoplasmic NH2 and COOH termini bear multiple consensus sites for Ser/Thr phosphorylation. Norepinephrine (NE) is depicted as cotransported with Na and Cl which provide the energy for uptake of catecholamine into the presynaptic terminal.
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00008-1
49
© 2012 Elsevier Inc. All rights reserved.
50
8. ANTIdEPRESSANT-SENSITIvE NoREPINEPHRINE TRANSPoRTERS: STRuCTuRE ANd REgulATIoN
NE
[3] TAPs dissociate
[4]
Phosphorylation NT
[5]
Recycling
Internalization
[6]
Dephosphorylation
[7]
FIGURE 8.2 Norepinephrine transporter regulation. Illustrated is a cycle for the regulated trafficking of NET proteins. NETs are depicted in complex with multiple associated proteins that may stabilize the transporter at the plasma membrane. Stimuli linked to receptor activation by other neurotransmitters, hormones or cytosolic second messengers influence the stability of the NET associated protein complex and enhance NET phosphorylation. In parallel with, or as a result of such stimulation, NET proteins internalize leaving reduced presynaptic NE transport capacity. NETs can recycle to the plasma membrane, a process that likely occurs at basal rates but which may be linked to regulatory stimuli. TAP, transporter-associated proteins.
stimulation that also leads to NET internalization. PP2Ac also appears to be required for alterations in hNET intrinsic activity triggered by insulin and MAP-kinase linked pathways [17]. Possibly, trafficking and intrinsic function are coregulated through kinase-dependent mechanisms. Insulin signaling to promote NET internalization, an effect mediated through protein kinase B (Akt), occurs in both brain and peripheral neurons in vivo, thus providing a potential link between diseases of metabolism and neurobehavioral disorders [2]. Although these are early days in molecular studies of NET regulation, it is already clear that NE clearance capacity is likely to involve multiple regulatory proteins that localize, stabilize and activate NET (Fig. 8.2). They may also influence the tendency of NET to support catecholamine efflux when ion gradients are perturbed as they can be in ischemic insults. Finally, successful assimilation of these proteins into a regulatory model of NE inactivation should offer new opportunities to manipulate NET in autonomic and mental disorders, such as depression, where altered noradrenergic signaling has been recognized.
Acknowledgements
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
M.K. Hahn gratefully acknowledges the NIMH for their support of studies on NET genetics and regulation. [19]
References [1] Iversen LL. Uptake processes for biogenic amines. In: Iversen LL, editor. Handbook of Psychopharmacology (third ed.). New York: Prenum Press; 1978. p. 381–442. [2] Robertson SD, Matthies HJ, Owens WA, Sathananthan V, Christianson NS, Kennedy JP, et al. Insulin reveals Akt signaling as
[20]
a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis. J Neurosci 2010;30(34):11305–11316. Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E, et al. Crystal structure of a bacterial homologue of Na/Cl -dependent neurotransmitter transporters. Nature 2005;437(7056):215–23. Pacholczyk T, Blakely RD, Amara SG. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 1991;350(6316):350–4. Melikian HE, McDonald JK, Gu H, Rudnick G, Moore KR, Blakely RD, et al. Human norepinephrine transporter. Biosynthetic studies using a site-directed polyclonal antibody. J Biol Chem 1994;269(16):12290–12297. Melikian HE, Ramamoorthy S, Tate CG, Blakely RD. Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition. Mol Pharmacol 1996;50(2):266–76. Galli A, Blakely RD, DeFelice LJ. Patch-clamp and amperometric recordings from norepinephrine transporters: channel activity and voltage-dependent uptake [see comments]. Proc Natl Acad Sci USA 1998;95(22):13260–13265. Matthies HJ, Han Q, Shields A, Wright J, Moore JL, Winder DG, et al. Subcellular Localization of the antidepressant-sensitive norepinephrine transporter. BMC Neurosci 2009;10(1):65. Pörzgen P, Bönisch H, Hammermann R, Brüss M. The human noradrenaline transporter gene contains multiple polyadenylation sites and two alternatively spliced C-terminal exons. Biochim Biophys Acta 1998;1398(3):365–70. Burton LD, Kippenberger AG, Lingen B, Bruss M, Bonisch H, Christie DL, et al. A variant of the bovine noradrenaline transporter reveals the importance of the C-terminal region for correct targeting to the membrane and functional expression. Biochem J 1998; 330(Pt 2):909–14. Kitayama S, Ikeda T, Mitsuhata C, Sato T, Morita K, Dohi T, et al. Dominant negative isoform of rat norepinephrine transporter produced by alternative RNA splicing. J Biol Chem 1999; 274(16):10731–10736. Bauman PA, Blakely RD. Determinants within the C-terminus of the human norepinephrine transporter dictate transporter trafficking, stability, and activity. Arch. Biochem Biophys 2002;404(1):80–91. Hastrup H, Karlin A, Javitch JA. Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment. Proc Natl Acad Sci U S A 2001;98(18):10055–10060. Kilic F, Rudnick G. Oligomerization of serotonin transporter and its functional consequences. Proc Natl Acad Sci USA 2000;97(7):3106–11. Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, et al. Clues to the origin of orthostatic intolerance: a genetic defect in the cocaine- and anti-depressant sensitive norepinephrine transporter. N Eng J Med 2000;342(8):541–9. Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, Miller GW. et al. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 2000;3(5):465–71. Apparsundaram S, Sung U, Price RD, Blakely RD. Traffickingdependent and -independent pathways of neurotransmitter transporter regulation differentially involving p38 mitogen-activated protein kinase revealed in studies of insulin modulation of norepinephrine transport in SK-N-SH Cells. J Pharmacol Exp Ther 2001;299(2):666–77. Bauman HJ, Apparsundaram S, Ramamoorthy S, Wadzinski BE, Vaughan RA, Blakely RD, et al. Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A. J Neurosci 2000;20(20):7571–8. Sung U, Apparsundaram S, Galli A, Kahlig K, Savchenko V, Schroeter S, et al. A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. J Neurosci 2003;23(5):1697–709. Torres GE, Yao W, Mohn AR, Quan H, Kim K, Levey AI, et al. Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron 2001;30(1):121–34.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
9 α1-Adrenergic Receptors Marion C. Mohl, Robert M. Graham
a1-ADRENORECEPTOR SUBTYPES
gene family in the human genome – α1-ARs are long, single chain, integral membrane proteins. Like rhodopsin and β-ARs, α1-ARs contain seven transmembrane (TM)spanning α-helical domains linked by three intracellular and three extracellular loops [1]. In addition, the juxtamembranous portion of the C-terminal tail likely forms an eighth α-helix that lies parallel to the plain of the membrane and is importantly involved in receptor signaling – a domain structure found in all class A GPCRs for which highresolutions structures are available, but not in the recently determined structure of the CXCR4 chemokine receptor [2]. As with all GPCRs, the N-terminus of α1-AR subtypes is located extracellularly and the C-terminus, intracellularly (Fig. 9.1). The ligand-binding pocket is formed by the clustering of the seven α-helical domains to form a water accessible region for agonist to bind, and is located in the outer (extracellular) one third of the membranespanning domain. Residues of the intracellular (cytoplasmic) domains, particularly the third intracellular loop, mediate specific interactions with their cognate G proteins and, thus, are involved in receptor-engagement with its signaling and regulatory pathways.
Three subtypes have been identified by molecular cloning in several species including humans. They are classified as the α1A (previously the α1A/c)-, the α1B- and α1D (previously the α1a or α1a/d)-ARs (for a detailed consideration of α1-AR subtype-classification, see ref. 1). For the α1A-AR, four splice variants (α1A-1, α1A-2, α1A-3, α1A-4) have been identified, and are expressed at different levels in various tissues, including the liver, heart and prostate. However, the functional significance of these splice variants is unclear, since they all display similar ligandbinding and functional activity when expressed in heterologous cell systems. The characteristics of the various α1-AR subtypes are shown in Table 9.1. In addition to these subtypes, a putative fourth subtype, the α1L-AR, which displays low affinity for prazosin and other α1-antagonists, has been identified by functional but not by molecular studies. This subtype is postulated to mediate contraction of prostate smooth muscle, but it remains unclear if it is a distinct subtype or a merely a functional variant of one of the cloned α1-subtypes, such as the α1A splice variants, since the latter all display some of the characteristics of an α1L-subtype when expressed in heterologous cell systems. Another molecular variant of the α1A-AR is a coding region polymorphism that involves an arginine to cysteine (Arg492Cys) substitution in an arginine-rich region of the C-terminal tail. This polymorphic receptor is found with higher frequency in African-Americans, but it is not associated with essential hypertension. In addition, it is unclear if it alters receptor regulation or produces any other functional effects.
LIGAND BINDING AND ACTIVATION OF a1-ADRENORECEPTORS Binding of catecholamines to α1-AR involves an ionic interaction between the basic aliphatic nitrogen atom common to all sympathomimetic amines and an aspartate (Asp125 in the hamster α1B-AR) in the third transmembranespanning segment (TMIII) [3]. In the ground state, this TMIII aspartate forms a salt bridge with a lysine residue (Lys331 in the α1B-adrenergic receptor) in TMVII. Activation of α1-ARs, likely involves disruption of this ionic interaction. This is due to competition between the protonated amine of catecholamines and the TMVII lysine, which is just favored by the slightly more basic pKa of the protonated amine (pKa 11.0) versus the lysine (pKa 10.5). Agonistbinding to α1-ARs also involves an H-bond interactions between the meta hydroxyl group of catecholamines and a serine residue (Ser188, α1A-receptor numbering) in TMV,
STRUCTURE OF a1-ADRENORECEPTORS α1-ARs are integral membrane glycoproteins and members of the biogenic amine or class A family (also includes α2- and β-ARs, as well as the light-activated photoreceptor, rhodopsin) of G-protein-coupled receptors (GPCRs) [1]. Like other members of the GPCR-superfamily – the largest family of membrane receptors and possibly the largest
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00009-3
51
© 2012 Elsevier Inc. All rights reserved.
52
9. α1-ADRENERGIC RECEPTORS
TABLE 9.1 Characteristics of the α1A-Adrenoreceptor Subtypes Receptor Subtype α1A
α1B
α1D
68
80
≈65
Amino acids
431–501
515–520
561–572
Gylcosylation sites (N-terminus)
3
4
2
Phosphorylation sites
PKA
PKA
–
Genomic organization Introns
1
1
2
2
2
8
5
20 p13
5-Methylurapidil, ()niguldipine, oxymetazoline, A-61603, SNAP5089, KMD-3213, RS17053
AH11110A, L-765,314
()Norepinephrine, BMY 7378, SKF105854
–
Prazosin, phentolamine, benoxathian, abanoquil, terazosin, doxazosin, tamulosin, phenylephrine, methoxamine, cirazoline
–
Prototypic tissues
Rat kidney and submaxillary gland, rabbit liver, human heart and liver
Rat spleen, liver, and heart
Rat aorta, lung, and cerebral cortex
Receptor-coupled signaling
–
Ca2 mobilization, PLC, PLA2, PLD
–
G-protein coupling
Gq/11/4
Gq/11/4/16, Gh
Gq11, Gh
Characteristics *
Mr
§
Exons †
Chromosomal localization
Pharmacological selectivity Subtype-selective agents
Nonselective agents‡
*Apparent molecular weights (Mr) determined by SDS-PAGE are shown (Table adapted from ref. 1). † Refers to the human genome. ‡ These characteristics are the same for all subtypes. § Differences due to species variability and/or to splice variants.
whereas an interaction between the para hydroxyl and another TMV serine (Ser192) contributes only minimally to receptor activation. A further important interaction, for both binding and activation, involves aromatic-aromatic bonding between the catecholamine ring and that of a phenylalanine (Phe310 for the α1B-adrenergic receptor) in TMVI [3]. This interaction is also important in receptor activation, which in addition to the TMIII–TMVII salt bridge disruption, mentioned above, involves movement of TMVI that is likely required to allow interaction between the intracellular third loop and the receptor’s cognate G-protein. Aromatic–aromatic interactions between two phenylalanines (Phe163 and Phe187) in TMIV and TMV, respectively, and the catecholamine ring, have also been suggested to be important for agonist binding [3], but not for activation, although that with Phe163 may be indirect, since this residue is replaced by a leucine in the α1B- and α1D-adrenergic receptors. Residues critical for subtype-selective agonist recognition have been evaluated and, importantly, just two of the approximately 172 residues in the transmembrane domains (Ala204 in TMV and Leu314 in TMVI, and Val185 in TMV and
Met293 in TMVI of the α1B- and α1A-receptors, respectively) have been shown to account entirely for the selective agonist-binding profiles of the α1A- and α1B-subtypes [1]. Interactions between antagonists and α1-ARs are less well-defined, although the selectivity of two α1Aantagonists, phentolamine and WB4101, involves interactions with three consecutive residues (Gly196, Val197 and Thr198) in the second extracellular loop [3].
FUNCTION OF a1-ADRENORECEPTORS The best characterized α1-AR-mediated function is that of smooth muscle contraction. As such, these receptors have a major role in the vascular system in controlling blood pressure, the baroreflex response to changes in blood pressure, and in temperature control. The importance of α1ARs in controlling sympathetically regulated arteriolar tone is evident, for example, from the fact that a component of the blood pressure lowering action of all currently available antihypertensive agents is attributable to an attenuation of α1-AR-responses. This is due either to a direct action at
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
FUNCTION OF α1-ADRENORECEPTORS
VI
VII
V
I
IV III
II
LIGAND
Extracellular
II
VII
IV
LIGAND
V
I Intracellular
III
FIGURE 9.1 Cut away 3D model of the hamster α1B-AR, showing the seven α-helical transmembrane domains indicated by Roman numerals and by dashed circles and backbone ribbons (corkscrews), with the catecholamine agonist, epinephrine (ball and stick model with surrounding dot surface) modeled in its binding pocket. Upper panel: top view (looking down onto the plane of the membrane). Lower panel: side view.
the level of post-junctional, vascular smooth muscle α1-ARactivation or signaling, or to an indirect effect via inhibition of sympathetic outflow and, thus, availability of the endogenous receptor-agonists, the catecholamines, epinephrine and norepinephrine. Therefore α1-ARs agonists or antagonists can be used in the treatment of hypotension or hypertension, respectively, although their use in hypertension may result in heart failure in susceptible patients, due possibly to blockade of important cardiomyocyte pro-survival effects [4,5]. Despite the critical role of α-ARs in mediating arteriolar vasoconstriction, the particular subtype(s) responsible remains unclear. Consistent with findings in rodents, clinical trials of α1A-selective blockers have implicated this subtype as a major regulator of blood pressure [11]. In contrast, studies of a patient with sympathotonic orthostatic hypotension indicate that the α1B-AR may be a major regulator of vascular resistance in humans. Moreover, expression of this subtype increases in the elderly at a time when hypertension is commonly manifested. Thus, there is evidence for both the α1A- and α1B-adrenergic receptors being involved in blood pressure control in humans. Studies in the rat and in mouse knockout-models indicate that the α1D-subtype
53
can also play a role in blood pressure regulation. Indeed, such studies of genetically engineered animal models [5] indicate that sympathetic regulation of vascular tone by the various α1-subtypes is complex and may involve crossregulation of their contractile effects and/or of their expression. For example, inactivation of the α1A-AR results in a small but significant decrease in basal blood pressure but no change in pressor responses to the α1-agonist, phenylephrine. However, inactivation of the α1B-AR results in no effect on basal blood pressure but the pressor responses to phenylephrine were significantly blunted or unchanged. Interestingly, with inactivation of both the α1A-AR and α1B-AR there was no significant fall in blood pressure. Inactivation of the α1D-AR, or both α1D-AR and α1B-AR resulted in a significant drop of the resting blood pressure and impaired vasoconstrictor responses to noradrenaline and phenylephrine. Given that overexpression of the α1Badrenergic receptor in transgenic mice does not increase systemic arterial blood pressure, and that inactivation of this subtype results in attenuation of phenylephrine pressorresponses, with no change in basal blood pressure, it could reasonably be suggested that the α1A- and α1D-AR are the mediators of vasoconstriction and that the α1B-AR has a modulatory rather than a direct contractile role. However, mice lacking both the α1A- and α1B-receptors, or both the α1B- and α1D-receptors, show profound attenuation of phenylephrine pressor-responses. Thus, under appropriate circumstances the α1B-subtype may contribute importantly to sympathetic regulation of arteriolar tone. Further studies are thus required to fully elucidate the mechanisms involved in this apparent latent contribution of the α1B-AR to peripheral resistance, and to determine if these findings in animal models are also germane to the regulation of vascular resistance and blood pressure in humans. Other functions mediated by α1-ARs, include bronchoconstriction, regulation of human lipid metabolism, uptake of glucose into adipocytes, and contractile effects in various tissues, such as the vas deferens and the myocardium. For example, inactivation of the α1A-AR in mice results in a 50% reduction in pregnancy rate, which is markedly enhanced to 10% in animals with inactivation of all three α1A/B/C-AR subtypes – an effect likely due to impaired contraction of the vas deferens and, thus, decreased sperm ejaculation. Cardiac specific overexpression of the wild type α1B-AR in mice results in depressed contractile responses to β-AR stimulation, whereas cardiac-specific overexpression of a constitutively active mutant α1B-AR results in hypertrophic responses to pressure overload, leading to heart failure and premature death. In contrast, α1A-AR overexpression leads to increased cardiac contractility but no hypertrophy and, furthermore, moderate overexpression (66–fold) improves outcomes after pressure overload and after myocardiac infarction. Marked overexpression (170–fold), however, leads to sudden cardiac death that is likely due to calcium overload rather than to arrhythmia development. α1-ARs, particularly, the α1Asubtype, also have important cardiomyocyte pro-survival and developmental growth effects [4,5].
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
54
9. α1-ADRENERGIC RECEPTORS
Other important smooth muscle constrictor effects mediated by α1-ARs, include those relating to the lower urinary tract (bladder and prostate). The role of the α1A-subtype, in particular, is well-documented with α1A-selective antagonists being useful to relax prostate smooth muscle, relieve bladder outlet obstruction and, thus, to enhance urine flow (reviewed in ref. 6). Moreover, urinary incontinence is an unfortunate side effect of therapy with α1-AR blockers in patients with impaired bladder neck function. α1-ARs also regulate prejunctional or pre-synaptic neurotransmitter release, including inhibition of norepinephrine, acetylcholine and vasopressin release, and stimulation of inhibitory GABAergic neurotransmission in neurons and glial cells [7].
SIGNALING OF a1-ADRENORECEPTORS All three α1-ARs subtypes couple to a variety of second messenger proteins via heterotrimeric G-proteins, particularly of the Gαq/11 family, to phospholipase C leading to increased Ca2 entry via voltage-dependent or TRPC3 and or TRPC6 channels, or to release of Ca2 from intracellular stores [8]. Activation of α1-ARs augments arachidonic acid release through stimulation of phospolipase A or D, which can increase cAMP levels [8]. Inotropic effects of α1-ARs in rat hearts involve stimulation of Gαs-protein and reduction of the K current via the cAMP/PKA-mediated pathway. In addition to signaling through hetertriomeric G-proteins, α1ARs also mediate responses through the RhoA/Rho-kinase signaling pathway leading to Ca2 sensitization through phosphorylation of the myosin light chain phosphatase (MLCP) and the α1B and α1D, but not the α1A-subtype may also couple to phospholipase δ1-activation via Gh [9]. There is also evidence that α1-ARs form hetero- and homodimers, which alter their ligand binding and signaling properties, as well as their trafficking [8].
REGULATION OF a1-ADRENORECEPTORS α1-ARs are subject to agonist-induced regulation that results in both short and long-term desensitization of signaling [8,10]. These regulatory responses are mediated by agonist-induced conformational changes that lead to C-terminal tail receptor-phosphorylation, both by
receptor-linked protein kinase C as well as by G-proteincoupled receptor kinases, followed by the binding of arrestins and internalization by the clathrin pathway. These responses have been studied in most detail for the α1Breceptors. With the α1A- and α1D-ARs, the carboxyl terminal tail appears not to be essential for signaling or desensitization, and receptor internalization is not associated with α1A-AR desensitization.
Acknowledgements We are most grateful to Dr J. Novotny for the α1B-AR 3D model. Work from the author’s laboratory is supported in part by a Program Grant from the National Health and Medical Research Council of Australia (#573732), and a Grant-in-Aid from the Heart Foundation of Australia (G09S4342).
References [1] Graham RM, Perez DM, Hwa J, Piascik MT. Alpha(1)-adrenergic receptor subtypes – molecular structure, function, and signaling. Circ Res 1996;78:737–49. [2] Wu B, Chien EYT, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, Hamel DJ, Kuhn P, Handel TM, Cherezov V, Stevens RC. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists. Science 2010;330:1066–71. [3] Perez DM. Structure-function of α1-adrenergic receptors. Biochem Pharmacol 2007;73:1051–62. [4] Huang Y, Wright CD, Merkwan CL, Baye NL, Liang Q, Simpson PC, O’Connell TD. An alpha1A-adrenergic-extracellualr signalregulated kinase signaling pathway in cardiac myocytes. Circulation 2007;115:763–72. [5] Woodcock EA, Du X-J, Reichelt ME, Graham RM. Cardiac α1-adrenergic drive in pathological remodelling. Cardiovasc Res 2008;77:452–62. [6] Schwinn DA. Novel role of α1-adrenerigc receptors in lower urinary tract symptoms. BJU Int 2000;86(Suppl. 2):11–22. [7] Docherty JR. Subtypes of functional alpha1-adrenoceptor. Cell Mol Life Sci 2010;67:405–17. [8] Cotecchia S. The α1-adrenergic receptors: diversity of signaling networks and regulation. J Recept Signal Transduct 2010;30:410–9. [9] Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003;4:140–56. [10] Finch A, Sarramegna V, Graham RM. Ligand binding, activation and agonist trafficking. In: Perez DM, editor. The Adrenergic Receptors in the 21st Century. : Humana Press Inc; 2006. p. 25–85. [11] Plascik MT, Kusiak JW, Barron KW. Alpha 1-adrenoceptor subtypes and the regulation of peripheral hemodynamics in the conscious rat. Eur J Pharmacol 1990;186:273–8.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
10 a2-Adrenergic Receptors Qin Wang
PHARMACOLOGY AND FUNCTIONS OF a2-AR SUBTYPES
to be critical for agonist-mediated lowering of blood pressure, sedation, anesthetic sparing, and working memory. The a2A-AR also appears to respond to endogenous catecholamines to suppress epileptogenesis (kindling) and depressive symptoms, the latter measured in mouse behavioral studies. The a2C-AR elicits depressive behaviors, behaving functionally the opposite of the a2A-AR subtype. The a2B-AR, in contrast to the a2A-AR, is involved in the vascular hypertensive effect of a2-AR agonists. Taken together, these findings suggest that subtype-selective agonists may be useful in manipulating one versus another adrenergic response in vivo. An even more refined therapeutic selectivity might be achieved using partial agonists of a2-ARs. It has been observed that agonist-mediated lowering of blood pressure can occur in mice heterozygous for the a2A-AR, whereas agonist-evoked sedation cannot. These data suggest that partial agonists with less than 50% intrinsic activity (efficacy) might be useful in a number of therapeutic settings, such as treatment of attention deficit/hyperactivity disorder (ADHD) and improvement of cognition in the elderly, where sedation as a side effect would undermine the therapeutic value of these agents. Interestingly, imidazoline compounds, for which there is evidence of a role in the central nervous system in regulating blood pressure, nonetheless appear to lower blood pressure via a2-ARs when administered peripherally. Thus, moxonidine and rilmenidine, developed as imidazoline I1-selective agents, are unable to lower blood pressure in D79N a2A-AR or a2A-AR knockout mice. Also of interest is the finding that these agents are partial agonists at the a2A-AR, which may explain their ability to lower blood pressure without evoking sedative side effects.
Alpha2-adrenergic receptors (a2-ARs) bind to their endogenous ligands, epinephrine and norepinephrine, and are blocked by the antagonist yohimbine. There are three subtypes of a2-AR, encoded by three independent, intronless genes. These subtypes are denoted as a2A- (human chromosome 10), a2B- (human chromosome 2), and a2C(human chromosome 4). Ligand selectivity for pharmacological agents does exist for the various a2-AR subtypes, although this selectivity has been observed principally in vitro, as not all of these ligands have been evaluated for their pharmacokinetic properties in vivo (see Table 10.1). The lack of truly specific ligands for each of the a2-AR subtypes, particularly antagonists, has prevented the unequivocal assignment of the differing a2-AR subtypes to various physiological responses. However, tools to genetically manipulate the mouse genome to create mutant (e.g. D79N a2A-AR) or null alleles of each of these subtypes shed light into subtype-specific functions of the different a2-AR subtypes, as outlined in Table 10.2. For example, both the a2A- and a2C-ARs are involved in suppression of catecholamine release from central neurons. However, the a2A-AR serves as the primary presynaptic autoreceptor. The a2C-AR is also critical for suppression of epinephrine release from the adrenal chromaffin cells. Moreover, the a2A-AR appears TABLE 10.1* Relative Selectivity for Ligands at the Three a2Adrenergic Receptor Subtypes Agonists
Shared: norepinephrine, epinephrine, aproclonidine
a2-AR SIGNALING AND TRAFFICKING
Selective: oxynetazoline (A C B), clonidine, guanabenz (A,C), UK 14304 (A C), dexmedetomidine (A,B) Antagonists
All three subtypes of the a2-AR share the same signaling pathways in native cells: decrease in adenylyl cyclase activity, suppression of voltage-gated Ca currents, and activation of receptor-operated K currents and MAP kinase activity. In heterologous cells, the a2A-AR has been shown to activate phospholipase A2 and phospholipase D,
Shared: yohimbine, rauwolscine, phentolamine, idazoxan, RX 821002, atipamezole Selective: ARC 239 (B C A), prazosin (B,C A), BRL 44408 (A C), mianserin (A,B)
*Modified from Saunders and Limbrid, Pharmacology & Therapeutics 84:193–205, 1999.
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00010-X
55
© 2012 Elsevier Inc. All rights reserved.
56
10. a2-ADRENERGIC RECEPTORS
TABLE 10.2*
Subtype-Specific Functions of a2-AR Derived From Gene-Targeted Mouse Models α2-AR Subtypes α2A-AR
Physiological Functions
α2B-AR
α2C-AR
CENTRAL EFFECTS Presynaptic inhibition of norepinephrine, dopamine, serotonin release
Xa
Hypotensive effect
X
Sedative effect
X
Antinociceptive effects of a2-adrenergic receptor agonist
X
Antinociceptive effects of moxonidine
X
Analgesic effect of nitrous oxide
X
X X
Anesthetic-sparing effects of dexmedetomidine
X
Adrenergic-opioid synergy in spinal antinociception
X
Anesthetic-sparing effects of dexmedetomidine
X
Hypothermic effects of dexmedetomidine
X
X
PERIPHERAL EFFECTS Inhibition of noradrenaline release from nerve terminal invaded into tissues
X
X
Inhibition of adrenaline release from adrenal cortex
X
Vasoconstriction, hypertensive effect
X
Salt-induced hypertension
X
Placenta angiogenesis
X
Platelet aggregation
X
X
Prevention of respiratory failure
X
BEHAVIOR EFFECTS Antiepileptogenic effect
X
Special working memory
X
Inhibition of startle responses
X
Antianxiety
X
Inhibition of locomotor stimulation of D-amphetamine
X
Latency to attack after isolation
X
*Above data summarized in Kable et al. J. Pharmacol. Exp. Ther. 2000;293(1):1–7; Brede et al. Biol Cell. 2004;96(5):343–8; and Knaus et al. Neurochem Int 2007;51(5):277–81. Also from Haubold et al. J Biol. Chem. 2010;285(44)34213–19. a Primary autoreceptor.
although these responses have yet to be observed in native target cells. Despite the similarity of the signaling pathways of the a2-AR subtypes, there are interesting differences in the trafficking itineraries of these receptors. Whereas the a2A- and a2B-AR subtypes are enriched on the surface at steady state, the a2C-AR is distributed between the surface and intracellular compartments. Upon agonist stimulation, both the surface a2A-AR and a2B-AR undergo internalization in an arrestin-dependent manner. a2A-AR internalization can be selectively promoted by different agonists such as clonidine and guanfacine, which, at least in part, account for distinct duration of signaling action of these drugs.
REGULATION BY INTERACTING PROTEINS a2-AR trafficking and signaling are tightly regulated by non-G protein interacting partners including GPCRs, kinases and scaffolding proteins such as arrestin and spinophilin (see Table 10.3). Some of these interactions serve to scaffold a2-ARs to particular cellular micro-compartments or to tether them to defined signaling molecules, while other receptor-protein interactions control a2-AR internalization and post-endocytotic sorting as well as the kinetics of a2AR-mediated signaling transduction. For example, whereas arrestin promotes a2A-AR and a2B-AR phosphorylation and
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
a2-AR POLYMORPHISMS
TABLE 10.3*
57
a2-AR-Interacting Proteins α2-AR Subtype(s)
Functional Role(s) Implicated
a2A
Precoupled to G proteins
a2C-AR
a2A
Attenuating agonist-induced a2A-AR to the a2A-AR phosphorylation, reducing arrestin binding
β1-AR
a2A
Altering ligand binding properties of β1-AR, leading to internalization of β1-AR in response to a2-agonist
β2-AR
a2C
Enhancing surface expression and internalization of a2C-AR, enhancing ERK activation by a2C-AR
μOR
a2A
Enhancing morphine-induced GTPγ S binding and ERK activation; however, no transactivation of G proteins, no interdependent internalization
δOR
a2A
Enhancing δOR-mediated neurite outgrowth
GRK2
a2A, a2B
Mediating agonist-induced phosphorylation and homologous desensitization
PKC
a2A
Mediating heterologous desensitization; Modulating constitutive activity of a2A-AR
14-3-3ζ
a2A, a2B, a2C
Function unknown, competed by phosphorylated Raf peptide
APLP1
a2A, a2B, a2C
Increasing a2A-AR-mediated inhibition of adenylyl cyclase activity
arrestin 2
a2B
Receptor affinity for arrestin 2 is lower than arrestin 3
arrestin 3
a2A, a2B
Stabilizing receptor phosphorylation, mediating endocytosis and desensitization, accelerating ERK signaling rate, enhancing sensitivity of in vivo response
arrestin 3
a2C
Mediating endocytosis
eIF-2B
a2A, a2B, a2C
Function unknown
Rab8
a2B
Promoting transport to cell surface
spinophilin
a2A, a2B
Stabilizing receptor at surface, attenuating phosphorylation, decelerating ERK signaling rate, decreasing in vivo response sensitivity
spinophilin
a2C
Function unknown
Uch-L1
a2A
Decreasing a2A-AR-mediated activation of ERK
Interacting Protein(s) GPCR DIMERIZATION HOMO-DIMERIZATION
HETERO-DIMERIZATION
KINASES
OTHER PROTEINS 14-3-3ζ
*Modified from Wang and Limbird, Biochem Pharm 2007;73(8):1135–1145; also from Weber et al. Cell Signal 2009;21(10):1513–21; Dong C et al. J Biol Chem 2010;285(26):20369–80.
internalization and accelerates the initial rate of signaling and desensitization, spinophilin blocks these activities by competing for GRK and arrestin interaction with these two a2-AR subtypes. Importantly, spinophilin antagonism of arrestin functions in regulating a2-ARs has in vivo relevance as manifested by reciprocal modulation of a2A-AR-evoked sedation by these two proteins in vivo.
a2-AR POLYMORPHISMS A number of individual human polymorphisms have been identified for each of the a2-AR subtypes. Some of
these have resulted in alterations in receptor density, G protein coupling, desensitization, or G protein receptor kinasemediated phosphorylation. Genetic association studies have linked a2-AR polymorphisms with a number of disease states and variations in drug responses in human populations. For example, a2A-AR polymorphisms have been linked to increased risk of ADHD, hypertension and type 2 diabetes. Additionally, genetic variants in all three subtypes have been associated with various forms of cardiovascular dysfunction. The study of a2-AR polymorphisms and their association with human diseases provides insights whose functional relevance can, in the future, be assessed by evaluating a variety of a2-AR in genetically engineered mouse
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
58
10. a2-ADRENERGIC RECEPTORS
models that introduce each polymorphism into the genome via homologous recombination. Given the new understanding of the a2-AR subtypes in manipulating different physiological effects, refinement of this understanding with regard to partial agonists at the receptor, and the impact of receptor interactions with other proteins in target cells beyond G protein coupling, it would seem possible that molecular entities might be developed to interfere with particular a2-AR–protein interactions or with a2-AR activation of various pathways and evaluated for efficacy as therapeutic interventions in disease settings still lacking appropriate a2-AR-system regulation.
Acknowledgement I am grateful to Dr. Lee Limbird (Vanderbilt University) for her critical reading of this chapter and invaluable suggestions.
Further Reading Flordellis C, Manolis A, Scheinin M, Paris H. Clinical and pharmacological significance of alpha2-adrenoceptor polymorphisms in cardiovascular diseases. Int J Cardiol 2004;97:367–72.
Kable JW, Murrin LC, Bylund DB. In vivo gene modification elucidates subtype-specific functions of alpha(2)-adrenergic receptors. J Pharmacol Exp Ther 2000;293:1–7. Knaus AE, Muthig V, Schickinger S, Moura E, Beetz N, Gilsbach R, et al. a2-Adrenergic subtypes-unexpected functions for receptors and ligands derived from gene-targeted mouse models. Neurochem Int 2007;51:277–81. Lu R, Li Y, Zhang Y, Chen Y, Shields AD, Winder DG, et al. Epitopetagged receptor knock-in mice reveal that differential desensitization of alpha2-adrenergic responses is due to ligand-selective internalization. J Biol Chem 2009;284:13233–243. Moore CA, Milano SK, Benovic JL. Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol 2007;69:451–82. Rosengren AH, Jokubka R, Tojjar D, Granhall C, et al. Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Science 2010;327:217–20. Saunders C, Limbird LE. Localization and trafficking of alpha2adrenergic receptor subtypes in cells and tissues. Pharmacol Ther 1999;84:193–205. Small KM, Liggett SB. Identification and functional characterization of alpha(2)-adrenoceptor polymorphisms. Trends Pharmacol Sci 2001;22:471–7. Tan CM, Wilson MH, MacMillan LB, Kobilka BK, Limbird LE. Heterozygous Alpha 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists. Proc Natl Acad Sci USA 2002;99:12471–12476. Wang Q, Zhao J, Brady AE, Feng J, Allen PB, Lefkowitz RJ, et al. Spinophilin Blocks Arrestin Actions in vitro and in vivo at G proteinCoupled Receptors. Science 2004;304:1940–4.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
11 β-Adrenergic Receptors C.Michael Stein INTRODUCTION
and norepinephrine, results from having different sub-types of β-ARs that are differentially expressed in particular tissues and that have differences in their affinity for agonists and signal transduction mechanisms, as well as the frequent concomitant presence of α-ARs – additional targets for epinephrine and norepinephrine. The three subtypes of β-ARs share approximately 60% sequence homology and are widely distributed in many cells and organs where they mediate several physiological responses (Figure 11.1; Table 11.1). Stimulation of β1-ARs mediates increased heart rate and cardiac contractility, β2-ARs mediate bronchodilation, vasodilation and presynaptic norepinephrine release, and β3-ARs mediate lipolysis and thermogenesis, relaxation of bladder, uterus and gut smooth muscle, and attenuated cardiac contractility (Table 11.1) [1,2].
There are three subtypes of β-adrenergic receptors (β1ARs, β2-ARs and β3-ARs) that mediate a wide range of physiological responses to the adrenergic agonists epinephrine and norepinephrine, and thus play an important role in regulating cardiovascular responses in health and disease (Table 11.1, Fig. 11.1). These receptors are also the targets of commonly used classes of drugs that block or stimulate signaling. β-Blockers are often used to treat hypertension and heart failure, and to control heart rate in atrial fibrillation, whereas β-agonists are used to treat asthma. There is a wide range of variation in responses to physiological and pharmacological stimulation or blockade of β-ARs; some of this variability is due to genetic variation among individuals in genes encoding β-ARs and their signal transduction proteins.
β-AR SUBTYPES AND THEIR DISTRIBUTION
β-ARs SIGNAL TRANSDUCTION β-ARs are 7-transmembrane spanning G proteincoupled receptors with an extracellular aminoterminus, an intracellular carboxyterminus, and three intracellular and three extracellular loops (Fig. 11.1). The binding of agonist
β-ARs mediate a wide range of responses (Table 11.1). The wide range of physiological responses mediated by just two primary endogenous adrenergic agonists, epinephrine TABLE 11.1 β Adrenergic Receptor Subtypes Subtype
Tissue Distribution
Functions
Gene Localization
Common Coding Variants
β1-AR
Heart Kidney Adipocytes
Positively inotropic and chronotropic Renin release Lipolysis
10q24-q26
Arg389Gly Ser49Gly
β2-AR
Lung and bronchial Vascular smooth muscle Heart Uterus Bladder Adipocytes Eye Liver Skeletal muscle Sympathetic terminal
Bronchodilation Vasodilation Positively inotropic and chronotropic Relaxation Relaxation Lipolysis Increase aqueous humor formation Glycogenolysis Glycogenolysis Norepinephrine release
5q31-q32
Gly16Arg Gln27Glu Thr164Ile
β3-AR
Adipocytes Uterus Bladder Heart
Lipolysis Relaxation Relaxation Negatively inotropic
8p12
Trp64Arg
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00011-1
59
© 2012 Elsevier Inc. All rights reserved.
60
11. β-ADRENERGIC RECEPTORS
β1AR Ser or Gly β2AR Arg or Gly
NH2
49
β2AR Gln or Glu
16
27
agonist binding β1AR Gly or Arg 389
β3AR Trp or Arg
64
164
β2AR Thr or IIe
subsequent responses. This occurs by three mechanisms – uncoupling of the receptor from its G-protein, a process mediated by G protein-coupled receptor kinases (GRKs) that phosphorylate the receptor; movement of receptors away from the cell membrane, known as internalization or sequestration; and loss of receptors (downregulation) mediated by several mechanisms including decreased transcription and increased ubiquitination and degradation [4]. β3-ARs are activated at higher concentrations of catecholamines than β1- and β2-ARs; thus they are more likely to activate under conditions of high sympathetic activity and they are also less likely to desensitize [5].
HOOC
THERAPEUTIC IMPORTANCE OF β-ARs
G-protein coupling
desensitization
FIGURE 11.1 Structure of β adrenergic receptors.
to receptor is translated into physiological response by complex signal transduction mechanisms that involves heterotrimeric GTP-binding regulatory proteins (termed G-proteins) and their associated second messenger and effector systems. G-proteins are made up of three subunits, an α subunit that is important for recognition and effector functions, and β and γ subunits that are important for membrane localization but also have effector functions. The α subunit may be stimulatory, for example Gsα stimulates adenylate cyclase and increases cyclic AMP production, or inhibitory, for example Giα decreases cyclic AMP production. All three β-ARs couple with Gsα, but β2- and β3-ARs can also couple to Giα. Receptors exist in a conformational equilibrium between the inactive and active states and this equilibrium shifts with the binding of a ligand. There are three types of ligands: agonists that shift the equilibrium towards the active conformation; inverse agonists that favor the inactive conformation; and neutral antagonists that do not affect the equilibrium. When agonist binds to the receptor there is a conformational change that allows the intracellular part of the receptor to couple with a G-protein. For example, the activated β-AR forms a complex with Gsα and guanosine triphosphate (GTP) and stimulates the production of cyclic AMP, that in turn affects secondary effectors such as protein kinase A (PKA). The signal transduction mechanism is modulated by many other mechanisms, for example desensitization (see later), phosphodiesterases that break down cyclic AMP, and regulators of G-protein signaling (RGS) proteins that promote GTP hydrolysis [3].
RECEPTOR DESENSITIZATION Exposure of β-ARs to agonist and consequent activation triggers a process known as desensitization that acts to limit
From a therapeutic perspective β1-ARs in the heart (the target for β-blockers), and β2-ARs in the lungs (the target for β2 agonists), are most important. β-blockers comprise more than 20 different drugs that vary in their selectivity for β1and β2-ARs, as well as their lipophilicity, distribution, elimination, and intrinsic sympathomimetic effects. The primary target of β-blockers in heart disease is the β1-AR, and drugs that preferentially block this receptor are termed cardioselective β-blockers (e.g. atenolol) whereas non-selective agent such as propranolol block both β1- and β2-ARs. Initially β-blockers were considered to be absolutely contraindicated in patients with heart failure. This was because the marked increase in sympathetic activity that accompanies heart failure was considered to be a beneficial compensatory response; therefore, agents such as β-blockers that antagonized the effects of catecholamines on the heart were considered harmful. However, interventions to increase sympathetic activity increased mortality in heart failure, and in vitro studies showed that β-AR numbers were decreased and the receptors were uncoupled (i.e. desensitization had occurred) [6]. These observations led to the current view that excessive sympathetic activation is harmful in heart failure and clinical studies confirmed that careful treatment with β-blockers could improve cardiac function and decrease mortality [2]. Available β-blockers such as metoprolol, atenolol and propranolol have much lower affinity for the β3-AR than they do for β1-ARs; thus, specific β3-AR antagonists were developed. These agents resulted in weight loss in animal models of obesity but were generally not effective in human clinical trials. Their lack of efficacy has been ascribed to poor selectivity for the β3-AR, and also to the fact that β3ARs appear to play a smaller role in mediating lipolysis in human adipose tissue than they do in rodents [1]. Potential therapeutic clinical applications for future β3-AR antagonists are premature labor, irritable bowel syndrome and overactive bladder [1]. β-agonists, particularly β2-AR selective agonists, are used primarily to treat bronchoconstriction associated with asthma and other diseases of the airways. Hydrophilic drugs such as albuterol have a rapid onset and relatively short
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
GENETIC VARIABILITY IN β-ARS
duration of action (4–6 hours), whereas lipophilic drugs such as formoterol and salmeterol partition into the membrane and have a prolonged action [4]. β2-AR selective agonists are also used to prevent preterm labor. Agonists that are more selective for the β1-AR, for example dobutamine, are used for their ability to increase cardiac contractility.
GENETIC VARIABILITY IN β-ARS Many studies reported ethnic differences in response to adrenergic agonists and antagonists but until recently the potential mechanisms for these observations were unclear. The identification of common genetic variants in all the adrenergic receptors and studies showing that some of these variations affect function in vitro and in vivo led to work to establish the genetic contribution to variability in responses among individuals, and the clinical significance of such variation.
61
changes: Gly16Arg, Gln27Glu, and Thr164Ile. In vitro the Gly16 increased desensitization, Glu 27 decreased desensitization, and the Ile164 receptor had decreased responses to agonist. The clinical pharmacogenetic studies in this area are difficult to interpret because the variants at positions 16 and 27 are in linkage disequilibrium and there are many other non-coding variants that may affect function. Some studies suggest that patients with asthma who carry the Arg16 allele, particularly homozygotes, are less responsive to β-agonist bronchodilators, but there is little consensus regarding the clinical importance of these observations [7,8].
ADRB3 There is a one common coding region variant in the β3AR gene (ADRB3) that results in an amino acid change: Trp64Arg. However, studies performed in vitro and in vivo have been inconsistent in defining functional and clinical consequences of this variant [7,8].
ADRB1
Acknowledgement
There are two common polymorphisms in the β1AR gene (ADRB1) that result in amino acid changes: Arg389Gly and Ser49Gly. The Gly389 variant has impaired coupling to Gs and therefore less response to agonist, and the Gly49 variant has increased desensitization after exposure to agonist in vitro. Thus, the Ser49 and Arg389 alleles code for a β1-AR likely to be associated with greater response. Concordantly, studies in healthy subjects, and patients with hypertension, studied under strictly controlled conditions found that carriers of the Arg389 and the Ser49 alleles were more responsive to β-blockers. Similarly, patients with heart failure who carried the Gly389 allele were less responsive to a β-blocker with a smaller improvement in ejection fraction. In the Beta Blocker Evaluation of Survival Trial (BEST) there was an interaction between Arg389Gly genotype and outcomes of bucindolol treatment. Patients with the Gly389 allele did not benefit, but Arg389 homozygotes receiving bucindolol had improved outcomes. However, other heart failure and hypertension studies found no effect of ADRB1 genotypes on responses – thus, the clinical significance of genotype in β-blocker therapy is uncertain. Genetic variation in other adrenergic receptors that may also affect sympathetic responses (e.g. α2C-AR), and in GRKs and other proteins important in regulating adrenergic responses, may also play a role [2,7].
The previous version of this chapter was written by Dr Stephen B. Liggett and forms the framework for the present chapter.
References [1] Ursino MG, Vasina V, Raschi E, Crema F, De PF. The beta3adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res 2009;59:221–34. [2] Dorn GW. Adrenergic signaling polymorphisms and their impact on cardiovascular disease. Physiol Rev 2010;90:1013–62. [3] McGraw DW, Liggett SB. Molecular mechanisms of beta2-adrenergic receptor function and regulation. Proc Am Thorac Soc 2005;2:292–6. [4] Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006;117:18–24. [5] Dessy C, Balligand JL. Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives. Adv Pharmacol 2010;59:135–63. [6] Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: beta-adrenergic receptors – alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med 2005;2:475–83. [7] Kirstein SL, Insel PA. Autonomic nervous system pharmacogenomics: a progress report. Pharmacol Rev 2004;56:31–52. [8] Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003;43:381–411.
ADRB2 There are three relatively common coding region variants in the β2-AR gene (ADRB2) that result in amino acid
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
12 Dopaminergic Neurotransmission Graeme Eisenhofer, Heinz Reichmann
Dopamine is produced as a neurotransmitter in the central nervous system (CNS) and as an intermediate in the synthesis of norepinephrine in peripheral sympathetic and CNS noradrenergic nerves and of epinephrine in adrenal chromaffin cells. Dopamine is also produced as a catecholamine end product in chromaffin-like glomus cells of the hypoxia-sensing carotid bodies as well as in numerous other peripheral tissues. Synthesis of dopamine within dopaminergic neurons depends on the rate-limiting conversion of tyrosine to L-dihydroxyphenylanaline (L-dopa) by tyrosine hydroxylase, an enzyme confined to catecholamine-producing cells (Fig. 12.1). L-dopa is then converted to dopamine by L-aromatic amino acid decarboxylase, an enzyme with a wide tissue distribution. After this step, dopamine is translocated by vesicular monoamine transporters into storage vesicles from where the amine is available for release by exocytosis. Reuptake back into neurons by the cell membrane dopamine transporter represents the main mechanism for terminating the actions of dopamine at receptor sites, including D2 presynaptic autoreceptors, which act as a break on secretion. Complete inactivation requires metabolism by intraneuronal deamination to dihydroxyphenylacetic acid or extraneuronal O-methylation and deamination to homovanillic acid, the major metabolic end product of dopamine. Dopaminergic neurons within the brain are sparse, representing less than one thousandth of a percent of all CNS neurons. Nevertheless, dopaminergic neurotransmission is crucial for regulating numerous aspects of brain function. Deranged CNS dopaminergic neurotransmission also contributes to several devastating neurological and psychiatric disorders. Consequently the various components of dopamine neuronal systems, such as dopamine transporters, receptors and second messenger systems, represent important therapeutic targets that continue to receive intense scientific attention. CNS dopaminergic neurons can be broadly divided into two major groups: neurons in the mesencephalon project to the striatum and forebrain and subserve diverse functions from the control of movement to modulation of cognition, mood, attention, reward seeking behavior and learning; the other major group located in the arcuate nucleus of the
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00012-3
hypothalamus has projections that release dopamine in the portal vessels with important neuroendocrine regulatory influences that include inhibition of the release of prolactin and thyroid stimulating hormone. In addition to these two major groups, there are also smaller groups in other CNS
FIGURE 12.1 Schematic representation of a slow synaptic transmission neuromodulatory dopaminergic nerve ending impinging on a dendritic spine of a fast synaptic transmission inhibitory GABAergic neuron. Abbreviations: DOPAC, dihydroxyphenylacetic acid; HVA, homovanillic acid; MTY, 3-methoxytyramine; TH, tyrosine hydroxylase; AADC, aromatic acid decarboxylase; MAO, monoamine oxidase; COMT, catechol-O-methyltransferase; DAT, dopamine transporter; EMT, extracellular monoamine transporter; D1, dopamine D1 receptor; D2 dopamine D2 receptor.
63
© 2012 Elsevier Inc. All rights reserved.
64
12. DoPAmINERgIC NEuRoTRANsmIssIoN
regions, such as the dopaminergic neurons in the retina and olfactory bulb that have ultra-short projections that transmit signals within these neuronal centers for vision and smell. Mesencephalon dopaminergic neurons localized in the substantia nigra project mainly to the striatum to form the neostriatal pathway, whereas those of the ventral tegmental area project to cortical and limbic regions to form respective mesocortical and mesolimbic pathways. Neostriatal dopaminergic pathways regulate the initiation and maintenance of motor function, while mesocortical and mesolimbic pathways respectively regulate cognitive activity and reward seeking behavior. The importance of neostriatal dopaminergic pathways for control of extrapyrimidal (involuntary) movement is reflected by the loss of motor control when nigro-striatal neurons degenerate in Parkinson’s disease. Rather than acting as a classic excitatory or inhibitory neurotransmitter, dopamine released from midbrain projections acts as a neuromodulator that alters responses of target neurons to other neurons (Fig. 12.1). Such neuromodulatory influences occur by slow modes of synaptic transmission involving complex second messenger systems rather than the ligand-operated ion-channels that characterize fast synaptic transmission. Accordingly, accumulating evidence also indicates that signals from dopamine are generated in a volume mode of transmission in which the amine transmitter does not act rapidly within classical synapses, but instead diffuses from sites of release to act at receptors on more distant neurons. These include glutamatergic and γ-aminobutyric acidergic (GABA) neurons, which respectively release the fast acting excitatory and inhibitory neurotransmitters, glutamate and GABA. Awareness of the above concepts has important implications for understanding the biology and pharmacology of neurological diseases involving dopamine systems, including an appreciation of therapeutic principles underlying the efficacy of L-dopa and dopamine receptor agonists for treatment of the movement disorder characteristic of Parkinson’s disease. In this disorder it is the overall absence of dopamine, not just of the dopaminergic neurons, that disrupts the patterning of firing of intact CNS networks and cell assemblies crucial for control of contextdependent movement. Amelioration of the motor symptoms of Parkinson’s disease, therefore, does not require restoration of the degenerated neural connections, but can be largely achieved at least initially by correcting for the absence of the transmitter itself. Apart from Parkinson’s disease and related syndromes (e.g., multiple system atrophy, progressive supranuclear palsy, diffuse Lewy body disease), derangements in CNS dopamine neuronal systems also appear to be involved in numerous other neuropsychiatric conditions including Huntington's disease, drug addictions, depression, obsessive compulsive behavior, attention deficit/hyperactivity disorder and schizophrenia. The wide-ranging nature of these disorders illustrates the diverse functions subserved by CNS dopamine, with different pathologies and clinical manifestations explained by differences in the nature or
locations of the abnormalities of dopaminergic systems and associated dysfunctions in other neuronal systems. Elucidation of some of the underlying CNS dopaminergic abnormalities associated with the above neuropsychiatric conditions has been achieved through advances in brain imaging technology using positron emission tomographic (PET) or single photon emission computed tomographic (SPECT) imaging with ligands that target components of dopamine neuronal systems (e.g., dopamine receptors and transporters). Whereas the dysfunction of Parkinson’s disease is mainly presynaptic, the lesions associated with Parkinson plus syndromes involve both pre- and postsynaptic deficiencies, explaining why patients with the latter disorders are often unresponsive to therapy with L-dopa and dopamine receptor agonists. PET or SPECT imaging utilizing ligands specific for dopamine D1 and D2 receptors has indicated that in patients with Huntington’s disease there are reductions in striatal D1 and D2 receptor binding indicating postsynaptic dysfunction. In patients with attention-deficit/hyperactivity the disorder appears to involve presynaptic deficits associated with increases in dopamine transporter binding. Patients with chronic drug abuse problems appear to have lowered dopamine release and D2 receptor numbers in dorsal or ventral striatal regions. Furthermore, in these regions and particularly the nucleus accumbens reward centers, many of drugs of abuse – including cocaine, amphetamine, heroin, alcohol and nicotine – stimulate dopamine release, thereby reinforcing drug consumption. A central role of CNS dopaminergic systems in the pathogenesis of schizophrenia followed recognition in the 1950s that antipsychotic drugs interfere with brain dopamine function. Indeed even today, all neuroleptic drugs approved to treat schizophrenia appear to exert their antipsychotic effects through blocking the dopamine D2 receptor. In line with this, PET and SPECT imaging studies have indicated that mid-brain regions in schizophrenia are characterized by increased subcortical dopamine release and sensitivity to D2 receptor activation. Beyond the generally accepted view that psychotic episodes in schizophrenia are associated with a hyperdopaminergic state, the precise neuroanatomical sites and underlying alterations of CNS dopamine systems remain imprecisely elucidated. It is often presumed that production of dopamine within the brain accounts for most of the production of this catecholamine by the body. From measurements of the overflow of dopamine metabolites from the brain into jugular venous blood it is now clear, however, that the contribution of the brain to circulating levels and urinary excretion of dopamine metabolites represents less than 20% of the overall production of dopamine within the body (Fig. 12.2). Furthermore, almost all of the dopamine formed in sympathetic nerves and the adrenal medulla is converted to norepinephrine and epinephrine. Thus, most of the dopamine and dopamine metabolites in the circulation and excreted into urine are derived from other peripheral sources. However, in contrast to norepinephrine, which functions
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
DoPAmINERgIC NEuRoTRANsmIssIoN
FIGURE 12.2 Schematic representation of the main sources of dopamine and the principal metabolites of dopamine in plasma and urine. The brain makes a relatively minor contribution, whereas dopamine synthesized in the gastrointestinal tract or derived from the diet contributes substantially to dopamine metabolites in the bloodstream and urine. This contrasts with the free dopamine excreted in urine, which is derived almost entirely from renal extraction of circulating L-dihydroxyphenylalanine and local decarboxylation to dopamine by L-aromatic amino acid decarboxylase. Abbreviations: HVA, homovanillic acid; DOPAC, dihydroxyphenylacetic acid; DA, Dopamine; DA-SO4, dopamine-sulfate; L-Dopa, L-dihydroxyphenylalanine; MTY; 3-methoxytyramine; MTY-SO4, 3-methoxytyramine-sulfate; AADC, aromatic acid decarboxylase.
as an important neurotransmitter in both the CNS and the peripheral sympathetic nervous system, evidence that dopamine acts as a neurotransmitter outside of the CNS is weak. Instead, available evidence indicates that dopamine in the periphery functions not as a neurotransmitter or circulating hormone, but rather as an autocrine or paracrine substance. Findings of increased plasma concentrations of L-dopa, dopamine and dopamine metabolites after consumption of foods indicate that dietary constituents also represent an important source of peripheral dopamine. Such food sources do not, however, account for the substantial amounts of dopamine produced in peripheral tissues outside of the digestive tract. Diet also does not account for findings in fasting individuals in which large arterial to portal venous increases in plasma concentrations of dopamine and its metabolites indicate substantial production of dopamine within mesenteric organs. These findings are consistent with morphological studies demonstrating the presence of cells in the gastrointestinal tract that contain dopamine and express components of dopamine signaling pathways, including catecholamine biosynthetic enzymes and specific dopamine receptors and transporters. In the
65
stomach, tyrosine hydroxylase is expressed in epithelial cells, including acid secreting parietal cells. In the small intestine, cells of the lamina propria, including immune cells, also express tyrosine hydroxylase. The enzyme is additionally found in pancreatic exocrine cells. Dopamine and dopamine receptor agonists stimulate bicarbonate secretion and protect against ulcer formation, whereas dopamine antagonists augment secretion of gastric acid and promote ulcer development. Dopamine also appears to influence GI motility, sodium transport, and gastric and intestinal submucosal blood flow. In the pancreas, dopamine may modulate secretion of digestive enzymes and bicarbonate. Thus, dopamine appears to act in mesenteric organs as an enteric neuromodulator or paracrineautocrine substance. In the kidneys, dopamine is an established autocrine and/or paracrine effector substance contributing to the regulation of sodium excretion. Unlike other catecholamine systems, production of dopamine in the kidneys is largely independent of local synthesis of L-dopa by tyrosine hydroxylase. Instead, production of dopamine in the kidneys depends mainly on proximal tubular cell uptake of L-dopa from the circulation. The L-dopa is then converted to dopamine by L-aromatic amino acid decarboxylase, the activity of which is up-regulated by a high-salt diet and down-regulated by a low-salt diet. The presence of a renal dopamine paracrine-autocrine system explains the considerable amounts of free dopamine excreted in the urine. Most derives from renal uptake and decarboxylation of circulating L-dopa and reflects the plasma levels of this amino acid and the function of the renal dopamine paracrine/ autocrine system.
Further Reading Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia – therapeutic implications. Brain Res Brain Res Rev 2000;31:342–9. Carlsson A. Thirty years of dopamine research. Adv Neurol 1993;60:1–10. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 2004;56:331–49. Flagel SB, Clark JJ, Robinson TE, Mayo L, Czuj A, Willuhn I, et al. A selective role for dopamine in stimulus-reward learning. Nature 2011; 469:53–7. Girault JA, Greengard P. The neurobiology of dopamine signaling. Arch Neurol 2004;61:641–4. Nikolaus S, Antke C, Kley K, Poeppel TD, Hautzel H, Schmidt D, et al. Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Rev Neurosci 2007;18:439–72. Reichmann H. Long-term treatment with dopamine agonists in idiopathic Parkinson’s disease. J Neurol 2000;247(Suppl 4):IV/17–19. Rice ME, Cragg SJ. Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. Brain Res Rev 2008;58:303–13. Sotnikova TD, Beaulieu JM, Gainetdinov RR, Caron MG. Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. CNS Neurol Disord Drug Targets 2006;5:45–56. Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol 2007;64:1575–9.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
13 Dopamine Receptors Sean M. Peterson, Nikhil Urs, Marc G. Caron
INTRODUCTION
receptors, both temporally and spatially, and is cataloged online at GENSAT [1].
Dopamine (DA) is one of the major monoamine neurotransmitters in the mammalian brain. It is generated by hydroxylation and decarboxylation of the amino acid tyrosine, and further metabolized into epinephrine and norepinephrine (collectively referred to as catecholamines). The role of DA in brain function was first proposed by Nobel Laureate, Arvid Carlsson, whereas Oleh Hornykeiwicz and colleagues first demonstrated a DA deficit in the brain of Parkinson’s patients. DA has been shown to regulate a variety of functions such as movement, reward, cognition and emotion. Dysfunction of DA neurotransmission has been implicated in numerous other disease states such as addiction, schizophrenia, ADHD and Tourette’s syndrome. These multiple effects of DA are mediated through its ability to bind to five distinct G protein-coupled receptors (GPCRs) that belong to two subfamilies, the D1-like (comprised of D1R and D5R) and the D2-like (comprised of D2R, D3R, and D4R) receptor families. These families are distinguishable not only by their unique pharmacology but also by their gene structure, expression patterns, protein structure, and signal transduction pathways. A large number of DA receptor (DAR) studies have focused on the receptors in the central nervous system (CNS); however the basic principles apply to both the CNS and autonomic nervous system (ANS).
Autonomic Nervous System DA neurons from the hypothalamus project to the anterior pituitary gland where D1 and D2 family receptors are expressed leading to an inhibition of prolactin release. All DAR subtypes are expressed in the kidney, blood vessels and heart. In the kidney, DARs regulate renin release as well as fluid and sodium reabsorption.
DOPAMINE RECEPTOR STRUCTURE Gene Structure Two distinct receptor families have evolved to bind DA. The D1 family is comprised of D1R, D5R, and the D5R pseudogenes, D5ψ1 and D5ψ2, which are not expressed. The D1 family is intronless in the protein coding region, as are approximately 50% of all GPCRs. The D2 family, which includes D2R, D3R, and D4R, has a more complex gene structure than the D1 family. The D2R gene, DRD2, contains six introns and is alternatively spliced to generate two functional proteins: D2LR (the long isoform) and D2SR (the short isoform lacking a 29 amino acid exon in the third intracellular loop of the receptor). D2SR is expressed predominantly on DA neurons, and functions as an autoreceptor to regulate extracellular levels of DA and modulate neuronal firing, while D2LR is expressed predominantly postsynaptically. The D3R gene, DRD3, contains five introns in the protein coding region and is alternatively spliced, however, DRD3 isoforms are not as well characterized, which may be due to nonsense mediated decay of mRNA products. The D4R gene, DRD4, contains three introns in the protein coding region, and contains a variable number tandem repeat (VNTR) of 48 nucleotides in exon 3 of the gene (which occurs in the intracellular loop 3 of the receptor). The VNTR can be 2–11 repeats, however, the four repeats (4R) is by far the most common, while 7R and 2R occur less frequently.
DISTRIBUTION AND EXPRESSION OF DOPAMINE RECEPTORS Central Nervous System Dopamine receptor distribution in the brain has been extensively studied. In the mammalian brain D1Rs and D2Rs are the most highly expressed receptors of all the five DARs. D1R and D2R expression is highest in areas of DA neuron innervation, whereas D3R, D4R and D5R expression is more specialized. The advent of BAC (bacterial artificial chromosome) recombineering technology has led to advances in clarifying the distribution patterns of these
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00013-5
67
© 2012 Elsevier Inc. All rights reserved.
68
13. DoPAmInE RECEPToRs
The DRD4 7R allele has been proposed to be a contributing factor to the development of ADHD, and has undergone strong positive selection throughout all of modern human history [2].
Receptor Structure Dopamine receptors belong to the superfamily of GPCRs and are all considered to be in the Rhodopsin-like Class A family of 7-transmembrane receptors based on sequence homology and function. For all the five DARs the N-terminus and extracellular loops are glycosylated and cysteine residues between the loops form disulfide bonds. The intracellular loops interact with G proteins, whereas these loops and C-terminal tails are phosphorylated by G protein-coupled receptor kinases (GRKs) and interact with β-arrestins and other kinases and signaling molecules (Table 13.1; Fig. 13.1). The D2 family of DARs have an especially long intracellular loop 3 (IC3) and a short C-terminal tail, while the D1 family has a relatively short IC3 and longer C-terminal tail. Recently, the crystal structure of D3R was solved [3]
TABLE 13.1 Dopamine Receptor signal Transduction Pathways
Receptor
Signaling Molecule
Downstream Effector
Second Messenger System
D1-like
Gαs
AC activation
Increased cAMP
D2-like
Gαi
AC inhibition
Decreased cAMP
D2R
Gαz
AC inhibition
Decreased cAMP
D2R/D1R and D2R/D5R dimers
Gαq
PLC activation
Increased IP3, DAG, and Ca2
D2R
Gβγ
GIRK
K
D1R
β-arrestin
ERK
N/A
D2R
β-arrestin
Akt/GSK3
N/A
Receptors are designated as their family (D1- or D2-like) or their specific receptor subtype. Canonical G protein signaling is compared and contrasted to non-canonical β-arrestin signaling. The details and relationship between these signal transduction pathways are further illustrated in Figure 13.1.
FIGURE 13.1 Relationship of dopamine receptor signal transduction pathways. Dopamine binds to dopamine receptors (DARs) to cause the exchange of GTP for GDP at the Gα subunit and the dissociation of Gβγ, which goes on to interact with effectors like ion channels. Gα hydrolyzes GTP (with the help of RGS proteins in the case of Gαi and Gαq family members) and then re-associates with Gβγ. In addition, binding of dopamine to DARs causes their phosphorylation and the recruitment of β-arrestin, which mediates desensitization of G protein signaling as well as internalization and recycling of competent DARs to the plasma membrane. The DAR/arrestin complex can initiate G protein independent receptor mediated signaling in its own right. Functional selectivity refers to agonists that are able to activate either G protein or β-arrestin pathways to a much greater extent than the other. The intracellular loop 3 and C-terminus of the receptor is represented as a dotted line because of structural differences between D1- and D2-family DARs (see text).
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
DoPAmInE RECEPToR FunCTIon: sIgnAl TRAnsDuCTIon PATHwAys
in complex with a selective D3R antagonist. This insight will undoubtedly provide an avenue for the design of highly potent D3R ligands. The importance of DAR pharmacological agents will be discussed in more detail in later sections.
DOPAMINE RECEPTOR FUNCTION: SIGNAL TRANSDUCTION PATHWAYS G protein-coupled receptors have long been known for transducing signals by acting as guanine nucleotide exchange factors for heterotrimeric G proteins, however, recent work has shown that most GPCRs signal through noncanonical pathways both in vitro and in vivo. Dopamine receptors are no exception and the following section summarizes both canonical and noncanonical DAR signal transduction pathways. Figure 13.1 provides a summary of the general relationship between these signaling pathways, while Table 13.1 provides specific details of the important DAR signaling molecules.
G Protein Dependent Signaling The D1 family of DARs activates members of the Gαs family, which are so named because they stimulate adenylate cyclase (AC) leading to the production of adenosine 3,5-cyclic monophosphate (cAMP) as a second messenger. The D2 family of DARs couples to both the pertussis sensitive Gαi and the pertussis insensitive Gαz families resulting in an inhibition of AC and lower cAMP. The D2 family is also known to signal through Gβγ, which activates G protein-coupled inward rectifying potassium channels, phospholipase Cβ, and other proteins.
69
molecules and promote signal transduction [6]. Recent studies from our laboratory have shown a role for β-arrestin dependent signaling through both D1R and D2R. D1Rs have been shown to promote β-arrestin dependent ERK signaling upon morphine-stimulated DA release and this signaling pathway regulates morphine/DA-induced psychomotor activation but not its rewarding effects [7]. D2Rs have been shown to promote β-arrestin dependent Akt and GSK3 signaling and regulate several DA sensitive behaviors in mice that can be modeled as endophenotypes of schizophrenia [8].
Oligomerization Higher order GPCR signaling structures have long been hypothesized to exist, however there remains some controversy over the biological significance of such structures. Evidence for oligomers (mostly dimers) between the D1 family and the D2 family has been provided from both in vitro and in vivo approaches. D2R was shown to interact with both D1R or D5R the consequence of which causes the coupling of the receptors to switch from Gαs or Gαi to a different family of G proteins, Gαq, which actives phospholipase C to cause the release of IP3 and Ca2 [9]. Receptor oligomerization adds a layer of complexity to an already complex signaling model, and new investigational tools have and will continue to illuminate these intricacies.
Dopamine Receptor Pharmacology Dopamine’s role in the regulation of complex functions in both the CNS and ANS makes DARs key targets in developing therapeutics for many diseases associated with DA function. Extensive work has been done in characterizing DAR agonists and antagonists.
Signal Regulation
Ligand Specificity
Regulator of G protein signaling (RGS) proteins function to accelerate GTP hydrolysis by the Gα subunit of G proteins, thereby attenuating GPCR signaling. D2Rs are regulated by RGS9, which has been implicated in Parkinson’s disease [4]. Receptor regulation is also accomplished through phosphorylation of the intracellular residues of the receptors by GRKs, which stabilize the receptor in a conformation conducive to β-arrestin binding. All five DARs interact with GRK2, GRK3, GRK5 and GRK6 as well as β-arrestin 1 and 2. Upon binding, β-arrestins desensitize GPCR signaling and induce internalization of receptors by interacting with clathrin-coated pits [5].
Many ligands have been shown to differentiate between the D1 and D2 family of receptors. Classically, the specificity of agonists and antagonists can be used to delineate the contribution of each receptor family in in vitro and in vivo studies. Selective ligands are also used as therapeutic agents in conditions like Parkinsonism and schizophrenia.
β-Arrestin Dependent Signaling In addition to its desensitizing and internalizing functions, recent work has shown a role for β-arrestin dependent signaling through its ability to scaffold signaling
Functional Selectivity The significance of arrestin dependent signaling for GPCRs may be many fold [7]. First, arrestin dependent signaling is usually more persistent than G protein signaling. Second, it has been shown that for certain GPCRs a given compound can act as an agonist at one signaling pathway and an antagonist at the other or vice versa. Moreover, examples are beginning to accumulate demonstrating that these two signaling modes can sub-serve distinct biological functions mediated by the same GPCR.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
70
13. DoPAmInE RECEPToRs
Interestingly, all clinically effective antipsychotics for the treatment of schizophrenia interact with D2R. Whereas antipsychotics have a mixed agonist/antagonist profile at D2R/G protein signaling, they appear to behave uniformly as antagonists at the D2R/β-arrestin interactions [10]. This principle is commonly referred to as functional selectivity or biased agonism/antagonism and should become an important element in the development of newer, more selective therapeutic agents.
References [1] The gene expression nervous system atlas (GENSAT) project. New York, NY: The Rockefeller University. [2] Wang E, Ding YC, Flodman P, Kidd JR, Kidd KK, Grady DL, et al. The genetic architecture of selection at the human dopamine receptor D4 (DRD4) gene locus. Am J Hum Genet 2004;74(5):931–44. [3] Chien EY, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, et al. Structure of the human dopamine d3 receptor in complex with a d2/d3 selective antagonist. Science 2010;330(6007):1091–5. [4] Gold SJ, Hoang CV, Potts BW, Porras G, Pioli E, Kim KW, et al. RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanineinduced dyskinesia in experimental Parkinson’s disease. J Neurosci 2007;27(52):14338–48.
[5] Laporte SA, Oakley RH, Zhang J, Holt JA, Ferguson SS, Caron MG, et al. The beta2-adrenergic receptor/beta-arrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci USA 1999;96(7):3712–7. [6] Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, et al. beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem 2006;281(2):1261–73. [7] Urs NM, Daigle TL, Caron MGA. Dopamine D1 Receptordependent beta-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice. Neuropsychopharmacology 2011; 36(3):551–8. [8] Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005;122(2):261–73. [9] So CH, Verma V, Alijaniaram M, Cheng R, Rashid AJ, O’Dowd BF, et al. Calcium signaling by dopamine D5 receptor and D5-D2 receptor hetero-oligomers occurs by a mechanism distinct from that for dopamine D1-D2 receptor hetero-oligomers. Mol Pharmacol 2009;75(4):843–54. [10] Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, Gainetdinov RR, et al. Antagonism of dopamine D2 receptor/betaarrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA 2008;105(36):13656–61.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
14 Cholinergic Neurotransmission Brett A. English, Carrie K. Jones
ACETYLCHOLINE BIOSYNTHESIS AND METABOLISM
enzymatic inactivation by the enzyme acetylcholinesterase (AChE), which hydrolyzes ACh into acetate and choline. AChE operates at near diffusion-limited rates, thus this enzyme is not rate limiting in overall ACh homeostasis. The byproduct of ACh hydrolysis, choline, is then recycled by the presynaptic cholinergic terminal in a carrier-mediated mechanism of high-affinity choline uptake (HACU) process, mediated by the high-affinity choline transporter (CHT) and which appears to be the critical step in modulating the rate and extent of ACh production. Within cholinergic nerve terminals, choline is required for the biosynthesis of ACh since these neurons cannot synthesize de novo, hence the requirement for a HACU process. Recent studies in transgenic mice exhibiting a genetic reduction in CHT demonstrated age-related reductions in cardiac function and histologic changes consistent with heart failure.
Acetylcholine (ACh), one of the first identified neurotransmitters, was originally termed vagusstoff due to its actions in supporting vagal slowing of heart rate (HR), and has been the focus of intense research for decades. ACh has been shown to regulate many physiologic functions within the central nervous system (CNS) modulating diverse functions including cognition, attention and arousal. Within the autonomic nervous system (ANS), ACh serves as the principal neurotransmitter mediating fast synaptic neurotransmission at the preganglionic junction by both the sympathetic (SNS) and parasympathetic (PNS) nervous systems. The PNS (via the vagus nerve) uses ACh as its primary postganglionic neurotransmitter modulating a number of physiologic processes including heart rate, gastrointestinal motility, exocrine gland secretions and smooth muscle tone (Tables 14.1 and 14.2). In addition to mediating a number of peripheral autonomic effects, recent experimental evidence has demonstrated a role of the PNS (vagus nerve) in mediating cytokine production in response to inflammation. The availability of ACh for cholinergic transmission involves a highly co-ordinated process of ACh synthesis, vesicular packaging, vesicular release, hydrolysis and reuptake into the presynaptic nerve terminal. Within the cholinergic presynaptic terminal, the enzyme choline acetyltransferase (ChAT) synthesizes ACh from the precursors choline and acetyl coenzyme-A (acetyl-CoA). ChAT is not believed to serve as the rate-limited step in the biosynthesis of ACh as the presynaptic concentrations of choline are much lower than the Km (affinity) for ChAT. Upon synthesis, ACh is packaged into synaptic vesicles by the vesicular ACh transporter (VAChT), and released into the synaptic cleft upon depolarization of the neuron by an action potential mediated by voltage-sensitive Ca2channels. Once released into the synaptic cleft, ACh interacts with either nicotinic acetylcholine receptors (nAChRs) or muscarinic acetylcholine receptors (mAChRs). ACh then rapidly dissociates from its receptor and undergoes
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00014-7
ACETYLCHOLINE RECEPTORS The postsynaptic effects of ACh neurotransmission are mediated by two major types of acetylcholine receptors. At the preganglionic junction, both the SNS and PNS use ACh to activate nicotinic acetylcholine receptors (nAChRs) on the postganglionic neuron. The postganglionic effects of ACh by the PNS occur by activating a number of postsynaptic muscarinic acetylcholine receptors (mAChRs) expressed in several target organs (Table 14.1). The classification of the different acetylcholine receptor subtypes is primarily established based upon binding of specific ligands, their respective effector-coupling systems and their primary amino-acid sequence homology. Within the muscarinic acetylcholine receptor family, there are five receptor subtypes that have been identified, termed M1-M5), each with unique tissue distribution and pharmacologic characteristics (Table 14.2). All mAChRs subtypes are monomeric proteins with seven transmembrane spanning domains and mediate their effects by coupling to G-proteins. M1, M3 and M5 receptors couple to Gq/11 and increase phospholipase C (PLC) activity subsequently increasing cytosolic concentrations of
71
© 2012 Elsevier Inc. All rights reserved.
72
14. CHolINERgIC NEuRoTRANsmIssIoN
TABLE 14.1 Cholinergic Pharmacology Target
Localization
Effect
Mechanism
Agonist
Antagonist
Nicotinic (N)N
Autonomic ganglia, CNS
Fast depolarization of postganglionic neuron
↑ Na/K channel conductance
Succinylcholine
Trimethaphan
Nicotinic (N)M
Neuromuscular junction (NMJ)
Motor end-plate depolarization, muscle contraction
↑ Na/K channel conductance
Succinylcholine
Tubocurarine
Muscarinic (M1)
CNS, autonomic ganglia
Attention, memory, arousal
Gq/11; ↑ PLC, PKC
Oxotremorine, cevimeline, xanomeline
Scopolamine, pirenzepine
Muscarinic (M3)
Smooth muscle, exocrine glands
Smooth muscle contraction, increased glandular secretions
Gq/11; ↑ PLC, PKC
Cevimeline, pilocarpine
Atropine, solifenacin
Muscarinic (M5)
CNS
?
Gq/11; ↑ PLC, PKC
Sabcomeline
Atropine
Muscarinic (M2)
CNS, heart (SA and AV node)
Reduced HR, AV nodal conduction
Gi; βγ, ↓ AC and ↑ K channel conductance
Carbachol, pilocarpine
Scopolamine, atropine
Muscarinic (M4)
CNS
Cognition
Gi; βγ, ↓ AC and ↑ Kchannel conductance
Xanomeline
Atropine, pirenzepine
Choline transporter (CHT)
Presynaptic; CNS, autonomic, lung
Rate-limiting step for synthesis of ACh
None Na/K-coupled high affinity choline transport
Choline acetyltransferase (ChAT)
Presynaptic terminal
Synthesis of ACh from choline & acetylCoA
AcetylCoA choline → ACh
None
None
Vesicular acetylcholine transporter (VAChT)
Presynaptic vesicles
Storage of ACh in presynpatic vesicles
H-coupled
None
Vesamicol
Postsynaptic
Hydrolysis of ACh
ACh→choline acetate
None
Physostigmine, donepezil
RECEPTOR
SYNTHESIS/STORAGE Hemicholinium-3
METABOLISM Acetylcholinesterase (AChE)
inositol-triphosphate (IP3) and diacylglycerol (DAG). Increased IP3 and DAG results in increased release of intracellular Ca2 from endoplasmic reticulum stores and activation of protein kinase C (PKC) respectively. M1 receptors are primarily expressed within the CNS and mediate a number of cognitive functions, while M3 receptors are involved in exocrine gland secretion and smooth muscle function in the PNS. M5 receptors are expressed only within the CNS where they serve to modulate midbrain dopamine release and cerebral vasculature tone. M2 and M4 receptors are coupled to Gi, which results in inhibition of adenylyl cyclase (AC) and activation of inwardly rectifying K-channels (IKACh) and suppression of voltage-gated Ca2-channels. These actions of G-protein coupling to Gi partly explain the cardiovascular effects of M2 activation in the heart via IKACh. Additionally, studies conducted in M2 knockout mice show increased sensitivity to the β-agonist, isoproterenol, developing abnormal ventricular functioning consistent with heart failure. Within the CNS, M2 and M4 receptors provide the major autoreceptor function for control of Ach release. Nicotinic acetylcholine receptors are also divided into nicotinic receptors that mediate neuromuscular junction
activation (NM) or neuronal activation (NN) at the autonomic ganglia and within the CNS. However, unlike muscarinic receptors, nAChRs are ligand-gated ion channels. Upon binding of Ach, these receptors undergo conformational changes that permit the rapid influx of Na with subsequent cellular depolarization. These distinctions are important pharmacologically as nicotinic receptors are an assembly of five heterologous subunits (α1–9 and β1–4) arranged symmetrically around a central ionic selectivity pore, each with different subunit arrangement and pharmacologic binding properties (nicotinic neurotransmission is discussed in detail in Chapter 15). While nAChRs do not directly affect peripheral organ systems, they mediate ganglionic transmission and can facilitate neurotransmission of postganglionic nerve fibers.
CHOLINERGIC PHARMACOLOGIC AGENTS Cholinomimetic drugs can be classified into three categories. Direct-acting cholinomimetics, indirect-acting agents and allosteric modulating compounds. Direct-acting agents bind to and activate either nAChRs or mAChRs; for
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
CHolINERgIC PHARmACologIC AgENTs
TABLE 14.2 Responses of Effectors organs to Cholinergic Transmission of the Autonomic Nervous system Effector Organ
Receptor
Effect
Sinoatrial node
M2
Bradycardia
Atrium
M2, M3
↓ lusitropy
Atrioventricular node
M2
↓ conduction velocity
Arteriole
M2
Vasodilation (via release of nitric oxide, NO)
HEART
GASTROINTESTINAL/UROLOGIC GI Motility
M2, M3
Increased
GI secretion
M3
↑ secretions
Gallbladder
M2
Contraction
Urinary detrusor
M2, M3
Contraction
Urinary sphincter
M2
Relaxation
Penis
M
Erection
M3, M1
Constriction; ↑ secretions
Sweat glands
M3
Diaphoresis
Salivary glands
M3
↑ secretions
Lacrimal glands
M3
↑ secretions
Nasopharyngeal glands
M3
↑ secretions
Iris (pupillae sphincter)
M3
Contraction (miosis)
Ciliary muscle
M3
Contraction (accommodation)
RESPIRATORY Bronchial muscle GLANDULAR
OCULAR
73
(iii) phosphoric acid organic derivatives (e.g. organophosphates). Organophosphates are considered “irreversible” inhibitors, while the other chemical classes of AChEIs are “reversible” acting. Recently, several novel cholinomimetic compounds have been identified that function as positive allosteric modulators (PAMs) or allosteric agonists instead of traditional orthosteric agonists at different mAChRs. Allosteric modulators and agonists of mAChRs do not bind to the orthosteric binding site of Ach but rather interact with topographically distinct binding sites on the receptor that are separate from the orthosteric sites. Because these allosteric modulators and agonists interact at less highly conserved regions of the mAChR, these compounds offer a tremendous advantage in conferring a high degree of subtype selectivity. In addition, since PAMs potentiate the effects of Ach and have no effect in the absence of the endogenous ligand, the physiological signal and transduction is preserved resulting in less receptor desensitization and development of tolerance. A number of mAChR selective PAMs, including the selective M1 PAM BQCA, are being investigated in several preclinical models of cognitive disorders associated with schizophrenia and Alzheimer’s disease. Similarly, cholinergic receptor antagonists are categorized based upon their acetylcholine receptor selectivity. There are few nAChR antagonists used clinically and these consist primarily of the non-depolarizing ganglionic blockers (e.g. hexamethonium) and the depolarizing blocker (e.g. succinylcholine). The prototypical muscarinic antagonist, scopolamine is a non-selective antagonist at all five mAChR subtypes resulting in a reversible blockade that is surmountable by increasing concentrations of ACh. Other muscarinic antagonists display relative selectivity for specific mAChR subtypes, but exhibit dose-dependent effects (e.g. pirenzepine, M1; oxybutynin, M3). Since muscarinic receptors are constitutively active, muscarinic antagonists shift the receptor to an inactive state preventing actions of IP3/DAG and AC.
Further Reading example chemical esters of choline such as carbachol or alkaloid compounds, including pilocarpine. Many of these compounds exhibit preferential selectivity for either nicotinic or muscarinic receptors. However, in the case of the mAChRs, subtype selective compounds within the mAChRs have been difficult to identify and develop due to the high conservation of the orthosteric binding site of ACh across M1–M5. Lack of subtype selectivity of orthosteric compound, especially for the mAChRs, has resulted in a number of adverse side effects due to activation of peripheral mAChRs. Indirect-acting agents increase synaptic concentrations of ACh by inhibiting the hydrolytic metabolism by AChE. While these agents all work by inhibition of AChE, they exhibit significant differences in their chemical properties and pharmacokinetics. There are three chemical groups of AChE inhibitors: (i) quaternary ammonium alcohols (e.g. edrophonium); (ii) carbamic acid esters (e.g. neostigmine);
Dhein S, Van Koppen CJ, Brodde OE. Muscarinic receptors in the mammalian heart. Pharmacol Res 2001;44(3):161–82. Digby GJ, Shirey JK, Conn PJ. Allosteric activators of muscarinic receptors for treatment of CNS disorders. Mol Biosyst 2010;6(8):1345–54. English BA, Appalsamy M, Diedrich A, Ruggiero AM, Lund D, Wright J, Keller NR, Louderback KM, Robertson D, Blakely RD. Tachycardia, reduced vagal capacity and age-dependent ventricular dysfunction arising from diminished expression of the presynaptic choline transporter. Am J Physiol Heart Circ Physiol 2010;299(3):H799–810. Ferguson SM, Blakely RD. The choline transporter resurfaces: new roles for synaptic vesicles. Mol Interv 2004;4:22–7. LaCroix C, Freeling J, Giles A, Wess J, Li YF. Deficiency of M2 muscarinic acetylcholine receptors increases susceptibility of ventricular function to chronic adrenergic stress. Am J Physiol Heart Circ Physiol 2008;294:H810–820. Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Therap 2008;117:232–43. Olshanksy B, Sabbah HN, Hauptman PJ, Colucci WS. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation 2008;118(8):863–71.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
74
14. CHolINERgIC NEuRoTRANsmIssIoN
Rosas-Ballina M, Tracey KJ. Cholinergic control of inflammation. J Intern Med 2009;265:663–79. Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, et al. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci 2009;29(45):14271–14286.
Westfall TC, Westfall DP. Neurotransmission: the autonomic and somatic motor nervous system. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill; 2006. p. 137–83.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
15 Acetylcholine and Muscarinic Receptors Joan Heller Brown, Nora Laiken The synthesis of acetylcholine (ACh) is catalyzed by choline acetyltransferase, a soluble cytoplasmic enzyme that transfers an acetyl group from acetyl coenzyme A to choline. The activity of choline acetyltransferase is much greater than the maximal rate at which ACh synthesis occurs, and inhibitors of this enzyme have little effect on ACh levels in cholinergic nerve terminals. The rate-limiting step in ACh synthesis is the transport of choline into the nerve terminal by the high-affinity choline transporter (CHT1), the activity of which is regulated in response to neuronal activity. Following its synthesis, ACh is transported into synaptic vesicles by the vesicular ACh transporter (VAChT). The depolarization of the cholinergic nerve terminal by an action potential activates voltage-gated calcium channels; the resulting calcium influx initiates the release of ACh into the junctional space by exocytosis. ACh release can be blocked by botulinum toxin, the etiologic agent in botulism. Botulinum toxin has been used to treat a variety of movement disorders and other conditions, both cosmetic (e.g., glabellar frown lines [facial wrinkles]) and pathological (e.g., strabismus [crossed eyes]); injected locally, the toxin can inhibit ACh release for as long as 3 to 4 months. The ACh released into the synapse associates with postsynaptic cholinergic receptors, triggering various physiological responses. The actions of ACh are terminated by its rapid hydrolysis into choline and acetic acid by acetylcholinesterase (AChE), which is found in the junctional space at all cholinergic junctions; thus, responses mediated by ACh tend to be transient and localized. The choline liberated by AChE can be taken back up into the nerve terminal by CHT1 and resynthesized into ACh. While not important for the hydrolysis of endogenous ACh, a nonspecific cholinesterase (pseudocholinesterase or butyrylcholinesterase) is present in plasma and some organs and important for metabolism of some drugs. Drugs that normally are hydrolyzed by pseudocholinesterase, such as succinylcholine (a neuromuscular blocking agent used in anesthesiology to produce skeletal muscle paralysis), are poorly metabolized by this variant enzyme; succinylcholine can produce a prolonged paralysis in affected patients. Cholinesterases are discussed in detail in Chapter 132 of this Primer. Cholinergic neurotransmission and drugs that affect it are further discussed in Chapter 14 and summarized in Table 15.1.
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00015-9
TABLE 15.1 Cholinergic Neurotransmission: Drug Mechanisms Cholinergic neurotransmission can be modified at several sites: (a)
Precursor transport blockade
Hemicholinium (blocks CHT1)
(b)
Choline acetyltransferase inhibition
No clinical example
(c)
Promote transmitter release
Black widow spider venom (latrotoxin)
(d)
Prevent transmitter release
Botulinum toxin
(e)
Storage
Vesamicol (blocks VAChT)
(f)
Cholinesterase inhibition
Physostigmine, neostigmine
(g)
Receptors
mAChR and nAChR agonists/antagonists
CHOLINERGIC NEUROTRANSMISSION: SITES AND RECEPTORS Cholinergic transmission occurs at five important locations: (i) all effector sites innervated by parasympathetic postganglionic neurons; (ii) a small number of effector sites innervated by sympathetic postganglionic neurons (most importantly, most sweat glands); (iii) all autonomic ganglia (including the adrenal medulla), innervated by parasympathetic and sympathetic preganglionic neurons; (iv) all motor end plates on skeletal muscle, innervated by somatic motor neurons; and (v) certain synapses in the CNS. As might be expected for an ancient and ubiquitous neurotransmitter, a variety of ACh (cholinergic) receptor types have emerged in evolution. Based on their responsiveness to the agonists muscarine and nicotine, cholinergic receptors can be divided into two groups, nicotinic cholinergic receptors (nAChRs) and muscarinic cholinergic receptors (mAChRs). nAChRs are found at the following locations: l l l
Autonomic ganglia (including the adrenal medulla). Neuromuscular junction of skeletal muscle. Central nervous system.
There are two nAChR subtypes, NN (neural nicotinic) and NM (muscle nicotinic). NN receptors mediate neurotransmission in autonomic ganglia, while NM receptors
75
© 2012 Elsevier Inc. All rights reserved.
76
15. ACETylCHolINE AND MusCARINIC RECEPToRs
TABLE 15.2 Muscarinic Receptor-Mediated Responses at Autonomic Effector sites Iris sphincter muscle
Contraction (miosis)
Ciliary muscle
Contraction (near vision)
Sinoatrial node
Bradycardia
Atrium
Decreased contractility
Atrioventricular node
Decreased conduction velocity
Arteriole
Dilation (through nitric oxide)
Bronchial smooth muscle
Contraction
Gastrointestinal motility
Increased
Gastrointestinal secretion
Increased
Gallbladder
Contraction
Bladder (detrusor)
Contraction
Bladder (trigone, sphincter)
Relaxation
Penis
Erection (but not ejaculation)
Sweat glands
Secretion
Salivary glands
Secretion
Lacrimal glands
Secretion
Nasopharyngeal glands
Secretion
mediate skeletal muscle contraction; thus, NN and NM antagonists are called ganglionic blockers and neuromuscular blockers, respectively. nAChRs in the CNS resemble NN receptors and are primarily presynaptic. nAChRs and the responses that they mediate are discussed in Chapter 16 of this Primer. mAChRs are found at the following locations: l
l
l
l
l
Effector sites innervated by parasympathetic postganglionic neurons. Effector sites innervated by sympathetic cholinergic postganglionic neurons (most sweat glands). Presynaptic sites on noradrenergic and cholinergic nerve terminals. Non-innervated sites in blood vessels (vascular endothelium, smooth muscle). Central nervous system.
Because of their physiological and therapeutic significance, it is important to review the specific responses mediated by mAChRs at autonomic effector sites. All of these sites are innervated by parasympathetic postganglionic neurons except for the sweat glands, which are innervated by sympathetic cholinergic postganglionic neurons (this innervation is sympathetic because of the thoracolumbar origin of the preganglionic neurons and is cholinergic because the postganglionic neurons release ACh). See Table 15.2. There are five mAChR subtypes, designated M1–M5. All mAChRs are G protein-coupled receptors. Stimulation of M1, M3, and M5 receptors generally results in the hydrolysis of phosphoinositides by activating the Gq-phospholipase C
pathway, resulting in mobilization of intracellular calcium; stimulation M2 and M4 receptors generally leads to the inhibition of adenylyl cyclase and the activation of potassium channels by activating Gi and Go. The five mAChR subtypes are widely distributed in both peripheral tissues and the CNS, with most cells expressing at least two subtypes. Due to the paucity of agonists and antagonists that are truly subtype-specific, identifying which subtype(s) mediate a particular mAChR response has been difficult. Studies in knockout mice have helped to elucidate the functions of specific mAChR subtypes. For example, M1 receptors modulate neurotransmitter signaling in the cortex and hippocampus and also have an important role in modulating cholinergic transmission in autonomic ganglia; M2 receptors are the predominant subtype mediating the parasympathetic control of the heart and also mediate mAChR agonist-induced tremor, hypothermia, and presynaptic inhibition of neurotransmitter release; M3 receptors are the predominant subtype mediating the parasympathetic control of smooth muscle contraction and glandular secretion, the sympathetic cholinergic control of sweating, and mAChR agonist-induced increases in food intake and body weight; M4 receptors modulate dopaminergic activity in motor tracts and also mediate the presynaptic inhibition of neurotransmitter release; and M5 receptors modulate central dopaminergic function and the tone of cerebral blood vessels.
MUSCARINIC AGONISTS ACh itself is rarely used as a mAChR agonist because of its rapid hydrolysis after oral or intravenous administration, but several choline esters that are resistant to hydrolysis (methacholine, carbachol, and bethanechol) are available for clinical use. Bethanechol has the additional favorable property of an overwhelmingly high mAChR (vs. nAChR) specificity. In addition, several natural alkaloids are mAChR agonists, including muscarine, pilocarpine, and arecoline; pilocarpine and arecoline (and their synthetic congeners) are used clinically. mAChR agonists are used in the treatment of urinary tract motility disorders and xerostomia (dry mouth due to decreased salivary secretion) and in the diagnosis of bronchial hyperreactivity; they also are used in ophthalmology to produce miosis and to treat glaucoma. Bethanechol, which primarily affects the urinary and GI tracts, is used to facilitate urination in patients with postoperative urinary retention, diabetic autonomic neuropathy, or neurogenic bladder (it formerly was used to increase GI motility in patients with postoperative abdominal distension, gastroparesis, and other motility impairments; more efficacious therapies are now available for these disorders). Pilocarpine is used to stimulate salivary gland secretion in patients with xerostomia resulting from damage to the salivary glands (e.g., due to head and neck radiation treatments) or Sjögren’s syndrome, an autoimmune disorder characterized by decreased secretions
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
MusCARINIC ANTAgoNIsTs
(particularly salivary and lacrimal); antibodies to mAChRs of the M3 subtype have been reported in some patients. Methacholine, administered by inhalation, is used in the diagnosis of bronchial airway hyperreactivity; elicitation of significant bronchoconstriction with inhaled methacholine challenge sometimes leads to the diagnosis of asthma in patients with little baseline abnormality in pulmonary function. Pilocarpine and carbachol are used topically in ophthalmology as miotic agents and to treat glaucoma. Most side effects of mAChR agonists are predictable and include increased salivation, increased sweating, worsening of asthma, diarrhea, nausea, hypotension, and bradycardia; occasionally mAChR agonists cause hiccups. In rare cases, high doses of bethanechol may cause myocardial ischemia in patients with a predisposition to coronary artery spasm; therefore, chest pain in a patient taking bethanechol should be taken seriously.
MUSCARINIC ANTAGONISTS The classical mAChR antagonists are alkaloids derived from plants in the Solanaceae family, including the deadly nightshade (Atropa belladonna), jimson weed (Datura stramonium), and henbane (Hyoscyamus niger). Atropine, scopolamine, and hyoscine are notable examples of the plant-derived mAChR antagonists; these compounds often are termed belladonna alkaloids. The name belladonna (Italian for “beautiful lady”) originates from the historic use of drops prepared from such plants by women who wished to dilate their pupils for beauty. mAChR antagonists cause pupillary dilation (mydriasis) by blocking mAChRs on the iris sphincter muscle; such compounds currently are used in ophthalmology as mydriatics. The hallucinogenic effects of the belladonna alkaloids have been known for centuries; for example, the tiny dark seeds from jimson weed pods were used in sacred ceremonies by aboriginal Americans. In addition to the belladonna alkaloids atropine and scopolamine, the mAChR antagonists used clinically include (i) semisynthetic derivatives of these alkaloids, which differ from their parent compounds primarily in their distribution in the body and/or duration of action; and (ii) synthetic derivatives of the belladonna alkaloids, some of which exhibit some selectivity for specific mAChR subtypes. Notable drugs in these two categories are homatropine and tropicamide, which have a shorter duration of action than atropine; ipratropium, tiotropium, and methscopolamine, which are quaternary amines and, therefore, do not cross the blood–brain barrier or readily cross membranes and epithelial cell barriers; and agents with some mAChR subtype selectivity, such as pirenzepine (selective for M1 receptors), darifenacin (selective for M3 receptors), and solifenacin (selective for M3 receptors). mAChR antagonists are used to inhibit parasympathetic stimulation of the urinary tract, respiratory tract, GI tract, heart, and eye; because of their CNS effects, they also are used to treat Parkinson’s disease, manage extrapyramidal
77
(motor) symptoms caused by antipsychotic drugs, and prevent motion sickness. Oxybutynin and tolterodine are examples of drugs used to treat overactive bladder; these agents also can be used to reduce urinary frequency in patients with spastic paraplegia and to treat enuresis in children. Ipratropium and tiotropium, administered by inhalation, are important drugs in the treatment of chronic obstructive pulmonary disease. Ipratropium, administered via a nasal inhaler, is used for the treatment of rhinorrhea associated with the common cold or perennial rhinitis. Pirenzepine (not available in the US) is used for the treatment of acid-peptic disease; however, H2 antihistamines and proton pump inhibitors are more efficacious and more widely used for this purpose. Atropine, hyoscyamine, and other mAChR antagonists are used to treat irritable bowel syndrome and other conditions in which GI motility is increased, although their efficacy is limited in most patients. Atropine also is used to increase heart rate and/ or atrioventricular conduction during situations in which parasympathetic stimulation of the heart is enhanced (e.g., acute myocardial infarction involving the inferior or posterior wall of the left ventricle). Homatropine, tropicamide, and other mAChR antagonists are used in ophthalmology to dilate the pupils and paralyze the accommodation reflex. Benztropine and trihexyphenidyl are used in Parkinson’s disease, especially for the treatment of tremor; these agents also can be used to treat extrapyramidal side effects (such as dystonia and parkinsonian symptoms) caused by antipsychotic drugs. Scopolamine is widely used in a transdermal preparation to prevent motion sickness. Most side effects of mAChR antagonists are predictable and include constipation, xerostomia, anhidrosis (decreased sweating), urinary retention, precipitation of attacks of angle-closure glaucoma in susceptible patients, tachycardia, decreased lacrimation, and decreased respiratory secretions.
Further Reading Abrams P, Andersson K-E, Buccafusco J, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148:565–78. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004;364:985–96. Brown JH, Laiken N. Muscarinic receptor agonists and antagonists. In: Brunton LL, editor. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill; 2011. p. 219–37. Bymaster FP, McKinzie DL, Felder CC, Wess J. Use of Ml-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 2003;28:437–42. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50:279–90. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Rev Drug Discov 2009;8:41–54. Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends in Pharmacol Sci 2009;30:148–55. Ferguson SM, Blakely RD. The choline transporter resurfaces; new roles for synaptic vesicles? Mol Interv 2004;4:22–37.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
78
15. ACETylCHolINE AND MusCARINIC RECEPToRs
Higgins CB, Vatner SF, Braunwald E. Parasympathetic control of the heart. Pharmacol Rev 1973;25:119–55. Taylor P, Brown JH. Acetylcholine. In: Siegel GJ, Albers RW, Brady ST, Price DL, editors. Basic neurochemistry: molecular, cellular, and medical aspects. Burlington, Massachusetts: Elsevier Academic Press; 2006. p. 185–209. Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren’s syndrome. Arthritis Rheum 2000;43:1647–54.
Wellstein A, Pitschner JF. Complex dose-response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors. Naunyn Schmiedebergs Arch Pharmacol 1988;338:19–27. Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nature Rev Drug Discov 2007;6:721–33.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
16 Nicotinic Receptors Palmer Taylor Nicotinic acetylcholine receptors are members of a large pentameric super family of ligand-gated ion channel receptors that include the 5-hydoxytryptamine3 (5-HT3), glycine, γ-aminobutyric acid (GABA), and Zn-activated families of receptors along with several invertebrate and prokaryotic receptors [1–4]. Less closely related are the ligand-gated ion channels that respond to the excitatory amino acids and adenosine. Owing to the abundance of nicotinic receptors in the electric fish and findings showing that several peptide toxins that block motor activity bind to subtypes of nicotinic receptor with high affinity and selectivity, the nicotinic receptor was the first pharmacologic receptor to be purified and the cDNAs encoding its subunits cloned. Appropriately, the nicotinic receptor became the prototype for the ligand-gated ion channel family.
conformational states that lead to activation and desensitization [1–5]. More recently, a soluble protein, termed the acetylcholine binding protein, exported from glial cells of snails, has been shown to bind acetylcholine and many of the classical nicotinic agonists and antagonists [6]. Homologous proteins have been found in other invertebrate species as well. This protein, with identical subunits of slightly over 200 amino acids, is composed of residues with homology to the amino-terminal, extracellular domain of family of nicotinic receptors. Its structural characterization by X-ray crystallography (Fig. 16.3) shows it to be pentameric and to contain an arrangement of amino acid residues consistent with findings of protein modification and site-specific mutagenesis studies conducted with acetylcholine receptors isolated from neuronal and muscle systems [5,6]. The binding protein protein is homomeric, and its five binding sites reside at the five subunit interfaces with binding site determinants coming from both of the proximal subunit surfaces. The ligands bind from an outer radial direction [6,7] and enlodge behind a loop that contains selective binding determinants and proximal cysteines at or near its tip (Fig. 16.3). Hence, consistent with other proteins that exhibit homotropic cooperativity, the binding protein and the nicotinic receptors have their binding sites located at the subunit interfaces.
STRUCTURAL CONSIDERATIONS Nicotinic receptors assemble as pentamers of individual subunits. Assembly occurs in a precise manner and order such that the assembled subunits encircle an internal membrane pore and the extracellular vestibule leading to the pore. The replicated pattern of front to back assembly of subunits insures that identical subunit interfaces are formed from the pentameric assembly of identical subunits. Moreover, the amino acid residues found at homologous positions in the receptors with heteromeric subunit assemblies should occupy the same position in three dimensional space (Fig. 16.1A). Each subunit encodes a protein with four transmembrane spans. The amino-terminal ~210 amino acids lie in the extracellular domain followed by three tightly threaded transmembrane spans. A relatively large cytoplasmic loop is found between transmembrane spans 3 and 4 with a short carboxyl terminus winding up on the extracellular side. The overall structure has been detailed in a series of electron microscopy imaging studies (Fig. 16.2) and reveals a large extracellular domain, a wide diameter vestibule on the extracellular side and the gorge constriction region controlling the gating function to exist within the transmembrane spanning region [3]. Rapid and slow binding of ligands appear to induce shape changes within the receptor structure reflective of the individual
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00016-0
SUBTYPE DIVERSITY OF NICOTINIC RECEPTORS The receptor from skeletal muscle and its homologous forms in the fish electric organ consist of four distinct subunits, where the pentamer has two copies of the α subunit and one copy of β, γ and δ subunits. When muscle becomes innervated, the γ subunit is replaced by an subunit. Within this pentameric structure, the two acetylcholine binding sites exist at the αδ and αγ() subunit interfaces. Opposing faces of the homologous α and γ, δ or subunits make up the two binding sites. The subunit compositions of the receptors expressed in the nervous system are far more complex where we find nine different α subtypes and four different β subtypes [8] (Table 16.1). The α subtypes have been defined as those containing vicinal cysteines on a loop on which
79
© 2012 Elsevier Inc. All rights reserved.
80
16. NICoTINIC RECEPToRs
TABLE 16.1 subtypes of Nicotinic Acetylcholine Receptors found in Muscle and Neuronal systems Composition α1, β1, γ, δ, α6 α7 α9
β2 β3 β4
α2βγδ or α2βδ Various pentameric assemblies of α and β or α alone
α1 (A)
β2
β2
δ
α4
αβγδAChR
β2
α
α αAChR
αβNeuronal AChR
α10
α
α
H2N
ELECTROPHYSIOLOGIC EVENTS ASSOCIATED WITH RECEPTOR ACTIVATION All of the nicotinic receptors that are well characterized, to date, are cationic channels resulting in depolarization after activation. They differ substantially with respect to the permeabilities of the open channel state to Na and Ca. Na permeability is most effective in initiating a rapid depolarization, whereas Ca permeability could
2
COOH
1
reside several binding site determinants. All α subunits, except α5, use the face with the vicinal cysteines to form the binding site. The β subunits which lack this sequence and presumably the α5 subunit use the opposite or complementary face to form the binding site (Fig. 16.1). The α subunits, α2, α3, α4 and α6, combine with certain β subunits, mainly β2 and β4, to form pentameric receptors. α5 has the capacity to substitute for a β subunit in the pentameric assembly. Typically, it is thought that two of the neuronal α subunits assemble with three β subunits. Hence, typical stoichiometries (subscripted) would be α2β3 or α2α51β3 where the generic α subtypes are usually α3 or α4 and the β subtypes β2 or β4. Each of these heteromeric receptors would have two binding sites. Receptors composed of α7 subunits appear as functional homomeric entities where five copies of a single subunit confer function, when assembled. α9 and α10 subunits assemble uniquely in a pentamer and may control nociceptive responses. While the assembly patterns of the neuronal nicotinic receptor subunits are diverse, only certain combinations yield functional receptors, and particular combinations seem to be prevalent within regional areas of the nervous system. For example, pentamers of α3β4 are prevalent in ganglia of the autonomic nervous system, α4β2 is most prevalent in the central nervous system, and α7 appears widely distributed [8]. Central and peripheral nicotinic receptors play a discrete role in nicotine addiction and cardiovascular actions [9]. Mutations in nicotinic receptors give rise to congenital myasthenic syndromes [10] and other manifestations that affect autonomic and central nervous system function.
4
α2 α3 α4 α5
β1
γ
3
Muscle Neuronal
Assembly
α
α4
α1
(B)
FIGURE 16.1 Structure of the nicotinic acetylcholine receptor. (A) Arrangement of receptor subunits as pentamers in muscle and neuronal receptors. The muscle receptor exists as a pentamer with two copies of α1 and one of β, γ and δ, as seen for the receptor found in embryonic muscle. The binding sites as designated are found at the αγ and αδ interfaces. In the case of the innervated receptor in skeletal muscle, an subunit of different composition replaces γ at the same position. Two types of neuronal receptors are shown: the heteromeric type is thought to have usually two copies of α, where α is α2,α3,α4, or α6, and three copies of β, where β can be β2, β3 or β4. α5 is thought to substitute for a β subunit at one of the non-binding positions. The homomeric neuronal receptors are made up of α7 pentamers. α7 subunits may form heteromeric subtypes with certain β subunits remains open, but not proven. α9 and α10 subunits associate with each other in presumed variable ratios to form pentamers. (B) Threading pattern of the α-carbon chain of the subunits of the nicotinic receptor. The first ~210 amino acids form virtually all of the extracellular domain, contain the residues on the primary and complementary subunit interfaces forming the binding site determinants and govern the assembly process. Transmembrane span 2 from the five subunits forms the inner perimeter of the channel and is involved in the ligand gating. The other transmembrane segments contribute to the structural integrity of the receptor. The extended segment between transmembrane spans 3 and 4 forms the bulk of the cytoplasmic domain.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
81
DIsTRIbuTIoN of NICoTINIC RECEPToRs
(A)
(B)
synapse
synaptic face
M
cytoplasm
N
S
I
S
S
S
L
L
T
G P
F
V
T
L
V
L
L
L
E
V
I
C
S
P
I
cytoplasmic face
(C)
M2
E T
V L K D
FIGURE 16.2 Overall dimensional characteristics of the nicotinic receptor. Image reconstruction of electron micrographs shows the receptor to be some ~140 Angstroms in length and perpendicular to the membrane. Its diameter is 80–90 Angstroms and contains a large central channel on the membrane surface. Rapid and prolonged exposure to acetylcholine followed by rapid freezing has yielded distinctive structures for the agonist bound, unligated and desensitized states of the receptor [3,6].
serve as an intrinsic activating function in cell signaling or in triggering an excitation step. However, depolarization per se through an increase in Na permeability can also mobilize Ca through voltage sensitive Ca channels. Typically postsynaptic nicotinic receptors, such as those found in ganglia and the neuromuscular junction, function through the simultaneous occupation of the receptor by more than a single agonist molecule. Agonist association and the ensuing channel opening reveals positive cooperativity in ligand binding. These rapid binding events cause channel openings to occur in a millisecond time frame. Several openings and closings may occur during the short interval of agonist occupation, and the intrinsic efficacy of an agonist may relate to whether the ligand-receptor complex favors an open or closed state. Upon continuous exposure to agonists, most receptors desensitize. Desensitization confers a receptor state wherein the agonist has a high affinity, but the receptor is locked in a closed channel state. Desensitization provides an additional means by which temporal responses to an agonist can be regulated. Antagonists may be competitive or non-competitive. Competitive antagonists show binding that is mutually exclusive with agonists and exhibit a surmountable block of the receptor in which the dose–response curve to the agonist is shift rightward in a parallel fashion. Occupation by a single antagonist molecule is sufficient to block function. Non-competitive antagonists typically block the channel through which ions pass in the open state of the receptor. In the case of ganglionic nicotinic receptors,
trimethaphan is a competitive agonist, while hexamethonium and mecamylamine are non-competitive, therein blocking channel function. Great interest has developed in allosteric sites where binding of a ligand at a non-agonist site, enhances or diminishes agonist function and are termed allosteric activators or inhibitors. Hence, they are distinguished from orthosteric ligands that occupy the primary agonist or antagonist sites.
DISTRIBUTION OF NICOTINIC RECEPTORS Nicotinic receptors are widely distributed in the central and peripheral nervous systems. In innervated skeletal muscle they are found in very high density localized to the motor end plate. Also, certain motor neurons may contain receptors at the presynaptic nerve ending to control release. In ganglia, the primary nicotinic receptor is found on the postsynaptic dendrite and nerve cell body. Others may exist presynaptically to control release from the presynaptic nerve ending. In the CNS, one finds that the majority of receptors are presynaptic or prejunctional. As such, they control the release of other transmitters or in the case of released acetylcholine, they play an autoreceptor role. Presynaptic nicotinic receptors found in the spinal cord and in higher centers of the brain have a functional role in modulating central control of autonomic function and sensory to autonomic control of reflexes and other functions.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
82
16. NICoTINIC RECEPToRs
(A)
(B)
FIGURE 16.3 X-ray crystallographic structure of the acetylcholine binding protein. The structure was produced from crystallographic coordinates of Sixma and colleagues [5]. Surfaces are represented as Connolly surfaces. Left, colors are used to delineate the subunit interfaces in the homomeric pentamer. The vestibule on the extracellular surface that represents the entry to the internal channel in the receptor is shown by the arrow. Right, a single subunit interface Note the residues that have been found to be determinants in the binding of agonists and alkaloid and peptidic antagonists to the receptor. Hence, the numbers delineate the probable binding surface(s) for large and small antagonists. These residues come from seven distinct segments of amino acid sequence in the subunit, as determined from extensive mutagenesis, labeling and crystallographic studies [3,5,6]. The right hand panel shows a superimposition of the acetylcholine binding protein with the presumed structure of the muscle receptor.
References [1] Changeux J-P, Edelstein SJ. Nicotinic acetylcholine receptors. New York: Odie Jacob; 2005. [2] Karlin A. Emerging structures of nicotinic acetylcholine receptors. Nat Rev Neurosci 2002;3:102–14. [3] Changeux J-P. Allosteric receptors: From electric organ to cognition. Annu Rev Pharmacol Toxicol 2010;50:1–38. [4] Thompson AJ, Lester HA, Lummis SCR. The structural basis of function in Cys-loop receptors. Q Rev Biophys 2010;43:449–99. [5] Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol 2005;346:967–89. [6] Brejc K, van Dijk WJ, Klaasen RV, Shuurmans M, van der Oost J, Smit AB, et al. Crystal structure of an acetylcholine binding protein
[7]
[8]
[9] [10]
reveals the ligand binding domain of nicotinic receptors. Nature (London) 2001;411:269–76. Hibbs RE, Sulzenbacher G, Shi J, Talley T, Conrod S, Kem WR, et al. Structural determinants for interaction of partial agonist with the acetylcholine binding protein and the neuronal alpha7 acetylcholine receptor. EMBO J 2009;28:3040–51. Various authors. Neuronal nicotinic receptors. In: Clementi F, Fornasi D, Gotti C, editors. Handbook of experimental pharmacology, vol. 144. Berlin: Springer-Verlag, 2000. 821 pp. Benowitz NL. Nicotine Addiction. N Eng J Med 2010;362:2295–303. Engel AG, Shen X-M, Selcen D, Sine SM. What we have learned from congenital myasthenic syndromes. J Mol Neurosci 2010;40:143–53.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
17 Serotonin Receptors and Neurotransmission Elaine Sanders-Bush, Charles D. Nichols Tryptophan hydoxylase, the rate limiting enzyme, is not saturated under normal conditions, rendering 5-HT levels sensitive to changes in blood tryptophan. This translates into the remarkable finding that brain levels of this neurotransmitter can be regulated by the dietary intake of tryptophan. Clinical studies have often utilized a tryptophan-free diet to lower brain 5-HT and, by inference, evaluate its role in a particular behavior or drug effect. The principal metabolism of 5-HT is mediated by the ubiquitous enzyme, monoamine oxidase (MAO), to form an inactive product, 5-hydroxyindole acetic acid (5-HIAA). 5-HIAA is subsequently secreted in the CSF and urine. MAO is a family of mitochondrial enzymes that metabolize all biogenic amines.
Serotonin (5–hydroxytryptamine) is a neurotransmitter as well as a circulating hormone. Serotoninergic neurons in the brain synthesize and store serotonin at axon terminals where it is released and interacts with cell-surface receptors on adjacent neurons. The action of serotonin is terminated by re-uptake into presynaptic terminal mediated by the serotonin transporter or by metabolism by monoamine oxidase. Of the 14 different receptor subtypes, most generate intracellular messengers by coupling to G-proteins and modulate, rather than mediate, fast neurotransmission. This multitude of receptors explains the variety of actions of serotonin in normal and abnormal states and provides ample opportunity for drug development for treatment of nervous system diseases.
NEUROTRANSMISSION
LOCALIZATION
In the central nervous system, the entire pathway of synthesis and metabolism exists at axon terminals. The life cycle of 5-HT at the synapse is illustrated in Figure 17.3. Both synthetic enzymes are present in the presynaptic terminal; MAO is also highly expressed in adjacent cells. Newly synthesized 5-HT is accumulated in synaptic vesicles to protect it from degradation by MAO. Uptake into vesicles is mediated by the vesicular monoamine transporter (VMAT). Stored 5-HT is released from synaptic vesicles by a complex series of phosphorylation-dependent protein-protein interactions initiated by the influx of calcium. Once released, 5-HT is inactivated by MAO in the synaptic cleft or its action is terminated by re-uptake into the presynaptic terminal by the 5-HT transporter (SERT). Once in the presynaptic terminal, 5-HT is either accumulated in synaptic vesicles via VMAT or metabolized by MAO. The two transporters in 5-HT nerve terminals, VMAT and SERT, belong to different gene families and have markedly different properties. SERT is a sodium-dependent carrier that translocates 5-HT into the presynaptic nerve terminal. VMAT is driven by a proton gradient; it is promiscuous, present in 5-HT and catecholamine vesicles. SERT is expressed exclusively in serotoninergic neurons
Serotonin, also referred to as 5-hydroxytrytamine (5-HT), is a simple indoleamine (Fig. 17.1), discovered over five decades ago. Since then, 5-HT has been shown to function as a neurotransmitter in central nervous system and also as circulating hormone [1]. The principal source of circulating 5-HT is the intestinal enterochromaffin cells, where 5-HT is synthesized, stored and released into the bloodstream. 5-HT in blood is concentrated in platelets by an active transport mechanism. In the pineal gland, 5-HT is converted by a two-step process to melatonin (5-methoxy-N-acetyltryptamine), a hormone that regulates ovarian function and has been implicated in the control of biological rhythms. The brain 5-HT containing neurons are localized in raphe nuclei of the brainstem, which project diffusely throughout the brain and spinal cord.
SYNTHESIS AND METABOLISM The pathway of synthesis is common throughout the body. 5-HT is synthesized from tryptophan, an essential amino acid obtained in the diet. 5-HT synthesis requires the action of two synthetic enzymes, as in Figure 17.2.
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00017-2
83
© 2012 Elsevier Inc. All rights reserved.
84
17. SERoToNIN RECEPToRS ANd NEuRoTRANSmISSIoN
FIGURE 17.1 The chemical structure of serotonin (5–hydroxytryptamine).
FIGURE 17.2 Biosynthetic and metabolic pathway of serotonin. TABLE 17.1 Serotonin Receptor Subtypes and Pharmacology Receptor Family 5-HT1
Primary Transduction Subtype Pathway
Activation of DOI phospholipase BW723C86 Lorcaserin C (Gaq)
MDL100907 RS127445 RS102221
5-HT3
Ligand gated ion channel
m-CPBG
Ondansetron
5-HT4
Activation of adenylate cyclase (Gas)
Cisapride
GR113808
5-HT6
RECEPTORS 5-HT in the synaptic cleft interacts with cell-surface receptors localized at the postsynaptic membrane or on the
WAY100635 SB224289 BRL15572
5-HT2A 5-HT2B 5-HT2C
5-HT5A 5-HT5B
in the CNS and is also found in the enteric nervous system and in blood platelets. Platelets are devoid of 5-HT synthetic enzymes; transport into platelets by SERT is responsible for the high level of 5-HT found in platelets.
U92016A Anpirtoline PNU-142633
Inhibition of adenylate cyclase (Gai)
5-HT5
5-HT is stored in synaptic vesicles to avoid metabolism to 5-HIAA by mitochondrial MAO. Released 5-HT interacts with receptors in the postsynaptic membrane or on autoreceptors in the presynaptic membrane. The principal mechanism of inactivation is reuptake into the presynaptic terminal by the 5-HT transporter.
Pharmacology: Antagonist
5-HT1A 5-HT1B 5-HT1D 5-HT1E 5-HT1F
5-HT2
FIGURE 17.3 Schematic of 5-HT nerve terminal. Newly synthesized
Pharmacology: Agonist
5-HT7
LY344864
Inhibition of adenylate cyclase (Gai) Activation of adenylate cyclase (Gas) Activation of adenylate cyclase (Gas)
SB699551
EMD386088
SB399885
AS-19
SB258719
presynaptic terminal. The 14 serotonin receptors, reclassified in 1994 [2], segregate into seven families (Table 17.1). All but one are members of the superfamily of G proteincoupled receptors (GPCRs), which are predicted to span the plasma membrane seven times with the N-terminus on the outside of the cell and the C-terminus, intracellular [3]. The intracellular loops and C-terminal tail interact directly with G proteins (Fig. 17.4). As illustrated in Figure 17.3, most of the G protein-coupled 5-HT receptors are localized on postsynaptic membranes and modulate
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
85
RolE IN AuToNomIC PRoCESSES
TABLE 17.2 Clinically Available 5-HT drugs
FIGURE 17.4 5-HT receptors couple to multiple G-proteins. G proteins are classified based on their alpha subunits. 5-HT receptors have been definitively shown to couple to four different families of G-proteins.
neurotransmission via second messenger pathways. In contrast, the 5-HT3 receptor is a multimeric 5-HT gaited cation channel; it is primarily localized on presynaptic terminals of non-serotoninergic neurons where it regulates the release of other neurotransmitters such as acetylcholine. GPCRs generate intracellular second messengers such as cyclic AMP and calcium, which stimulate or inhibit various kinases and phosphatases that, in turn, regulate proteins by changes in phosphorylation state [4]. As such these receptors act as neuromodulators, modulating other receptors and ion channels that mediate fast neurotransmission. The 5-HT3 receptor is the only 5-HT receptor that gates ions, hence directly altering membrane potential. The other 5-HT receptors indirectly modify the membrane potential by regulating voltage-gated ion channels (such as Ca or K channels) or ligand-gated ion channels (such as glutamate receptors). For example, presynaptic 5-HT1B receptors inhibit N-type calcium channels via Go G-protein, thereby decreasing 5-HT release. This receptor, as well as other G protein-coupled 5-HT receptors, are expressed on the presynaptic terminals of other neurotransmitter releasing neurons, where these so-called heteroreceptors inhibit or potentiate neurotransmitter release. Thus, the possibilities of neurotransmitter cross-talk are numerous and widespread.
PHARMACOLOGY AND ROLE IN DISEASE The large number of receptors translates into a complex pharmacology and a myriad of targets for drug development. Specific drugs do exist, but they are rare. The drugs listed in Table 17.1 are at least 50-fold more potent at their primary target, which translates into reasonable specificity in vivo. Readers interested in more information about pharmacological properties should access the extensive database at http://pdsp.med.unc.edu/indexR.html. Serotonin plays a role in a myriad of behaviors [5]. Advances in genetically modified mice have advanced our understanding of the role of specific receptors in behaviors and drug actions [6]. The clinically available drugs that target 5-HT neurotransmission (Table 17.2) have a range of disease targets
Target
Action
Clinical Use
Examples
MAO
Antagonist
Major depressive Tranylcypromine illness
5-HT Transporter Channel blocker
Major depressive Fluoxetine, illness, panic, escitalopram anxiety, OCD
5-HT1A receptor
Agonist
Anxiety
Buspirone
5-HT1D receptor
Agonist
Migraine
Sumatriptan
5-HT2 receptor
Antagonist
Migraine
Methysergide
5-HT2A receptor
Antagonist
Schizophrenia
Clozapine, risperidone
5-HT4 receptor
Agonist
Irritable bowel syndrome
Prucalopride (Europe)
5-HT3 receptor
Channel blocker
Nausea/emesis
Ondansetron
and varying degrees of specificity. Esitalopram, for example, is a highly specific inhibitor of 5-HT transporter with three orders of magnitude lesser affinity for secondary targets (catecholamine transporters). On the other hand, tranylcypromine blocks the degradation of serotonin, dopamine and norepinephrine equally well. One of the most exciting areas of current research deals with genetic variations in 5HT receptor and transporter genes and their association with human diseases, such as schizophrenia and major depressive illness. Research has focused on more common genetic alterations referred to as single nucleotide polymorphisms (SNPs) and, although inconsistent, the early results suggest that SNPs in serotoninrelated genes may be associated with disease symptoms as well as drug response [7].
ROLE IN AUTONOMIC PROCESSES 5-HT serves a key role in the regulation of gut function and motility [8]. Enterochromaffin cells synthesize and store 5-HT in granules, and release 5-HT upon stimulation by norepinephrine released from the myenteric plexus. This 5-HT can then bind to 5-HT4 and 5-HT2 receptors and activate secretion from enterocytes into the intestinal lumen. Furthermore, 5-HT also binds to 5-HT3/4 receptors on the submucosal plexus of the enteric nervous system to modulate smooth muscle contractility and peristalsis. Too much 5-HT in the gut, resulting from a carcinoid tumor or cisplatin chemotherapy for example, induces diarrhea and emesis. Too little 5-HT in the gut results in slow transit times and constipation. Antagonists of 5-HT3 receptors, including ondansetron, are effective anti-emetics to block the nausea associated with chemotherapy. Although agonists of 5-HT4 receptors like cisapride have had some success in the clinic to increase gut motility associated with irritable bowel syndrome and constipation, they have been
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
86
17. SERoToNIN RECEPToRS ANd NEuRoTRANSmISSIoN
withdrawn from the market due to their ability to produce fatal cardiac arrhythmias in some patients. Other 5-HT4 agonists are available in Europe. Many cardiovascular functions, including heart rate and blood pressure, are modulated by 5-HT acting at a variety of receptors located in the sympathetic ganglia, parasympathetic ganglia, the vagus nerve, and the heart itself [9]. The interactions of 5-HT with its receptors are complex in mediating cardiovascular effects. Increasing circulating 5-HT levels primarily produces tachycardia. Receptor selective drugs, however, can produce either bradycardia or tachycardia, influence heart rate, cardiac outflow, or blood pressure, as well as have adverse developmental effects like cardiac valvulopathies depending on the receptor targeted and site of action.
References [1] Sanders-Bush E, Hazelwood L. 5-Hydroxytryptamine (serotonin) and dopamine. In: Brunton LL, editor. The pharmacological basis of therapeutics. New York: McGraw-Hill; 2011. p. 335–62.
[2] Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994;46:157–203. [3] Nichols DE, Nichols CD. Serotonin Receptors. Chem Rev 2008;46:1614–41. [4] Millan MJ, Marin P, Bockaert J, Mannoury la Cour C. Signaling at G-Protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci 2008;29:454–64. [5] Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychiatry 1998;44:151–62. [6] Murphy DL, Wichems C, Li Q, Heils A. Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission. Trends Pharmacol Sci 1999;20:246–52. [7] Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002;297:400–3. [8] Spiller R. Serotonin and GI clinical disorders. Neuropharmacology 2008;55:1072–80. [9] Villalon CM, Centurion D. Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. NaunynSchmiedeberg’s Arch Pharmacol 2007;376:45–63.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
18 Purinergic Neurotransmission and Nucleotide Receptors Geoffrey Burnstock
PURINERGIC NEUROTRANSMISSION
Another concept that has had a significant influence on our understanding of purinergic transmission was that of cotransmission. Burnstock wrote a Commentary in Neuroscience in 1976 [4] entitled: “Do some nerves release more than one transmitter?” This position challenged the single-neurotransmitter concept, which became known as “Dale’s Principle”, even though Dale himself never defined it as such. The commentary was based on hints about cotransmission in the early literature describing both vertebrate and invertebrate neurotransmission, and, more specifically, with respect to purinergic cotransmission, on the surprising discovery in 1971 that ATP was released from sympathetic nerves supplying the taenia coli as well as from NANC inhibitory nerves. The excitatory junction potentials (EJPs) recorded in the vas deferens were blocked by α,β-meATP, a selective desensitizer of P2X receptors (Fig. 18.3a and b). This clearly supported the earlier demonstration of sympathetic cotransmission in the vas deferens in the laboratory of Dave Westfall, following an earlier report of sympathetic cotransmission in the cat nictitating membrane. Sympathetic cotransmission was later described in a variety of blood vessels. The proportions of ATP and noradrenaline (NA) vary in different tissues and species, during development and ageing and in different pathophysiological conditions. Acetylcholine (ACh) and ATP are cotransmitters in parasympathetic nerves supplying the urinary bladder. Subpopulations of sensory nerves have been shown to utilize ATP in addition to substance P and calcitonin gene-related peptide; it seems likely that ATP cooperates with these peptides in “axon reflex” activity. ATP, vasoactive intestinal polypeptide and nitric oxide (NO) are cotransmitters in NANC inhibitory nerves. ATP and NA act synergistically to release vasopressin and oxytocin from the hypothalamus, which is consistent with ATP cotransmission in the hypothalamus involved in central nervous system (CNS) control of autonomic functions. Release of ATP from autonomic nerves is by vesicular exocytosis and after release it is broken down by ectonucleotidases. Much is now known about the
The existence of non-adrenergic, non-cholinergic (NANC) neurotransmission in the gut was established in the mid 1960s (Fig. 18.1a). Several years later, after many experiments, a study was published that suggested that the NANC transmitter in the guinea-pig taenia coli and stomach, rabbit ileum, frog stomach and turkey gizzard was adenosine 5-triphosphate (ATP) [1]. The experimental evidence included mimicry of the NANC nervemediated response by ATP (Fig. 18.1b); measurement of release of ATP during stimulation of NANC nerves with luciferin-luciferase luminometry; histochemical labeling of subpopulations of neurons in the gut with quinacrine, a fluorescent dye known to selectively label high levels of ATP bound to peptides; the later demonstration that the slowly-degradable analog of ATP, α,β-methylene ATP (α,β-meATP), which produces selective desensitization of the ATP receptor, blocked the responses to NANC nerve stimulation. Soon after, evidence was presented for ATP as the neurotransmitter for NANC excitatory nerves in the urinary bladder (Fig. 18.1c and d). The term “purinergic” was proposed in a short letter to Nature in 1971 and the evidence for purinergic transmission in a wide variety of systems was presented in Pharmacological Reviews in 1972 [2] (Fig. 18.2). This concept met with considerable resistance for many years. Perhaps understandably, this was probably partly because it was felt that ATP was established as an intracellular energy source involved in various metabolic cycles and that such a ubiquitous molecule was unlikely to be involved in extracellular signaling. However, ATP was one of the biological molecules to first appear and, therefore, it is not really surprising that it should have been utilized for extracellular, as well as intracellular, purposes early in evolution. The fact that potent ectoATPases were described in most tissues in the early literature was also a strong indication for the extracellular actions of ATP. Purinergic neurotransmission is now generally accepted (see [3]).
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00018-4
87
© 2012 Elsevier Inc. All rights reserved.
88
18. PuRINERgIC NEuRoTRANsmIssIoN ANd NuClEoTIdE RECEPToRs
FIGURE 18.1 (a) Sucrose gap recording of membrane potential changes in smooth muscle of guinea-pig taenia coli in the presence of atropine (0.3 μM) and guanethidine (4 μM). Transmural field stimulation (0.5 ms, 0.033 Hz, 8 V) evoked transient hyperpolarizations, which were followed by rebound depolarizations. Tetrodotoxin (TTX, 3 μM) added to the superfusing Kreb’s solution (applied at arrow) rapidly abolished the responses to transmural field stimulation, indicating that they were inhibitory junction potentials in response to stimulation of NANC inhibitory nerves. (Reproduced from [19] with permission of Blackwell Publishing.) (b) Mechanical responses of the guinea-pig taenia coli to intramural nerve stimulation (NS, 1 Hz, 0.5 ms pulse duration, for 10 s at supramaximal voltage) and ATP (2 10–6 M). The responses consist of a relaxation followed by a “rebound contraction”. Atropine (1.5 10–7 M) and guanethidine (5 10–6 M) were present. (Reproduced from [20] with permission of the Nature Publishing Group). (c) A comparison of the contractile responses of the guinea-pig bladder strip to intramural nerve stimulation (NS: 5 Hz, 0.2 ms pulse duration and supramaximal voltage) and exogenous ATP (8.5 μM). Atropine (1.4 μM) and guanethidine (3.4 μM) were present throughout. (Reproduced from [21] with permission of the Nature Publishing Group). (d) Effect of changing the calcium ion (Ca2) concentration on the release of ATP from the guinea pig isolated bladder strip during stimulation of intramural nerves. Upper trace: mechanical recording of changes in tension (g) during intramural nerve stimulation (NS: 20 Hz, 0.2 ms pulse duration, supramaximal voltage for 20 seconds). Lower trace: concentration of ATP in consecutive 20 s fractions of the superfusate. The Ca2 concentration in the superfusate varied as follows: (i) 2.5 mM (normal Krebs); (ii) 0.5 mM; (iii) 0.25 mM; (iv) 2.5 mM. The successive contractions were separated by 60 min intervals as indicated by the breaks in the mechanical trace. Atropine (1.4 μM) and guanethidine (3.4 μM) were present throughout. The temperature of the perfusate was between 22°C and 23°C. (Reproduced from [21] with permission).
ectonucleotidases that break down ATP released from neurons and non-neuronal cells. Several enzyme families are involved: ecto-nucleoside triphosphate diphosphohydrolases (E-NTPDases) of which NTPDase 1, 2, 3 and 8 are extracellular; ectonucleotide pyrophosphatase (E-NPP) of three subtypes; alkaline phosphatases; ecto-5-nucleotidase and ecto-nucleoside diphosphokinase (E-NDPK). NTPDase1 hydrolyses ATP directly to AMP and uridine 5-triphosphate (UTP) to uridine diphosphate (UDP), while NTPDase 2 hydrolyses ATP to adenosine 5-diphosphate (ADP) and 5-nucleotidase AMP to adenosine (see [5]). Purinergic receptors have been cloned and characterized in amoeba, Schistosoma and green algae, which resemble P2X receptors found in mammals, suggesting that purinergic signaling was present early in evolution (see [6]). This perhaps explains the wide distribution of purinergic receptors in most non-neuronal as well as neuronal cell types (see [7]).
An important conceptual step was when, in addition to purinergic neuromuscular transmission, purinergic nerve– nerve synaptic transmission was described in coeliac ganglion in 1992 by Silinsky, Surprenant and colleagues. Synaptic transmission has also been demonstrated in the enteric plexuses and in various sensory sympathetic, parasympathetic and pelvic ganglia (see [3]). A hypothesis was proposed that purinergic mechanosensory transduction occurred in visceral tubes and sacs, including ureter, bladder and gut, where ATP, released from epithelial cells during distension, acted on P2X3 homomultimeric and P2X2/3 heteromultimeric receptors on subepithelial sensory nerves initiating impulses in sensory pathways to pain centers in the CNS. Subsequent studies of bladder, ureter, gut, tongue and tooth pulp have produced evidence in support of this hypothesis (see [8]).
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
RECEPToRs foR PuRINEs ANd PyRImIdINEs
89
FIGURE 18.2 Purinergic neuromuscular transmission depicting the synthesis, storage, release and inactivation of adenosine 5-triphosphate (ATP). ATP, stored in vesicles in nerve varicosities, is released by exocytosis to act on postjunctional ATP receptors on smooth muscle. ATP is broken down extracellularly by ATPases and 5-nucleotidase to adenosine, which is taken up by varicosities to be re-synthesized and restored in vesicles. If adenosine is broken down further by adenosine deaminase to inosine and hypoxanthine, they are removed by the circulation. (Reproduced from [2] with permission from the American Society for Pharmacology and Experimental Therapeutics.)
While the early emphasis was on short-term purinergic signaling in neurotransmission, neuromodulation and secretion, it was later recognized that ATP, released from autonomic nerves and by paracrine or autocrine release from non-neuronal cells, is involved in long-term (trophic) signaling, involved in cell proliferation, differentiation and death in development and regeneration [9]. Purinergic signaling in the brain stem is involved in control of autonomic functions, including cardiovascular and respiratory control and in the regulation of hormone secretion and body temperature at the hypothalamic level. The nucleus tractus solitarius (NTS) is a major integrative center of the brain stem involved in reflex control of the cardiovascular system; stimulation of P2X receptors in the NTS evokes hypotension. P2X receptors expressed in neurons in the trigeminal mesencephalic nucleus might be involved in the processing of proprioceptive information.
RECEPTORS FOR PURINES AND PYRIMIDINES Implicit in the purinergic neurotransmission hypothesis was the presence of purinoceptors. A basis for distinguishing two types of purinoceptor, identified as P1 and P2 for adenosine and ATP/ADP, respectively, was recognized in
FIGURE 18.3 (a) Excitatory junction potentials in response to repetitive stimulation of adrenergic nerves (white dots) in the guinea pig vas deferens. The upper trace records the tension, the lower trace the electrical activity of the muscle recorded extracellularly by the sucrose gap method. Note both summation and facilitation of successive junction potentials. At a critical depolarization threshold an action potential is initiated which results in contraction. (Reproduced from [22] with permission from Springer). (b) The effect of various concentrations of α,β-methylene ATP (α,β-meATP) on EJPs recorded from guinea pig vas deferens (intracellular recordings). The control responses to stimulation of the motor nerves at 0.5 Hz are shown on the left. After at least 10 min in the continuous presence of the indicated concentration of α,β-meATP, EJPs were recorded using the same stimulation parameters. (Reproduced from [23] with permission from Elsevier.)
1978 [10]. This helped resolve some of the ambiguities in earlier reports, which were complicated by the breakdown of ATP to adenosine by ectoenzymes, so that some of the actions of ATP were directly on P2 receptors, whereas others were due to indirect action via P1 receptors. However, it was not until 1985 that a pharmacological basis for distinguishing two types of P2 receptors (P2X and P2Y) was proposed [11]. A year later, two further P2 receptor subtypes were named, a P2T receptor selective for ADP on platelets and a P2Z receptor on macrophages. Further subtypes followed, perhaps the most important of which being the P2U receptor, which could recognize pyrimidines such as UTP in addition to ATP. However, to provide a more manageable framework for newly identified nucleotide receptors, Abbracchio and Burnstock proposed in 1994 [12] that purinoceptors should belong to two major families: a P2X family of ligand-gated ion channel receptors and a P2Y family of G protein-coupled receptors. This was based on studies of transduction mechanisms and the cloning of nucleotide receptors: P2Y receptors were cloned first in 1993 and a year later P2X receptors were cloned (Fig. 18.4). This nomenclature has been widely adopted and currently seven P2X subtypes and eight P2Y
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
90
18. PuRINERgIC NEuRoTRANsmIssIoN ANd NuClEoTIdE RECEPToRs
FIGURE 18.4 Membrane receptors for extracellular ATP. (a) The P2X family of receptors are ligand-gated ion channels (S-S; disulphide bond; M1 and M2, transmembrane domains), and (b) the P2Y family are G protein-coupled receptors (S-S; disulphide bond; pale blue circles represent amino acid residues that are conserved between P2Y1, P2Y2 and P2Y3 receptors; fawn circles represent residues that are not conserved; and purple circles represent residues that are known to be functionally important in other G protein-coupled receptors). (Part (a) reproduced from [24] with permission from Nature; Part (b) modified from [25] with permission from Elsevier.)
receptor subtypes are recognized, while four subtypes of P1 receptor have been cloned and characterized (see [13]; Table 18.1).
P2X Receptors Members of the family of ionotropic P2X1–7 receptors show a subunit topology of intracellular N- and C- termini possessing consensus binding motifs for protein kinases; two transmembrane-spanning regions (TM1 and TM2), the first involved with channel gating and the second lining the ion pore; a large extracellular loop, with 10 conserved cysteine residues forming a series of disulfide bridges and an ATP-binding site, which may involve regions of the extracellular loop adjacent to TM1 and TM2 (see [14]). The crystal structure of the P2X4 receptor was recently described [15]. Heteromultimers as well as homomultimers are involved in forming the trimer ion pore. P2X2/3, P2X1/2, P2X1/5, P2X2/6, P2X4/6 and P2X1/4 receptor heteromultimers have been identified. P2X7 does not form heteromultimers, and P2X6 will not form a functional homomultimer. Advances have been made by the preparation of knockout mice for P2X1, P2X2, P2X3, P2X4 and P2X7 receptors, and transgenic mice that over-express the P2X1 receptor. Adenoviral expression of a P2X1 receptor-green fluorescent protein construct in vas deferens shows the receptor to be localized in clusters, with larger ones apposing nerve varicosities. The P2X2 receptor is generally described as non-desensitizing, compared with the P2X1 and P2X3 receptors. P2X3 receptors are prominently expressed on nociceptive sensory neurons. P2X2/3 heteromer receptors have been identified in subpopulations of sensory neurons and sympathetic ganglion cells. Homomeric P2X4 receptors
are activated by ATP, but not by α,β-meATP. The most useful distinguishing feature of ATP-evoked currents at P2X4 receptors is their potentiation by ivermectin. The P2X5 receptor cDNA was first isolated from cDNA libraries constructed from rat coeliac ganglion and heart. Cells expressing the heteromeric P2X1/5 receptor are very sensitive to ATP, concentrations as low as 3 or 10 nM evoking measurable currents. The P2X6 subunit is only functionally expressed as a heteromultimer. P2X2/6 heteromeric receptors are prominently expressed by respiratory neurons in the brainstem. The main feature of the P2X7 receptor is that, in addition to the usual rapid opening of the cationselective ion channel, with prolonged exposure to high concentrations of ATP large pores form and this usually leads to cell death. Vesicles are shed after activation of P2X7 receptors, which release inflammatory cytokines.
P2Y Receptors At present, there are eight accepted human P2Y receptors: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14 (see [16] and Table 18.1). The missing numbers represent either non-mammalian orthologs, or receptors having some sequence homology to P2Y receptors, but for which there is no functional evidence of responsiveness to nucleotides. In contrast to P2X receptors, P2Y receptor genes do not contain introns in the coding sequence, except for the P2Y11 receptor. Site-directed mutagenesis of the P2Y1 and P2Y2 receptors has shown that some positively charged residues in TM3, TM6 and TM7 are crucial for receptor activation by nucleotides. From a phylogenetic and structural (i.e., protein sequence) point of view, two distinct P2Y receptor subgroups characterized by a relatively high level of sequence divergence have been
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
91
RECEPToRs foR PuRINEs ANd PyRImIdINEs
TABLE 18.1 Characteristics of Purine-mediated Receptors Transduction Mechanisms
Receptor
Main Distribution
Agonists
Antagonists
P1 (adenosine) A1
Brain, spinal cord, testis, heart, autonomic nerve terminals
CCPA, CPA, S-ENBA
DPCPX, N-0840, MRS1754
Gi/o ↓cAMP
A2A
Brain, heart, lungs, spleen
CGS 21680, HENECA
KF17837, SCH58261, ZM241385
GS ↑cAMP
A2B
Large intestine, bladder
NECA (non-selective)
Enprofylline, MRE2029-F20, MRS17541, MRS 1706
GS ↑cAMP
A3
Lung, liver, brain, testis, heart
IB-MECA, 2-Cl-IB-MECA, DBXRM, VT160
MRS1220, L-268605, MRS1191, MRS1523, VUF8504
Gi/o Gq/11 ↓cAMP ↑IP3
P2X1
Smooth muscle, platelets, cerebellum, dorsal horn spinal neurons
α,β-meATP ATP 2-MeSATP (rapid desensitization), L-β,γ-meATP
TNP-ATP, IP5I, NF023, NF449
Intrinsic cation channel (Ca2 and Na)
P2X2
Smooth muscle, CNS, retina, chromaffin cells, autonomic and sensory ganglia
ATP ATPγS 2-MeSATP α,β-meATP (pH zinc sensitive)
Suramin, isoPPADS, RB2, NF770
Intrinsic ion channel (particularly Ca2)
P2X3
Sensory neurones, NTS, some sympathetic neurons
2-MeSATP ATP α,βmeATP Ap4A (rapid desensitization)
TNP-ATP, PPADS, A317491, NF110
Intrinsic cation channel
P2X4
CNS, testis, colon
ATP α,β-meATP, CTP, Ivermectin
TNP-ATP (weak), BBG (weak)
Intrinsic ion channel (especially Ca2)
P2X5
Proliferating cells in skin, gut, bladder, thymus, spinal cord
ATP α,β-meATP, ATPγS
Suramin, PPADS, BBG
Intrinsic ion channel
P2X6
CNS, motor neurons in spinal cord
– (does not function as homomultimer)
–
Intrinsic ion channel
P2X7
Apoptotic cells in, for example, immune cells, pancreas, skin
BzATP ATP 2-MeSATP α,β-meATP
KN62, KN04, MRS2427 Intrinsic cation channel Coomassie brilliant and a large pore with blue G prolonged activation
P2Y1
Epithelial and endothelial cells, platelets, immune cells, osteoclasts
2-MeSADP ADPβS 2-MeSATP ADP ATP, MRS2365
MRS2179, MRS2500, MRS2279, PIT
Gq/G11; PLC-β activation
P2Y2
Immune cells, epithelial and endothelial cells, kidney tubules, osteoblasts
UTP ATP, UTPγS, INS 37217
Suramin RB2, AR-C126313
Gq/G11 and possibly Gi; PLC-β activation
P2Y4
Endothelial cells
UTP ATP, UTPγS
RB2 Suramin
Gq/G11 and possibly Gi; PLC-β activation
P2Y6
Some epithelial cells, placenta, T cells, thymus
UDP UTP ATP, UDPβS
MRS2578
Gq/G11; PLC-β activation
P2Y11
Spleen, intestine, granulocytes
AR-C67085MX BzATP ATPγS ATP
Suramin RB2, NF157, 5-AMPS
Gq/G11 and GS; PLC-β activation
P2Y12
Platelets, glial cells
2-MeSADP ADP ATP
CT50547, AR-C69931MX, INS49266, AZD6140, PSB0413, ARL66096, 2-MeSAMP
Gi/o; inhibition of adenylate cyclase
P2Y13
Spleen, brain, lymph nodes, bone marrow Placenta, adipose tissue, stomach, intestine, discrete brain regions
ADP 2-MeSADP ATP & 2-MeSATP UDP glucose UDP-galactose
MRS2211, 2-MeSAMP
Gi/o
–
Gq/G11
P2X
P2Y
P2Y14
Updated from [18] with permission from Elsevier. Abbreviations: BBG, Brilliant blue green; BzATP, 2-&3-O-(4-benzoyl-benzoyl)-ATP; cAMP, cyclic AMP; CCPA, chlorocyclopentyl adenosine; CPA, cyclopentyl adenosine; CTP, cytosine triphosphate; IP3, inosine triphosphate; Ip5I, di-inosine pentaphosphate; 2-MeSADP, 2-methylthio ADP; 2-MeSATP, 2-methylthio ATP; NECA, 5-N-ethylcarboxamido adenosine; PLC, phospholipase C; RB2, reactive blue 2.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
92
18. PuRINERgIC NEuRoTRANsmIssIoN ANd NuClEoTIdE RECEPToRs
identified. The first subgroup includes P2Y1,2,4,6,11 and the second subgroup encompasses the P2Y12,13,14 subtypes. Selective antagonists have been identified for some P2Y receptor subtypes (see Table 18.1). P2Y1, P2Y2, P2Y4 and P2Y6 receptors couple to G proteins to increase inositol triphosphate (IP3) and cytosolic calcium. Activation of the P2Y11 receptor by ATP leads to a rise in both cAMP and in IP3, whereas activation by UTP produces calcium mobilization without IP3 or cAMP increase. The P2Y13 receptor can simultaneously couple to G16, Gi and, at high concentrations of ADP, to Gs. The activation of several P2Y receptors is commonly associated with the stimulation of several mitogen-activated protein kinases, in particular extracellular signal regulated protein kinase 1/2. In most species, ADP is a more potent agonist than ATP at P2Y1 receptors. Site-directed mutagenesis studies on the human P2Y1 receptor have shown that amino acid residues in TM3, TM6 and TM7 are critical determinants in the binding of ATP. P2Y2 receptors are fully activated by ATP and UTP, whereas ADP and UDP are much less effective agonists. Expression of P2Y2 receptor mRNA and protein has been detected in many peripheral tissues. UTP is the most potent activator of the recombinant human P2Y4 receptor. In human and mouse, P2Y4 mRNA and protein was most abundant in the intestine, but was also detected in other organs. The mouse, rat and human P2Y6 receptors are UDP receptors. A wide tissue distribution of P2Y6 mRNA and protein has been demonstrated, with the highest expression in spleen, intestine, liver, brain and pituitary. ATPγS is a more potent agonist at the P2Y11 receptor than ATP. ADP is the natural agonist of the P2Y12 receptor. It is heavily expressed in platelets where it is the molecular target of the active metabolite of the antiplatelet drug clopidogrel. The P2Y13 ADP-sensitive receptor is strongly expressed in the spleen, followed by placenta, liver, heart, bone marrow, monocytes, T-cells, lung and various brain regions. The P2Y14 receptor is activated by UDP, UDPglucose as well as UDP-galactose, UDP-glucuronic acid and UDP-N-acetylglucosamine. The formation of oligomers by P2Y receptors is likely to be widespread and to greatly increase the diversity of purinergic signaling. P2X receptors are often expressed in the same cells as P2Y receptors. Thus, there is the possibility of bi-directional cross-talk between these two families of nucleotide-sensitive receptors. P2X receptors in general mediate fast neurotransmission, but are sometimes located prejunctionally to mediate increase in release of cotransmitters, for example glutamate in terminals of primary afferent neurons in the spinal cord. P2Y receptors are particularly involved in prejunctional inhibitory modulation of transmitter release, as well as cell proliferation. P2Y1,2,4,6 receptors have been described on subpopulations of sympathetic neurons, P2Y2 and P2Y4 receptors in intracardiac ganglia, P2Y1 and P2Y2 receptors on sensory neurons while P2Y1 receptors appear to be the dominant subtype on enteric neurons. P2Y2 (and/or P2Y4) receptors are expressed on enteric glial cells.
CONCLUSIONS Purinergic neurotransmission is now widely established for both autonomic neuromuscular transmission to smooth muscle and synaptic transmission in ganglia and it is a rapidly expanding field. There is particular interest in the physiology and pathophysiology of purinergic signalling in autonomic systems and therapeutic interventions are being explored [17]. The autonomic nervous system shows marked plasticity: that is, the expression of cotransmitters and receptors show dramatic changes during development and ageing, in nerves that remain after trauma or surgery and in disease conditions. There are several examples where the purinergic component of cotransmission is increased in pathological conditions. The parasympathetic purinergic nerve-mediated component of contraction of the human bladder is increased to 40% in pathophysiological conditions such as interstitial cystitis, outflow obstruction, idiopathic instability and also some types of neurogenic bladder. ATP also has a significantly greater cotransmitter role in sympathetic nerves supplying hypertensive compared to normotensive blood vessels. Receptors for purines and pyrimidines have been cloned and characterized. There are 4 subtypes of P1(adenosine) receptors, 7 subtypes of P2X ion channel receptors and 8 subtypes of P2Y G protein-coupled receptors. These are widely distributed in non-neuronal cells as well as neurons.
References [1] Burnstock G, Campbell G, Satchell D, Smythe A. Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut. Br J Pharmacol 1970;40:668–88. [2] Burnstock G. Purinergic nerves. Pharmacol Rev 1972;24:509–81. [3] Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 2007;87:659–797. [4] Burnstock G. Do some nerve cells release more than one transmitter? Neuroscience 1976;1:239–48. [5] Zimmermann H. Ectonucleotidases: some recent developments and a note on nomenclature. Drug Dev Res 2001;52:44–56. [6] Burnstock G, Verkhratsky A. Evolutionary origins of the purinergic signalling system. Acta Physiologica 2009;195:415–47. [7] Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 2004;240:31–304. [8] Burnstock G. Purine-mediated signalling in pain and visceral perception. Trends Pharmacol Sci 2001;22:182–8. [9] Burnstock G, Verkhratsky A. Long-term (trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death. Cell Death Dis 2010;1:e9. [10] Burnstock G. A basis for distinguishing two types of purinergic receptor. In: Straub RW, Bolis L, editors. Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach. New York: Raven Press; 1978. p. 107–18. [11] Burnstock G, Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol 1985;16:433–40. [12] Abbracchio MP, Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Therap 1994;64:445–75. [13] Burnstock G. Purine and pyrimidine receptors. Cell Mol Life Sci 2007;64:1471–83. [14] North RA. Molecular physiology of P2X receptors. Physiol Rev 2002;82:1013–67.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
CoNClusIoNs
[15] Kawate T, Michel JC, Birdsong WT, Gouaux E. Crystal structure of the ATP-gated P2X4 ion channel in the closed state. Nature 2009;460:592–8. [16] Abbracchio MP, Burnstock G, Boeynaems J-M, Barnard EA, Boyer JL, Kennedy C, et al. International Union of Pharmacology. Update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 2006;58:281–341. [17] Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 2006;58:58–86. [18] Burnstock G. Introduction: ATP and its metabolites as potent extracellular agonists. In: Schwiebert EM, editor. Current Topics in Membranes, vol 54. Purinergic Receptors and Signalling. San Diego: Academic Press; 2003. p. 1–27. [19] Burnstock G. The changing face of autonomic neurotransmission. (The First von Euler Lecture in Physiology). Acta Physiol Scand 1986;126:67–91. [20] Burnstock G, Wong H. Comparison of the effects of ultraviolet light and purinergic nerve stimulation on the guinea-pig taenia coli. Br J Pharmacol 1978;62:293–302.
93
[21] Burnstock G, Cocks T, Crowe R, Kasakov L. Purinergic innervation of the guinea-pig urinary bladder. Br J Pharmacol 1978;63:125–38. [22] Burnstock G, Costa M. Adrenergic Neurones: Their Organization, Function and Development in the Peripheral Nervous System. London: Chapman and Hall; 1975. pp. 1–225 [23] Sneddon P, Burnstock G. Inhibition of excitatory junction potentials in guinea-pig vas deferens by α,β-methylene-ATP: further evidence for ATP and noradrenaline as cotransmitters. Eur J Pharmac 1984;100:85–90. [24] Brake AJ, Wagenbach MJ, Julius D. New structural motif for ligandgated ion channels defined by an ionotropic ATP receptor. Nature 1994;371:519–23. [25] Barnard EA, Burnstock G, Webb TE. G protein-coupled receptors for ATP and other nucleotides: a new receptor family. Trends Pharmacol Sci 1994;15:67–70.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
19 Adenosine Receptors and Autonomic Regulation Italo Biaggioni
Adenosine is an endogenous nucleoside formed by the degradation of adenosine-triphosphate (ATP) during energy-consuming processes. Adenosine modulates many physiological processes through activation of four subtypes of G-protein coupled membrane P1 purinergic receptors, A1, A2A, A2B and A3. Its physiological importance depends on the affinity of these receptors and the extracellular concentrations reached. Extracellular concentrations of adenosine are usually low, but adenosine may have tonic actions even during physiological conditions, mostly through activation of high affinity A2A and A1 receptors. Theoretically, adenosine can be formed within the synapse, from the degradation of ATP that is released as a co-transmitter (see Chapter 18). Significant increases of extracellular adenosine, however, occur mostly in ischemic tissues, when energy demands exceed oxygen supply. Thus, adenosine is considered a “retaliatory” metabolite, whose actions are physiologically relevant during ischemic conditions. Adenosine has perhaps the shortest half-live of all autacoids, particularly in humans. It is rapidly and extensively metabolized to inactive inosine by adenosine deaminase. It is also quickly transported back into cells by an energydependent uptake mechanism, which is part of a purine salvage pathway designed to maintain intracellular levels of ATP. The effectiveness of this adenosine transport system is species-dependent. It is particularly active in humans, and is mainly responsible for the extremely short half-life of adenosine in human blood, which is probably less than one second. Adenosine mechanisms are the target of commonly used drugs. Dipyridamole (Persantin, Aggrenox) acts by blockade of adenosine reuptake, thus potentiating its actions. Conversely, caffeine and theophylline are antagonists of adenosine receptors. Adenosine receptors are ubiquitous and, depending on their localization, may mediate opposite effects. This phenomenon is particularly evident in the interaction of adenosine and the autonomic nervous system; adenosine can produce either inhibition or excitation of autonomic
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00019-6
neurons [1]. I will first outline the effects of adenosine in the efferent, central, and afferent autonomic pathways, emphasizing those with clinical relevance. I will then propose an integrated view that may explain how these seemingly contradictory effects may work together. ATP shares many of the modulatory effects of adenosine on autonomic function and we will discuss these similarities when appropriate. A comprehensive review of the effects of ATP and its P2 purinergic receptors is found in Chapter 18.
POSTSYNAPTIC ANTI-ADRENERGIC EFFECTS OF ADENOSINE Adenosine A1 receptors are found in target organs innervated by the sympathetic nervous system. A1 receptors are coupled to inhibition of adenylate cyclase and their effects are opposite to those of β-adrenoreceptor agonists. For example, adenosine will oppose β-mediated tachycardia and lipolysis. This phenomenon is translated functionally as an “anti-adrenergic” effect. The physiological relevance of this effect is not entirely clear, but some studies suggest that adenosine is more effective in reducing heart rate during isoproterenol-induced tachycardia than in the baseline state or during atropine-induced tachycardia.
PRESYNAPTIC EFFECTS OF ADENOSINE ON EFFERENT NERVES AND GANGLIONIC TRANSMISSION Adenosine inhibits the release of neurotransmitters through putative presynaptic A1 receptors in both the brain and the periphery. Blockade of forearm adenosine receptors with intrabrachial theophylline potentiates sympathetically mediated forearm vasoconstriction, suggesting that endogenous adenosine inhibits noradrenergic neurotransmission in vivo in humans.
95
© 2012 Elsevier Inc. All rights reserved.
96
19. AdEnosInE RECEPToRs And AuTonomIC REgulATIon
A few studies have investigated the effects of adenosine on ganglionic neurotransmission, and most of them show an inhibitory effect. Adenosine inhibits the release of acetylcholine presynaptically and blocks calcium current postynaptically in ganglia.
ADENOSINE AND CENTRAL AUTONOMIC REGULATION Adenosine acts as a neuromodulator within the central nervous systems, mostly through interaction with A1 and A2A receptors. Of particular relevance to this review are its actions on brainstem nuclei involved in autonomic cardiovascular regulation. In general, the central actions of adenosine result in inhibition of sympathetic tone through complex, and incompletely understood, mechanisms of action. Microinjection of adenosine into the nucleus tractus solitarii (NTS) evokes a dose-related decrease in blood pressure, heart rate, and renal sympathetic nerve activity. These effects appear to be mediated, at least partially, through A2A receptors. The NTS is the site of the first synapse of afferent fibers arising from baroreceptors. The NTS provides excitatory input to the caudal ventrolateral medulla, which in turn provides inhibitory input to the rostro ventrolateral medulla (RVLM), where sympathetic activity is thought to originate. Thus, stimulation of baroreceptor afferents (e.g., by an increase in blood pressure) activates the NTS and this results in inhibition of the RVLM and a reduction in sympathetic tone. The effect of adenosine in the NTS is similar to that of the excitatory neurotransmitter glutamate, implying that adenosine has excitatory neuromodulatory effects on the NTS. The precise mechanisms that explain this phenomenon are not known. It has been proposed that adenosine releases glutamate within the NTS [2,3], or blunts the release of the inhibitory neuromodulator GABA. The effects of adenosine in the NTS are also blunted by microinjection of the nitric oxide synthase inhibitor L-NAME, suggesting an interaction between adenosine and nitric oxide in the NTS. Regardless of the mechanism of action, microinjections of adenosine receptor antagonists into the NTS results in blunting of the baroreflex gain, suggesting a role of endogenous adenosine on central cardiovascular regulation. A1 and A2A receptors are also found in the RVLM and may modulate neuronal activity either directly, or through inhibition of GABA release [4]. ATP and P2 receptors are also important in central autonomic regulation of cardiovascular and respiratory functions [5].
carotid body chemoreceptors, renal afferents, and myocardial and skeletal muscle afferents. The neuroexcitatory actions of adenosine were first recognized in animals in the early 1980s when it was found that adenosine activates arterial chemoreceptors in rats and cats, and renal afferents in rats and dogs. The functional relevance of these findings, however, was not apparent until human studies were done. The most striking effect of intravenous adenosine in humans is a dramatic stimulation of respiration and sympathetic activation. This effect can be explained by carotid body chemoreceptor activation because it is observed when adenosine is injected into the aortic arch at a site proximal to the origin of the carotid arteries, but not if adenosine is injected into the descending aorta. Activation of vagal C-fibers may also contribute to adenosine-induced dyspnea. The effects of intravenous adenosine are dramatically different if autonomic nervous system is absent. For example, adenosine lowers blood pressure and heart rate in autonomic failure patients. Pain resembling angina has been reported with intravenous and intracoronary administration of adenosine presumably because of activation of sensory afferents. Intracoronary adenosine also elicits a pressor reflex in humans, which may be explained by activation of myocardial afferents. The few animal studies that have tested this hypothesis have yielded conflicting results, perhaps because of the confounding effects of anesthesia or to species differences. There is also controversy over whether adenosine activates skeletal muscle chemoreceptors that trigger sympathetic activation in response to ischemic exercise. Studies favoring [6] or opposing [7] the possibility that adenosine is a metabolic trigger of the exercise pressor reflex have been published. ATP has also been implicated as a trigger of skeletal muscle afferent activation [8]. In summary, whereas adenosine inhibits sympathetic efferents, it activates afferent nerves, including arterial chemoreceptors (in animals and humans), renal afferents (animals), and possibly cardiac and muscle afferents (humans). The autonomic excitatory actions of adenosine clearly predominate when adenosine is given intravenously to conscious human subjects [9]. This sympathetic activation may explain the usefulness of intravenous adenosine as a challenge test to diagnose neurogenic syncope during tilt table tests [10]. It remains speculative whether or not endogenous adenosine plays a role in the generation of spontaneous neurogenic syncope. The adenosine receptor antagonist theophylline is used in the treatment of neurogenic syncope, but controlled studies are lacking.
NEUROEXCITATORY ACTIONS OF ADENOSINE ON AFFERENT PATHWAYS
INTEGRATED VIEW OF ADENOSINE AND CARDIOVASCULAR AUTONOMIC REGULATION
In contrast to the “inhibitory” actions of adenosine in efferent pathways, adenosine excites a variety of afferent fibers that evoke systemic sympathetic activation including
These neuroexcitatory actions seem at odds with the postulated protective role of adenosine, which heretofore has been assigned to its “inhibitory” effects. We postulate,
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
InTEgRATEd VIEw of AdEnosInE And CARdIoVAsCulAR AuTonomIC REgulATIon
97
Sympathetic activation NE NE Systemic
Systemic vasoconstriction blood pressure perfusion pressure
NE
III Local inhibition of NE release and F– vasodilation I Adenosine
Local
F+ II. Activation of afferent fibers
ATP
Ischemic exercise
FIGURE 19.1 Postulated modulation by purines (adenosine and ATP) of autonomic cardiovascular regulation. See text for details.
however, that the neuroexcitatory actions of adenosine work in tandem with its inhibitory effects to provide protection against ischemia. It is also likely that ATP, in addition to or instead of adenosine, participate in these actions. This framework is presented in Figure 19.1. 1. Interstitial levels of adenosine increase under conditions of increased metabolic demand (exercise) and decreased energy supply (ischemia), reaching physiologically relevant concentrations. ATP can also be released as a co-transmitter from noradrenergic neurons. 2. Adenosine (or ATP) then activates sensory afferent fibers that produce pain, and muscle or myocardial afferents (metaboreceptors) that trigger an ischemic pressor reflex. Pain sensation is a primordial defense mechanism that signals the individual to stop exercising. Sympathetic activation leads to systemic vasoconstriction, increase in blood pressure and improved perfusion pressure. 3. This systemic vasoconstriction would be deleterious to the ischemic organ, if it were not for the simultaneous local inhibitory actions of adenosine that produce vasodilation and inhibit norepinephrine (NE) release. These actions are, for the most part, circumscribed to the local ischemic tissue so that it is protected from sympathetically-mediated vasoconstriction while it benefits from the improved perfusion pressure. ATP has been proposed as a mediator of this “functional sympatholysis” [11]. We propose, therefore, that the excitatory actions of adenosine and ATP work in tandem with their inhibitory effects to provide local protection against ischemia, even at the expense of the rest of the organism. Furthermore, we propose that adenosine (and ATP) provides a link between
local mechanisms of blood flow autoregulation and systemic mechanisms of autonomic cardiovascular regulation, heretofore thought to work independent from each other.
References [1] Biaggioni I. Contrasting excitatory and inhibitory effects of adenosine in blood pressure regulation. Hypertension 1992;20:457–65. [2] Phillis JW, Scislo TJ, O’Leary DS. Purines and the nucleus tractus solitarius: effects on cardiovascular and respiratory function. [Review] [29 refs]. Clin Exp Pharmacol Physiol 1997;24:738–42. [3] Biaggioni I, Mosqueda-Garcia R. Adenosine in cardiovascular homeostasis and the pharmacological control of its activity. In: Laragh J, Brenner BM, editors. Hypertension: pathophysiology, managements and diagnosis. New York: Raven Press; 1995. [4] Spyer KM, Thomas T. A role for adenosine in modulating cardiorespiratory responses: a mini-review. Brain Res Bull 2000;53:121–4. [5] Gourine AV, Wood JD, Burnstock G. Purinergic signalling in autonomic control. Trends Neurosci 2009;32:241–8. [6] Costa F, Diedrich A, Johnson B, Sulur P, Farley G, Biaggioni I. Adenosine, a metabolic trigger of the exercise pressor reflex in humans. Hypertension 2001;37:917–22. [7] Cui J, Leuenberger UA, Blaha C, Yoder J, Gao Z, Sinoway LI. Local adenosine receptor blockade accentuates the sympathetic responses to fatiguing exercise. Am J Physiol Heart Circ Physiol 2010;298:H2130–H2137. [8] McCord JL, Tsuchimochi H, Kaufman MP. P2X2/3 and P2X3 receptors contribute to the metaboreceptor component of the exercise pressor reflex. J Appl Physiol 2010;109:1416–23. [9] Biaggioni I, Killian TJ, Mosqueda-Garcia R, Robertson RM, Robertson D. Adenosine increases sympathetic nerve traffic in humans. Circulation 1991;83:1668–75. [10] Shen WK, Hammill SC, Munger TM, Stanton MS, Packer DL, Osborn MJ, et al. PA Adenosine: potential modulator for vasovagal syncope. J Am Coll Cardiol 1996;28:146–54. [11] Rosenmeier JB, Yegutkin GG, Gonzalez-Alonso J. Activation of ATP/UTP-selective receptors increases blood flow and blunts sympathetic vasoconstriction in human skeletal muscle. J Physiol 2008;586:4993–5002.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
20 Nitric Oxide and Autonomic Regulation Alfredo Gamboa GMP causes activation of cyclic GMP-dependent protein kinases, with reduction of intracellular Ca2 and a decrease in the sensitivity of contractile elements to Ca2.
Since the discovery that nitric oxide (NO) was a naturally occurring signal molecule in blood vessels, it has become one of the most widely studied substances in biology. Now it is recognized as an endogenous mediator of numerous physiological processes ranging from regulation of cardiovascular function to memory formation. NO is probably one of the most important metabolic modulator of blood pressure; our previous studies suggest that NO tonically restrains blood pressure by at least 30 mmHg in healthy young adults [1]. The autonomic nervous system is a major regulatory mechanism for both short and long term adjustments of the cardiovascular system in general, and blood pressure in particular. In addition to its control of local vasomotor tone and arterial pressure, NO has been proposed to also modulate autonomic regulation of blood pressure through interactions with autonomic pathways in the central nervous system and at peripheral sites.
CENTRAL NO–AUTONOMIC NERVOUS SYSTEM INTERACTIONS In the central nervous system, nitric oxide functions mainly as a neuromodulator. Nitric oxide can have both central neural sympathoinhibitory and sympathoexcitatory actions. In humans, intravenous infusion of L-NMMA (a competitive stereospecific non-selective inhibitor of NOS) induces an increase of mean arterial pressure of about 10% without the expected compensatory inhibition of sympathetic firing rate mediated by baroreflex loading. In comparison, the same increase in blood pressure induced by phenylephrine produced a decrease of about 50% in sympathetic firing rate. When sodium nitroprusside was given in addition to L-NMMA in order to prevent the increase in mean arterial blood pressure, muscle sympathetic nerve activity increased more than double its baseline values [3]. Furthermore, it has been shown that acute and/or chronic (3 weeks) intracerebroventricular injection of L-NMMA, at a dose ineffective to produce systemic effects; increases mean arterial pressure in normotensive rats [4]. Taken together these findings suggest that NO tonically inhibits central sympathetic tone. Thus, NOS inhibition increases blood pressure in part by increasing sympathetic firing rate but this effect is partially masked by the baroreflex. The excitatory effects of NO on neural sympathetic outflow, and their physiological relevance, are less well understood. In rat brain slices, L-arginine, the substrate to produce NO, stimulates the neuronal activity of some nucleus tractus solitarius neurons and this effect can be blocked by co-infusion of L-NMMA [5]. It should be noted that the NTS provides inhibitory input (through the caudal ventrolateral medulla) to the rostral ventrolateral medulla (RVLM) where sympathetic tone is thought to originate. Therefore, neuroexcitation of NTS neurons by NO may contribute to its tonic inhibition of sympathetic tone. On the other hand, in vivo studies in rabbits have shown that NO has an excitatory effect on renal
NO SYNTHESIS AND ACTIONS NO is produced from L-arginine by three isoforms of the enzyme nitric oxide synthase (NOS). An inducible form is found mostly in macrophages (iNOS). Two isoforms are expressed constitutively, one in epithelial and neural cells (nNOS), and another in endothelial cells, platelets, and myocardial cells (eNOS). Both eNOS and nNOS consists of a C-terminal reductase domain and an N-terminal oxygenase domain, differing only in one aminoacid, namely, Asp597 in nNOS is Asn368 in eNOS [2]. The monomer of NOS is inactive, while the dimer is its active form and the dimerization requires tetrahydrobiopterin (BH4), heme and L-arginine binding. Overall, NOS catalyzes the oxidation of L-arginine to generate citrulline and NO. The synthesis of nitric oxide by these NOS isoforms is inhibited non-selectively by L-arginine analogs, including NG-monomethyl-L-arginine (L-NMMA), NG-nitro-Larginine (L-NA), L-NA methylester (L-NAME), and asymmetric dimethylarginine (ADMA). There are also selective nNOS inhibitors such as 7-nitroindazol (7-NI), S-methylL-thiocitrulline (SMTC) and N[omega]-propyl-L-arginine. Once formed, NO activates soluble guanylyl cyclase and produces cyclic guanosine monophosphate (GMP) from guanosine triphosphate (GTP). Accumulation of cyclic
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00020-2
99
© 2012 Elsevier Inc. All rights reserved.
100
20. NITRIC OxIdE ANd AuTONOmIC REgulATION
FIGURE 20.1 Schematic illustration of the effects of NO and of NOS inhibition on blood pressure regulation both centrally and in the periphery.
sympathetic preganglionic neurons [6]. Additionally, in eNOS/KO mice, selective inhibition of neural NOS produces a drop in blood pressure and it has been hypothesized that NO released in the central nervous system and/or the baroreceptor pathways may increase sympathetic nerve activity and increase blood pressure, while the inhibition of NO may have the opposite effect [7]. In summary, nitric oxide in the central nervous system may have both excitatory and inhibitory effects on sympathetic activity, but the evidence from human studies suggest that tonic inhibition of sympathetic tone by NO predominates and may contribute to its role in lowering blood pressure.
NO–AUTONOMIC NERVOUS SYSTEM INTERACTIONS IN THE PERIPHERY In addition to its role as a central modulator of sympathetic activity, NO may also modulate sympathetic vasoconstrictor tone peripherally. Nitric oxide synthase activity has been localized by immunohistochemistry in preganglionic autonomic fibers and postganglionic parasympathetic nerves innervating vascular smooth muscle. There is
evidence that NO released from nitrergic nerves interferes with the release of norepinephrine from adrenergic nerve terminals and with its vasoconstrictive actions on smooth muscle. In anesthetized paralyzed, baroreflex denervated cats, systemic NOS inhibition by L-NAME produced a greater pressor response compared to intact cats [8]. In humans undergoing thoracic sympathectomy, the vasoconstrictor response to systemic infusion of L-NMMA has been evaluated and it has been found that sympathectomy potentiates the vasoconstrictor effect of NOS inhibition only in the denervated limb. This effect is thought to be NO-dependent since a similar increase in forearm vasoconstriction in both limbs was observed during phenylephrine infusion [9]. NO is tonically produced by endothelial cells and in disease states (e.g. during inflammation) also possibly by vascular smooth muscle cells (iNOS) to induce local vasodilatation and, simply through this mechanism, counteract sympathetically-mediated vasoconstriction. NO can be formed locally by either eNOS and nNOS and their relative contribution to endothelial dependent vasodilatation remains a work in progress driven by the availability of selective nNOS inhibitors. The importance of neuronally derived NO in regulating basal vascular tone independently
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
NO–AuTONOmIC NERvOus sysTEm INTERACTIONs IN HEART RATE CONTROl
of eNOS has been recently studied in humans [10] and in isolated mouse aorta [11]. These studies suggest a role for neurally derived NO in regulating basal vascular tone. In summary, NO acting in the CNS places a brake on sympathetic outflow decreasing sympathetic vasoconstriction. In the periphery, NO produced locally from endothelial and vascular smooth muscle cells, or nitrergic nerves innervating them, produces vasodilatation and counteracts sympathetically-mediated vasoconstriction. NOS inhibition has been shown to produce an increase in sympathetic outflow as well as an increase in NE release. These effects however are masked by the baroreflex. Thus the final effect of NOS inhibition on blood pressure will be the resultant of these effects (Figure 20.1).
NO–AUTONOMIC NERVOUS SYSTEM INTERACTIONS IN HEART RATE CONTROL In addition to modulation of vascular tone, NO has been implicated in the control of cardiac function but its exact role is not completely understood. The effects of NO on heart rate modulation appear to be not merely a baroreflex-mediated response to vasodilatation. NO donors have been shown to elicit a positive chronotropic response [12] that seems to be at least in part independent of the autonomic nervous system since this effect is also seen in heart rate transplant recipients with cardiac denervation [13]. Inhibition of NOS with non-isoform specific inhibitors has shown either no effect on baseline heart rate or a modest negative chronotropic effect. Chronic inhibition of NOS in animal models results in sustained bradycardia. Studies on eNOS/ or nNOS/ KO mice show conflicting results and it may be a reflection on the complex interactions between the different NOS isoforms, the regulation of heart rate by the autonomic nervous system and the specific localization of the different NOS isoforms.
101
References [1] Gamboa A, Shibao C, Diedrich A, Choi L, Pohar B, Jordan J, et al. Contribution of endothelial nitric oxide to blood pressure in humans. HTN 2007;49:170–7. [2] Flinspach ML, Li H, Jamal J, Yang W, Huang H, Hah JM, et al. Structural basis for dipeptide amide isoform-selective inhibition of neuronal nitric oxide synthase. Nat Struct Mol Biol 2004;11:54–9. [3] Owlya R, Vollenweider L, Trueb L, Sartori C, Lepori M, Nicod P, et al. Cardiovascular and sympathetic effects of nitric oxide inhibition at rest and during static exercise in humans. Circulation 1997;96:3897–903. [4] Sakima A, Teruya H, Yamazato M, Matayoshi R, Muratani H, Fukiyama K. Prolonged NOS inhibition in the brain elevates blood pressure in normotensive rats. Am J Physiol 1998;275:R410–417. [5] Tagawa T, Imaizumi T, Harada S, Endo T, Shiramoto M, Hirooka Y, et al. Nitric oxide influences neuronal activity in the nucleus tractus solitarius of rat brainstem slices. Circ Res 1994;75:70–6. [6] Hakim MA, Hirooka Y, Coleman MJ, Bennett MR, Dampney RA. Evidence for a critical role of nitric oxide in the tonic excitation of rabbit renal sympathetic preganglionic neurones. J Physiol 1995;482:401–7. Pt 2 [7] Kurihara N, Alfie ME, Sigmon DH, Rhaleb NE, Shesely EG, Carretero OA. Role of nNOS in blood pressure regulation in eNOS null mutant mice. HTN 1998;32:856–61. [8] Zanzinger J, Czachurski J, Seller H. Inhibition of sympathetic vasoconstriction is a major principle of vasodilation by nitric oxide in vivo. Circ Res 1994;75:1073–7. [9] Lepori M, Sartori C, Duplain H, Nicod P, Scherrer U. Sympathectomy potentiates the vasoconstrictor response to nitric oxide synthase inhibition in humans. Cardiovasc Res 1999;43:739–43. [10] Melikian N, Seddon MD, Casadei B, Chowienczyk PJ, Shah AM. Neuronal nitric oxide synthase and human vascular regulation. Trends Cardiovasc Med 2009;19:256–62. [11] Capettini LS, Cortes SF, Lemos VS. Relative contribution of eNOS and nNOS to endothelium-dependent vasodilation in the mouse aorta. Eur J Pharmacol 2010;643:260–6. [12] Musialek P, Lei M, Brown HF, Paterson DJ, Casadei B. Nitric oxide can increase heart rate by stimulating the hyperpolarizationactivated inward current, I(f). Circ Res 1997;81:60–8. [13] Chowdhary S, Harrington D, Bonser RS, Coote JH, Townend JN. Chronotropic effects of nitric oxide in the denervated human heart. J Physiol 2002;541:645–51.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
21 Glutamatergic Neurotransmission Deborah Bauer, Michael Robinson Unlike the neuromuscular junction, where acetylcholine mediates rapid excitatory signaling, glutamate mediates essentially all rapid excitatory signaling in the mammalian CNS. This excitatory signaling is counterbalanced by GABA- or glycine-mediated inhibition (see Chapter 22). The levels of glutamate are 1,000 to 10,000fold higher than most of the other “classical” neurotransmitters, including dopamine, serotonin, norepinephrine, and acetylcholine; they approach 10 mmol/Kg. Glutamatedependent signaling is required for essentially all sensory and motor processing. It contributes to neuronal migration and synapse formation during development. In addition, there is substantial evidence to suggest that plasticity of excitatory synapses contributes to memory formation [1]. In considering glutamate as a neurotransmitter, it may be helpful to remember that glutamate has multiple functions that are not necessarily unique to the nervous system. It is an amino acid and is incorporated into proteins. It is one metabolic step from α-ketoglutarate, an intermediate in the tricarboxylic acid cycle. This cycle is responsible for ~90% of the ATP generated from glycolysis. In the brain there is no intact urea cycle; waste nitrogen (ammonia) is incorporated into glutamate with the subsequent export of glutamine to the periphery. Glutamate is the only precursor for the inhibitory neurotransmitter, GABA. In addition, there are other substances in the brain, such as aspartate, that may serve as excitatory neurotransmitters in the CNS using many of the same receptors as glutamate. For the purposes of this review, we will refer to all of this as glutamatergic neurotransmission. From a disease perspective, stroke and head trauma cause an increase in extracellular glutamate, excessive activation of glutamate receptors, and cell death [2]. This form of cell death is referred to as “excitotoxicity”. Remarkably, evidence for an excitotoxic contribution to stroke-induced brain damage first emerged in the late 1980s, and no effective therapies have emerged in spite of significant efforts by pharmaceutical firms. Excitotoxicity may also contribute to the cell loss that accompanies many neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis [2]. An imbalance of excitatory and inhibitory signaling contributes to seizure disorders, and glutamate receptor antagonists reduce seizure activity [3]. Finally,
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00021-4
there is significant evidence that altered glutamatergic function contributes to psychiatric conditions and to developmental disorders. Several drugs targeting specific glutamate receptors have entered clinical trials for psychiatric conditions (anxiety, depression, schizophrenia) and Fragile X syndrome [4,5]. While therapeutics targeting glutamatergic neurotransmission are promising, it may be difficult to target glutamate in specific pathways without altering the myriad signals that are required for normal brain function. In this chapter, we provide an overview of our current understanding of glutamate signaling in the nervous system and describe a few specific roles for glutamate in the autonomic nervous system. A simplified schematic of an excitatory synapse is provided (Fig. 21.1).
SYNTHESIS AND VESICULAR RELEASE Although glutamate is available in the diet, it cannot efficiently cross the intact blood brain barrier and rapid signaling requires a robust mechanism to replenish vesicular pools [6]. Although there are several possible routes for glutamate synthesis, it is generally thought that neurotransmitter pools of glutamate are generated from glutamine by glutaminase [6]. Glutamate can also be synthesized from α-ketoglutarate by glutamate dehydrogenase [6]. There are also other routes for glutamate synthesis from proline or from the dipeptide N-acetyl-alpha-L-aspartyl-L-glutamate (NAAG), but these are not thought to be robust sources of neurotransmitter pools of glutamate [7]. After synthesis, glutamate is actively transported into vesicles by a family of vesicular glutamate transporters (VGLUT1-3) [8]. These transporters utilize a proton electrochemical gradient to actively accumulate glutamate in synaptic vesicles to concentrations estimated to be as high as 100 mM. None of these vesicular transporters can package aspartate, but recently a distant member of the same gene family was shown to transport aspartate [9]. Interestingly, VGLUT1 and 2 have a complementary distribution in the nervous system with VGLUT1 found in the cerebrum and cerebellum and VGLUT2 enriched in brainstem areas. It is not known why there are two VGLUTs, but it has been suggested that the rhythmic activity of
103
© 2012 Elsevier Inc. All rights reserved.
104
21. GluTAmATERGIC NEuRoTRANsmIssIoN
PRESYNAPTIC NEURON Gln Gln
Glutaminase
Glu
Glutamine Synthetase
VGLUTs
Glutamine Dehydrogenase
ASTROCYTE
Krebs Cycle
GLAST
mGluRII,III
mGluRII,III
Glu
Kainate Glu
Glu
GLT-1
Kainate
Glu
Glu Glu
GLT-1
EAAC1
mGluRI
Glu
AMPA NMDA
mGluRII
Gammaglutamylcysteine + Glutathione Synthetase
EAAT4
Glutathione
POSTSYNAPTIC NEURON
FIGURE 21.1 Schematic of the glutamate synapse. (Adapted from [27].) Glutamate is synthesized from glutamine with the enzyme glutaminase. Glutamate is packaged into presynaptic vesicles by vesicular glutamate transporters (VGLUTs) and released into the synaptic cleft where it can activate NMDA, AMPA, kainate, and metabotropic glutamate receptors (mGluRs). Glutamate is cleared from the synapse by the plasma membrane glutamate transporters EAAC1 in neurons, and GLAST and GLT-1 in astrocytes. Glutamate can then enter the Krebs cycle, be converted into glutathione, or be converted back into glutamine for the cycle to begin again.
brainstem neurons necessitates a specific vesicular transporter. VGLUT3 is mostly found in presynaptic termini of neurons that are not classically considered glutamatergic, including those that utilize serotonin, acetylcholine, and GABA [8]. This provides further evidence that Dale’s hypothesis, postulating that a neuron only uses one neurotransmitter, is no longer supported by experimental findings.
RECEPTORS Once released into the synapse, glutamate activates ionotropic (ligand-gated ion channel) or metabotropic (G-protein-coupled) glutamate receptors, called iGluRs or mGluRs. iGluRs are named for exogenous agonists that selectively activate subtypes of glutamate receptors, including N-methyl-aspartate (NMDA), α-amino-3hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), and kainate [10]. Both groups of receptors are found on
various aspects of the synapse, including the postsynaptic bouton, presynaptic terminus, and nearby astrocytes. AMPA receptors are ligand-gated channels permeable to sodium and potassium, and under some circumstances calcium [11]. Thus, activation of AMPA receptors causes depolarization of the postsynaptic membrane. AMPA receptors are tetramers comprised of the subunits GluR1-4 [10]. These receptors are responsible for the majority of fast glutamate-mediated neurotransmission [2]. Like AMPA receptors, kainate receptors are also ligand-gated channels permeable to sodium and potassium [2]. Kainate receptors are comprised of GluR5-7 and KA1-KA2 [2]. They can exist as homotetramers or heterotetramers [10]. NMDA receptors are ligand-gated channels permeable to Na, K, and Ca2 [11]. Activation of these receptors requires two compounds, glutamate and glycine (or possibly D-serine) [2]. Therefore, in addition to its accepted role as an inhibitory neurotransmitter in brainstem and spinal cord, glycine also contributes to excitatory signaling. NMDA receptors are comprised of four subunits, two
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
GluTAmATE IN THE AuToNomIC NERvous sysTEm
105
of which must be NR1 subunits, and the other two can be comprised of either NR2 or NR3 subunits [2]. Thus, it is a dimer of dimers. The binding of both glutamate and glycine is not sufficient to activate NMDA receptors when the membrane is near 70 mV because physiologic concentrations of Mg2 bind to and block channel function [2]. This effect of magnesium is voltage-dependent, such that depolarization removes the Mg2 from the channel and allows current to pass through the channel. Thus, the NMDA receptor is considered a “coincidence detector”, it is activated when another receptor causes sufficient membrane depolarization, as would be expected to occur with high frequency stimulation. This unique property of the NMDA receptor is linked to synaptic plasticity that may underlie memory formation [12]. In addition to the ionotropic receptors, there also exist a series of seven transmembrane domain metabotropic glutamate receptors (mGluR1-8) [2]. These receptors are grouped into three families, based on the sequence similarity and their signaling properties [2]. Type I receptors include mGluR1 and 5. These receptors primarily activate phospholipase C and IP3 production. Type II receptors includes mGluR2 and 3. Type III receptors includes mGluR4, 6, 7, and 8. These two families of receptors primarily signal through inhibition of adenylate cyclase and a reduction in cAMP levels. The mGluRs are situated on all aspects of the synapse and might be considered sensors of glutamate; they regulate neurotransmitter release from the presynaptic nerve terminal, iGluR channel opening, and aspects of astrocytic function [13].
EAAC1/EAAT3 expression is enriched in neurons in the CNS [18]. It is found on postsynaptic excitatory neurons, GABAergic neurons, and on the presynaptic nerve terminal. On GABAergic neurons, it may directly provide glutamate for the synthesis of GABA as a complement to the normal source of carbon backbone, which is thought to be glutamine (see Chapter 22). EAAC1/EAAT3 participates in neuronal import of cysteine, the rate limiting ingredient for the synthesis of glutathione. Interestingly, these transporters also gate Cl– ions to a varying degree. In fact, EAAT4 and EAAT5 are quite slow as transporters, but gate substantial Cl– currents [14,19]. Rather than having significant roles in the clearance of glutamate, these two transporters may serve as receptors in the cerebellum and retina, respectively [19].
CLEARANCE OF GLUTAMATE
GLUTAMATE IN THE AUTONOMIC NERVOUS SYSTEM
Unlike some other neurotransmitters, there is no evidence that glutamate is metabolized by extracellular enzymes [14]; instead, it is cleared by a family of Nadependent transporters. In mammals, there are five related gene products that perform this function, including GLAST, GLT-1, EAAC1 (called EAAT1-3, respectively in human), EAAT4 and EAAT5 [14]. These transporters exist as homotrimers [15] and co-transport 3 Na and 1 H with each molecule of glutamate and counter-transport 1 K ion. With this stoichiometry, these transporters are capable of generating a 1 million-fold concentration gradient of glutamate across the membrane [16]. The vast majority of glutamate uptake is mediated by GLT-1 and GLAST with GLT-1 having a larger role in forebrain and GLAST a larger role in cerebellum [17]. These transporters are found on many cell types in the nervous system, but are highly enriched on glial cells. Therefore, unlike any of the other classical neurotransmitters that are recycled back into the presynaptic nerve terminal (see chapters on dopamine, serotonin, and norepinephrine; 6, 8, 12 and 17), glutamate is not substantially recycled back into the presynaptic nerve terminal.
GLUTAMATE METABOLISM After clearance into astrocytes, most, if not all of the glutamate carbon backbone is conserved, by conversion to glutamine by the astrocyte specific enzyme, glutamine synthetase [6]. Glutamine is then exported by a specific transporter, called System N [20]. Glutamine is thought to be imported back into the presynaptic nerve terminal and used for regeneration of glutamate. This is referred to as the glutamate-glutamine cycle. Glutamate can also be converted to α-ketoglutarate by either glutamate-dehydrogenase or a transaminase (either aspartate aminotransferase or glutamate oxalacetate transaminase), and enter the citric acid cycle [6].
In contrast to the CNS, glutamate is not the predominant excitatory neurotransmitter in the periphery. The sodium dependent glutamate transporters are found throughout the body and thus are not a good marker for glutamatergic signaling. However, glutamate receptors and vesicular glutamate transporters have been detected in a variety of peripheral tissues including the kidney, bone, heart, intestine, pancreas, and platelets [14,21]. Thus, while their role in signaling has not been fully elucidated, glutamate is involved in signaling outside of the CNS. For example, glutamate is critical in regulation of the enteric nervous system. Glutamatergic neurons innervate the gut and influence both motility and secretion [22]. Both ionotropic and metabotropic glutamate receptors have been identified in the gut. Although the sympathetic and parasympathetic nervous systems innervate the organs using norepinephrine and acetylcholine, respectively, glutamate is important for central control of these systems. The nucleus tractus solitarii (NTS) of the medulla, often considered the command center of the autonomic nervous system, controls
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
106
21. GluTAmATERGIC NEuRoTRANsmIssIoN
cardiovascular and digestive tract reflexes and contains both glutamatergic afferents and efferents [23] (see Fig. 21.2). The importance of glutamatergic signaling in the NTS is clearly illustrated in the baroreceptor reflex (see Fig. 21.2). This reflex begins with activation of baroreceptors, pressure sensitive neurons, found in the aortic arch and carotid sinus that project to the NTS [24]. At this point, the reflex splits into two pathways, the cardioinhibitory pathway and the sympathoinhibitory pathway [24]. In the cardioinhibitory pathway, second order glutamatergic neurons in the NTS excite cholinergic neurons in the nucleus ambiguus (NA) that project to the cardiac ganglion. The cardiac ganglion projects cholinergically to the heart and controls heart rate. This activation of muscarinic acetylcholine receptors causes a decrease in heart rate [24]. In the sympathoinhibitory pathway, second order glutamatergic neurons in the NTS excite GABAergic interneurons in caudal ventrolateral medulla (CVL) [24]. These CVL interneurons project to and inhibit glutamatergic neurons in the rostral ventrolateral medulla (RVLM), which in turn innervate preganglionic sympathetic neurons in the spinal cord. These spinal cord neurons release acetylcholine at the sympathetic ganglion. Finally, noradrenergic neurons in the sympathetic ganglion activate vasoconstriction. However, because excitation of GABAergic interneurons in the CVL causes downstream inhibition of the pathway, the net result is decreased
-
GABA
CVL
Glutamate
+
Some estimates suggest that glutamate mediates upwards of 80% of all neuron–neuron communication in the mammalian CNS. It is required for virtually every physiologic function in mammals, including most brainstem pathways that contribute to autonomic control. In addition to normal physiologic function, excessive activation of glutamate receptors contributes to cell death observed in both acute and chronic neurodegenerative diseases. As our understanding of this system evolves, it seems likely that therapeutic targeting of this system will become more sophisticated.
NTS
+
Sympathoinhibitory
Cardioinhibitory
Glutamate
SUMMARY
Glutamate
+
Glutamate
Glutamate
RVLM
vasoconstriction. Thus, activation of baroreceptors activates two homeostatic pathways collectively known as the baroreceptor reflex, causing heart rate and blood pressure to decrease. Another major output of the NTS where glutamate plays a role is the hypothalamus. Glutamatergic activity in the hypothalamus also influences the baroreceptor reflex. Microinjection of glutamate in the paraventricular nucleus (PVN) of the hypothalamus results in baroreflex bradycardia through activation of NMDA receptors [25]. In fact, glutamate is the major excitatory neurotransmitter providing input to the PVN and supraoptic nucleus of the hypothalamus [26].
+
Heart Acetylcholine
Acetylcholine
NA
+ Cardiac Ganglion
-
+
Acetylcholine
+ SC
Sympathetic
Norepinephrine
Ganglion
FIGURE 21.2 Simplified baroreflex circuit. (Adapted from [24].) Baroreceptors in the aortic arch and carotid sinus project to the nucleus tractus solitarii (NTS) and release glutamate. In the cardioinhibitory pathway, second order glutamatergic neurons in the NTS excite cholinergic neurons in the nucleus ambiguus (NA) that project to the cardiac ganglion. Cholinergic neurons of the cardiac ganglion project to the heart and decrease heart rate. In the sympathoinhibitory pathway, second order glutamatergic neurons in the NTS excite GABAergic interneurons in caudal ventrolateral medulla (CVL). CVL interneurons project to and inhibit glutamatergic neurons in the rostral ventrolateral medulla (RVLM), which in turn innervate preganglionic sympathetic neurons in the spinal cord. These spinal cord neurons release acetylcholine at the sympathetic ganglion which activate noradrenergic neurons in the sympathetic ganglion causing vasoconstriction. The final result of the baroreceptor reflex is a decrease in heart rate and blood pressure.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
summARy
References [1] Izquierdo I. Pharmacological evidence for a role of long-term potentiation in memory. FASEB J 1994;8:1139–45. [2] Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 2010;460:525–42. [3] LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004;291:605–14. [4] Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009;46:266–71. [5] Olive MF. Metabotropic glutamate receptor ligands as potential therapeutics for addiction. Curr Drug Abuse Rev 2009;2:83–98. [6] Palmada M, Centelles JJ. Excitatory amino acid neurotransmission. Pathways for metabolism, storage and reuptake of glutamate in brain. Front Biosci 1998;3:d701–18. [7] Robinson MB, Blakely RD, Couto R, Coyle JT. Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem 1987;262:14498–14506. [8] Takamori S. VGLUTs: “exciting” times for glutamatergic research? Neurosci Res 2006;55:343–51. [9] Miyaji T, Echigo N, Hiasa M, Senoh S, Omote H, Moriyama Y. Identification of a vesicular aspartate transporter. Proc Natl Acad Sci USA 2008;105:11720–11724. [10] Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 2005;179:4–29. [11] Mayer ML, Armstrong N. Structure and function of glutamate receptor ion channels. Annu Rev Physiol 2004;66:161–81. [12] Tsien JZ. Linking Hebb’s coincidence-detection to memory formation. Curr Opin Neurobiol 2000;10:266–73. [13] Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995;34:1–26. [14] Danbolt NC. Glutamate uptake. Prog Neurobiol 2001;65:1–105. [15] Gendreau S, Voswinkel S, Torres-Salazar D, Lang N, Heidtmann H, Detro-Dassen S, et al. A trimeric quaternary structure is conserved in bacterial and human glutamate transporters. J Biol Chem 2004;279:39505–39512. [16] Zerangue N, Kavanaugh MP. Flux coupling in a neuronal glutamate transporter. Nature 1996;383:634–7.
107
[17] Robinson MB. The family of sodium-dependent glutamate transporters: a focus on the GLT-1/EAAT2 subtype. Neurochem Int 1998;33:479–91. [18] Shashidharan P, Huntley GW, Murray JM, Buku A, Moran T, Walsh MJ, et al. Immunohistochemical localization of the neuronspecific glutamate transporter EAAC1 (EAAT3) in rat brain and spinal cord revealed by a novel monoclonal antibody. Brain Res 1997;773:139–48. [19] Dehnes Y, Chaudhry FA, Ullensvang K, Lehre KP, StormMathisen J, Danbolt NC. The glutamate transporter EAAT4 in rat cerebellar Purkinje cells: a glutamate-gated chloride channel concentrated near the synapse in parts of the dendritic membrane facing astroglia. J Neurosci 1998;18:3606–19. [20] Fei YJ, Sugawara M, Nakanishi T, Huang W, Wang H, Prasad PD, et al. Primary structure, genomic organization, and functional and electrogenic characteristics of human system N 1, a Na- and Hcoupled glutamine transporter. J Biol Chem 2000;275:23707–23717. [21] Morrell CN, Sun H, Ikeda M, Beique JC, Swaim AM, Mason E, et al. Glutamate mediates platelet activation through the AMPA receptor. J Exp Med 2008;205:575–84. [22] Kirchgessner AL. Glutamate in the enteric nervous system. Curr Opin Pharmacol 2001;1:591–6. [23] Baude A, Strube C, Tell F, Kessler JP. Glutamatergic neurotransmission in the nucleus tractus solitarii: structural and functional characteristics. J Chem Neuroanat 2009;38:145–53. [24] Benarroch EE. The arterial baroreflex: functional organization and involvement in neurologic disease. Neurology 2008;71:1733–8. [25] Crestani CC, Alves FH, Busnardo C, Resstel LB, Correa FM. N-Methyl-D-aspartate glutamate receptors in the hypothalamic paraventricular nucleus modulate cardiac component of the baroreflex in unanesthetized rats. Neurosci Res 2010;67:317–26. [26] Iremonger KJ, Benediktsson AM, Bains JS. Glutamatergic synaptic transmission in neuroendocrine cells: Basic principles and mechanisms of plasticity. Front Neuroendocrinol 2010;31:296–306. [27] Bauer D, McCullumsmith RE, Meador-Woodruff JH. A role for glutamate receptors, transporters, and interacting proteins in cortical dysfunction in schizophrenia. In: O’Donnell P, editor. In Cortical Deficits in Schizophrenia. New York, NY: Springer; 2008. p. 113–48.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
22 GABAergic Neurotransmission Andre H. Lagrange, Mark D. Grier OVERVIEW OF GABA MEDIATED SIGNALING GABA is the primary mediator of neuronal inhibition in the brain, as well as being a very important neurotransmitter in the spine and peripheral nervous system. Major components of the GABAergic neurotransmission system include two enzymes that synthesize GABA, two classes of receptors, two types of transporters, and an enzyme that degrades GABA. Nearly all GABA found in the mammalian brain is synthesized by decarboxlyation of glutamate by two forms of glutamic acid decarboxylase, GAD65 and GAD67. While GAD67 is present as a nearly constitutively active enzyme throughout the cell, GAD65 is localized primarily to the axon terminals and only becomes highly active in periods of increased demand. After GABA is synthesized, it is packaged into synaptic vesicles by the vesicular GABA transporter vGAT (also known as vesicular inhibitory amino acid transporter, VIAAT). Upon stimulation of the neuron, these vesicles fuse to the presynaptic terminal and release GABA into the synapse via calcium dependent exocytosis. GABA is removed from the synapse by another class of GABA transporter, GATs. It is important to note that while the function of vGAT and GAT are similar, their structure and mechanisms of transport are very different. To date, there have been four GAT isoforms identified, each with unique pharmacology and cellular localization. In the CNS, the main transporters are GAT1 and GAT3, expressed primarily on presynaptic terminals and astrocytes, respectively. Once GABA is cleared from the synapse it is degraded by GABA-transaminase. Inhibitors of GABA reuptake and breakdown effectively produce increased levels of extracellular GABA and are used clinically in conditions of CNS hyperexcitability, such as spasticity and epilepsy [1].
GABA RESPONSES ARE MEDIATED BY BOTH IONOTROPIC AND METABOTROPIC RECEPTORS The neuronal response to GABA is mediated through two populations of receptors, GABAA and GABAB receptors. While both populations generally produce neuronal
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00022-6
inhibition, they do so through wholly different mechanisms. GABAA receptors are primarily postsynaptic ligand-gated Cl ion channels, while GABAB receptors are G-protein coupled receptors found on both pre- and postsynaptic terminals. Activation of GABAA receptors produces Cl ion fluxes that directly alter membrane potential. In contrast, the effects GABAB receptor stimulation are mediated by G-proteins that produce a variety of responses, including activation of potassium channels, inhibition of presynaptic voltage-gated calcium channels and modulation of intracellular second messenger systems, including adenylate cyclase and phospholipase C. This review will focus primarily on GABAA receptors; however it is important to note that GABAB receptors also play an important role in inhibition in the central nervous system.
GABAA RECEPTORS MEDIATE MULTIPLE MODES OF NEURONAL SIGNALING GABAA receptors have the important ability to convey two different types of inhibition within the brain [2]. Phasic inhibition involves temporally and spatially precise responses to very brief, high levels of synaptic GABA (≈1 mM, 1 ms). In comparison, synaptic spillover produces prolonged low levels of GABA in the extrasynaptic space that activate highly sensitive GABAA receptor subtypes, thereby producing a tonic inhibitory current (Fig. 22.1). Despite its small amplitude, the prolonged duration of tonic inhibition produces an overall charge transfer that exceeds that of synaptic neurotransmission in certain brain regions. Furthermore, by effectively reducing membrane resistance, tonic inhibition reduces the ability of excitatory currents to depolarize the cell toward the action potential threshold. These dual effects allow tonic inhibition to serve as a critical determinant of overall network excitability in a number of important brain regions. While classically thought of as an inhibitory neurotransmitter, GABAA receptors also have the unusual capacity to convey excitatory responses, depending on the Cl reversal potential across the neuronal membrane [3]. In normal adult neurons, robust activity of the Cl transporter KCC2 results in low intracellular Cl levels
109
© 2012 Elsevier Inc. All rights reserved.
110
22. GABAERGIC NEuRoTRANsmIssIoN
Strong Synaptic Input
Weak Synaptic Input
Presynaptic Neurons
Presynaptic Neurons Glia
Glia
Metabolism
Metabolism
GABA-T
GABA-T
VGAT
GABA
GABA
Postsynaptic Neuron GABA A Receptor GAT
GABA B Receptor Synaptic Vesicle
Postsynaptic Neuron GABA A Receptor GAT
GABA B Receptor Synaptic Vesicle
FIGURE 22.1 GABA receptors mediate multiple forms of neurotransmission. During weak synaptic activity, brief surges of GABA activate the ionotropic GABAA receptors clustered within the synapse, producing transient inhibitory postsynaptic currents. However, during more pronounced synaptic activity, GABA can overflow beyond the synapse, activating highly sensitive GABAA receptor subtypes that exist outside the synapse to produce a long-lived tonic current. G-protein coupled GABAB receptors on both the pre- and postsynaptic neurons are also activated by synaptic overflow to help suppress neuronal activity.
compared to the extracellular fluid, thereby producing a hyperpolarizing influx of negative Cl ions when GABAA receptors are activated. In contrast, maturing neurons express very little KCC2, and anion homeostasis is largely determined by a different Cl transporter (NKCC1) that preferentially transports Cl into the cell. This produces high levels of intracellular Cl that allow GABAA receptor activation to produce a depolarizing efflux of anions [3] that can generate action potentials, intracellular calcium waves, and relieve Mg block of NMDA receptors. These excitatory responses regulate a number of important steps in brain development, including the formation of both excitatory and inhibitory synapses. Interestingly, similar depolarizing responses can be found in specific subcellular regions in the normal adult neurons, as well as more widely following brain injury. Furthermore, these excitatory GABA responses may be involved in the pathogenesis of some neurological disorders (e.g. epilepsy) and selective inhibition of NKCC1 with drugs like bumetanide, has been proposed as a potential future treatment for some of these conditions [4].
NEUROTRANSMISSION IS MEDIATED BY A DIVERSE SET OF GABAA RECEPTOR SUBTYPES GABAA receptors are heteropentameric protein complexes, generally composed of a combination of 2α, 2β and either a γ or δ subunit. To date, there are 6α, 3β, 3γ and a single δ isoform subtypes. Despite a vast array of possible subunit combinations, only a limited number of GABAA receptor subunit combinations are actually found in native tissue. The expression of individual subunit combinations is highly region and cell-type specific. While most synaptic responses throughout the brain are thought to be mediated by postsynaptic α1β2γ2 containing GABAA receptors, other
subunit combinations are highly expressed in select brain regions (thalamus, hypothalamus, hippocampus), as well as in specific subcellular domains, including the axon initial segment (α2βxγ) or extrasynaptic space (α4βxδ and α5β3γ2). Since the identity of the constituent subunit isoforms is the primary determinant of GABAA receptors’ sensitivity to GABA and current kinetic properties, specific subunit isoform combinations likely serve very different physiological functions. For example, α4βxδ containing receptors are more than 10–100 times more sensitive to low levels of GABA than some other subunit combinations, allowing them to respond to the very low levels of ambient GABA in the extrasynaptic space. In contrast, the less sensitive, but rapidly activating α1β2γ2 containing GABAA receptors are found clustered within inhibitory synapses, where they are able to convert extremely brief, high levels of GABA to more prolonged postsynaptic currents. However, these receptors also desensitize quickly, and respond poorly during repetitive input. Replacement of the α1 subunit with the α3 subunit, produces receptors that are even less sensitive to low GABA, but are more slowly desensitizing and deactivate extremely slowly, resulting in very prolonged IPSCs that can produce a summating response during repetitive stimulation [5,6]. More recently, it has become clear that these patterns of subunit expression can be profoundly disrupted in a variety of pathological states like ischemia and seizures [7,8]. These changes may be compensatory, but are also thought to contribute to some of the pathological plasticity that occurs after brain injury.
SUBTYPE PREFERRING DRUGS ALLOW FOR SELECTIVE MODULATION OF GABA SIGNALING Given that essentially every neuron in the mammalian brain expresses GABAA receptors, it is not surprising that
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
suBTyPE PREfERRING DRuGs Allow foR sElECTIvE moDulATIoN of GABA sIGNAlING
a number of the most useful medications used in neurology and psychiatry target these receptors. Nonselective GABAA receptor-active drugs, like barbiturates, and inhaled anesthetics, propofol and etomidate, are commonly used for surgery. At low concentrations, these agents enhance the effects of endogenous GABA, but at higher concentrations they directly and indiscriminately activate GABAA receptors throughout the brain. While this allows these agents to serve as general anesthetics, it also introduces the possibility of lethal effects on respiration and blood pressure. Fortunately, there are also a variety of subunit-preferring medications that allow selective modulation of specific GABAA receptor subunits combinations. For example, benzodiazepines increase the GABA affinity of α(1, 2, 3 or 5)βxγx containing GABAA receptors. Even more selective is the benzodiazepine-like hypnotic compound, zolpidem. This drug potently enhances α1βxγ2 mediated inhibition, has much weaker effects on α2,3βxγ2 mediated currents, and is virtually inactive at all other GABAR subunit combinations. Since synaptic GABAA receptors are usually exposed to saturating levels of GABA, the affinityenhancing effects of benzodiazepines and zolpidem produce prolonged IPSCs, without much effect on current amplitude. In contrast, extrasynaptic α5β3γ2 GABAA receptors on hippocampal neurons are exposed to prolonged, low levels of GABA. Consequently, benzodiazepines, but not zolpidem, produce increased tonic current amplitude in these cells. This form of inhibition is thought to be important in learning/memory, and suppression of tonic inhibition with α5βxγ-selective benzodiazepine site inverse agonists is currently being evaluated as a potential mechanism for cognitive enhancement. Similar agents that modulate α2 and α3 containing receptors are in more preliminary stages of development as anxiolytics, muscle relaxants and analgesics [9]. The other predominant mediators of tonic inhibition in the brain are α4βδ containing GABAA receptors. These relatively small GABA-evoked currents can be enhanced several fold by barbiturates and ethanol. While truly α4βδ selective agents are lacking, the drug gaboxadol is a superagonist with particularly high potency and efficacy at this particular subunit combination, and low concentrations of this drug are often used to selectively enhance α4βδ mediated tonic inhibition. Interestingly, these receptors are also especially prone to modulation by endogenous neuroactive steroid hormones produced in the gonads, adrenals and even in the CNS itself. While steroid hormones are generally associated with long-term changes at the genomic level, neuroactive steroids, like allopregnanolone (3α,5α-tetrahydroprogesterone) and THDOC (allotetrahydrocorticosterone) enhance GABAergic signaling within seconds. This enhancement is not mediated by the classic nuclear steroid hormone receptors, nor is it mediated by changes in protein synthesis. Instead, these neuroactive steroids are thought to interact directly with GABAA receptors, possibly involving specific binding site(s) in the transmembrane region. While allopregnanolone and THDOC enhance most GABAA receptor subunit
111
combinations to some degree, αxβxδ containing receptors are especially sensitive to even extremely low neurosteroid concentrations. Moreover, αxβxδ containing receptors typically produce small currents due to a lower single channel conductance and mean open times. However, nanomolar concentrations of neurosteroids shift the activation properties of αxβxδ containing receptors, producing a nearly ten-fold increase in the maximal GABA evoked current [10]. In summary, GABA is a multifunctional neurotransmitter capable of producing brief, phasic responses or tonic currents that may be either excitatory or inhibitory, depending on the age, brain region, and cell-type being studied. In addition, the control of GABAergic signaling involves multiple proteins, many of which have multiple isoforms. The regulation of GABAergic signaling is a critical determinant of nervous system function, and disruption of this system is thought to play a crucial role in many neurological disorders. Fortunately, the availability of a number of isoform-selective drugs at these diverse preand postsynaptic targets provides an unparalleled potential for pharmacological manipulation of neuronal activity in the treatment of human illness.
References [1] Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 2004;61:1–48. [2] Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci 2005;6:215–29. [3] Ben Ari Y, Gaiarsa JL, Khazipov R. GABA: A pioneer transmitter that excites immature neurons and generates primitive oscillations. Phys Rev 2007;87:1215–84. [4] Dzhala VI, Talos DM, Sdrulla DA, Brumback AC, Mathews GC, Benke TA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med 2005;11:1205–13. [5] Cox CL, Huguenard JR, Prince DA. Nucleus reticularis neurons mediate diverse inhibitory effects in thalamus. Proc Natl Acad Sci USA 1997;94:8854–9. [6] Rula EY, Lagrange AH, Jacobs MM, Hu N, Macdonald RL, Emeson RB. Developmental modulation of GABA(A) receptor function by RNA editing. J Neurosci 2008;28:6196–201. [7] Clarkson AN, Huang BS, Macisaac SE, Mody I, Carmichael ST. Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke. Nature 2010;468:305–9. [8] Zhang N, Wei W, Mody I, Houser CR. Altered localization of GABA(A) receptor subunits on dentate granule cell dendrites influences tonic and phasic inhibition in a mouse model of epilepsy. J Neurosci 2007;27:7520–31. [9] Mohler H. GABA(A) receptor diversity and pharmacology. Cell Tissue Res 2006;326:505–16. [10] Wohlfarth KM, Bianchi MT, Macdonald RL. Enhanced neurosteroid potentiation of ternary GABA(A) receptors containing the delta subunit. J Neurosci 2002;22:1541–9.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
23 Renin-Angiotensin Amy C. Arnold, Debra I. Diz INTRODUCTION The renin-angiotensin system (RAS) plays an important role in the regulation of blood pressure under normal and pathophysiological conditions. The RAS interacts with the autonomic nervous system for blood pressure regulation, with angiotensin receptors localized to brain regions involved in modulation of both sympathetic and parasympathetic nervous system activity. The following provides a brief overview of the classical and brain RAS, focusing on interactions of this hormonal system with autonomic brain regions integral to cardiovascular control.
THE CLASSICAL RAS
Recent Advances in the Classical RAS
Components and Features of the Classical RAS As recently reviewed [1,2] the classical circulating RAS is a series of enzyme-substrate interactions that generates angiotensin peptides involved in cardiovascular, fluidelectrolyte and neuroendocrine homeostasis. The ratelimiting enzyme, renin, is synthesized in juxtaglomerular cells of the kidney and is secreted into the circulation in response to various stimuli. As illustrated in Figure 23.1, circulating renin acts upon hepatic-derived angiotensinogen to form angiotensin I. Angiotensin converting enzyme (ACE), a lung-derived dipeptidyl carboxypeptidase, subsequently cleaves angiotensin I into angiotensin II, the main effector peptide of the RAS. However, other enzymes including chymase are capable of forming angiotensin II in pathological conditions. Four subtypes of the angiotensin II g-protein coupled receptor (AT1–AT4) have been identified. The majority of angiotensin II effects are mediated by ubiquitously expressed AT1 receptors. Depending on the cell and tissue type, AT1 receptor activation is associated with inhibition of adenylyl cyclase, activation of phospholipase C or phosphoinositide hydrolysis. Angiotensin II stimulation of AT1 receptors induces vasoconstriction, sympathetic activation, suppression of baroreflex function, sodium and water reabsorption, cellular proliferation and hypertrophy, inflammation, oxidative stress and release of aldosterone, vasopressin and noradrenaline (Table 23.1). Angiotensin II also binds AT1 receptors on juxtaglomerular
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00023-8
cells to provide negative feedback suppression of renal renin release. These actions are collectively abrogated by ACE inhibitors or AT1 receptor antagonists, to prevent the formation or binding of angiotensin II, respectively. Angiotensin II also binds AT2 receptors, with expression of these receptors abundant during fetal life, but declining into adulthood. The AT2 receptor opposes AT1 activation with respect to blood pressure and cellular proliferation and is also involved in growth, repair, pain threshold and neuronal cell maturation and differentiation (Table 23.1). Angiotensin II is degraded by aminopeptidases A and N into the shorter fragments angiotensin III and IV, respectively (Fig. 23.2, Table 23.1).
New pathways for the production of angiotensin peptides have been recently revealed, including the formation of the heptapeptide angiotensin-(1-7) (Figs. 23.1 and 23.2). Angiotensin-(1-7) can be formed via cleavage of angiotensin I by various endopeptidases including neprilysin (NEP), thimet oligopeptidase (TOP) and prolyl oligopeptidase (POP) [3,4]. Alternatively, angiotensin-(1-7) is formed through cleavage of angiotensin II by ACE2, a novel homolog of ACE (Fig. 23.1) [3–5]. The actions of angiotensin-(1-7) are mediated by g-protein coupled mas receptors and are blocked by the selective receptor antagonist [D-Ala7]angiotensin-(1-7) [3]. Angiotensin-(1-7) is degraded into the inactive metabolite angiotensin-(1-5) by ACE [3]. The complexity of the RAS is further increased by the recent discovery of angiotensin-(1-12), a C-terminally extended peptide longer than angiotensin I (Figs. 23.1 and 23.2) [6]. Angiotensin-(1-12) is found in plasma and peripheral tissues and appears to serve as a renin-independent precursor for the production of angiotensin peptides [4].
The Classical RAS and Autonomic Regulation Systemic angiotensin II elicits vasoconstriction, sympathetic activation, baroreflex dysfunction and neuroendocrine and fluid-electrolyte changes (Table 23.1), all of which can contribute to blood pressure elevations [1,7]. The sympathetic and baroreflex actions of circulating angiotensin II involve interactions with AT1 receptors in specialized circumventricular organs lacking a functional
113
© 2012 Elsevier Inc. All rights reserved.
114
23. REnIn-AngIoTEnsIn
FIGURE 23.1 Schematic diagram of the current view of the reninangiotensin system showing biochemical pathways involved in the formation, degradation and actions of the biologically active peptides angiotensin II and angiotensin-(1-7). Ang, angiotensin; ACE, angiotensin converting enzyme; NEP, neprilysin; TOP, thimet oligopeptidase; POP, prolyl oligopeptidase; AT1-R, angiotensin type 1 receptor; AT2-R, angiotensin type II receptor; mas-R, mas receptor.
TABLE 23.1 Receptors and Actions of Angiotensin Peptides Receptor
Actions
Potential Ligands
AT1
Increase blood pressure, vasoconstriction, sympathetic activation, decrease baroreceptor reflex sensitivity for heart rate control and increase baroreflex set-point, pro-inflammation, pro-oxidative, thirst behaviors, cell growth and hypertrophy, anxiety, stress, neuronal excitation, and stimulate aldosterone, norepinephrine and vasopressin release
Angiotensin II Angiotensin III Angiotensin-(1-12)– likely after conversion to Angiotensin II
AT2
Vasodilation, decrease in blood pressure, apoptosis, antiinflammation, neuronal development and differentiation
Angiotensin II Angiotensin III
AT1-7 [mas]
Vasodilation, decrease in blood pressure, anti-inflammation, anti-oxidant, increase baroreceptor sensitivity for heart rate control, neuronal excitation
Angiotensin-(1-7)
AT4
Memory, learning, Angiotensin IV depression, anxiety, prevents insulin-regulated aminopeptidase (IRAP)mediated metabolism of vasoactive peptides
FIGURE 23.2 Amino acid sequences for peptides of the renin-angiotensin system.
blood-brain barrier [7]. The importance of circulating angiotensin II to hypertension is illustrated by the finding that ACE inhibitors or AT1 receptor blockers lower blood pressure, reset the baroreflex set-point and improve baroreflex sensitivity in hypertensive populations [8]. These therapies also increase levels of angiotensin-(1-7), a peptide that stimulates mas receptor-mediated vasodilation and improvement of baroreflex function (Table 23.1) [1,3]. In rodents, low doses of angiotensin-(1-7) increase vasodilation through interactions with prostaglandinbradykinin-nitric oxide systems [3,4]. However, the systemic effects of angiotensin-(1-7) on blood pressure in humans are controversial. The counter-regulatory actions of angiotensin II and angiotensin-(1-7) suggest that the balance of these two peptides is important to cardiovascular physiology and pathophysiology. Indeed, emerging evidence suggests that cardiovascular diseases are associated with an imbalance in the angiotensin II/ACE and angiotensin-(1-7)/ACE2 axes [3–5]. Possibly shifting the balance of the RAS in the circulation, angiotensin-(1-12) acts as a precursor to angiotensin II for peripheral cardiovascular actions including vasoconstriction and elevations in blood pressure [4,6].
THE BRAIN RAS All components of the RAS are present in distinct, independently-regulated tissue systems including adipose, kidneys, blood vessels, heart and brain [2]. As early as 1961, studies demonstrated that angiotensin II acts centrally to increase blood pressure [7]. At this time, it was hypothesized that angiotensin II interacted with the brain through AT1 receptors in circumventricular organs. A few years later, the existence of an independent brain RAS was postulated by Ganten and colleagues. Indeed, all necessary precursors and enzymes required for the local formation and metabolism of angiotensins are found in brain [2,7]. However, controversy still exists regarding the cellular localization, independence from the circulating system and authenticity of brain RAS peptides [9].
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
THE BRAIn RAs
Components of the Brain RAS Angiotensinogen is widely expressed in the central nervous system with high levels in cerebrospinal fluid, hypothalamic and brainstem regions [2,7]. While angiotensinogen is primarily produced in astrocytes, it is also present in neuronal cells of key cardiovascular nuclei [7]. Renin immunoreactivity is described in discrete glial and neuronal cells of the pituitary, choroid plexus, medulla and hypothalamus. However, renin expression in brain is low suggesting alternate pathways exist for central production of angiotensin peptides [2,7]. All enzymes necessary for processing angiotensin I into bioactive peptides are found in brain (ACE, ACE2, NEP and aminopeptidases) [7]. While the exact mechanisms involved in their formation remains unclear, angiotensin peptides are all reported in brain, with the highest levels demonstrated for angiotensin II and angiotensin-(1-7) [7]. Angiotensin II AT1 receptors are highly localized to brain regions associated with autonomic outflow as well as areas involved in energy homeostasis, respiration, salt appetite, vasopressin release and thirst [2,7]. Low levels of AT2 receptors are also found in brain regions associated with cardiovascular, motor, sensory and limbic activity [7]. The active fragment angiotensin III binds central AT1 receptors to mediate actions attributed to angiotensin II including regulation of blood pressure and vasopressin release (Table 23.1) [1]. Central stimulation of AT4 receptors by angiotensin IV prevents insulin-regulated aminopeptidase-mediated metabolism of vasoactive peptides [7] and is also implicated in depression, learning, memory and anxiety (Table 23.1) [7].
Influence of the Brain RAS on Autonomic Regulation Angiotensin II AT1 and angiotensin-(1-7) mas receptors are abundant at each synaptic relay of the sympathetic and parasympathetic nervous systems, including spinal cord and ganglia [7,8]. AT1 receptors are distributed in sympathetic preganglionic neurons, sympathetic ganglia, sympathetic nerve terminals and sympathetic regulatory brain sites including hypothalamus, dorsal medullary and ventral medullary regions [10]. Central angiotensin II infusion increases arterial pressure and stimulates whole body and regional sympathetic activity in rodents, in part mediated by stimulatory interactions with other neurotransmitters including norepinephrine, dopamine and substance P [10]. Angiotensin II also acts at AT1 receptors within the solitary tract nucleus (NTS) to attenuate baroreflex restraint of sympathetic outflow to the heart, kidney and vasculature [8,10]. The NTS has descending projections to brainstem vasomotor nuclei, including the rostral and caudal ventrolateral medullas, which respond to angiotensin peptides to influence sympathetic activity, blood pressure and baroreflex function [8]. Importantly, a positive feedback loop exists between the RAS and sympathetic nervous system as increased renal sympathetic nerve activity is a major
115
stimulus for β-adrenergic receptor-mediated renal renin release [10]. Angiotensin receptors are also distributed in vagal pathways influencing control of the parasympathetic nervous system [7,8,10]. High-affinity AT1 receptor binding sites are located on presynaptic vagal afferent terminals and on NTS cell bodies, with a small population of AT2 receptors in this brain region [8]. Central infusion or NTS microinjection of angiotensin II or angiotensin III impairs the baroreflex sensitivity for control of heart rate for bradycardia to increases in arterial pressure, an established marker of parasympathetic function, independent of changes in resting pressure [8,10]. Furthermore, NTS administration of AT1 receptor antagonists improves baroreflex sensitivity in rats suggesting that angiotensin II endogenous to the brain attenuates baroreflex function [8]. Illustrating the importance of brain angiotensin II to blood pressure regulation, transgenic rodents with increased brain angiotensin II generation are hypertensive and have impaired baroreflex sensitivity while those with reduced brain angiotensin II synthesis are hypotensive and have lower sympathetic and higher parasympathetic tone [2]. Studies in transgenic rodents also suggest that the source of angiotensin II for baroreflex modulation is of glial origin, whereas the source of the peptide for blood pressure regulation is neuronal [11]. Similar to the periphery, central actions of angiotensin-(1-7) oppose angiotensin II. However, both peptides can elicit similar pressor/depressor actions in specific brain nuclei and stimulate hypothalamic vasopressin release [3,4]. Numerous studies document that central administration of angiotensin-(1-7) lowers blood pressure, increases baroreflex sensitivity for control of heart rate and reduces norepinephrine release in hypertensive rodents [5]. Moreover, [D-Ala7]-angiotensin-(1-7) impairs baroreflex sensitivity in normotensive rats suggesting angiotensin-(1-7) endogenous to the brain facilitates baroreflex function [11]. Thus, the prevailing level of baroreflex sensitivity appears to reflect the balance of angiotensin II and angiotensin-(1-7) actions in the brain. This balance may in part depend on local levels of ACE2, the enzyme that converts angiotensin II to angiotensin-(1-7). Indeed, central genetic deletion or NTS pharmacologic inhibition of ACE2 reduces baroreflex sensitivity in rodents [5]. In contrast, central overexpression of ACE2 lowers blood pressure and restores baroreflex function in hypertensive animals demonstrating an emerging role for brain ACE2 in central cardiovascular regulation [5]. The angiotensinogen: renin mismatch is an ongoing topic of controversy for synthesis of angiotensin peptides within brain [9]. Levels of angiotensin-(1-12) are reported similar or higher to angiotensin II in brain [6]. In tissues, angiotensin-(1-12) can form either angiotensin II or angiotensin-(1-7) depending on the local enzyme milieu [4]. However, central immunoneutralization of angiotensin-(1-12) lowers blood pressure and improves baroreflex sensitivity in hypertensive rats [12] and NTS
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
116
23. REnIn-AngIoTEnsIn
microinjection of angiotensin-(1-12) impairs baroreflex sensitivity in normotensive animals [13]. The baroreflex actions of angiotensin-(1-12) within the NTS are blocked by either an AT1 receptor antagonist or ACE inhibitor suggesting that angiotensin-(1-12) serves as a precursor to angiotensin II in brain pathways regulating blood pressure and autonomic function. Since angiotensin-(1-12) metabolism is independent of renin [4], this peptide may provide an alternate pathway for central angiotensin peptide formation.
SUMMARY Due to its key role in blood pressure regulation, the RAS has been an intense subject of research and an important therapeutic target for cardiovascular disease. Independent of blood pressure lowering effects, blockade of angiotensin II activity with ACE inhibitors or AT1 receptor antagonists reduces sympathetic activity and restores baroreflex function, in part mediated by increased levels of angiotensin-(1-7). These observations illustrate the importance of interactions between the RAS and autonomic nervous system in central regulation of blood pressure. A wider influence of the RAS on other facets of autonomic function, including energy metabolism, body weight regulation and glucose homeostasis at peripheral and central nervous system sites is emerging. The discovery of new RAS components, including ACE2, angiotensin-(1-7) and angiotensin-(1-12), will improve our understanding of these interactions that contribute broadly to autonomic regulation and may open new avenues for pharmacologic targeting of this system.
Acknowledgement
References [1] Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008;264:224–36. [2] Bader M. Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 2010;50:439–65. [3] Trask AJ, Ferrario CM. Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev 2007;25:162–74. [4] Varagic J, Trask AJ, Jessup JA, Chappell MC, Ferrario CM. New angiotensins. J Mol Med 2008;86:663–71. [5] Xia H, Lazartigues E. Angiotensin-converting enzyme 2: central regulator for cardiovascular function. Curr Hypertens Rep 2010;12:170–5. [6] Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun 2006;350:1026–31. [7] McKinley MJ, Albiston AL, Allen AM, Mathai ML, May CN, McAllen RM, et al. The brain renin-angiotensin system: location and physiological roles. Int J Biochem Cell Biol 2003;35:901–18. [8] Averill DB, Diz DI. Angiotensin peptides and baroreflex control of sympathetic outflow: pathways and mechanisms of the medulla oblongata. Brain Res Bull 2000;51:119–28. [9] Grobe JL, Xu D, Sigmund CD. An intracellular renin-angiotensin system in neurons: fact, hypothesis, or fantasy. Physiology (Bethesda) 2008;23:187–93. [10] Phillips MI. Functions of angiotensin in the central nervous system. Annu Rev Physiol 1987;49:413–35. [11] Sakima A, Averill DB, Kasper SO, Jackson L, Ganten D, Ferrario CM, et al. Baroreceptor reflex regulation in anesthetized transgenic rats with low glia-derived angiotensinogen. Am J Physiol Heart Circ Physiol 2007;292:H1412–H1419. [12] Isa K, Garcia-Espinosa MA, Arnold AC, Pirro NT, Tommasi EN, Ganten D, et al. Chronic immunoneutralization of brain angiotensin-(1-12) lowers blood pressure in transgenic (mRen2)27 hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2009;297:R111–5. [13] Arnold AC, Isa K, Shaltout HA, Nautiyal M, Ferrario CM, Chappell MC, Diz DI. Angiotensin-(1-12) requires angiotensin converting enzyme and AT1 receptors for cardiovascular actions within the solitary tract nucleus. Am J Physiol Heart Circ Physiol 2010;299:H763–71.
Funding: NIH HL-51952.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
24 Aldosterone and the Mineralocorticoid Receptor J. Howard Pratt Aldosterone, the only true mineralocorticoid, is secreted by the zona glomerulosa, a thin layer of cells at the periphery of the adrenal cortex. Aldosterone’s principal functions are to contain extracellular potassium (K) concentration within narrow limits and to maintain adequate extracellular volume by guarding against sodium (Na) loss. The two stimuli that regulate its secretion are therefore K (only small increments are required to significantly augment the levels of aldosterone) and angiotensin II (which increases in response to the need for volume expansion and retention of additional Na). Although not as well-established, there is compelling evidence that the adrenergic nervous system influences aldosterone secretion. Rays of adrenal medullary cells extending out to the zona glomerulosa have been described in the rat adrenal, and catecholamines have been shown to stimulate aldosterone secretion in vitro. More recently, variants in the β-adrenergic receptor were found to associate with low renin hypertension. Taken together, the findings suggest the possibility of a significant contribution by the adrenergic nervous system to hypertensive states resulting from overproduction of aldosterone [1].
K channel. The amount of K secreted is a principal determinant of extracellular K concentration. Thus, by increasing the number of ENaCs residing on the apical surface, aldosterone achieves a needed level of Na reabsorption, together with maintenance of K homeostasis.
Effects of Aldosterone That Target Distal Nephron
Excess Aldosterone and the Development of Hypertension
The functions of aldosterone begin with its occupancy of the nuclear receptor known as the mineralocorticoid receptor (MR). The ligand coupled to its receptor becomes a functioning transcription factor, and thus there is genomic delay in the onset of its actions. MR is expressed in a variety of tissues including the heart and brain, but the major site for its expression is the kidney’s distal nephron. Here, the principal target is the epithelial Na channel or ENaC located in cortical collecting duct [2]. Aldosterone induces translation for the protein serum glucocorticoid kinase type I (Sgk-1) [3]. The ultimate effect is to render an ubiquitin ligase (Nedd4-2) incapable of removing ENaC from the apical surface of the cell [4]. The Na that reaches the cell interior via ENaC exits the cell at the basolateral surface via the Na,K-ATPase; the exchange of Na for K leads to secretion of K into the tubular lumen via a
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00024-X
Specificity of MR for Aldosterone; Role of 11-β-Hydroxysteroid Dehydrogenase Type II (11BHSD2) Cortisol is also a ligand for MR and its circulating levels are much higher than those of aldosterone. However, under normal circumstances cortisol is converted to cortisone by 11BHSD2, an enzyme expressed in the vicinity of MR. Cortisone is biologically inactive; it has no binding affinity to MR. A deficiency in 11BHSD2 can result from a rare genetic disorder (apparent mineralocorticoid excess), from eating licorice (glycyrrhizynic acid in licorice inhibits 11BHSD2) or from Cushing’s syndrome (typically due to ectopic ACTH secretion where extremely high cortisol levels overwhelm the enzyme). In each case, there can be hypertension and typically hypokalemia.
Autonomous hypersecretion of aldosterone (primary aldosteronism) not uncommonly results in severe hypertension due to excessive reabsorption of Na in the distal nephron. The ensuing volume expansion suppresses the renin-angiotensin axis. The diagnosis is established when the plasma level of aldosterone is increased while the level of plasma renin activity (PRA) is low. An additional diagnostic approach is to utilize the ratio of plasma aldosterone to PRA (aldosterone/renin ratio). (Fig. 24.1) There are two types of primary aldosteronism (Fig. 24.2): that which is caused by a solitary adrenal adenoma (frequently 1 cm in diameter), also known as Conn’s syndrome [5]; and, the most common form, bilateral adrenal hyperplasia. The prevalence of primary aldosteronism is now estimated to be 10% of patients with hypertension
117
© 2012 Elsevier Inc. All rights reserved.
118
24. AldosTERonE And THE MInERAloCoRTICoId RECEPToR
Two types of primary aldosteronism
Solitary adenoma MR ENaC (α - β - γ subunits)
Right
Left
Bilateral adrenal hyperplasia
FIGURE 24.2 The great majority of cases of primary aldosteronApical
Basolateral
FIGURE 24.1 Schematic depiction of mechanism for how aldosterone increases Na uptake by ENaC in principal cells of collecting duct. ENaC residing on the apical surface consists of three subunits (alpha, beta, gamma). ENaC is removed from the cell surface by the ubiquitin ligase Nedd4-2. Aldosterone binds to MR in the cell’s interior resulting in a transcription factor that increases expression of Sgk-1. The latter phosphorylates Nedd4-2, and by so doing, inactivates it to where it can no longer displace ENaC from the apical surface. The result is a prolonged residency time with greater Na reabsorption.
[6]. The prevalence increases with age and is exceptionally high in patients with resistant hypertension [7] (patients with uncontrolled hypertension on three or more antihypertensive drugs). Although it was initially thought that hypokalemia was a requisite feature, it is now well accepted that most patients with primary aldosteronism have a normal serum K concentration. Treatment approaches depend on whether the source of excess aldosterone is from a unilateral adrenal adenoma or arises from hyperplasia of both adrenals. Once it is confirmed, often by performing an adrenal venous catheterization, that a single adenoma is causative, it can be removed using laparoscopic surgery. Medical management for bilateral disease is employed most often. There are currently two MR blockers, spironolactone and eplerenone. In addition, direct inhibitors of ENaC can be used such as amiloride. A description of medical treatment options is listed in Table 24.1.
Low-Renin Hypertension but not Primary Aldosteronism Many patients with hypertension who may require multiple antihypertensive drugs and patients who are typically older have suppressed levels of PRA. Their aldosterone levels are in the normal range and thus do not have primary aldosteronism based on established criteria. These patients more often than not respond extremely
ism are caused either by an adrenal adenoma or by bilateral adrenal hyperplasia. The former is less common and is removed with surgery, usually laparoscopically. In the instance where there is bilateral disease, medical management that mitigates the actions of aldosterone is preferred.
TABLE 24.1 Medical Treatment options for Treating AldosteroneInduced Hypertension (Primary Aldosteronism and low-Renin, normal Aldosterone, Hypertension) Drug
Mechanism
Advantages
Disadvantages
Spironolactone
Competive antagonist of MR.
1. Extremely effective in lowering blood pressure. 2. Reduced mortality rate by 30% in RALES clinical trial with CHF patients [9]. 3. Cost is trivial; only pennies a day.
Spironolactone also binds to the androgen receptor which can result in dose-dependent side effects.
Eplerenone
Competive antagonist of MR.
1. Selective for MR (no binding to androgen receptor. 2. Also shown to improve outcomes in CHF [10–11].
Although generic version available, cost is considerably more than cost of spironolactone.
Amiloride
Direct inhibitor of ENaC.
1.Effective in lowering blood pressure. 2. Few side effects. 3. Inexpensive.
A theoretical disadvantage is that it does not block aldosterone’s effects at the tissue level (e.g. the heart).
MR, mineralocorticoid receptor; ENaC, epithelial Na channel; RALES, Randomized Aldactone Evaluation Study.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
AldosTERonE And THE MInERAloCoRTICoId RECEPToR
well to MR blockade. Indeed, recognition of this large body of hypertensive patients who respond to this targeting of antihypertensive therapy has been one of the recent breakthroughs in the area of hypertension.
Aldosterone as a Mediator of Tissue Injury Angiotensin II infused into an experimental animal produces injury to multiple organ systems. It is now known that the injury can be prevented by concurrent treatment with an MR antagonist such as spironolactone indicating that aldosterone and not angiotensin II conveys much of the tissue damage [8]. Thus, aldosterone has more than a single undesirable feature: too much causes not only hypertension but damage to a variety of tissues including kidney, heart, and vasculature. Some of the largest and most noteworthy clinical trials of the effectiveness of MR blockade have been in patients with congestive heart failure (Table 24.1). In summary, aldosterone plays a pivotal role in maintaining K homeostasis and extracellular volume. Its Na reabsorptive actions bolstered by today’s typically rich in Na diet is thought to participate in the pathogenesis of hypertension and in some instances to confer risk of injury to vital tissues such as heart and kidney. Treatment regimens that include MR antagonist are becoming increasingly utilized.
119
[2] Canessa CM, Horisberger JD, Rossier BC. Epithelial sodium channel related to proteins involved in neurodegeneration. Nature 1993;361:467–70. [3] Pearce D, Verrey F, Chen SY, Mastroberardino L, Meijer OC, Wang J, et al. Role of SGK in mineralocorticoid-regulated sodium transport. Kidney Int 2000;57:1283–9. [4] Debonneville C, Flores SY, Kamynina E, Plant PJ, Tauxe C, Thomas MA, et al. Phosphorylation of Nedd4-2 by Sgk1 regulates epithelial Na() channel cell surface expression. EMBO J 2001;20:7052–9. [5] Conn JW. Primary aldosteronism, a new clinical sydrome. J Lab Clin Med 1955;45:6–17. [6] Young Jr WF. Minireview: Primary aldosteronism–changing concepts in diagnosis and treatment. Endocrinology 2003;144:2208–13. [7] Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403–19. [8] Rocha R, Chander PN, Khanna K, Zuckerman A, Stier Jr CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451–8. [9] Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators. N Engl J Med 1999;341:709–17. [10] Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–21. [11] Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21.
References [1] Pratt JH. The adrenergic nervous system conversing with the adrenal cortex: New implications for salt-sensitive hypertension. Hypertension 2006;48:820–1.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
25 Vasopressin and Disorders of Water Homeostasis Joseph G. Verbalis VASOPRESSIN SECRETION The primary physiologic action of arginine vasopressin (AVP) is its function as a water-retaining hormone. The central sensing system (osmostat) for control of release of AVP is located in the hypothalamus anterior to the third ventricle that also includes the circumventricular organ, the organum vasculosum of the lamina terminalis (OVLT). The osmostat controls release of AVP to cause water retention, and also stimulates thirst to cause water repletion. Osmotic regulation of AVP release and thirst are usually tightly coupled, but experimental lesions and some pathologic situations in humans demonstrate that each can be regulated independently. The primary extracellular osmolyte to which the osmoreceptor responds is sodium. Under normal physiologic conditions, glucose and urea readily traverse neuron cell membranes and do not stimulate release of AVP. Basal osmolality in normal subjects lies between 280 and 295 mOsm/kg H2O, but for each individual osmolality is maintained within narrow ranges. Increases in plasma osmolality as little as 1% will stimulate the osmoreceptors to release AVP. Basal plasma levels of AVP are 0.5 to 2 pg/mL, which are sufficient to maintain urine osmolality above plasma osmolality and urine volume in the range of 2–3 L/day. When AVP levels are suppressed below 0.5 pg/ml, urine osmolality decreases to less than 100 mOsm/kg H2O and a free water diuresis ensues to levels approaching 800–1000 ml/h (18–24 L/d). Increases in plasma osmolality cause a linear increase in plasma AVP and a corresponding linear increase in urine osmolality. At a plasma osmolality of approximately 295 mOsm/kg H2O, urine osmolality is maximally concentrated to 1000–1200 mOsm/kg H2O. Thus, the entire physiologic range of urine concentration is accomplished by relatively small changes in plasma AVP of 0 to 5 pg/ml. AVP secretion is also stimulated by low blood volume and pressure. High-pressure baroreceptors are located in the aorta and carotid sinus, and low-pressure baroreceptors are located in the right and left atria. Stimuli for pressure and volume receptors are carried via the glossopharyngeal (ninth) and vagal (tenth) cranial nerves to the nucleus tractus solitarius in the brainstem. Subsequent
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00025-1
secondary and tertiary projections converge on the magnocellular neurons, where they provide inhibitory as well as excitatory inputs. Decreases in blood pressure or vascular volume stimulate AVP release, whereas situations that increase blood volume or left atrial pressure (e.g., negative-pressure breathing) decrease secretion of AVP. The release of AVP in response to changes in volume or pressure is less sensitive than the release in response to osmoreceptors, and generally a 10–15% reduction in blood volume or pressure is needed to stimulate release of AVP. However, once arterial pressure falls below this threshold, the stimulated response is exponential, and plasma levels of AVP achieved that are markedly greater than those achieved by osmotic stimulation. Other nonosmotic stimuli, such as nausea and intestinal traction, also act through similar nonosmotic neural pathways to release AVP.
VASOPRESSIN ACTIONS Three known receptor subtypes mediate the actions of AVP. They all are classical G protein-coupled receptors with seven transmembrane domains, and are classified according to the second messenger system to which they are coupled. The AVP V1a (V1aR) and V1b (V1bR) receptors are linked to the phosphoinositol signaling pathway via Gaq/11 GTP binding proteins that activate phospholipase C activity, with intracellular calcium acting as the second messenger. V1aR are present on vascular smooth muscle cells, hepatocytes, and platelets, and mediate the well-known pressor effects of AVP on peripheral resistance and blood pressure. V1bR are found predominately on corticotrophs cells of the anterior pituitary, where they mediate corticotrophin (ACTH) release in concert with the well-known effects of corticotrophin releasing hormone (CRH). V2R, or antidiuretic receptors, are mainly localized in the collecting duct cells of the kidney where they regulate water excretion. V2R are G protein-coupled receptors that activate adenylyl cyclase with subsequent increased intracellular cyclic AMP levels upon ligand activation. The increased cAMP initiates the movement of
121
© 2012 Elsevier Inc. All rights reserved.
122
25. VAsoPREssIn AnD DIsoRDERs of WATER HomEosTAsIs
aquaporin-2 (AQP2) water channels from the cytoplasm to the apical (luminal) membrane of the collecting duct cells. Once inserted into the apical membrane, these channels allow facilitated rapid transport of water from the collecting duct lumen into the cell along osmotic gradients. The water then exits the cell through the basolateral membrane and into the kidney medullary circulation via aquaporin-3 and aquaporin-4 water channels, which are constitutively present in the basolateral membrane. This entire process is termed antidiuresis. In the absence of AVP, the AQP2 channels are re-internalized from the apical membrane into subapical vesicles. This prevents active reabsorption of water from the collecting duct lumen, resulting in diuresis. In addition to this rapid “shuttling” of the AQP2 water channels to regulate water reabsorption on a minute-to-minute basis, AVP also acts via V2R to regulate long-term stores of AQP2; i.e., increased AVP stimulates AQP2 synthesis and the absence of AVP results in decreased AQP2 synthesis. The hypertonic medullary interstitium determines the maximum concentration of the final urine, which is isotonic with the inner medulla of the kidney under conditions of maximal antidiuresis.
TABLE 25.1 Pathogenesis of Hypoosmolar Disorders DEPLETION (PRIMARY DECREASES IN TOTAL BODY SOLUTE SECONDARY WATER RETENTION)a Renal solute loss Diuretic use Solute diuresis (glucose, mannitol) Salt wasting nephropathy Mineralocorticoid deficiency Non-renal solute loss Gastrointestinal (diarrhea, vomiting, pancreatitis, bowel obstruction) Cutaneous (sweating, burns) Blood loss DILUTION (PRIMARY INCREASES IN TOTAL BODY WATER SECONDARY SOLUTE DEPLETION)b Impaired renal free water excretion Increased proximal reabsorption Hypothyroidism Impaired distal dilution
DISORDERS OF BODY WATER HOMEOSTASIS Disorders of body fluids are among the most commonly encountered problems in clinical medicine. This is because many different disease states can potentially disrupt the finely balanced mechanisms that control the intake and output of water and solutes. Although solute and water homeostasis are closely linked, clinical disorders of body fluids are generally divided into disorders of water homeostasis and disorders of solute homeostasis. Since body water is the primary determinant of the osmolality of the extracellular fluid (ECF), disorders of water homeostasis can be broadly divided into hypoosmolar disorders, in which there is an excess of body water relative to body solute, and hyperosmolar disorders, in which there is a deficiency of body water relative to body solute. Because sodium is the main constituent of plasma osmolality, these disorders are typically characterized by hyponatremia and hypernatremia, respectively.
HYPOOSMOLALITY Hypoosmolality indicates excess water relative to solute in the ECF; because water moves freely between the ECF and the intracellular fluid (ICF), this also indicates an excess of total body water relative to total body solute. Imbalances between body water and solute can be generated either by depletion of body solute more than body water, or by dilution of body solute from increases in body water more than body solute (Table 25.1). This is an oversimplification of complex physiology, and most
Syndrome of Inappropriate antidiuretic hormone secretion (SIADH) Glucocorticoid deficiency Combined increased proximal reabsorption and impaired distal dilution Congestive heart failure Cirrhosis Nephrotic syndrome Decreased urinary solute excretion Beer potomania Excess water intake Primary polydipsia Dilute infant formula a Virtually all disorders of solute depletion are accompanied by some degree of secondary retention of water by the kidneys in response to the resulting intravascular hypovolemia; this mechanism can lead to hypoosmolality even when the solute depletion occurs via hypotonic or isotonic body fluid losses. b Disorders of water retention primarily cause hypoosmolality in the absence of any solute losses, but in some cases of SIADH secondary solute losses occur in response to the resulting intravascular hypervolemia and this can then further aggravate the hypoosmolality (however, this pathophysiology does not likely contribute to the hyponatremia of edema-forming states such as congestive heart failure and cirrhosis, since in these cases multiple factors favoring sodium retention will result in an increased total body sodium).
hypoosmolar states include components of both solute depletion and water retention. Nonetheless, this general concept has proven to be useful because it provides a simple framework for understanding the basic etiologies of hypoosmolar disorders. Definitive identification of the etiology of hypoosmolality is not always possible at the time of presentation, but categorization according to the patient's
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
HyPoosmolAlITy
ECF volume status represents the first step in ascertaining the underlying cause of the disorder.
Decreased ECF Volume (Hypovolemia) Clinically detectable hypovolemia indicates some degree of solute depletion. Even isotonic or hypotonic fluid losses can cause hypoosmolality if water or hypotonic fluids are subsequently ingested or infused. A low urine sodium concentration (UNa) suggests a non-renal cause of solute depletion, whereas a high UNa suggests renal causes of solute depletion. Diuretic use is the most common cause of hypovolemic hypoosmolality. Most etiologies of solute losses causing hypovolemic hypoosmolality will be clinically apparent, although some salt-wasting nephropathies and mineralocorticoid deficiency may be difficult to diagnose during early phases of these diseases.
123
TABLE 25.2 Criteria for the Diagnosis of sIADH ESSENTIAL 1. Decreased effective osmolality of the extracellular fluid (Posm 275 mOsm/kg H2O). 2. Inappropriate urinary concentration (Uosm 100 mOsm/kg H2O with normal renal function) at some level of hypoosmolality. 3. Clinical euvolemia, as defined by the absence of signs of hypovolemia (orthostasis, tachycardia, decreased skin turgor, dry mucous membranes) or hypervolemia (subcutaneous edema, ascites). 4. Elevated urinary sodium excretion while on a normal salt and water intake. 5. Normal thyroid, adrenal and renal function. SUPPLEMENTAL 6. Abnormal water load test (inability to excrete at least 80% of a 20 ml/ kg water load in 4 hours and/or failure to dilute Uosm to 100 mOsm/ kg H2O). 7. Plasma AVP level inappropriately elevated relative to plasma osmolality. 8. No significant correction of serum [Na] with volume expansion but improvement after fluid restriction.
Normal ECF Volume (Euvolemia) Virtually any disorder causing hypoosmolality can present with a volume status that appears normal by standard methods of clinical evaluation. Because clinical assessment of volume status is not very sensitive, the presence of normal or low blood urea nitrogen and uric acid concentrations are helpful laboratory correlates of relatively normal ECF volume. In these cases, a low UNa (30 mmol/L) suggests depletional hypoosmolality secondary to ECF losses with subsequent volume replacement by water or other hypotonic fluids. Such patients may appear euvolemic by the usual clinical parameters used to assess hydration status. A high UNa (30 mmol/L) generally indicates a dilutional hypoosmolality such as SIADH, the most common cause of euvolemic hypoosmolality. The clinical criteria necessary to diagnose SIADH remain as initially defined by Bartter and Schwartz in 1967 (Table 25.2). Many different disorders are associated with SIADH, which can be divided into four major etiologic groups: tumors, CNS disorders, drug effects, and pulmonary diseases.
Increased ECF Volume (Hypervolemia) Clinically detectable hypervolemia indicates whole body sodium excess, and hypoosmolality in these patients suggests a relatively decreased intravascular volume and/or pressure leading to water retention as a result of elevated plasma AVP levels and decreased distal delivery of glomerular filtrate to the kidneys. Such patients usually have a low UNa because of secondary hyperaldosteronism, but under certain conditions the UNa may be elevated (e.g., diuretic therapy). Hyponatremia generally does not occur until relatively advanced stages of congestive heart failure, cirrhosis, or the nephrotic syndrome, by which time diagnosis is usually not difficult. Renal failure can also cause retention of both sodium and water.
The clinical manifestations of hyponatremia are largely neurological, and primarily reflect brain edema resulting from osmotic water shifts into the brain. These range from nonspecific symptoms such as headache and confusion, to more severe manifestations such as decreased sensorium, coma, seizures, and death. Significant central nervous system (CNS) symptoms generally do not occur until the serum sodium concentration ([Na]) falls below 125 mmol/L, and the severity of symptoms can be roughly correlated with the degree of hypoosmolality. Individual variability is marked, and for any patient the level of serum [Na] at which symptoms will appear cannot be accurately predicted. Several factors other than the severity of the hypoosmolality also affect the degree of neurological dysfunction. The most important is the time course over which hypoosmolality develops. Rapid development of severe hypoosmolality frequently causes marked neurological symptoms, whereas gradual development over several days or weeks is often associated with relatively mild symptomatology despite profound degrees of hypoosmolality. This is because the brain counteracts osmotic swelling by extruding extracellular and intracellular solutes, including potassium and a variety of small organic molecules (amino acids, polyols and methylamines) called organic osmolytes. Since this is a time-dependent process, rapid development of hypoosmolality can result in brain edema before this adaptation occurs, but with slower development of the same degree of hypoosmolality brain cells can lose solute sufficiently rapidly to prevent cell swelling, brain edema, and neurological dysfunction. Underlying neurological disease also affects the level of hypoosmolality at which CNS symptoms appear; moderate hypoosmolality is of little concern in an otherwise healthy patient, but can cause morbidity
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
124
25. VAsoPREssIn AnD DIsoRDERs of WATER HomEosTAsIs
in a patient with an underlying seizure disorder. Nonneurological metabolic disorders (hypoxia, hypercapnia, acidosis, hypercalcemia, etc.) similarly can affect the level of osmolality at which CNS symptoms occur.
HYPEROSMOLALITY Hyperosmolality indicates a deficiency of water relative to solute in the ECF. Because water moves freely between the ICF and ECF, this also indicates a deficiency of total body water relative to total body solute. Although hypernatremia can be caused by an excess of body sodium, the vast majority of cases are due to losses of body water in excess of body solutes, caused by either insufficient water intake or excessive water excretion. Consequently, most of the disorders causing hyperosmolality are those associated with inadequate water intake and/or deficient pituitary AVP secretion (Table 25.3). Although hyperosmolality from inadequate water intake is seen frequently in clinical practice, this is usually not due to an underlying defect in thirst but rather results from a generalized incapacity to obtain and/or ingest fluids, often stemming from a depressed sensorium. Evaluation of the patient’s ECF volume status is important as a guide to fluid replacement therapy, but is not as useful for differential diagnosis since most hyperosmolar patients will manifest some degree of hypovolemia. Rather, assessment of urinary concentrating ability provides the most useful data with regard to the type of disorder present. Using this approach, disorders of hyperosmolality can be categorized as those in which renal water conservation mechanisms are intact but are unable to compensate for inadequately replaced losses of hypotonic fluids from other sources, or those in which renal concentrating defects are a contributing factor to the deficiency of body water.
Diabetes Insipidus Diabetes insipidus (DI) can result from either inadequate AVP secretion (central or neurogenic DI) or inadequate renal response to AVP (nephrogenic DI). Central DI is caused by a variety of acquired or congenital anatomic lesions that disrupt the neurohypophysis, including pituitary surgery, tumors, trauma, hemorrhage, thrombosis, infarction, or granulomatous disease. Severe nephrogenic DI is most commonly congenital due to defects in the gene for the AVP V2R (X-linked recessive pattern of inheritance) or in the gene for the AQP2 water channel (autosomal recessive pattern of inheritance), but relief of chronic urinary obstruction or therapy with drugs such as lithium can cause an acquired form sufficient to warrant treatment. Short-lived nephrogenic DI can result from hypokalemia or hypercalcemia, but the mild concentrating defect generally does not by itself cause hypertonicity and responds to correction of the underlying disorder. Regardless of the
TABLE 25.3 Pathogenesis of Hyperosmolar Disorders WATER DEPLETION (DECREASES IN TOTAL BODY WATER IN EXCESS OF BODY SOLUTE) 1. Insufficient water intake Unavailability of water Hypodipsia (osmoreceptor dysfunction, age) Neurological deficits (cognitive dysfunction, motor impairments) 2. Hypotonic fluid loss* A. Renal: diabetes insipidus Insufficient AVP secretion (central DI, osmoreceptor dysfunction) Insufficient AVP effect (nephrogenic DI) B. Renal: other fluid loss Osmotic diuresis (hyperglycemia, mannitol) Diuretic drugs (furosemide, ethacrynic acid, thiazides) Post-obstructive diuresis Diuretic phase of acute tubular necrosis C. Non-renal fluid loss Gastrointestinal (vomiting, diarrhea, nasogastric suction) Cutaneous (sweating, burns) Pulmonary (hyperventilation) Peritoneal dialysis SOLUTE EXCESS (INCREASES IN TOTAL BODY SOLUTE IN EXCESS OF BODY WATER) 1. Sodium Excess Na administration (NaCl, NaHCO3) Sea water drowning 2. Other Hyperalimentation (intravenous, parenteral) *Most hypotonic fluid losses will not produce hyperosmolality unless insufficient free water is ingested or infused to replace the ongoing losses, so these disorders also usually involve some component of insufficient water intake.
etiology of the DI, the end result is a water diuresis due to an inability to concentrate urine appropriately. Because patients with DI do not have impaired urine Na conservation, the ECF volume is generally not markedly decreased and regulatory mechanisms for maintenance of osmotic homeostasis are primarily activated: stimulation of thirst and pituitary AVP secretion (to whatever degree the neurohypophysis is still able to secrete AVP). In cases where AVP secretion is totally absent (complete DI), patients are dependent entirely on water intake for maintenance of water balance. However, in cases where some residual capacity to secrete AVP remains (partial DI), plasma osmolality can eventually reach levels that allow moderate degrees of urinary concentration. Although untreated DI can lead to both hyperosmolality and volume depletion, until the water losses become severe, volume depletion is minimized by osmotic shifts of water from the ICF into the more osmotically concentrated ECF.
Osmoreceptor Dysfunction The primary osmoreceptors that control AVP secretion and thirst are located in the anterior hypothalamus, and lesions of this region in animals cause hyperosmolality through a combination of impaired thirst and osmotically
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
DIsoRDERs of WATER HomEosTAsIs AnD THE AuTonomIC nERVous sysTEm
stimulated AVP secretion. Initial reports in humans described this syndrome as “essential hypernatremia,” and subsequent studies used the term “adipsic hypernatremia” in recognition of the profound thirst deficits found in most of the patients. All of these syndromes are now grouped together as disorders of osmoreceptor function. Most of the cases reported to date have represented various degrees of osmoreceptor destruction associated with different brain lesions. In contrast to lesions causing central DI, these lesions usually occur more rostrally in the hypothalamus. For all cases of osmoreceptor dysfunction it is important to remember that afferent pathways from the brainstem to the hypothalamus generally remain intact; therefore, these patients will usually have normal AVP and renal concentrating responses to baroreceptor-mediated stimuli such as hypovolemia and hypotension. The clinical manifestations of hyperosmolality can be divided into the signs and symptoms produced by dehydration, which are largely cardiovascular, those caused by the hyperosmolality itself, which are predominantly neurological and reflect brain dehydration as a result of osmotic water shifts out of the central nervous system, and those which are secondary to excessive renal water losses in patients with DI. Cardiovascular manifestations of hypertonic dehydration include hypotension, kidney failure secondary to decreased renal perfusion, acute tubular necrosis or rhabdomyolysis, and in severe cases hypotensive shock. Neurological manifestations range from nonspecific symptoms such as irritability and decreased sensorium to more severe manifestations such as chorea, seizures, coma, focal neurological deficits, and cerebral infarction. The severity of symptoms can be roughly correlated with the degree of hyperosmolality, but individual variability is marked and for any single patient the level of serum [Na] at which symptoms will appear cannot be predicted. Similar to hypoosmolar syndromes, the length of time over which hyperosmolality develops can markedly affect clinical symptomatology. Rapid development of severe hyperosmolality is frequently associated with marked neurological symptoms, whereas gradual development over several days or weeks generally causes milder symptoms. In this case the brain counteracts osmotic shrinkage by increasing intracellular content of solutes. These include electrolytes such as potassium and organic osmolytes which previously had been called “idiogenic osmoles” (for the most part these are the same organic osmolytes that are lost from the brain during adaptation to hypoosmolality discussed previously). The net effect of this process is to protect the brain against excessive shrinkage during sustained hypertonicity. However, once the brain has adapted by increasing its solute content, rapid correction of the hyperosmolality can cause brain edema since it takes a finite time (24–48 h in animal studies) to dissipate the accumulated solutes, and until this process has been completed the brain will accumulate excess water as the plasma osmolality is normalized. This effect is most often seen in dehydrated pediatric
125
patients, who can develop seizures as a result of rapid rehydration.
DISORDERS OF WATER HOMEOSTASIS AND THE AUTONOMIC NERVOUS SYSTEM The major relation between the autonomic nervous system and disorders of water retention such as hyponatremia results from effects on AVP secretion. Osmotic regulation of AVP secretion is not known to be influenced significantly by autonomic inputs to osmoreceptive cells. However, a wide variety of non-osmotic stimuli also stimulate AVP secretion, many of which originate in peripheral baroreceptors or chemoreceptors, and travel to the brainstem via vagal and glossopharyngeal afferent nerves. Prominent among these are hypovolemia, hypotension and nausea. Secretion of AVP from the neurohypophysis represents a balance between excitatory and inhibitory stimuli. In the presence of strong non-osmotic stimuli, osmotic inhibition of AVP secretion is dampened, or prevented, resulting in inappropriate AVP secretion that can lead to water retention with resulting hypoosmolality and hyponatremia. Thus, many cases of SIADH are due to afferent signaling through the autonomic nervous system. Neither hyponatremia nor hypernatremia are known to cause direct effects on autonomic efferent outputs.
Further Reading Anderson RJ, Chung H-M, Kluge R, et al. Hyponatremia: A prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985;102:164–8. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 1967;42:790–806. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007;356:2064–72. Ghirardello S, Malattia C, Scagnelli P, Maghnie M. Current perspective on the pathogenesis of central diabetes insipidus. J Pediatr Endocrinol Metab 2005;18:631–45. Knepper MA. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am J Physiol 1997;272:F3–F12. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis and pregnancy. New Engl J Med 1988;319:1065–72 and 1127–1134. Verbalis JG. The syndrome of inappropriate antidiuretic hormone secretion and other hypoosmolar disorders. In: Schrier RW, editor. Diseases of the Kidney. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 2511–48. Verbalis JG. Brain volume regulation in response to changes in osmolality. Neuroscience 2010;168:862–70. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: Expert panel recommendations. Am J Med 2007;120:S1–S21. Zerbe R, Stropes L, Robertson G. Vasopressin function in the syndrome of inappropriate antidiuresis. Annu Rev Med 1980;31:315–27.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
26 Calcitonin Gene-Related Peptide and Adrenomedullin Donald J. DiPette, Scott C. Supowit INTRODUCTION Calcitonin gene-related peptide (CGRP) and adrenomedullin (AM) belong to a superfamily of closely related genes that also includes calcitonin and amylin. The potent vasodilator activity of CGRP (a sensory neuropeptide) and AM (acting as a circulating endocrine/paracrine factor) and their widespread distribution in peripheral tissues indicate a critical role in protecting tissues from injury, in addition to regulating systemic hemodynamics and regional organ blood flows under normal physiological and pathophysiological conditions. Considerable evidence indicates that both of these peptides possess significant protective activity against hypertension-induced heart and kidney damage, heart failure, and ischemia/reperfusion injury. These protective functions of CGRP and AM are mediated not only by their potent vasodilator activity, but also through the inhibition of oxidative stress, inflammation, and necrosis/apoptosis. The effects of CGRP and AM on these three mechanisms will be the focus of this chapter.
SYNTHESIS AND LOCALIZATION OF CGRP AND AM There are two forms of the 37 amino acid CGRP, α and β, which differ in only two amino acids in rats and three in humans. α-CGRP is derived from the tissue specific splicing of the calcitonin/CGRP gene. Whereas calcitonin is produced mainly in the C cells of the thyroid, CGRP synthesis is limited almost exclusively to specific regions of the central and peripheral nervous systems. The β-CGRP gene does not produce calcitonin and is also synthesized primarily in neuronal tissues. α-CGRP is prevalent in the central nervous system and in the peripheral sensory neural network. β-CGRP is also prevalent in the central nervous system, but peripherally is common in intestinal neurons. However, the biological activities of both peptides are similar in most vascular beds. CGRP and its receptors are widely distributed in the nervous and cardiovascular systems. In the periphery, prominent sites of
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00026-3
CGRP synthesis are the dorsal root ganglion (DRG). These structures contain the cell bodies of sensory nerves that terminate peripherally on blood vessels and all other tissues innervated by sensory nerves and centrally in laminae I/II of the dorsal horn of the spinal cord. A dense perivascular CGRP neural network is seen around the blood vessels in all vascular beds. In these vessels CGRP containing nerves are found at the junction of the adventitia and the media passing into the muscle layer. It is thought that circulating CGRP is largely derived from these perivascular nerve terminals and represents a spillover phenomenon related to the release of these peptides to promote vasodilation or other tissue functions. Receptors for CGRP have been identified in the media and intima of resistance vessels as well as the endothelial layer. Adrenomedullin (AM) is a 52 amino acid peptide that was originally isolated from pheochromocytoma cells. Since that time it has been shown to be produced in a number of different cells and tissues that are relevant to the cardiovascular system including vascular smooth muscle (VSMCs) and endothelial cells. A number of cytokines, growth factors, and hormones have been reported to increase AM expression including TNF-α and -β, IL-1α and -β, dexamethasone, cortisol, retinoic acid, thyroid hormone, and shear stress.
RELEASE OF CGRP FROM SENSORY NERVE TERMINALS CGRP-rich nerve fibers are components of the primary afferent nervous system, comprising principally capsaicin-sensitive C- and Aδ-fiber nerves that respond to chemical, thermal, and mechanical stimuli. Although these nerves have traditionally been thought to “sense” stimuli in the periphery and transmit the information centrally, there was early evidence that they also have an efferent function. It is clear that DRG neuron-derived peptides are released at peripheral sensory nerve terminals in the absence of afferent nerve stimulation. The continuous release of peptides from DRG neurons may reflect a paracrine function implying that these neurons participate in
127
© 2012 Elsevier Inc. All rights reserved.
128
26. CAlCITonIn GEnE-RElATEd PEPTIdE And AdREnomEdullIn
the continuous regulation of blood flows and other tissue activities. Sensory nerve terminals can either increase or decrease the release of CGRP in response to factors including protons, nerve growth factor, vascular wall tension, bradykinin/prostaglandins, endothelin, the sympathetic nervous system and the renin-angiotensin-aldosterone system.
CGRP AND AM SIGNALING The CGRP receptor is unique in that CGRP and AM signal through the common receptor CLR (calcitonin-like receptor). Ligand specificity is determined by co-expression of either of two chaperone proteins, receptor activity modifying proteins: RAMP1 for CGRP and RAMP2 for AM. Another RAMP (RAMP3) has also been postulated to confer AM specificity to the CLR. It now appears that a functional CGRP (or AM) receptor must include 3 proteins in a complex: the ligand binding, membrane spanning peptide, CLR, the chaperone peptide, RAMP1 or RAMP2, as well as a third peptide, the receptor component protein, RCP, that couples the receptor to the cellular signal transduction pathway. The CGRP/AM receptor is coupled to G-proteins with the CGRP/AM receptor-mediated stimulation of cAMP, downstream of Gαs, being the primary and best understood signal transduction pathway for CGRP and AM. There are, however, reports that the CGRP/AM receptor can activate other G proteins thereby providing a mechanism for fine-tuning CGRP and/or AM signaling in different cell types and tissues. Other reports indicate that CGRP and AM are capable of activating K-ATP channels of vascular smooth muscle. There is additional evidence that the vasodilator and other responses evoked by CGRP and AM are mediated, in part, by NO release, which in turn stimulates cGMP production, and that various vascular beds differ in their dependence on the endothelium for the dilator response to CGRP. Therefore, the biological activities can be mediated via endothelium-dependent and -independent mechanisms.
ATTENUATION OF OXIDATIVE STRESS BY CGRP AND AM In disease states such as hypertension, heart failure, and ischemia/reperfusion injury, overproduction of reactive oxygen (ROS) species lowers antioxidant defenses and alters signaling pathways resulting in endothelial and vascular dysfunction. Oxidative stress leads to the activation of transcription factors such as NFκ-B resulting in the up-regulation of inflammatory response genes. Multiple studies of vascular inflammation have focused on a critical role for NADPH oxidase. Endothelial, VSCMs, and adventitial cells contain NADPH oxidase. The activation of this enzyme is dependent on multiple stimuli including Ang II, norepinephrine, high glucose, shear stress, and a
number of inflammatory cytokines. Increased NADPH oxidase activity, and subsequent ROS production, plays a central role in a number of cardiovascular disease states. Indirect evidence for an antioxidant role for CGRP is provided by evidence that AM binds and activates the same receptor as CGRP. The mechanisms underlying this activity vary depending on cell types and experimental conditions. In addition, we, and other investigators, have reported that AM can attenuate Ang II-evoked ROS generation in VSMCs and ECs primarily through the inhibition of NADPH oxidase. We have recently demonstrated, for the first time, virtually identical results with CGRP. It has also been demonstrated that AM can inhibit ROS production via thiol redox systems and that CGRP can inhibit mitochondrial generated ROS in cardiac myocytes.
ATTENUATION OF INFLAMMATION BY CGRP AND AM Sensory nerves have long been considered to be involved in the development of inflammation. However, more recent studies indicate that chemical ablation of sensory nerves and genetic deletion of the sensory neuropeptide α-CGRP or the TRPV receptor, a primary activator of sensory nerve fibers, results in a marked increase in the severity of inflammation in hypertension-induced end organ damage and ischemia/reperfusion injury in the heart, liver, and gut. Likewise, AM has been implicated in both the progression and remission of the inflammatory response with the weight of the evidence indicating a protective, anti-inflammatory role for AM in a number of cardiovascular disease states. The enhanced inflammatory response in the aforementioned pathological conditions exhibits increased levels of pro-inflammatory markers and cytokines as well as tissue accumulation of neutrophils. Attenuation of inflammatory responses in the liver and the gut by sensory nerve activation appears to be due, at least in part, to a CGRP-induced increase in the endothelial production of prostacyclin, a potent anti-inflammatory agent. In vitro evidence indicates that CGRP can markedly stimulate prostacyclin production and release in endothelial cells. CGRP can significantly increase intracellular Ca2 in several different cell types including epithelial cells. In one study it was reported that this increase in intracellular Ca2 was mediated by the activation of phospholipase C (PLC). It was demonstrated that CGRP activates adenylate cyclase and releases prostacyclin from human umbilical vein endothelial cells, however, a mechanism for prostacyclin release was not established. As described previously it is well established that CGRP and can significantly induce NO production in vascular endothelial cells. It has also been reported that in endothelial cells endogenous and exogenous NO is a potent activator of cyclooygenase 1 (COX 1), a key enzyme for prostacyclin synthesis. AM treatment of bovine aortic endothelial cells induced a marked increase in cAMP accumulation and intracellular
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
129
ConClusIon
Ca2 through independent pathways. The intracellular free Ca2 increase resulted from PLC activation and inositol 1,4,5-triphosphate formation. This increase in free Ca2+ resulted in an activation of endothelial NO synthase (eNOS). Similarly, studies involving the AM-evoked endothelium-dependent vasorelaxation in rat aorta indicated that AM induced the PI3K/Akt pathway that was implicated in the production of NO, which in turn induced endothelium-dependent vasodilation.
INHIBITION OF APOPTOSIS BY CGRP AND AM In cardiovascular disease states such as hypertensioninduced end organ damage, heart failure, and ischemia/ reperfusion injury, there are two types of cell death, necrosis and apoptosis. Activation of pro-survival kinase cascades has been hypothesized to attenuate cell death via anti-apoptosis mechanisms. The PI3K-Akt and Erk 1/2 kinase cascades activate the cardio-protective pathway. Several lines of evidence suggest that both CGRP and AM have significant anti-apoptotic activity in vivo and in vitro (isolated rat vascular smooth muscle cells and isolated rat cardiomyocytes) in the context of cardiovascular disease states and that this is correlated with the activation of PI3K-Akt and Erk 1/2 kinase pathways. The PI3K-AKT and ERK 1/2 kinase cascades are activated by a number of receptors including G-protein coupled receptors. These pathways participate in the regulation of proliferation, differentiation, and survival. The mechanism of the pro-survival activities of these pathways is mediated, in part, by the inhibition, via phosphorylation, of the pro-apoptotic proteins BAD, BAX, BIM, inactivation of capsases, and inhibition of Bcl-2. CGRP has also been implicated in the attenuation of ischemia/reperfusion-evoked cardiac mitochondrial dysfunction through inhibition of GSK 3β via its phosphorylation by the PI3k-Akt and ERK 1/2 kinase cascades. Both CGRP and AM also appear to be protective against necrosis in cardiovascular diseases, however, it is beyond the scope of this chapter to address this issue.
CONCLUSION The CGRP/AM system represents a unique homeostatic mechanism that is relevant to normal cardiovascular function and the pathophysiology of several cardiovascular disease states. There are two related vasodilator peptides where one is a sensory neuropeptide (CGRP) and the other acts as a circulating hormone (AM). Both proteins signal through the same receptor, which has a unique composition compared to other G-protein coupled receptors. While both CGRP and AM contribute to the progression of the inflammatory response and tissue damage in some contexts, in a number of cardiovascular pathological conditions CGRP and/or AM play a compensatory protective role via the attenuation of oxidative stress, inflammation, and necrosis/apoptosis.
Further Reading Bowers MC, Katki KA, Rao A, Koehler M, Spiekerman A, DiPette DJ, et al. Role of calcitonin gene-related peptide in hypertension-induced renal damage. Hypertension 2005;46:51–7. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 2004;84:903–34. Dickerson I. The CGRP-receptor component protein: a regulator for CLR signaling. In: Hay DL, Dickerson IM, editors. The calcitonin generelated peptide family: form, function, and future perspectives. New York, NY: Springer Business Media; 2010. p. 59–73. Huang R, Ma H, Karve A, DiPette DJ, Bowers MC, Supowit SC, et al. Deletion of the mouse α-calcitonin gene-related peptide gene increases the vulnerability of the heart to ischemia/reperfusion injury. Am J Physiol. Heart Circ Physiol 2008;294:1291–7. Okajima K, Harada N. Regulation of inflammatory responses by sensory neurons: Molecular mechanisms and possible therapeutic applications. Cur Med Chem 2006;13:2241–51. Prado MA, Evans-Bain B, Dickerson IM. Receptor component protein (RCP): a member of a multi-protein complex required for G-proteincoupled signal transduction. Biochem Soc Trans 2002;30:460–4. Supowit SC, Rao A, Bowers MC, Zhao H, Fink G, Patel P, et al. Calcitonin gene-related peptide protects against hypertension-induced heart and kidney damage. Hypertension 2005;45:109–14. Walker CS, Conner AC, Poyner DR, Hay DL. Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends in Pharm Sci 2010;31:476–83. Yanagawa B, Nagaya N. Adrenomedullin: molecular mechanisms and its role in cardiac disease. Amino Acids 2007;32:157–64.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
27 Leptin Signaling and Energy Homeostasis Kamal Rahmouni INTRODUCTION Historically, the importance of the central nervous system in the regulation of energy homeostasis derived from the clinical observation of excessive subcutaneous fat in patients with pituitary tumors. The role of the hypothalamus in body energy storage was later established using discrete lesions or surgical transection of neural pathways [1]. For years, it was postulated that to control body fat stores, the brain must receive afferent input in proportion to the current level of body fat. The identification in 1994 of leptin [2], the ob gene product, provided powerful support for the concept of a feedback loop between the periphery and the brain for energy homeostasis (Fig. 27.1). Leptin, a 167-amino acid protein secreted by adipocytes, circulates in proportion to the adipose tissue mass. This hormone relays a satiety signal to the hypothalamus after entering the brain by a saturable specific transport mechanism. Leptin gene expression and secretion are increased by overfeeding, high fat diet, insulin and glucocorticoids and decreased by fasting and sympathetic nerve activation. The severe obesity and the hyperphagia caused by the absence of leptin or its receptor in rodents and humans make it clear that this hormone is fundamental for the control of body weight and food intake. Leptin promotes weight loss by reducing appetite and by increasing energy expenditure through stimulation of sympathetic nerve activity (Fig. 27.1). The effect of leptin on the sympathetic nervous system is an important aspect in the regulation of energy homeostasis and several other physiological functions. Leptin is also involved in regulation of glucose metabolism, sexual maturation and reproduction, the hypothalamic-pituitary-adrenal system, thyroid and growth hormone axes, angiogenesis and lipolysis, hematopoiesis, immune or proinflammatory responses, and bone remodeling (Fig. 27.1). Leptin also contributes to the regulation of cardiovascular function and appears to be involved in the pathophysiology of obesity-associated hypertension [3].
LEPTIN RECEPTOR The leptin receptor is a single transmembrane protein belonging to the cytokine-receptor super-family. Due to alternative splicing of the mRNA, at least six leptin
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00027-5
receptor isoforms have been identified (designated Ob-Ra to Ob-Rf). Five isoforms (Ob-Ra to Ob-Rd and Ob-Rf) differ in the length of their intracellular domain, while Ob-Re, which lacks the transmembrane domain, is a soluble form of the receptor [4]. The Ob-Rb form encodes the full receptor, including the long intracellular domain, which contains all the motifs necessary to stimulate the intracellular machinery involved in leptin signaling. The high levels of the short intracellular domain forms in the choroid plexus may act to transport leptin across the blood–brain barrier [4].
INTRACELLULAR MECHANISMS ASSOCIATED WITH THE LEPTIN RECEPTOR The divergent signaling capacities of the leptin receptor, ObRb, mediate the stimulation of various intracellular pathways that are important for leptin control of physiological processes (Fig. 27.2). Leptin binding to ObRb triggers the activation of the receptor-associated Janus kinase (Jak) 2 tyrosine kinase. Once activated, Jak2 phosphorylates other tyrosine residues within the ObRb including tyrosine (Tyr)1138, Tyr1077 and Tyr985, each of which mediates the activation of distinct downstream signaling pathways [5]. ObRb activation also promotes the activation of phosphatidylinositol 3 kinase, although this appears to be cell-type specific and the mechanisms underlying this regulation remain unclear. Whereas phosphorylated Tyr1138 of ObRb recruits and activates signal transducer and activator of transcription STAT3, the phosphorylation of Tyr1077 promotes the tyrosine phosphorylation and activation of STAT5. Activated STAT3 and STAT5 translocate to the nucleus to modulate gene transcriptional with important implications for the regulation of metabolism and body energy balance. For instance, knock-in mice that have a mutation at Tyr1138 of ObRb, which disrupts leptininduced STAT3 signaling, are severely obese and hyperphagic, but in contrast to the mice lacking leptin or ObRb these mice remain fertile and are less diabetic [5]. On the other hand, phosphorylation of Tyr985 creates a binding site for the COOH-terminal SH2 domain of the tyrosine phosphatase, PTPN11 (also known as SHP2), leading to the activation of extracellular signal-related kinase (ERK)
131
© 2012 Elsevier Inc. All rights reserved.
132
27. LEPTIn SIgnALIng And EnERgy HomEoSTASIS
-Insulin secretion and sensitivity -Kidney function -Endothelium function -Hematopoiesis -Immune system -Angiogenesis -Thermogenesis -Reproduction -Wound healing
↑ SNA
↑ Leptin ↓ Food intake
↑ Energy expenditure -Blood pressure -Neuroendocrine function -Osteogenesis -Reproduction -Insulin secretion -Glucose homeostasis
Fat tissue
FIGURE 27.1 Role of leptin in the negative loop regulating body weight. Leptin is secreted by adipocytes and circulate in the blood in concentration proportional to fat mass content. Action of leptin on its receptor in the brain inhibits food intake and increases energy expenditure through stimulation of sympathetic nerve activity (SNA). This leads to a decrease in adipose tissue mass and body weight. In addition, leptin is involved in the regulation of several physiological processes either directly or through its action in the brain.
ObRb
Tyr
P
IRS IRS
Tyr985
P
Tyr1138
P
Shp2 Shp2
P Tyr1077
STAT5 STAT5
STAT3 STAT3
ERK ERK
PI3K PI3K
FIGURE 27.2 Molecular mechanisms involved in leptin receptor (ObRb) signaling. In the central nervous system, there are four primary intracellular signaling pathways that emanate from ObRb: signal transducer and activator of transcription STAT3 and STAT5 proteins, phosphoinositol-3 kinase (PI3K) and the extracellular signal-related kinase (ERK). Each pathway is activated by phosphorylation of specific tyrosine residues in ObRb.
signaling pathway. While Tyr985 mediates most ERK stimulation during ObRb signaling, tyrosine phosphorylation sites on Jak2 appear to account for a fraction of ERK activation by leptin independently from ObRb phosphorylation. Tyr985 also binds suppressors of cytokine signaling-3 which act as a negative regulator to inhibit STAT3 signaling.
SITES OF LEPTIN ACTION IN THE BRAIN The arcuate nucleus of the hypothalamus is considered a major site for the regulation of physiological processes by leptin [5–7]. Supporting this view, the arcuate nucleus contains the highest concentration of ObRb and
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
133
InTERACTIon of LEPTIn And nEuRoPEPTIdES In THE HyPoTHALAmuS
is the most responsive brain nucleus to leptin in terms of activation of intracellular signaling pathways associated with the leptin receptor (e.g. STAT3). The relevance of leptin signaling in the arcuate nucleus was further supported by lesioning studies which demonstrated a lack of feeding response to leptin after the arcuate nucleus had been destroyed. In addition, restoration of the expression of ObRb in the arcuate nucleus of leptin receptor-deficient Koletsky rats or in mice that have a leptin receptor null allele leads to decreased food intake and body weight. These findings indicate that leptin receptor signaling in the arcuate nucleus is critical to the effects of leptin on energy homeostasis. However, recent evidence demonstrating ObRb expression and leptin actions in several other brain regions has led to the concept of a distributed brain network of leptin action [8].
INTERACTION OF LEPTIN AND NEUROPEPTIDES IN THE HYPOTHALAMUS After activation of leptin receptors in the central nervous system, the signal is transduced by a series of integrated neuronal pathways that regulate endocrine and autonomic function [1,6]. Although the arcuate nucleus contains several neuronal populations, two classes of neurons have been well characterized with regard to leptin action: proopiomelanocortin (POMC) neurons (which also express cocaine- and amphetamine-related transcripts (CART) that are activated by leptin; and neuropeptide Y (NPY) neurons (which also express agouti-related protein (AgRP) that are inhibited by leptin (Fig. 27.3).
Melanocortin System There is strong evidence that many of leptin’s actions are mediated by stimulation of the melanocortin system [6,7,9]. The melanocortins are peptides that are processed from the polypeptide precursor POMC, which is produced by neurons in the arcuate nucleus of the hypothalamus and the nucleus of the tractus solitarius. POMC neurons are known to express the leptin receptor, and leptin binding leads to stimulation of neuronal firing activity and increase the gene expression of POMC and CART genes. This result in higher secretion of alpha-melanocyte stimulating hormone (α-MSH), which in turn binds to a number of a family of melanocortin receptors. Five melanocortin receptors (MC-1R to MC-5R) have been identified. The MC-3R and MC-4R are highly expressed in the central nervous system [9]. The critical role for MC-4R in energy balance was demonstrated by target disruption of the MC-4R gene inducing hyperphagia and obesity in mice [9,10]. Antagonism of a central melanocortin receptor is also important in the regulation of energy homeostasis [7,9]. This concept emerged with the discovery of production within the hypothalamic neuron of a potent and selective
Leptin
⊕
NPY neuron
POMC neuron
α −MSH
NPY
AgRP
-
⊕
MC3/4-R
NPY-R
Energy balance FIGURE 27.3 Schematic illustration of the leptin-sensitive neuronal populations in the hypothalamic arcuate nucleus; those activated (catabolic pathway represented by proopiomelanocortin (POMC) neurons) and those inhibited (anabolic pathway represented by the neuropeptide Y (NPY) neurons which also express agouti related protein, AgRP). In POMC neurons, leptin increases neuronal firing and POMC gene expression promoting the secretion of alpha-melanocyte stimulating hormone (α-MSH), an agonist of the melanocortin 3 and 4 receptors (MC3/4-R) located in the second order neurons. Conversely, in NPY neurons, leptin inhibits the neuronal firing rate and decreases the expression and secretion of NPY and AgRP (antagonist of the MC3/4-R), promoting MC3/4-R activation and NPY-R inhibition, respectively. Leptin suppression of the NPY anabolic pathway and stimulation of the POMC catabolic pathway reduce food intake and promote thermogenesis (resulting in a decrease in body weight).
antagonist of MC-3R and MC-4R. This molecule known as agouti related peptide (AgRP) is expressed only in the arcuate nucleus of the hypothalamus by the same neurons that express NPY. The expression levels of AgRP are upregulated by fasting and by leptin deficiency.
Neuropeptide Y NPY, a 36-amino acid peptide, is the most potent orexigenic (promote increased energy intake) peptide activated by decreases in leptin [9]. In the hypothalamus, NPY is synthesized by neurons of the arcuate nucleus and secreted from their terminals in the paraventricular nucleus and lateral hypothalamus. Injection of NPY into the cerebral ventricles or direct hypothalamic administration increases food intake and promotes obesity. In NPY neurons, leptin inhibits neuronal firing and decreases the expression of NPY and AgRP genes. Accordingly, levels of NPY are dramatically increased in the hypothalamus of leptin-deficient mice. Moreover, knockout of the NPY gene reduces the obesity and other endocrine alterations resulting from chronic leptin deficiency in ob/ob mice by about 50% [9].
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
134
27. LEPTIn SIgnALIng And EnERgy HomEoSTASIS
Other Mediators
CONCLUSION
The complicated nature of leptin signaling pathways may be suggested from the essentially normal phenotype of NPY knockout mice [9], despite the potent stimulatory effects of NPY on food intake and body weight. This suggests that there are complementary and/or overlapping effector systems that compensate for the absence of NPY. Subsequently, other candidate molecules that can mediate the effects of leptin have been identified. For example, leptin-dependent sympathetic activation to brown adipose tissue appears to be mediated by corticotrophin releasing factor as the sympathoexcitatory effect of leptin to this tissue was substantially inhibited by pretreatment with the corticotrophin releasing factor receptor antagonist [10]. Several hypothalamic neuropeptides, monoamines, and other transmitter substances have emerged as candidate mediators of leptin action in the central nervous system (Table 27.1). TABLE 27.1 Example of neuropeptide and monoamine Candidate mediators in the Transduction of Leptin Action in the Central nervous System Catabolic Molecules
Anabolic Molecules
Proopiomelanocortin (POMC) and Neuropeptide Y (NPY) derived peptides Corticotrophin releasing factor (CRF)
Agouti related peptide (AgRP)
Cocaine-and amphitamineregulated transcript (CART)
Melanin-concentrating hormone (MCH)
Urocortin
Hypocritin 1 and 2/Orexin A and B
Neurotensin
Galanin
Interleukin 1β
Noradrenaline
Glucagon like peptide 1 Oxytocin Neurotensin
Energy balance is a highly regulated phenomenon, and the importance of the central nervous system in this regulation of energy homeostasis is well-established. The centers of regulation of food intake and body weight are distributed throughout the central nervous system with the hypothalamus playing a major role. The discovery of leptin has illuminated this field of neuroscience. This hormone constitutes the signal from adipose tissue that acts in the brain to complete the feedback loop that regulates appetite and energy expenditure. The identification of the leptin receptor and its sites of action in the brain have resulted in the striking progress in dissecting the brain circuitries that regulate energy homeostasis. Despite the lack of many pieces of this puzzle, the network of the brain pathways that control energy balance is rapidly being defined.
References [1] Elmquist JK, Elias CF, Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 1999;22:221–32. [2] Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425–32. [3] Rahmouni K. Obesity, sympathetic overdrive and hypertension: the leptin connection. Hypertension 2010;55:844–5. [4] Tartaglia LA. The leptin receptor. J Biol Chem 1997;272:6093–6. [5] Myers Jr MG. Deconstructing leptin: from signals to circuits. Diabetes 2010;59:2708–14. [6] Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006;443:289–95. [7] Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004;116:337–50. [8] Grill HJ. Distributed neural control of energy balance: Contributions from hindbrain and hypothalamus. Obesity 2006;14:216–21. [9] Inui A. Transgenic approach to the study of body weight regulation. Pharmacol Rev 2000;52:35–61. [10] Rahmouni K, Haynes WG. Leptin and the cardiovascular system. Recent Prog Horm Res 2004;59:225–44.
Serotonin Dopamine
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
28 The Endothelin System Ernesto L. Schiffrin INTRODUCTION: ENDOTHELIN SYSTEM COMPONENTS The 21 amino acid peptide endothelin (ET) was isolated and cloned in 1985 by Yanagisawa et al. [1] ET-1, -2 and -3 are isopeptides with different functions [2], and there are also larger 31 and 32-amino acid peptides. ET-1 is the most abundant ET produced in blood vessels and the kidney, whereas ET-3 is mainly a neuropeptide. In endothelial and other cells, furin and other enzymes act on proETs to generate 38–39 amino acid peptides (big ETs) that are converted into mature 21-amino acid ETs by zinc-dependent endoproteases, the endothelin-converting enzymes (ECE-1 and 2). ECEs cleave big ET-1 at the Val21-Trp22 bond, yielding ET-1. ECE-1, of which there are four differentially spliced isoforms encoded by a single gene resulting from four alternative promoters, is present in endothelial cells. The four isoforms of ECE-1 differ by their N-terminal amino-acid, which is responsible for their cellular localization. ECE-1a, c and d are extracellular, whereas ECE-1b is an intracellular enzyme which heterodimerizes with other ECE-1 isoforms and regulates their activity. ECE-2 in smooth muscle cells converts big ET-1 to ET-1 in the vicinity of ET receptors, thus protecting it from degradation. Other enzymes that generate ETs include matrix metalloproteinase-2 that cleaves the Gly32-Leu33 bond to generate ET-1[1–32], chymase from mast cells that cleaves big ET-1 at the Tyr31-Gly32 peptide bond, yielding ET-1[1–31], and neutral endopeptidase, but their physiological importance is unclear. ET production is modulated by inhibitors such as shear stress (in blood vessels) and nitric oxide (NO), and stimulators (epinephrine, thrombin, angiotensin II (Ang II), vasopressin, cytokines, insulin, growth factors (TGF-β1) and hypoxia). Leptin stimulates ET-1 generation by endothelial cells, which may be a mechanism involved in vascular injury in the metabolic syndrome and in type 2 diabetes mellitus. ET-1 induces potent vasoconstriction, inflammation and cell growth by acting on ETA and ETB receptors present in the vascular wall on smooth muscle cells, whereas endothelial cells only possess ETB receptors which stimulate release of NO and prostacyclin, mediating vasodilation [2]. ETA or ETB receptors appear to predominate in the
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00028-7
adrenal gland depending on the species [3]. ETA receptors predominate in the kidney. ETB receptors are the predominant receptor subtype in the brain and peripheral nervous system.
EFFECTS OF PREPROET-1 OR ET RECEPTOR GENE DELETION Inactivation in mice of the ET-1 gene or the ETA receptor gene results in minor blood pressure elevation [4]. This occurs as a consequence of abnormal craniofacial development that interferes with breathing and raises blood pressure through anoxia. The aorta exhibits developmental abnormalities as well, with the phenotype resembling the Pierre Robin syndrome. ET-3 is the cognate ligand of ETB receptors and acts mainly on neural or neurally derived tissues. It regulates migration of neural crest cells, and mutations or gene inactivation of ETB receptors induce aganglionic megacolon and pigmentary abnormalities. Hereditary and sporadic human aganglionic megacolon (Hirschprung’s disease) result in some cases from mutations of the ETB receptor gene. Heterozygous ETB receptor knockout mice have slightly elevated blood pressure, which supports the hypothesis that the physiological action of ETB receptors is vasodilatory.
MECHANISM OF ACTION OF ET ET receptors stimulate phospholipase C, inositol trisphosphate generation and calcium release, leading to calmodulin activation, diacylglycerol production and protein kinase C stimulation [2]. The ras-raf-mitogen activated kinase (MAPK) cascade and non-receptor tyrosine kinases also participate in the intracellular signaling pathways activated by ET receptor stimulation. Reactive oxygen species (ROS) generation by reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, xanthine oxidase, mitochondria, and uncoupled NO synthase contribute to intracellular signaling via growth factor receptor transactivation and MAPK activation. ETA receptors also induce cell growth and apoptosis through NFκB activation. ETB receptors may also have apoptotic effects.
135
© 2012 Elsevier Inc. All rights reserved.
136
28. THE EndoTHElIn SySTEm
PreproET-1 N
C Furinor PC7 N
ET-1[1-32] MMP-2
Big ET-1(38-39 aa)
RENAL EFFECTS OF ET-1
C ECE-1 M t Met
Leu
Ser Ser
Cys
Ser Cys
Asp
N
ET‐1(1‐21)
Lys Glu Cys
Val
Tyr
Phe Cys
ETA receptors
His
Leu Asp
ETB receptors
Ile
mice have enhanced vascular lipid biosynthetic enzyme gene expression, and demonstrate increased atherosclerosis when crossed with apoE knockout mice [11].
Ile
Trp C
ET-3
FIGURE 28.1 Biosynthesis and molecular structure of endothelin-1 (ET-1). PreproET-1 is cleaved by furin or protein convertase (PC)7 to generate the 38 or 39 amino acid (aa) big ET-1. The latter is cleaved by endothelin convertase-1 (ECE-1a, b, c, d) to generate the mature 21-aa ET-1, which can bind with high affinity to both ETA and ETB receptors. ET-2 and ET-3 exhibit 2 and 5 aa differences respectively. ET-3 is the cognate ligand of ETB receptors. ET-1 [1-31] is an additional peptide of the system produced in the vasculature and the airway that functions as a vasoconstrictor of tracheal and vascular smooth muscle and could be involved in allergic inflammation ET-1 [1-32] is generated in the vascular wall by the action of matrix metalloproteinase-2 (MMP-2).
PATHOPHYSIOLOGY OF THE ENDOTHELIN SYSTEM IN EXPERIMENTAL MODELS The endothelin system plays a pathophysiological role in hypertension [5–7], atherosclerosis, coronary artery disease, heart failure, subarachnoid hemorrhage and cerebral vasospasm, diabetes, primary pulmonary hypertension (the only approved indication of ET antagonists), pulmonary fibrosis, scleroderma, diabetic and non-diabetic renal disease, renal failure, hepatorenal syndrome, glaucoma, prostate cancer and its metastasis, and may also be involved in pheochromocytoma. In salt-dependent models of experimental hypertension such as DOCA-salt hypertension or Dahl salt-sensitive rats, and in severe hypertension such as stroke-prone spontaneously hypertensive rats (SHRsp), in particular when salt-loaded or treated with the nitric oxide synthase inhibitor L-NAME, enhanced production of ET-1 [8] induces hypertrophic remodeling of large and small arteries rather than the usual “eutrophic” remodeling without true vascular hypertrophy more often found in essential hypertension and in SHR, which regresses after treatment with ET antagonists [6–9]. In a mouse that overexpresses human preproET-1 in the endothelium by use of the endothelium-specific promoter Tie-2, small artery hypertrophic remodeling, vascular inflammation and endothelial dysfunction occurs despite the fact that blood pressure is not elevated, demonstrating the ability of ET-1 to induce blood pressure-independent vascular remodeling [10]. These
Although salt loading stimulates ET-1 production, activation of renal ETB receptors inhibits sodium reabsorption [12]. In Ang II-infused mice, the dual ETA/ETB receptor blocker bosentan partially prevented activation of the procollagen gene and rats overexpressing human angiotensinogen and human renin which develop malignant hypertension, exhibited reduced renal and myocardial damage after treatment with bosentan. In salt-loaded SHRsp, increased expression of ET-1 was associated with enhanced generation in the kidney of transforming growth factor (TGF)-β1, basic fibroblast growth factor (bFGF), procollagen I expression and matrix metalloproteinase (MMP)-2 activity, and were reduced by a selective ETA antagonist. ETs are implicated in both the development and progression of chronic kidney disease (CKD) [13]. The major pathological effects in CKD are ETA receptor-mediated. In a recent study, selective ETA receptor antagonism slightly reduced blood pressure, and to greater degree proteinuria and arterial stiffness in renal patients suggesting that the reduction in proteinuria and arterial stiffness is partly independent of blood pressure, and that selective ETA receptor antagonism may confer cardiovascular and renal benefits in patients with CKD [14,15].
CARDIAC EFFECTS OF ET-1 TGF-β1 expression and collagen deposition in the heart of DOCA-salt hypertensive rats are increased, and are prevented by ETA blockade. ETA receptor antagonism also blocked the expression of inflammatory mediators (NFκB and adhesion molecules) and the anti-apoptotic molecule X inhibitor of apoptosis peptide (xIAP) [16]. ETA receptor blockade prevented aldosterone-induced cardiac and vascular fibrosis, which suggests that ET-1 mediates in part effects of aldosterone on the heart and blood vessels [17]. Patients with essential hypertension, primary aldosteronism or renovascular hypertension have enhanced ultrasound backscatter signals resulting from tissue heterogeneity in the myocardium, which correlates with plasma aldosterone and immunoreactive ET, suggesting that as in experimental animal models, aldosterone and ET-1 contribute to myocardial fibrosis in human hypertension. However, studies using ETA receptor antagonists in heart failure patients have not demonstrated efficacy in chronic studies, although acute short-term trials suggested beneficial effects.
ET-1 IN ESSENTIAL HYPERTENSION In primary human hypertension plasma concentrations of immunoreactive ET are normal in Caucasians,
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
EndoTHElInS And THE nERvouS SySTEm
SFO Hypothalamus AP
PVN VLM PP
Sympathetic Outflow Baroreceptors
Vasopressin
Kidney
Blood vessels
NTS
Sympathetic ganglia
Heart
Adrenal medulla
FIGURE 28.2 Role of endothelins (ETs) in the brain and sympathetic nervous system. ETs produced in rostral areas of the brain including the subfornical organ (SFO) act on the hypothalamus to stimulate secretion of vasopressin and on the brainstem to stimulate cardiovascular regulatory centers. The latter, in the ventrolateral medulla (VLM) area postrema (AP) and nucleus tractus solitariius (NTS) modulated by baroreceptor input, stimulate sympathetic outflow, which via sympathetic ganglia, modulates heart rate, vascular tone, kidney blood flow and renin secretion as well as water and sodium handling, and catecholamine release by the adrenal medulla. ETA receptors are involved at most stages, except some in which ETB receptors play a role.
but elevated in African-Americans, who have a volume expanded low-renin form of hypertension and in whom an increase in vascular smooth muscle vasoconstrictor ETB receptors has been documented. High plasma ET levels may be related to subclinical renal dysfunction and smoking rather than hypertension. However, vascular mRNA levels of preproET are increased in stage 2 hypertension of the JNC 7 classification [7]. ETA receptor antagonists caused greater vasodilatation in the forearm of hypertensive than normotensive subjects, suggesting that ETA receptors play an important role in ET-1-dependent vascular tone in essential hypertension [18,19]. The ETB blocker BQ-788 constricted forearm resistance arteries in normotensive subjects, which suggests that ETB receptors are vasodilator in normotensive subjects, whereas the forearm in hypertensive subjects was vasodilated, suggesting that ETB receptors are vasoconstrictor in hypertensive patients. Whereas in normotensive subjects forearm blood flow response to the ETA receptor blocker BQ-123 was similar in white and black subjects, ETA receptor antagonism was a more potent vasodilator in blacks than in whites among hypertensive individuals although ET-1 induced equipotent vasoconstriction, which suggests that increased ETA-mediated vasoconstriction
137
may contribute to blood pressure elevation in hypertensive blacks. ET-1 at concentrations of 1011 mol/L may potentiate other vasoconstrictors (e.g. phenylephrine or serotonin), a mechanism which is under the influence of the EDN1 K198N polymorphism in the coding region of the preproET-1 gene, and could be enhanced in hypertension, contributing to blood pressure elevation [20]. Clinical trials in human hypertension with the ETA/ETB antagonist bosentan [21] and the ETA antagonist darusentan resulted in reduced blood pressure. However, ETA antagonists may induce liver damage and liver enzyme elevation, which has resulted in halting of human hypertension studies with ETA antagonists.
MOLECULAR GENETICS OF THE ENDOTHELIN SYSTEM A polymorphism (EDN1 K198N) in the coding region of the prepro-ET-1 gene has been associated with hypertension in overweight individuals [22], and with increased vasoreactivity [20]. ECE1 C-388A is a polymorphism present in the 5-regulatory region of the ECE-1b gene. It results in enhanced expression of ECE-1b, with increased generation of ET-1. Its presence was reported in untreated hypertensive German women in whom the A allele had effects on daytime and night-time BP, and in women in the French epidemiological study Étude du Vieillissement Artériel (EVA). However, the EDN1 K198N polymorphism of preproET-1 was not associated with BP in either men or women in this study, but interacted with the ECE1 C-338A variant to influence systolic and mean BP levels in women. Stimulation of ET by androgens could explain the absence of effect in males.
ENDOTHELINS AND THE NERVOUS SYSTEM ETs are found in rostral portions of the brain, in the hypothalamus (paraventricular nuclei, colocalized with vasopressin containing neurons) and the dorsal motor nucleus of the vagus and medulla oblongata as well as brainstem areas [23] known to regulate cardiovascular function such as the area postrema, the ventrolateral medulla and the nucleus tractus solitarius. ETs cans stimulate the central and peripheral sympathetic nervous system and act on the carotid bodies and on cervical superior and nodose ganglia, influencing hemodynamic regulation by the baroreflex and by chemoreflexes [24–29]. Also, ETs released by postganglionic sympathetic neurons modulate catecholamine release and vascular tone. They also stimulate catecholamine release from adrenal glands via ETA and possibly ETB receptors [30]. ET release has been implicated in vasospasm in the cerebral circulation, and particularly in the vasospasm
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
138
28. THE EndoTHElIn SySTEm
of subarachnoid hemorrhage (SAH). In the latter condition, high concentrations of immunoreactive ET have been reported in cerebrospinal fluid (CSF). Although in experimental models of SAH endothelin antagonists have demonstrated some efficacy in combatting vasospasm, ET antagonists are not indicated in SAH in humans. Recently, the interactions between the sympathetic nervous system and endogenous endothelin in patients with essential hypertension have been studied by recording muscle sympathetic nerve activity during infusion of an ETA antagonist [31]. Endogenous ET-1 appeared to have a sympatho-excitatory effect both in normotensive and hypertensive subjects through ETA receptors, contributing to basal sympathetic vasomotor tone. Essential hypertensive subjects demonstrated an increased susceptibility to the sympatho-excitatory effect of endogenous ET-1.
CONCLUSION ET-1 is a potent vasoconstrictor that also promotes cardiac, vascular and renal inflammation, hypertrophy and fibrosis. ET receptor antagonists could prevent some of the complications of hypertension, atherosclerosis and diabetes, and it is possible that they could achieve blood pressure-independent cardiovascular protection. However, because of side effects, their potential usefulness in hypertension, heart failure, atherosclerosis, CKD, diabetes and other diseases cannot be currently exploited. The only approved indication to date of ETA receptor blockade is primary pulmonary hypertension. Whether the role of ETs on the central and sympathetic nervous system will allow their therapeutic use in humans in the future is uncertain.
Acknowledgements The work of the author was supported by grant 37917 from the Canadian Institutes of Health Research (CIHR), a Canada Research Chair (CRC) from the CIHR/ Government of Canada CRC Program, and a Canada Fund for Innovation grant.
References [1] Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411–5. [2] Schiffrin EL, Touyz RM. Vascular biology of endothelin. J Cardiovasc Pharmacol 1998;32:S2–S13. [3] Davenport AP, Hoskins SL, Kuc RE, Plumpton C. Differential distribution of endothelin peptides and receptors in human adrenal gland. Histochem J 1996;28:779–89. [4] Clouthier DE, Hosoda K, Richardson JA, Williams SC, Yanagisawa H, Kuwaki T, et al. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 1998;125:813–24. [5] Larivière R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993;21:294–300.
[6] Schiffrin EL. Endothelin: Potential role in hypertension and vascular hypertrophy. Hypertension 1995;25:1135–43. [7] Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens 1997;15:57–63. [8] Goel A, Su B, Flavahan S, Lowenstein CJ, Berkowitz DE, Flavahan NA. Increased endothelial exocytosis and generation of endothelin-1 contributes to constriction of aged arteries. Circ Res 2010;107:242–51. [9] Li JS, Larivière R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetatesalt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994;24:183–8. [10] Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 2004;110:2233–40. [11] Simeone SMC, Li Melissa W, Paradis P, Schiffrin EL. Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium. Physiol Genomics 2011;43:148–60. [12] Kohan DE, Rossi NF, Inscho EW, Pollock DM. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 2011;91:1–77. [13] Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension 2010;56:942–9. [14] Dhaun N, MacIntyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease. Hypertension 2009;54:113–9. [15] Wenzel RR, Littke T, Kuranoff S, Jurgens C, Bruck H, Ritz E, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Amer Soc Nephrol 2009;20:655–64. [16] Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCAsalt hypertensive rats: role of ET(A) receptors. Hypertension 2002;39:679–84. [17] Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003;42:49–55. [18] Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO, Panza JA. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999;33:753–8. [19] Haynes WG, Hand MF, Johnstone HA, Padfield PL, Webb DJ. Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1. J Clin Invest 1994;94:1359–64. [20] Iglarz M, Benessiano J, Philip I, Vuillaumier-Barrot S, Lasocki S, Hvass U, et al. Preproendothelin-1 gene polymorphism is related to a change in vascular reactivity in the human mammary artery in vitro. Hypertension 2002;39:209–13. [21] Krum H, Viskoper RJ, Lacourcière Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998;338:784–90. [22] Tiret L, Poirier O, Hallet V, McDonagh TA, Morrison C, McMurray JJV, et al. The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension 1999;33:1169–74. [23] Giaid A, Gibson SJ, Herrero MT, Gentleman S, Legon S, Yanagisawa M, et al. Topographical localisation of endothelin mRNA and peptide immunoreactivity in neurons of the human brain. Histochemistry 1991;95:303–14. [24] Dai X, Galligan JJ, Watts SW, Fink GD, Kreulen DL. Increased .O2– production and upregulation of ETB receptors by sympathetic neurons in DOCA-salt hypertensive rats. Hypertension 2004;43:1048–54.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
ConCluSIon
[25] Dai SM, Shan ZZ, Miao CY, Yin M, Su DF. Hemodynamic responses to endothelin-1 and endothelin antagonists microinjected into the nucleus tractus solitarius in rats. J Cardiovasc Pharmacol 1997;30:475–80. [26] Itoh S, van den Buuse M. Sensitization of baroreceptor reflex by central endothelin in conscious rats. Amer J Physiol 1991;260:H1106–H1112. [27] Kopp UC, Grisk O, Cicha MZ, Smith LA, Steinbach A, Schluter T, et al. Dietary sodium modulates the interaction between efferent renal sympathetic nerve activity and afferent renal nerve activity: role of endothelin. Amer J Physiol Regul Integr Comp Physiol 2009;297:R337–51.
139
[28] Lau YE, Galligan JJ, Kreulen DL, Fink GD. Activation of ETB receptors increases superoxide levels in sympathetic ganglia in vivo. Amer J Physiol Regul Integr Comp Physiol 2006;290:R90–5. [29] Mosqueda-Garcia R, Inagami T, Appalsamy M, Sugiura M, Robertson RM. Endothelin as a neuropeptide: cardiovascular effects in the brainstem of normotensive rats. Circ Res 1993;72:20–35. [30] Yamaguchi N. Role of ET(A) and ET(B) receptors in endothelin-1induced adrenal catecholamine secretion in vivo. Amer J Physiol 1997;272:R1290–R1297. [31] Bruno RM, Sudano I, Ghiadoni L, Masi L, Taddei S. Interactions between sympathetic nervous system and endogenous endothelin in patients with essential hypertension. Hypertension 2011;57:79–84.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
C H A P T E R
29 Pharmacology of the Nucleous Tractus Solitarii Ching-Jiunn Tseng, Pei-Wen Cheng, Che-Se Tung The nucleus tractus solitarii (NTS) is the primary integrative center for cardiovascular control and other autonomic functions in the central nervous system (CNS). The NTS not only integrates covergent information but itself is the site of substantial modulation. Several neurotransmitters or neuromodulators are involved in cardiovascular regulation in the NTS. This section presents some of the recent findings and their molecular mechanisms in the NTS.
NUCLEUS TRACTUS SOLITARII The NTS is located in the dorsal aspect of the medulla oblongata, and receives visceroceptive information from cardiopulmonary and gastrointestinal sites. It is a bilateral structure, that when extending caudally, comes medial and close to the walls of the fourth ventricle. At the level of the posterior tip of the area postrema, the neuronal groups within the NTS fuse medially and form the commisural nucleus of the NTS. This part of the NTS lies dorsal to the central canal and the dorsal motor nucleus of the vagus. The caudal limit of the NTS is located at the level of the pyramidal decussation [1]. The NTS has long been identified as a site where the first synape of the baroreceptor reflex is located. Therefore the NTS, as well as other key central nuclei in the hypothalamus and other forebrain regions, have important roles in mediating cardiovascular responses to acute stresses. From the NTS, pathways project to cholinergic parasympathetic neurons located in the dorsal vagal motor nucleus and the nucleus ambiguus, as well as to a group of inhibitory neurons in the caudal ventrolateral medulla (CVLM), which, in turn, project to tonically active sympathoexcitatory neurons in the rostral ventrolateral medulla (RVLM). A rise in arterial blood pressure in the periphery is detected by baroreceptors located in the carotid arteries and aortic arch and these activate neurons in the NTS via the branches of the vagus and glossopharyngeal nerves. The activation of NTS neurons stimulates inhibitory neurons in the CVLM, which attenuate the activity of the RVLM neurons, leading to
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00029-9
a reduction in sympathetic activity and a fall in blood pressure [2]. Hypertension can be due to central interruption of baroreflexes in the NTS since electrolytic lesions of blood flow was similar to that produced by sinoaortic denervation [3]. An analogous condition has also been found in the clinic: a very rare case of continuous hypertension and tachycardia after excision of a cerebellar hemangioblastoma at the dorsal medulla oblongata showed a small injury at the dorsocaudal medulla that was located at the caudal site of the NTS by postoperative MR imaging [4]. The NTS is richly innervated by neurons containing a number of potential neurotransmitters and neuromodulators, such as glutamate, noradrenaline, adrenaline, acetylcholine, serotonin, angiotensin II (Ang II), vasopressin, β-endorphin, enkephalins, neuropeptide Y, adenosine, nitric oxide (NO), insulin, etc. Among these neuromodulators related to central cardiovascular regulation, this chapter addresses the cardiovascular effects of NO, insulin, adenosine and Ang II and their molecular signaling pathways in the NTS.
CARDIOVASCULAR EFFECTS OF NO IN THE NTS NO, synthesized from the semiessential amino acid L-arginine by nitric oxide synthase (NOS), is a remarkable regulatory molecule and plays an important role in physiological functions. By using immunohistochemistry, NADPH-diaphorase staining and autoradiography, neuronal NOS (nNOS) was found at a high concentration in regions of the brain stem, especially in the NTS and rostral ventrolateral medulla. Unilateral microinjection of L-arginine into the NTS produced prominent doserelated depressor and bradycardic effects and reduced renal sympathetic nerve activity [5]. In addition, 4 to 6 hours after intravenous injection of bacterial endotoxinlipopolysaccharide, there was a time-related potentiation of the L-arginine-induced depressor and bradycardic effects in the NTS. In the investigation of the mechanisms of action of NO in the NTS, evidence suggests that
141
© 2012 Elsevier Inc. All rights reserved.
142
29. PHARmACology of THE NuClEouS TRACTuS SolITARII
the cardiovascular effects produced by L-arginine in the NTS are inhibited by pharmacological interventions that block NO production and the cGMP-PKG signaling pathway within the nucleus [5]. Furthermore, the interactions among NO and other important neurotransmitters have been investigated in the NTS. NO, adenosine and glutamate have reciprocal inhibition in the release of other transmitters [6,7].
CARDIOVASCULAR EFFECTS OF ADENOSINE IN THE NTS The endogenous nucleoside adenosine has been studied for its potential role as a neuromodulator in a number of autonomic functions. The highest density of adenosine uptake sites within the CNS has been observed in the NTS. The natural precursor of adenosine in the CNS is ATP, which is dephosphorylated and rapidly becomes adenosine via the activity of ectonucleotidases to synaptic release. Among four adenosine receptor subtypes, A2A receptor is expressed at high levels in limited regions of the brain that are primarily linked to adenylyl cyclase activation. In the NTS, activation of A2A receptors has been demonstrated to elicit dose-related decreases in blood pressure (BP). These studies suggest that the cardiovascular modulatory effects of adenosine in the NTS are mediated predominantly by the A2A receptor. Based on the finding, adenosine has been shown to play an important role in central cardiovascular control. The depressor and bradycardic effects of adenosine in the NTS are attenuated by a NOS inhibitor [6]. Endothelial NOS (eNOS), originally identified in vascular endothelium, is expressed in several nonendothelial cell types, including neurons of various rat brain regions. In addition, eNOS-generated NO in the NTS plays a role in the control of baroreflex gain and arterial pressure [8]. Suppression of the endogenous eNOS by overexpression of dominant-negative eNOS in bilateral NTS increased spontaneous baroreceptor reflex gain in conscious Wistar rats and decreased BP in mature spontaneously hypertensive rats [8]. Signaling molecules that regulate eNOS activity include phosphatidylinositol 3-kinase (PI3K)/Akt, cyclic nucleotide-dependent kinases (protein kinase A and protein kinase G), protein kinase C, CaMKII and ribosomal protein S6 kinase (RSK). Experimental studies demonstrate that adenosine may phosphorylate eNOS through activation of MEK/ERK cascades in the NTS [9]. This result is further supported by reports that inhibition of ERK1/2 activation attenuated the eNOS phosphorylation that was induced by estrogen and vascular endothelial growth factor [9]. Although it has been reported for years that ERKs could phosphorylate and activate eNOS, the exact signaling mechanisms that couple the activated ERK1/2 to eNOS activation remained uncertain. Evidence indicates that there is a novel adenosine-ERKeNOS signaling pathway related to the production of NO in the regulation of BP and heart rate in the NTS [9].
CARDIOVASCULAR EFFECTS OF INSULIN IN THE NTS Insulin receptors are unevenly distributed throughout the brain, with a particularly high density in the choroid plexus, cerebral cortex, olfactory bulb, hippocampus, cerebellum, and hypothalamus, which indicates the significant role of insulin in the CNS. Recent evidence has demonstrated that the peripheral and central influence of insulin on cardiovascular regulation is due to effects on the sympathetic nervous system (SNS). However, the significance of the insulin-mediated system in the control of blood pressure is not well-understood. It is well-known that the binding of insulin with its receptors results in activation of the insulin receptor (IR) tyrosine kinase. The activated kinase then phosphorylates tyrosine residues of IR substrates (IRSs). IRSs are adaptor proteins that are linked to the activation of two main signaling pathways including PI3K-Akt/protein kinase B (PKB) pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-mitogen-activated protein kinase (MAPK) pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation [10]. In addition, several studies have shown that enhancing insulin sensitivity with insulin sensitizers may improve insulin resistance and limit the development of adverse cardiovascular consequences. These observations suggest that signaling defects at the IR or post-receptor levels can lead to insulin resistance and may be associated with cardiovascular diseases, including hypertension We reported a novel insulin-PI3K-Akt-NOS signaling pathway related to the production of NO in the regulation of BP and HR in the NTS of normotensive rats [11]. Conversely, there is an additional signal transduction pathway involved in insulin-mediated cardiovascular effects in the NTS of insulin resistance rats that is NOSdependent but independent of the protein kinase Akt [12].
CARDIOVASCULAR EFFECTS OF ANGIOTENSIN II IN THE NTS Ang II is a powerful vasoconstrictor. Hyperactivity of Ang II has been shown to play a major role in hypertension. However, the underlying molecular mechanisms are still not fully understood. These pathological and physiological actions of Ang II are mediated through its type 1 receptor (AT1R). It is wellknown that the expression of the AT1R is 2 to 4-fold higher in the neurons from spontaneously hypertensive rat (SHR) compared with those from WKY rat. In normotensive rats, the Ang II-AT1R-PKC-eNOS signaling pathway relates to production of NO in the regulation of BP and HR. Several lines of evidence demonstrate that reactive oxygen species (ROS) play a role in central autonomic networks that are involved in Ang II-mediated signaling [13]. For instance,
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
CoNCluSIoN
143
FIGURE 29.1 The proposed adenosine, insulin and Ang II signaling pathway in the regulation of blood pressure in the NTS.
inhibition of Ang II activity by losartan (AT1R antagonist) significantly increased the expression of extracellular signal-regulated kinase (ERK)1/2, RSK, and also increased nNOS phosphorylation, which is involved in Ang II- ROSmediated modulation of BP in the NTS of SHR [14]. Thus the ERK1/2-RSK-nNOS signaling pathway may play a significant role in Ang II-mediated central BP regulation [14].
CONCLUSION The sympathetic nervous system has moved toward center stage in cardiovascular medicine. Recently studies have shown that sympathetic hypereractivity participates in the development, maintenance and progression of elevated blood pressure. The CNS–mean arterial pressure (CNS-MAP) set-point theory has recently been proposed. It has been hypothesized that hypertension occurs as the result of a primary shift of the CNS-MAP set point to a higher operating pressure, which results in increased sympathetic nerve activity. The NTS, located at the dorsal part of the brainstem, is recognized to be an important integral center in the CNS. Ubiquitously distributed neuromodulators such as adenosine, insulin and Ang II, were found to participate in sympathetic activity regulation in the NTS. Several
studies have investigated the signaling mechanism of neuromodulator with regard to cardiovascular modulation in the NTS and found that the adenosine-ERK-eNOS, insulin-PI3K-Akt-NOS and Ang II-ERK1/2-RSK-nNOS signaling pathways participate in central cardiovascular control (Fig. 29.1). Further investigation of the molecular mechanisms involved in sympathetic nervous activity modulation might elucidate the pathogenesis of the CNS-MAP set-point shift and sympathetic overactivity in essential hypertension. These observations should be of help in further understanding of the pathogenesis and optimal treatment of blood pressure disorders.
References [1] Mosqueda-Garcia R. Central autonomic regulation. In: Robertson D, Low PA, Polinsky RJ, editors. Primer on the autonomic neuvous system. U.S.A: Academic Press; 1996. p. 3–12. [2] Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci 2006;7:335–46. [3] Doba N, Reis DJ. Role of central and peripheral adrenergic mechanisms in neurogenic hypertension produced by brainstem lesions in rat. Circ Res 1974;34:293–301. [4] Ideguchi M, Kajiwara K, Yoshikawa K, Kato S, Ishihara H, Fujii M, et al. Continuous hypertension and tachycardia after resection of a hemangioblastoma behind the dorsal medulla oblongata: relationship to sympathetic overactivity at the neurogenic vasomotor center. J Neurosurg 2010;113:369–73.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
144
29. PHARmACology of THE NuClEouS TRACTuS SolITARII
[5] Tseng CJ, Liu HY, Lin HC, Ger LP, Tung CS, Yen MH. Cardiovascular effects of nitric oxide in the brain stem nuclei of rats. Hypertension 1996;27:36–42. [6] Lo WC, Jan CR, Wu SN, Tseng CJ. Cardiovascular effects of nitric oxide and adenosine in the nucleus tractus solitarii of rats. Hypertension 1998;32:1034–8. [7] Lin HC, Wan FJ, Kang BH, Wu CC, Tseng CJ. Systemic administration of lipopolysaccharide induces release of nitric oxide and glutamate and c-fos expression in the nucleus tractus solitarii of rats. Hypertension 1999;33:1218–24. [8] Waki H, Murphy D, Yao ST, Kasparov S, Paton JF. Endothelial NO synthase activity in nucleus tractus solitarii contributes to hypertension in spontaneously hypertensive rats. Hypertension 2006;48:644–50. [9] Ho WY, Lu PJ, Hsiao M, Hwang HR, Tseng YC, Yen MH, et al. Adenosine modulates cardiovascular functions through activation of extracellular signal-regulated kinases 1 and 2 and endothelial nitric oxide synthase in the nucleus tractus solitarii of rats. Circulation 2008;117:773–80.
[10] Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006;7:85–96. [11] Huang HN, Lu PJ, Lo WC, Lin CH, Hsiao M, Tseng CJ. In situ Akt phosphorylation in the nucleus tractus solitarii is involved in central control of blood pressure and heart rate. Circulation 2004;110:2476–83. [12] Hsiao M, Lu PJ, Huang HN, Lo WC, Ho WY, Lai TC, et al. Defective phosphatidylinositol 3-kinase signaling in central control of cardiovascular effects in the nucleus tractus solitarii of spontaneously hypertensive rats. Hypertens Res 2008;31:1209–18. [13] Sun C, Zubcevic J, Polson JW, Potts JT, Diez-Freire C, Zhang Q, et al. Shift to an involvement of phosphatidylinositol 3-kinase in angiotensin II actions on nucleus tractus solitarii neurons of the spontaneously hypertensive rat. Circ Res 2009;105:1248–55. [14] Cheng WH, Lu PJ, Ho WY, Tung CS, Cheng PW, Hsiao M, et al. Angiotensin II inhibits neuronal nitric oxide synthase activation through the ERK1/2-RSK signaling pathway to modulate central control of blood pressure. Circ Res 2010;106:788–95.
II. BIOCHEMICAL AND PHARMACOLOGICAL MECHANISMS
P A R T III
AUTONOMIC PHYSIOLOGY
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00001-9
© 2012 Elsevier Inc. All rights reserved.
C H A P T E R
30 Entrainment of Sympathetic Rhythms Michael P. Gilbey SYMPATHETIC RHYTHM The term “sympathetic rhythm” describes the mo ment to moment waxing and waning in amplitude (sig nal strength) of population activity recorded from whole sympathetic nerves that contain thousands of fibers. Such rhythms are commonly observed in the discharges of pre and postganglionic nerves regulating the heart and blood vessels. Rhythm is frequently only an emergent property of population activity; i.e., the discharges of single neurons sampled from the population may not necessarily dem onstrate rhythmicity, however, the tendency for subpopu lations of neurons to discharge action potentials almost coincidentally but intermittently gives rise to rhythmic ity in aggregate activity. Although Adrian and colleagues described rhythmic activity in the first published record ings of mammalian sympathetic nerves in 1932, underly ing mechanism(s) and possible functional significance are still uncertain [1–3].
Cardiac- and Respiratory-related Rhythms The most common sympathetic rhythms are cardiac (pulse) and respiratoryrelated. Concerning respiratory rhythm, two components can be distinguished; one as sociated with central respiratory activity and another dependent upon afferent activity related to pulmonary ventilation (e.g., from arterial baroreceptors and/or pul monary stretch receptors) [4,5]. Mechanisms Underlying Rhythms Two major hypotheses have been proposed to account for cardiac and respiratoryrelated rhythms in sympa thetic discharges. Phasic Inputs Generate Rhythms The classic view holds that these rhythms are imposed upon sympathetic discharge by “external” inputs. In the case of the cardiacrelated rhythm, an increase in barore ceptor discharge during systole is considered to inhibit tonic excitatory drive to sympathetic nerves and thereby give rise to waxing and waning of sympathetic discharges [3]. A similar mechanism is proposed for rhythms related
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00030-5
to pulmonary ventilation cycles where activation of lung stretch and/or baroreceptor afferents, for example, may cause periodic inhibition of activity (independent of the central respiratory rhythm generating network) [4,4a,5]. Concerning central respiratoryrelated rhythms it is sug gested that elements within the central respiratory net work provide excitatory and/or inhibitory inputs to central networks providing tonic drive to sympathetic nerves [4,5]. Additionally, Richter and Spyer have argued for the existence of a common cardiorespiratory network [6], and see Chapter 31. Entrainment of Rhythms The observation of a nonrespiratory and noncardiac related sympathetic rhythm (“10 Hz” rhythm: Green and Hoffman, 1967) provided the first indication that sympa thetic rhythms might not arise exclusively from phasic inputs to tonic sympathetic tone generating networks. Some 8 years later Taylor and Gebber observed that sym pathetic rhythms with a frequency similar to heart rate persisted following baroreceptor denervation [1,3]. As a result the idea developed that cardiacrelated rhythms in sympathetic nerve discharge might be a consequence of the entrainment of central oscillator(s) within the brain stem (i.e., that central networks driving sympathetic out flow may be intrinsically capable of generating their own rhythms). In this scheme, phasic baroreceptor input acts as a forcing input that can entrain a central oscillator. Consequently, in the absence of, or with reduced barore ceptor activity, there is a continuous phase shift between cardiac cycle and sympathetic rhythm resulting from lack of entrainment [1–3]. Additionally, there is evidence to support the hypothesis that respiratoryrelated rhythms in sympathetic discharges arise from oscillator(s) other than those within the central respiratory networks [7]. First, in vagotomized anesthetized animals, a “slow” rhythm in the frequency range of the central respiratory rhythm has been observed during central apnea (indicated by absence of rhythmic phrenic discharge). Second, “slow” rhythms in the discharges of pairs of sympathetic nerves at the fre quency of central respiratory drive have been observed to remain correlated after mathematical removal of the com ponent of these signals common to phrenic nerve activity (an indicator of central respiratory drive); i.e., “theoretical
147
© 2012 Elsevier Inc. All rights reserved.
148
30. ENTRAINMENT Of SYMPATHETIC RHYTHMS
removal of central respiratory drive”. Third, locking ratios other than 1:1 can be observed between rhythmic phrenic and sympathetic discharge (e.g. 2:1, 3:1, 2:3). It is also apparent that afferents activated during pulmonary ventilation can act as an entraining force [2]. However, the observations concerning the entrainment of respira tory rhythm must be mindful of findings that indicate great complexity in central respiratory rhythm generating networks and their differential influence on the various somatic motor outflows driving respiratory muscles.
How Many Central Oscillators? Gebber and colleagues have provided evidence that separate oscillators, capable of coupling, may drive activ ity to different sympathetic nerves: they noted from paired nerve recordings, that rhythmic discharges of similar fre quency could be phaselocked, but this was not obliga torily; their variation in amplitude was not necessarily proportionate [7]. In addition, the observations of Gilbey and colleagues have raised the intriguing possibility that activity of sympathetic neurons regulating the same tar get may be influenced by a family of weakly coupled or uncoupled oscillators and that their degree of synchro nization is influenced by inputs related to lung inflation, central respiratory drive, various afferents (e.g., somatic and baroreceptor) and possibly arousal state [2,8].
The Spinal Cord and Sympathetic Rhythms Traditionally, supraspinal sites have been the focus of interest regarding sympathetic rhythm generation [1,5,6]. However, recently it has been demonstrated, both in situ and in isolated slices, that sympathetic rhythms can be generated within the spinal cord [2,9]. Therefore, it appears that sympathetic rhythms generated within the spinal cord may be entrained by inputs arising both from peripheral afferents and supraspinal networks; e.g., respi ratory [2]. Intrathecal application of 5hydroxytryptamine (5HT) induced a cutaneous vasomotor sympathetic rhythm in a spinalized rat preparation similar to that seen in an intact preparation [2] and spontaneous rhythmic activity was recorded from the intermediolateral cell columns (IML: the location of the cell bodies of sympathetic pregangli onic neurons) of thoracic spinal cord slices taken from neonatal rats [9]. In a spinal cord slice preparation, rhyth mic activity could be induced or enhanced by 5HT recep tor agonists and reduced by gap junction blockers. These neurophysiological observations are strengthened by the findings that the IML receives a dense 5HTcontaining innervation and membrane localized Cx36 immunoreac tivity, indicative of gap junctions, has been observed in sympathetic preganglionic neurons. These findings point to a potentially important func tion of spinal cord circuitry both for the generation and
entrainment of sympathetic rhythms. Furthermore, they demonstrate the potential for the neurochemical modula tion of sympathetic rhythmogenesis both at the single cell and neural network level. Consequently, aberrant sympa thetic rhythm generation and/or entrainment induced by changes in CNS function may result in peripheral disease (e.g., cardiovascular: see Chapter 31).
Functional Significance Whatever mechanism(s) lie behind the generation of sympathetic rhythms, their characteristic phasic nature in dicates coordination of neuronal discharges. Whereas it is clear why coordinated phasic discharges are required in locomotor and respiratory motor control, the need for pat terning and synchronization in sympathetic motor control of heart and blood vessels is not readily apparent. With regard to neuroeffector transmission, many rhythms will be filteredout (i.e., a sympathetic rhythm above 1 Hz will not lead to a 1 Hz vasomotion) as the time constant for response is ~2 seconds [1–3]. It has been suggested that coordination may be par ticularly easy to achieve between oscillating neural networks. Gebber and colleagues have suggested, based upon experimental observation, that coupled sympa thetic oscillators may be important in the generation of differential patterns of sympathetic activity to blood ves sels of muscle, skin and viscera associated with behav ioural alerting [1]. Furthermore, the observations on entrainment of sympathetic rhythms indicate that when appropriate sympathetic and respiratory networks may “bind” together to form a highly coordinated “supernet work” [2]. There are also many indications that pattern and syn chrony coding are used in addition to rate coding in vari ous nervous system functions [2]. At the level of the single neuron, pattern of firing appears important in determin ing probability of transmitter release, synaptic plasticity, types of transmitter released/coreleased and receptors activated. In these ways, firing pattern probably influ ences ganglionic and neuroeffector transmission [2,3,10]. Synchrony may be important as it favours summation, which raises the efficacy of transmission and can also have longerterm influences on synaptic and neuroeffec tor function. Synchrony therefore may enhance ganglionic transmission by increasing the probability of summa tion of weak inputs and improve neuroeffector control by coordinate activation of postjunctional receptors [2,3]. Consequently, if as suggested by Gilbey and coworkers [2] a population of neurons regulating a single target is influenced by a family of oscillators their dynamic and graded synchronization through variable entrainment could lead to the modulation of target organ function. In this manner aberrant entrainment of sympathetic rhythms might lead to peripheral pathology consequent to inappro priate sympathetic activity.
III. AUTONOMIC PHYSIOLOGY
SYMPATHETIC RHYTHM
References [1] Barman SM, Gebber GL. “Rapid” rhythmic discharges of sympa thetic nerves: Sources, mechanisms of generation, and physiological relevance. J Biol Rhythm 2000;15:365–79. [2] Gilbey MP. Sympathetic rhythms and nervous integration. Clin Exp Pharmacol Physiol 2007;34:356–61. [3] Malpas SC. The rhythmicity of sympathetic nerve activity. Prog Neurobiol 1998;56:65–96. [4] Habler HJ, Janig W, Michaelis M. Respiratory modulation in the activity of sympathetic neurons. Prog Neurobiol 1994;43:567–606. [4a] Huang C, Marina N, Gilbey MP. Impact of lung inflation cycle fre quency on rat muscle and skin sympathetic activity recorded using suction electrodes. Auton Neurosci 2009;150:70–5. [5] Koepchen HP, Klussendorf D, Sommer D. Neurophysiological background of central neural cardiovascularrespiratory coordina tion: Basic remarks and experimental approach. J Auton Nerv Syst 1981;3:335–68.
149
[6] Richter DW, Spyer KM, Gilbey MP, Lawson EE, Bainton CR, Wilhelm Z. On the existence of a common cardiorespiratory network. In: Koepchen HP, Huopaniemi T, editors. In cardiorespiratory and motor coordination. Berlin: Springer Verlag; 1991. p. 118–30. [7] Zhong S, Zhou SY, Gebber GL, Barman SM. Coupled oscillators account for the slow rhythms in sympathetic nerve discharge and phrenic nerve activity. Am J Physiol 1997;272:R1314–R1324. [8] Staras K, Change HS, Gilbey MP. Resetting of sympathetic rhythm by somatic afferents causes postreflex coordination of sympathetic activity in rat. J Physiol London 2001;533:537–45. [9] Pierce ML, Deuchars J, Deuchars SA. Spontaneous rhythmogenic capabilities of sympathetic neuronal assemblies in the rat spinal cord slice. Neuroscience 2010;170:827–38. [10] Karila P, Horn JP. Secondary nicotinic synapses on sympathetic B neurons and their putative role in ganglionic amplification of activ ity. J Neurosci 2000;20:908–18.
III. AUTONOMIC PHYSIOLOGY
C H A P T E R
31 Cross-talk Between Body Systems: Respiratory-Cardiovascular Coupling in Health and Disease Julian F.R. Paton, Anthony E. Pickering
INTRODUCTION Although the common perception of the pulse is one of a stable and constant beat, periodic heart rate variability has been observed in fish, amphibians, reptiles and mammals suggesting that its appearance during evolution was not coincidental and that it confers a survival advantage. Much of this periodic heart rate fluctuation is linked to the phases of respiration. Classically, in man, heart rate increases on inhalation and falls during exhalation (so called respiratory sinus arrhythmia; RSA) and is most prominent in the young and well trained athletes. Why RSA exists is not wholly clear, yet we know that its loss is a powerful predictor of morbidity and mortality from cardiovascular disease [1]. The latter indicates a major protective role for RSA in cardiovascular health, which is a good reason to discuss its potential function. Blood pressure also expresses a respiratory oscillation, often called the high frequency oscillation or HFO. The functional significance of the HFO is if anything even less clear than that of RSA but both oscillations demonstrate the strong cross-talk between the circulatory and respiratory systems. This chapter focuses on the central neural inter-connectivity between the brainstem respiratory pattern generator and neural networks governing sympathetic and parasympathetic activity. The putative functional roles of RSA and HFO in health are discussed; additionally their plasticity will be illustrated with examples of alterations in coupling strength and patterns between respiration and cardiovascular autonomic motor outputs. The importance of these changes is discussed in the context of disease states and how this may provide novel insights into our mechanistic understanding of cardiovascular pathologies.
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00031-7
CARDIOVASCULAR AUTONOMIC ACTIVITY: COUPLING TO THE RESPIRATORY PATTERN GENERATOR Anrep et al. [2] described RSA for the first time and provided mechanistic insight into its causes. These included a baroreceptor reflex-mediated modulation of heart rate, triggered by respiratory induced changes in venous return (secondary to oscillations in intrathoracic pressure) and abdominal thoracic pumping, and consequent blood pressure waves in time with the respiratory cycle. When this peripheral change in venous return was negated, RSA still persisted leaving the heart rate modulation as being due either to pulmonary stretch receptor feedback following lung inflation and/or direct coupling to central respiratory drive. Both mechanisms were found to play a role. Since those seminal studies, it has been found that cardiac sympathetic motor activity exhibited prominent bursting during late-inspiration [3] whereas cardiac vagal activity fired preferentially during early expiration (postinspiration) [4]. Recordings from in situ perfused preparations (without either pulmonary stretch receptor activation or respiratory related changes in venous return) show prominent respiratory sinus arrhythmia, confirming the important role of central coupling between the respiratory and cardiac parasympathetic preganglionic neurons (Fig. 31.1) [5]. The burst of cardiac vagal activity seems to originate centrally at the level of the preganglionic neurons in the nucleus ambiguus that are inhibited during inspiration but excited during post-inspiration [4]. The magnitude of RSA is principally a function of this cardiac vagal tone or the excitability state of the preganglionic cardiac vagal motoneurons [4]. Differences in the cardiac vagal tone explain the variable degree of RSA between individuals.
151
© 2012 Elsevier Inc. All rights reserved.
152
31. CRoSS-TAlk BETwEEn BoDy SySTEmS: RESPIRAToRy-CARDIovASCulAR CouPlIng In HEAlTH AnD DISEASE
In terms of vasomotor sympathetic neurons, recordings at either the pre- or post-ganglionic levels show respiratory related busting during late-inspiration and early expiration contributing to the HFO [6–8]. The respiratory-related alterations in venous return/cardiac output described above also contribute to the respiratory modulation of arterial pressure. However, the fluctuations persist in the working heart brainstem preparation indicating again there is an important central neural component to the coupling [8]. These data provided unequivocal evidence that manifestation of both RSA and HFO was dependent, in part, on a central respiratory modulation of both limbs of the autonomic nervous system. An argument supporting the concept that the cardiovascular and respiratory systems are actually a single system (even within the brain) comes
Respiration Phrenic nerve
BRAINSTEM
inspiration - 120
Arterial blood Pressure mmHg
- 80 - 70
Heart rate beats/min
3s
- 60
FIGURE 31.1 Respiratory sinus arrhythmia is in part due to central nervous coupling between the brainstem respiratory rhythm generator and autonomic motor outflows. Schematic depicting respiratory sinus arrhythmia expressed here as a rise in heart rate during central inspiratory drive (i.e. phrenic nerve discharge) and a bradycardia coincident with the start of expiration. These data were obtained in the absence of lung inflation; the latter removes any influence from pulmonary stretch receptor feedback and baroreceptor reflex activation secondary to respiratory induced changes in venous return. This indicates that cross-talk between the central respiratory pattern generator with sympathetic and cardiac vagal neural circuitry within the brainstem contributes significantly to the arrhythmia.
WKY
WHY IS THE CIRCULATORY SYSTEM RESPIRATORY-MODULATED? The exact function/s of RSA and HFO are debated with no unified consensus and require further investigation.
RSA Four suggestions are: 1. The most likely role is to provide close matching of ventilation with pulmonary perfusion. It has been experimentally demonstrated that oxygenation of blood is optimized if increases in cardiac output are timed to occur when fresh air arrives within the alveoli [9], which is the case with RSA as heart rate rises during inspiration. However, no respiratory related alterations in arterial tension of oxygen are detectable but there could be in the pulmonary veins. In contrast, “reverse” RSA increased ventilatory dead space and intrapulmonary shunting [9]. 2. Based on the fact that a red blood cell spends the same amount of time in an alveolar capillary per cardiac cycle (in human), it has been proposed that RSA enhances cardio-respiratory efficiency and prevents “wasted” heart beats by decreasing heart rate/cardiac output on exhalation [9]. 3. The bradycardia of RSA assists in stabilizing blood pressure and counter acts the respiratory related increase in cardiac output that results from increased venous return. 4. It is plausible that slowing of heart rate during expiration enhances coronary blood flow by prolonging diastole. A constant frequency of cardiac contraction (B)
SHR
PNA
PNA
HF(SBP) (mmHg/Hz)
1/2
(A)
from their tight central nervous coupling reflecting the commonality of function.
7
**
6
5
4
Wistar
SHR
FIGURE 31.2 Enhanced respiratory-sympathetic (SNA) coupling in the spontaneously hypertensive rat (SHR). (A) comparison of phrenic nerve activity (PNA) triggered sympathetic activity between normotensive (Wistar Kyoto, WKY) and SHR from the in situ arterially perfused rat preparation. In the SHR there was a greater strength in coupling as central inspiratory drive was comparable between rat strains. Note, the increased coupling produced a larger wave in arterial perfusion pressure (PP). (B) in conscious rats blood pressure was measured using radio-telemetry and showed a high frequency (HF) component in the systolic blood pressure (SBP) that was greater in the SHR than the normotensive control rat. Data from ref 8.
III. AUTONOMIC PHYSIOLOGY
153
CARDIovASCulAR DISEASE: oPPoSITE EffECTS on RSA AnD Hfo
(i.e. loss of RSA) could limit coronary blood flow at any given blood pressure as may occur in heart failure and hypertension. The loss of this mechanism may contribute to the increased susceptibility of patients with these diseases to left ventricular tachycardia and sudden cardiac death. Of these four possibilities direct evidence only exists to support the first hypothesis.
CARDIOVASCULAR DISEASE: OPPOSITE EFFECTS ON RSA AND HFO
HFO There is no definitive explanation for the functional role of HFO. This may be related to the experimental difficulty in removing and reconstituting the sympathetic vasomotor drive as has been elegantly done for vagal tone and RSA [9]. Rhythmic contraction and relaxation of vascular smooth muscle of arterioles (i.e., vasomotion) is a physiological process thought to aid blood flow through tissues by reducing resistance [10]. Such a process may become more important when metabolic demand increases such as during exercise. It is likely that the increased central respiratory drive that accompanies exercise may augment HFO to optimise vascular conductance in skeletal muscle to both increase oxygenation and remove end products. There is no reason why such a mechanism cannot also apply to the lungs to optimize ventilation perfusion matching, although this has not been directly shown to our knowledge. HFO may also improve capillary exchange to ensure both low interstitial pressure and constant para-capillary fluid flux [10]. In diabetic patients with neuropathy the amplitude of flow-motion was reduced compounding issues with perfusion. However, in diabetics without neuropathy no such reduction in
(A)
vasomotion was seen indicating a high dependence on sympathetic innervation [10]. In hypertensive animals and humans, vasomotion is increased and this positively correlates with increased blood pressure [10]. Whether hypertension triggers more vasomotion or whether excessive vasomotion drives the hypertension is unclear but discussed below (see HFO, below.)
RSA Loss of vagal tone in cardiovascular diseases can be clearly demonstrated by the diminished change in heart rate on administration a vagolytic drug like atropine and also by the loss of RSA [11]. The cause of this absence of cardiac vagal tone and RSA may have a common origin – depression of the cardiac vagal limb of the baroreceptor reflex. The latter normally provides a major excitatory synaptic drive to cardiac vagal motoneurons [4]. At which point this depression occurs (afferent, brainstem, efferent) is not known. Depressed synaptic transmission at the level of the cardiac vagal ganglion in heart failure dogs was reported [12] and this could be restored by the administration of acetycholinesterase inhibitors. Whether this involves a pre- and/or postsynaptic effect and the precise mechanism(s) involved remain unknown. Interestingly it has been shown that reductions in nitric oxide within the cardiac ganglia dis-faciliate vagal transmission, which can be restored by over expression of neuronal nitric oxide synthase [13]. However, transmission failure at the neuroeffector junction cannot be ruled out. A central component
central apnea
(B) ∗
∆ PP with return of PNA (mmHg)
20 15 10 5 0
1 min
WKY
SHR
Tone developed by respiratorysympathetic coupling
FIGURE 31.3 In hypertension the increased vascular resistance is driven, in part, by the enhanced respiratory-sympathetic coupling. (A) Reinstating breathing after suppressing central respiratory drive (with hypocapnia) allows an assessment of the contribution of respiratorysympathetic coupling to vasomotor tone. As phrenic nerve activity (PNA) returns this couples to sympathetic nerve activity (SNA) driving up arterial perfusion pressure (PP). Notice the immediate saw-toothed increase in PP when PNA returns with summation of the PP oscillations driving pressure up. (B) Graph indicates that the respiratory-sympathetic coupling contributed more to PP (and vascular resistance) in the SHR than the normotensive Wistar Kyoto rat (WKY). All data from the arterially perfused in situ preparation. From ref 8.
III. AUTONOMIC PHYSIOLOGY
154
31. CRoSS-TAlk BETwEEn BoDy SySTEmS: RESPIRAToRy-CARDIovASCulAR CouPlIng In HEAlTH AnD DISEASE
to this vagal dysfunction is suggested from a model of intermittent hypoxia induced cardiovascular pathology exhibiting decreased excitability of cardiac vagal preganglionic neurons [14].
the stimulus coincides with the onset of expiration [20]. This may aid in reducing arterial pressure transiently by limiting venous return.
NEW HORIZONS
HFO In contrast to a decline in RSA, HFO are augmented in hypertension, at least in the spontaneously hypertensive (SH) rat (Fig. 31.3) [8]. The amplitude of respiratory-related sympathetic bursting was augmented in SH compared to normotensive rats and showed a phase shift peaking in late inspiration rather than early expiration [8]; the significance of the latter is unknown but agrees with earlier observations in the SHR [15]. The increased coupling of respiratory-sympathetic modulation was without significant change in central inspiratory drive [8]. This supporting the notion that the coupling strength was augmented. The resultant increase in coupling strength produced greater HFO in arterial pressure in the SH rat. These waves summated raising vascular resistance and arterial pressure was greater in the SH than normotensive rat (i.e. 15 vs. 5 mmHg) (Fig. 31.2) [8]. Alteration in coupling strength and pattern of coupling have also been seen in the angiotensin II/high salt induced hypertensive rat [16], the Goldblatt hypertensive rat (Oliveira-Sales EB, Campos RR and Paton, JFR – unpublished) and rats treated with chronic intermittent hypoxia (CIH) [17]. In the latter case, CIH produced hypertension associated with increased respiratory modulation of sympathetic activity produced by the unique appearance of an extra respiratory-related burst in sympathetic activity occurring during late expiration. This was subsequently found to correlate with abdominal motor discharge, which was not present in control animals, suggesting that CIH treated rats expire actively (i.e. forced expiration) and that this rhythm drives the additional sympathetic burst contributing to the hypertension [17]. The importance of increased blood pressure variability in mediating the end organ damage is increasingly appreciated in animal models such as the SHR [18] and also in man [19]. This respiratory-sympathetic coupling therefore represents an interesting alternative potential target for treatment.
CARDIOVASCULAR MODULATION OF RESPIRATORY ACTIVITY This review would be incomplete without mentioning the emerging data supporting the reciprocity of cardiovascular-respiratory coupling. Brainstem neurons receptive to pulmonary stretch receptor inputs (essential for inspiratory phase termination) receive convergent inputs from baroreceptors. This now appears important for mediating baroreceptor reflex depression of breathing [20]. Prolongation of the expiratory pause can be evoked by baroreceptor stimulation but this is most effective when
There are some key studies that need to be performed. Given its protective role, the site(s) and mechanisms of blockade of cardiac vagal transmission must be identified in cardiovascular disease to allow novel, targeted therapy to be devised. Regarding HFO we need a better comprehension of its functional role from basic experimental investigations and the factors that govern its plasticity and amplification. Similarly we need to know whether such amplified coupling exist in human patients with heart failure and/or hypertension. Our pilot data support that this may be the case (Fisher J, Pickering AE & Paton JFR – unpublished). If so, an understanding of the changes in breathing rate and/ or pattern may provide new insight into methods to control excessive sympathetic activity in cardiovascular diseases. Changes in the sensitivity of central and peripheral chemoreception are potentially most relevant. Breathing rate and pattern may be a sensitive prognostic indicator for cardiovascular disease allowing earlier intervention and prevention treatment. All said, cardiovascular-respiratory coupling is in take-off mode for translation to the clinic.
References [1] La Rovere MT, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998;351:478–84. [2] Anrep GV, Pascual W, Rössler R. Respiratory variations of the heart rate. II. The central mechanism of the sinus arrhythmia and the inter-relationship between central and reflex mechanism. Proc Roy Soc Lond 1936;119(Series B):218–30. [3] Paton JF, Boscan P, Pickering AE, Nalivaiko E. The yin and yang of cardiac autonomic control: vago-sympathetic interactions revisited. Brain Res Rev 2005;49:555–65. [4] McAllen RM, Spyer KM. The baroreceptor input to cardiac vagal motoneurons. J Physiol 1978;282:365–74. [5] Paton JFR. A working heart-brainstem preparation. J Neurosci Meth 1996;65:63–8. [6] Adrian ED, Bronk DW, Phillips G. Discharges in mammalian sympathetic nerves. J Physiol 1932;74:115–33. [7] Habler HJ, Janig W, Michaelis M. Respiratory modulation in the activity of sympathetic neurons. Prog Neurobiol 1994;43:567–606. [8] Simms AE, Paton JF, Pickering AE, Allen AM. Amplified respiratory– sympathetic coupling in the spontaneously hypertensive rat: does it contribute to hypertension? J Physiol 2009;587:597–610. [9] Hayano J, Yasuma F, Okada A, Mukai S, Fujinami T. Respiratory sinus arrhythmia. A phenomenon improving pulmonary gas exchange and circulatory efficiency. Circ 1996;94:842–7. [10] Nilsson H, Aalkjaer C. Vasomotion: mechanisms and physiological importance. Mol. Interv. 2003;3:79–89. 51 [11] Polson JW, McCallion N, Waki H, Thorne G, Tooley MA, Paton JFR, et al. Evidence for cardiovascular autonomic dysfunction in neonates with coarctation of the aorta. Circ 2006;113:2844–50. [12] Bibevski S, Dunlap ME. Ganglionic mechanisms contribute to diminished vagal control in heart failure. Circ 1999;99:2958–63.
III. AUTONOMIC PHYSIOLOGY
nEw HoRIzonS
[13] Wang L, Li D, Dawson TA, Paterson DJ. Long-term effect of neuronal nitric oxide synthase over-expression on cardiac neurotransmission mediated by a lentiviral vector. J Physiol 2009;587:3629–37. [14] Yan B, Soukhova-O'Hare GK, Li L, Lin Y, Gozal D, Wead WB, et al. Attenuation of heart rate control and neural degeneration in nucleus ambiguus following chronic intermittent hypoxia in young adult Fischer 344 rats. Neuroscience 2008;153:709–20. [15] Czyzyk-Krzeska MF, Trzebski A. Respiratory-related discharge pattern of sympathetic nerve activity in the spontaneously hypertensive rat. J Physiol 1990;426:355–68. [16] Toney GM, Pedrino GR, Fink GD, Osborn JW. Does enhanced respiratory-sympathetic coupling contribute to peripheral neural mechanisms of angiotensin II-salt hypertension? Exp Physiol 2010;95:587–94.
155
[17] Zoccal DB, Simms AE, Bonagamba LH, Braga VA, Pickering AE, Machado BH, et al. Increased sympathetic outflow in juvenile rats submitted to chronic intermittent hypoxia correlates with enhanced expiratory activity. J Physiol 2008;586:3253–65. [18] Miao CY, Xie HH, Zhan LS, Su DF. Blood pressure variability is more important than blood pressure level in determination of endorgan damage in rats. J Hypertens 2006;24:1125–35. [19] Tatasciore A, Renda G, Zimarino M, Soccio M, Bilo G, Parati G, et al. Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension 2007;50:325–32. [20] Baekey DM, Molkov YI, Paton JFR, Rybak IA, Dick TE. Effect of baroreceptor stimulation on the respiratory pattern: Insights into respiratory-sympathetic interactions. Resp Physiol Neurobiol 2010;174:135–45.
III. AUTONOMIC PHYSIOLOGY
C H A P T E R
32 Circadian Rhythms and Autonomic Function Diego A. Golombek Nested deep within the brain, a master clock guides most of our temporal regulation of physiology and behavior. Indeed, mammalian diurnal rhythms are generated by the hypothalamic suprachiasmatic nuclei (SCN) and finely tuned to environmental periodicities, the most important being the light–dark cycle. Light reaches the clock through a direct retinohypothalamic tract (RHT), primarily through glutamatergic innervation, and its action is probably regulated by a variety of other neurotransmitters. The SCN continue to work precisely under constant conditions, originating circadian (i.e., with a period of about 24 h) rhythms in free-running conditions. This simple scheme can be better described by considering diverse entrainment agents (zeitgebers) which include food availability, arousal and temperature. In addition. a variety of so-called peripheral oscillators are able to generate autonomous circadian cycles in vitro (e.g., the liver, fibroblasts, diverse brain regions, lung, retina, etc.), although their influence is probably restricted to their local environment. Photic entrainment is achieved primarily by stimulation of retinal photoreceptors that include the classical rod and cone signal transduction, but also through melanopsin, a photopigment present in retinal ganglion cells involved in non-visual responses. Within the SCN, rhythms are generated in circadian pacemaker cells by a complex of molecular feedback loops that positively and negatively regulate the transcription of core genes (e.g. period, cryptochrome, bmal1) of the circadian clock. The transcription-translation loop that generates molecular oscillations of clock genes is remarkably conserved among species and even distant groups, suggesting a possibly monophyletic origin of such mechanism. Forward genetic approaches have unraveled several genetic components isolated from distinct circadian phenotypes, advancing our knowledge of the molecular circadian clock. In the mid-1990s the first mammalian clock gene (CLOCK) was discovered and led to the description of the loop in which CLOCK and BMAL heretodimerize and promote the transcription of PER (period) and CRY (cryptochrome) genes, whose proteic products in turn heterodimerize, translocate to the nucleus and negatively regulate the activity of CLOCK/BMAL. Deletions or
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00032-9
mutations in these genes or in their post-transcriptional regulation (such as phosphorylation) result in arrhythmicity or in profound changes in the circadian structure. In addition, genome-wide identification of clock-controlled genes, as well as their protein products and their interactions, provides important information for the understanding of the systemic behavior of circadian cogs and wheels within and between cells. In addition, post-translational modifications of clock proteins are deeply related to circadian regulation, as well as the recent description of epigenetic mechanisms that are controlled by the clock and also regulate the transcription of clock genes.
SCN OUTPUT AND AUTONOMIC CONTROL The output of the SCN includes both humoral (i.e., by vasopressin release) and neural mechanisms, which are directly related to the autonomic nervous system and, in turn, to the circadian regulation of body functions. The best known example of SCN output is probably the regulation of melatonin synthesis by the pineal gland. Pineal melatonin content exhibits a clear diurnal and circadian rhythm which is regulated by light in a daily and seasonal fashion. The SCN regulates pineal function by innervation of paraventricular (PVN) neurons which project to pre-ganglionic neurons in the intermediolateral nucleus of the thoracic spinal cord, which in turn project to the noradrenergic neurons of the superior cervical ganglion (SCG) (Fig. 32.1). The noradreneregic unnervation of the pineal is crucial in the activation and light-response of the enzymes responsible for melatonin synthesis and release. Melatonin (and, as stated below, corticosterone) might be considered the humoral hand of the circadian clock that might help in setting the pace and phase of diverse physiological variables. This SCN control of pineal melatonin can be extrapolated to other autonomic controls of hormonal secretion. For example, tracing experiments revealed a SCNPVN-sympathetic nervous system-adrenal gland axis that controls corticosterone release, by means of a diurnal
157
© 2012 Elsevier Inc. All rights reserved.
158
32. CIRCAdIAn RHyTHms And AuTonomIC FunCTIon
FIGURE 32.1 The circadian clock located in the hypothalamic suprachiasmatic nuclei (SCN) sends temporal information to the body through humoral and neural pathways interacting with the autonomic nervous system. The SCN is entrained by photic stimulation through the retinohypothalamic tract (RHT) which receives information from retinal photoreceptors (PRs) and intrinsically photoreceptive ganglion cells (iPRGCs). Besides targeting neuroendocrine neurons directly (depicted here as “endocrine cells”, such as GnRH- or CRH-releasing cells), the SCN synapses with diverse hypothalamic nuclei such as the medial preoptic nucleus or the dorsomedial nucleus, as well as thalamic projections (all of which are here grouped as “other nuclei”). However, the best known efferent target of the SCN are the paraventricular nuclei (PVN), which integrate sympathetic and parasympathetic signals from the circadian system and connect with relay stations in the brainstem and the spinal cord. Parasympathetic projections to the dorsal motor nucleus of the vagus (DMV) and sympathetic projections to preganglionic neurons of the intermediolateral column of the spinal cord (IML). Autonomic circadian control of peripheral organs follows these pathways. As an example, noradrenergic innervation from the IML, through the sympathetic superior cervical ganglion, to the pineal gland (P) is shown.
change in ACTH responsiveness. In a similar fashion, the SCN regulates glucose metabolism by a circadian modulation of insulin sensitivity and hepatic glucose production. In addition, the SCN relays neural information to the pancreas, the liver and the adipose tissue, the heart and the kidney (among others) by sympathetic/parasympathetic pathways. Metabolism is linked to the circadian system not only through autonomic innervation but also because the core clock genes, expressed in several tissues throughout the body, are directly related to cellular metabolic pathways. Besides the humoral and neural regulation of autonomic pathways, the SCN can be modulated by feedback from the periphery, by means of hormones (e.g., melatonin), immune factors or information conveyed by circumventricular organs such as the arquate nuclei. In addition, the master clock in the SCN might use autonomic signaling in order to keep peripheral clock oscillations synchronized, as suggested by experiments in which manipulations of autonomic connections to peripheral organs such as the liver reset clock gene expression. Disruption of the normal synchrony between central and peripheral circadian oscillators may result in severe pathological outcomes, as suggested by recent reports that indicate that abnormalities in circadian sympathetic homeostasis results in tumor developments in mice.
CIRCADIAN AND SLEEP-CONTROL OF THE AUTONOMIC NERVOUS SYSTEM The light–dark cycle influences autonomic activity, and it has been demonstrated that this regulation depends on the SCN, since lesions of the nuclei eliminate photic modulation. Clever tracing experiments performed by the group of Kalsbeek and Buijs in the Netherlands demonstrated that control of parasympathetic and sympathetic pre-autonomic neurons is completely separated and independent along the circadian pathway from the hypothalamus to the brainstem. In this way, the SCN and the circadian system are able to modulate both subdivisions of the autonomic nervous system independently, thus resulting in the most adequate responses depending on the time of day and other environmental and internal temporal cues. An imbalanced temporal regulation of sympathetic and parasympathetic activity might lead to profound changes in metabolic physiology and, eventually, to metabolic syndrome-like disease. Indeed, in experimental forced desynchronization clear endogenous circadian regulation of autonomic activity has been demonstrated (assessed by, for example, R-R interval variation in the electrocardiogram), by independent control of sympathetic and vagal innervation of the heart. However, besides it endogenous circadian control, autonomic activity also exhibits profound changes throughout
III. AUTONOMIC PHYSIOLOGY
CARdIAC EvEnTs And CIRCAdIAn RHyTHms
the sleep–wake cycle. For example, sympathetic activation is reduced significantly in the transition from wakefulness to slow-wave sleep stage 4 (accompanied by a decrease in arterial blood pressure and bradycardia) determining the parasympathetic predominance typical of this stage – although it goes back to awake levels during REM sleep. Indeed, sleep styles affect autonomic regulation of several variables, including blood pressure and cardiac function: among other changes, short sleep duration correlates with the development of hypertension (as well as diabetes). It is also well-known that cardiovascular incidents do not occur at random throughout the day, but tend to be more common in the morning, suggesting that at the rest-activity transition the SCN is crucial in regulating the sympathetic/parasympathetic balance to the heart, and any changes in clock function put the system at risk. Treatments that increase the amplitude of circadian rhythms (such as exercise, diet, chronobiotics, etc.) might be useful to prevent such clock-dependent risks.
CARDIAC EVENTS AND CIRCADIAN RHYTHMS As an example of circadian autonomic regulation, we shall mention that most (if not all) cardiovascular variables exhibit strong diurnal and/or circadian rhythms, including blood pressure, heart rate, heart rate variability and many others. As a consequence, cardiovascular events also tend to occur at specific times of day, with higher frequencies in the morning and lower risks during sleep which relate to rhythmic changes in human susceptibility to such events. Besides the general pattern of higher blood pressure and heart values during the day, there are marked interindividual differences in temporal allocation of physiological variables (i.e., chronotypes), with extreme morning (“larks”) and evening types (“owls”) exhibiting a difference of several hours in the maxima of temperature, blood pressure and heart rate. Forced desynchronization protocols have demonstrated a mixed contribution from both endogenous circadian factors and sleep in the regulation of diurnal autonomic variations such as changes in heart rate and heart rate variability. Although less studied, seasonal variations in cardiac function have also been reported, including pathological consequences. As for pathological situations, it has long been known that there is a significant peak of acute myocardial infarction in the morning hours (and sometimes a secondary peak in the afternoon), as well as for ischemic and hemorrhagic stroke. Moreover, an alteration of circadian cardiac regulation in coronary disease has been demonstrated.
159
Circadian desynchronization of autonomic (sympathetic/ parasympathetic) regulation of the heart correlates closely with heart disease. Finally, extreme environments (e.g., space missions, Antarctic expeditions) can also induce an autonomic/circadian disruption with accompanying neurovegetative changes. In summary, the mammalian circadian system is deeply interrelated with the autonomic nervous system. The two main output channels for the circadian clock are through humoral release or sympathetic/parasympathetic relay stations that convey temporal information throughout the body. The SCN sends neural projections to other hypothalamic nuclei and from there to the brainstem or spinal cord autonomic centers that control physiological activity. In addition, neurovegetative mechanisms exhibit a double modulation by the circadian system (and, in turn, are synchronized to environmental synchronizers) and by arousal/sleep-related mechanisms in a homeostaticlike process. In this sense, autonomic regulation should not only be regarded as a spatial/functional control of physiology and behavior but also in terms of a strong temporal modulation that helps the body to adequately devote resources and energy throughout the day.
Further Reading Buijs RM, Kalsbeek A. Hypothalamic integration of central and peripheral clocks. Nat Rev Neurosci 2001;2:521–6. Golombek DA, Rosenstein RE. Physiology of circadian entrainment. Physiol Rev 2010;90:1063–102. Kalsbeek A, Bruinstroop E, Yi CX, Klieverik LP, La Fleur SE, Fliers E. Hypothalamic control of energy metabolism via the autonomic nervous system. Ann NY Acad Sci 2010;1212:114–29. Kalsbeek A, Fliers E, Hofman MA, Swaab DF, Buijs RM. Vasopressin and the output of the hypothalamic biological clock. J Neuroendocrinol 2010;22:362–72. Kalsbeek A, Kreier F, Fliers E, Sauerwein HP, Romijn JA, Buijs RM. Circadian control of metabolism by the suprachiasmatic nuclei. Endocrinology 2007;148:5635–9. Lee S, Donehower LA, Herron AJ, Moore DD, Fu L. Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS One 2010;5(6):e10995. Maywood ES, O’Neill JS, Reddy AB, Chesham JE, Prosser HM, Kyriacou CP, et al. Genetic and molecular analysis of the central and peripheral circadian clockwork of mice. Cold Spring Harb Symp Quant Biol 2007;72:85–94. Scheer FA, Kalsbeek A, Buijs RM. Cardiovascular control by the suprachiasmatic nucleus: neural and neuroendocrine mechanisms in human and rat. Biol Chem 2003;384:697–709. Schibler U. Circadian time keeping: the daily ups and downs of genes, cells, and organisms. Prog Brain Res 2006;153:271–82. Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet 2008;9:764–75.
III. AUTONOMIC PHYSIOLOGY
C H A P T E R
33 Baroreceptor Reflexes Mark W. Chapleau Changes in blood pressure (BP) and/or blood volume are “sensed” within specific compartments of the cardiovascular system by “baroreceptors” (Fig. 33.1). Baroreceptors are mechanosensitive nerve endings that are activated by vascular and/or cardiac distension during increases in intraluminal BP. The activity of arterial baroreceptors innervating large arteries (primarily aortic arch and carotid sinuses) is increased when arterial BP rises, and decreased when BP falls. The changes in baroreceptor activity evoke rapid reflex adjustments that buffer or oppose the changes in arterial BP in a negative-feedback manner. Cardiopulmonary baroreceptors innervate the heart, vena cava, and pulmonary vasculature. Since the activity of cardiopulmonary baroreceptors correlates with intrathoracic (central) blood volume, these nerve endings are often referred to as “volume receptors” or “low-pressure” baroreceptors. The reflex adjustments triggered by changes in cardiopulmonary baroreceptor activity regulate blood volume in addition to influencing BP.
NEURAL PATHWAYS AND EFFECTOR MECHANISMS Arterial Baroreflex The neural pathways and effector mechanisms involved in baroreflex control of the circulation are summarized in Figures 33.1 and 33.2. The cell bodies (somata) of carotid sinus and aortic arch baroreceptor neurons are located in petrosal and nodose ganglia, respectively. The corresponding afferent baroreceptor activity is transmitted to the nucleus tractus solitarius (NTS) in the medullary brain stem via carotid sinus and glossopharyngeal nerves, and aortic depressor and vagus nerves, respectively. The baroreceptor inputs are integrated and relayed through a network of central nervous system (CNS) neurons controlling efferent parasympathetic nerve activity (paraSNA), sympathetic nerve activity (SNA), and release of the vasoconstrictor and antidiuretic peptide vasopressin (AVP) from the posterior pituitary gland (Figs 33.1 and 33.2). The multiple effector mechanisms by which these systems buffer increases in BP are depicted in Figure 33.2. The effector mechanisms operate in the opposite direction when arterial BP and baroreceptor activity are reduced.
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00033-0
BP-sensitive sensory nerves also innervate the juncture of the right carotid and right subclavian arteries (Fig. 33.1) and the coronary arteries. These nerves travel in the aortic depressor and vagus nerves with cell bodies located in the nodose ganglia. Activation of the coronary artery baroreflex modulates peripheral SNA and vascular resistance, but unlike carotid sinus and aortic arch baroreflexes, has little or no affect on HR.
Cardiopulmonary Baroreflex The cardiopulmonary region is innervated by multiple types of mechanosensitive and chemosensitive sensory nerves that affect autonomic and cardiovascular functions in a variety of ways (see Chapter 35). We focus here on vagal afferent neurons with cell bodies in the nodose ganglia and nerve endings in the heart, vena cava, and pulmonary vasculature that are sensitive to changes in central blood volume (Fig. 33.1). The electrophysiological properties of these sensory neurons, the CNS pathways engaged by their activation, and their influence on efferent effectors are similar to that of arterial baroreceptor neurons (see Figs 33.1 and 33.2), but not identical. While changes in cardiopulmonary baroreceptor activity during changes in central blood volume evoke powerful reflex changes in peripheral SNA, vascular resistance, and release of renin and AVP; the reflex has little affect on HR. The changes in SNA and vascular resistance contribute to orthostatic adjustments. Renal actions of SNA, the renin-angiotensinaldosterone system, and AVP leading to changes in Na and water reabsorption play a major role in regulation of blood volume.
DETERMINANTS OF AFFERENT BARORECEPTOR ACTIVITY Rate Sensitivity of Baroreceptors Baroreceptor activity is dependent not only on the mean level of BP, but also on the direction and rate of change in BP. Consequently, baroreceptor activity will increase or decrease to a greater extent when the change in BP occurs more rapidly leading to a more effective reflex compensation. Similarly, baroreceptor activity is higher
161
© 2012 Elsevier Inc. All rights reserved.
162
33. BARoRECEPToR REflExEs
FIGURE 33.1 Location of baroreceptors and neural pathways mediating baroreflex responses. (A) Arterial baroreceptor afferents innervate carotid sinuses, aortic arch and the right carotid artery-right subclavian artery juncture. Cardiopulmonary baroreceptors innervate veno-atrial juncture, atria, ventricles and pulmonary vasculature. The baroreflexes modulate paraSNA and SNA to numerous organ systems and vasopressin (AVP) release. Key targets involved in cardiovascular regulation are illustrated. (B) Major nuclei involved in baroreflex control. Increases in BP and baroreceptor activity activate excitatory neural projections from nucleus tractus solitarius (NTS) to preganglionic parasympathetic neurons in nucleus ambiguus (NA) and dorsal motor nucleus of the vagus (DMNX) resulting in increases in paraSNA and decreases in HR. Activation of excitatory projections from NTS to caudal ventrolateral medulla (CVLM) causes subsequent inhibition of premotor sympathetic neurons in rostral ventrolateral medulla (RVLM) that project to preganglionic sympathetic neurons in the intermediolateral (IML) column of the thoracolumbar spinal cord. Increased baroreceptor activity also inhibits secretion of AVP from magnocellular neurons in paraventricular nucleus (PVN) and supraoptic nucleus (SON) of hypothalamus. Other CNS regions interact with these areas to modulate baroreflexes.
FIGURE 33.2 Effector mechanisms mediating reflex responses to increases in baroreceptor activity. Increases in arterial BP and baroreceptor activity increase paraSNA, decrease SNA, and inhibit release of AVP leading to an array of cardiovascular, hormonal and renal responses. Decreases in arterial BP evoke directionally opposite reflex responses. A-V node, atrio-ventricular node; Ang II, angiotensin II; H2O, water.
III. AUTONOMIC PHYSIOLOGY
DECREAsED BARoREflEx sENsITIVITY IN DIsEAsE
during the systolic phase of the arterial pressure pulse and lower or absent during diastole. The phasic discharge of afferent activity facilitates reflex inhibition of SNA.
163
and autocrine/paracrine factors including norepinephrine, prostacyclin, serotonin, nitric oxide, and reactive oxygen species modulate baroreceptor sensitivity through actions on these ion channels and membrane pumps.
Large Artery Compliance Baroreceptors are not directly sensitive to BP, but rather are sensitive to mechanical deformation of the nerve endings during distension of the arterial wall. Therefore, large artery compliance (specifically of the carotid sinuses and aortic arch) is a major determinant of the baroreceptor sensitivity to changes in BP. Decreased arterial compliance contributes to decreased baroreceptor sensitivity in atherosclerosis, hypertension, and aging.
Neuronal Mechanisms Mediating Sensory Transduction The prevailing view is that baroreceptors are activated by the opening of mechanosensitive ion channels in the sensory terminals. The resulting depolarization, if of sufficient magnitude, will trigger action potential discharge upon opening of voltage-gated Na and K channels. The action potentials are propagated towards the CNS at frequencies related to the magnitude of deformation and depolarization of the sensory terminals. Evidence suggests that members of the epithelial sodium channel (ENaC) superfamily including acid-sensing ion channel 2 (ASIC2) are components of the mechanosensitive ion channel complex. Transient receptor potential (TRP) channels have also been implicated in baroreceptor sensory transduction and/ or signaling, perhaps functioning as a mechanosensor. A variety of voltage- and ligand-gated ion channels and membrane pumps modulate the membrane potential and excitability of baroreceptors including Kv1, Kv4, BK and KCNQ (M-type) K channels; tetrodotoxin-insensitive, voltage-gated Na channels; hyperpolarization-activated cyclic nucleotide-gated (HCN) channels; serotonin 5HT3 receptor/ channels; and the Na/K–ATPase. Several neurohumoral
BAROREFLEX ADAPTATION AND RESETTING IN ACUTE HYPERTENSION Baroreceptor activity increases with a rise in arterial BP but declines over time if the acute hypertension is maintained. Furthermore, “post-excitatory depression” (PED) of baroreceptor activity occurs when BP decreases rapidly after a period of increased BP. Different mechanisms have been implicated in these two phenomena with opening of 4-aminopyridine sensitive K channels contributing to adaptation and activation of the Na/K–ATPase causing PED. Baroreceptor adaptation and PED contribute to acute resetting of the baroreceptor pressure-activity relationship to higher mean pressures in hypertension. The baroreceptor function curve is shifted in a parallel manner with little or no change in baroreceptor sensitivity (slope), and is usually accompanied by resetting of the arterial BP-HR relation (Fig. 33.3). Central mechanisms may exacerbate or oppose resetting of the baroreflex function curve. While baroreflex resetting compromises the ability to counter the sustained hypertension, it helps preserve the ability to buffer acute fluctuations in BP at the new higher prevailing level of BP.
DECREASED BAROREFLEX SENSITIVITY IN DISEASE Control of HR vs. SNA and BP, and Underlying Mechanisms Baroreflex sensitivity (BRS) for control of HR is consistently decreased in numerous pathological states including chronic hypertension, coronary artery disease,
FIGURE 33.3 Baroreceptor and baroreflex resetting during acute hypertension. An increase in mean arterial BP increases baroreceptor activity (left) and reflexively decreases HR (right). During a sustained increase in BP, baroreceptor activity decreases or adapts over time (left) and HR increases at the same level of BP (right). The baroreceptor and baroreflex function curves are shifted (reset) to higher BP during acute hypertension with preservation of the slope of the curves (sensitivity) (dashed lines).
III. AUTONOMIC PHYSIOLOGY
164
33. BARoRECEPToR REflExEs
post-myocardial infarction, heart failure, diabetes mellitus, and obesity, and with aging. Afferent, central, and efferent mechanisms contribute to varying degrees to decreased BRS in these diseases. Chronic structural changes such as decreased large artery compliance and cardiac hypertrophy impair the afferent sensitivity of arterial and cardiopulmonary baroreceptors. In addition, neurohumoral activation and oxidative stress impair baroreflex function. For example, increased circulating levels of angiotensin II (Ang II) reset the baroreflex function curve to a higher mean level of arterial BP. This resetting is mediated by actions of Ang II on circumventricular organs that lack a blood–brain barrier (e.g., area postrema) and is independent of the rise in BP. Furthermore, Ang II acts at multiple central and peripheral sites in the nervous system to increase SNA, and decrease paraSNA and BRS. Aldosterone inhibits BRS by reducing afferent baroreceptor activity and by central actions. Factors released from activated platelets and reactive oxygen species decrease baroreceptor afferent sensitivity. Oxidative stress in the CNS contributes to increased SNA and BP in animal models of hypertension. Antioxidant therapies improve BRS in hypertension, heart failure, and in aging. In contrast to control of HR, the effects of cardiovascular disease and aging on arterial baroreflex control of SNA and BP are controversial with reports of both impaired and preserved BRS. Differences in results between studies can be explained in part by differences in: (i) the methods used to quantify changes in SNA and evaluate BRS; (ii) engagement of arterial vs. cardiopulmonary baroreflexes; (iii) control of SNA to different peripheral targets; (iv) severity of disease; and (v) experimental conditions (e.g., use of anesthesia). In most conditions, decreased BRS for parasympathetic control of HR usually precedes and/ or exceeds the decrease in BRS for sympathetic control. Structural damage to baroreceptor afferents, usually resulting from surgery or radiation, can cause “baroreflex failure” with loss of cardiovagal tone and severe, episodic periods of sympathetic-mediated hypertension (see Chapter 72). A similar phenotype is observed in patients with familial dysautonomia, a rare genetic disease with severe developmental sensory nerve defects (see Chapter 103).
Genetic Determinants of BRS Decreased BRS may be secondary to underlying cardiovascular disease or may precede and contribute to disease. BRS for control of HR is impaired in normotensive subjects with a family history of hypertension, and heritability of BRS has been confirmed in twin studies. Polymorphisms in several genes have been reported to be associated with BRS (see Chapter 34). Therefore, BRS screening in high risk patients identified by disease and/ or by the presence of specific polymorphisms may be advisable. The ability to measure BRS noninvasively from spontaneous fluctuations in systolic BP and pulse interval makes this clinical application feasible.
BRS: A DETERMINANT OF CARDIOVASCULAR RISK AND THERAPEUTIC TARGET Decreased BRS and Cardiovascular Risk Increased BP variability causes target organ damage, e.g., endothelial dysfunction, vascular and cardiac hypertrophy, kidney disease and cerebral vascular dysfunction. These insults lead to myocardial infarction, stroke, and heart and kidney failure. By minimizing BP variability and restraining SNA and BP, the arterial and cardiopulmonary baroreflexes reduce target organ damage. In addition to regulating BP, baroreflexes exert a major influence on the electrical properties of the heart through modulation of cardiac SNA and paraSNA. Myocardial infarction, heart failure, and diabetes are associated with decreased BRS for control of HR, cardiac arrhythmias, and sudden cardiac death. The decrease in BRS predicts occurrence of arrhythmias and mortality in patients suffering from these diseases suggesting a causal relationship.
BRS is a Therapeutic Target The strong inverse relationship between BRS and cardiovascular risk encourages targeting therapy to improve BRS. Baroreflexes may contribute to the benefit of standard antihypertensive therapies. For example, lowering of BP of hypertensive patients by pharmacological or dietary interventions rapidly resets the baroreflex function curve to lower mean arterial BPs. The baroreflex resetting helps stabilize BP at the new lower prevailing level of BP. Reversal of vascular and cardiac stiffening and hypertrophy with longer periods of antihypertensive treatment increases BRS. Antagonists of the renin-angiotensinaldosterone system and antioxidants increase BRS independent of BP lowering, thus providing further reductions in cardiovascular risk. Recent findings have rejuvenated the concept of specific therapeutic targeting of baroreflex pathways in cardiovascular disease. Cholinesterase inhibitors promote increases in cardiovagal tone and BRS by increasing the concentration of the neurotransmitter acetylcholine at cholinergic synapses and sinoatrial node, and amplify cholinergic signaling in left ventricle. Administration of cholinesterase inhibitors and chronic electrical stimulation of the vagus nerve each result in novel downstream anti-inflammatory effects and increased survival post-myocardial infarction. A recent study examining effects of chronic vagus nerve stimulation in patients with heart failure has provided promising results. Chronic electrical stimulation of carotid sinus baroreceptors in dog models of hypertension and in patients with drug-resistant hypertension have demonstrated long-term efficacy in lowering BP and reducing target organ damage. Chronic carotid sinus baroreceptor stimulation has also been shown to improve cardiac function, decrease arrhythmias, and prolong survival in
III. AUTONOMIC PHYSIOLOGY
BRs: A DETERmINANT of CARDIoVAsCulAR RIsk AND THERAPEuTIC TARgET
dog models of heart failure. Clearly, favorable effects of increasing baroreceptor activity extend far beyond shortterm control of BP.
Further Reading Brooks VL, Sved AF. Pressure to change? Re-evaluating the role of baroreceptors in the long-term control of arterial pressure. Am J Physiol Regul Integr Comp Physiol 2005;288:R815–8. Chapleau MW, Li Z, Meyrelles SS, Ma X, Abboud FM. Mechanisms determining sensitivity of baroreceptor afferents in health and disease. Ann NY Acad Sci 2001;940:1–19. Chapleau MW, Lu Y, Abboud FM. Mechanosensitive ion channels in blood pressure-sensing baroreceptor neurons. Hamill OP, editor. Current topics in membranes, Vol 59. : Elsevier Science; 2007. p. 541–67. Chapleau MW, Sabharwal R. Methods of assessing vagus nerve activity and reflexes. Heart Fail Rev 2011;16:109–27. Glazebrook PA, Ramirez AN, Schild JH, Shieh C-C, Doan T, Wible BA, et al. Potassium channels Kv1.1, Kv1.2 and Kv1.6 influence excitability of rat visceral sensory neurons. J Physiol 2002;541.2:467–82. Glazebrook PA, Schilling WP, Kunze DL. TRPC channels as signal transducers. Pflugers Arch 2005;451:125–30. Guyenet PG. The sympathetic control of blood pressure. Nature Rev Neurosci 2006;7:335–46. Hainsworth R. Reflexes from the heart. Physiol Rev 1991;71(3):617–58. Handa T, Katare RG, Kakinuma Y, Arikawa M, Ando M, Sasaguri S, et al. Anti-Alzheimer’s drug, donepezil, markedly improves long-term survival after chronic heart failure in mice. J Cardiac Fail 2009;15:805–11.
165
Korner PI. Baroreceptor resetting and other determinants of baroreflex properties in hypertension. Clin Exp Pharmacol Physiol Suppl 1989;15:45–64. La Rovere MT, Bigger Jr. JT, Marcus FI, Mortara A, Schwartz PJ for the ATRAMI investigators. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. The Lancet 1998;351:478–84. Lu Y, Ma X, Sabharwal R, Snitsarev V, Morgan D, Rahmouni K, et al. The ion channel ASIC2 is required for baroreceptor and autonomic control of the circulation. Neuron 2009;64:885–97. Monahan KD, Eskurza I, Seals DR. Ascorbic acid increases cardiovagal baroreflex sensitivity in healthy older men. Am J Physiol Heart Circ Physiol 2004;286:H2113–H2117. Parati G, Di Rienzo M, Mancia G. How to measure baroreflex sensitivity: from the cardiovascular laboratory to daily life. J Hypertens 2000;18:7–19. Schwartz PJ, De Ferrari GM, Sanzo A, Landolina M, Rordorf R, Raineri C, et al. Long term vagal stimulation in patients with advanced heart failure: First experience in man. Eur J Heart Fail 2008;10:884–91. Sun H, Li D-P, Chen S-R, Hittelman WN, Pan H-L. Sensing of blood pressure increase by transient receptor potential vanilloid 1 receptors on baroreceptors. J Pharmacol Exp Ther 2009;331:851–9. Taylor JG, Bisognano JD. Baroreflex stimulation in antihypertensive treatment. Curr Hypertens Rep 2010;12:176–81. Wladyka CL, Feng B, Glazebrook PA, Schild JH, Kunze DL. The KCNQ/ M-current modulates arterial baroreceptor function at the sensory terminal in rats. J Physiol 2008;586.3:795–802. Wright C, Drinkhill MJ, Hainsworth R. Reflex effects of independent stimulation of coronary and left ventricular mechanoreceptors in anaesthetized dogs. J Physiol 2000;528.2:349–58.
III. AUTONOMIC PHYSIOLOGY
C H A P T E R
34 Genetic Determinants of Baroreflex Function Italo Biaggioni The baroreflex is the archetypical mechanism of autonomic cardiovascular regulation. Its neural pathways, physiological relevance, and pathological consequences of its failure are described in detail in Chapters 33 and 72 and will not be repeated here. The importance of the baroreflex in a given subject can be assessed by the gain of the system, i.e., the magnitude of the reciprocal change in heart rate or sympathetic activity in response to alterations in blood pressure. The slope of the relationship between blood pressure and heart rate or sympathetic activity is used as a measure of baroreflex sensitivity (BRS). There is substantial inter-individual variability in these parameters. This is not surprising given the complex neural pathways involved and the biological measurements used in its estimation. Furthermore, most of the methods used to assess baroreflex function cannot isolate the predominant contribution of carotid sinus arterial baroreceptors to that of other arterial and venous afferents. In this chapter we will review the evidence suggesting that a significant component of the variability in baroreflex function is genetically determined. Less is known about the determinants of this genetic influence. A few studies have identified discrete polymorphisms associated with BRS. In general these studies have included relatively small number of subjects and results have not always been replicated. In some cases, the predicted functional consequences of these polymorphisms in the gene products provide a plausible biological explanation of their putative effect in BRS, but a direct causal relationship has been difficult to document. Earlier studies showed that baroreflex function was decreased in normotensive offspring of hypertensive parents, and that decreased baroreflex gain was a predictive factor for the subsequent development of hypertension [1]. More definitive proof of genetic influences on baroreflex function came from studies in twins showing significant correlation for BRS in monozygotic but not dizygotic twins [2]. It has been difficult to ascertain the role of individual genes in the modulation of complex phenotypes like the baroreflex. The baroreflex is the result of the interplay between afferent fibers located in vascular structures
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00034-2
responsive to stretch, the integration of these afferent signals in brainstem nuclei, efferent fibers carrying sympathetic and parasympathetic outflow and coupling of these fibers with cardiac and vascular structures (Chapter 33). It is likely that different genes influence each of these individual components of the baroreflex. A case in point is the observation that normotensive children with Williams syndrome have a significant reduction in BRS [3]. This syndrome is caused by the microdeletion of the long arm of chromosome 7 encompassing the locus of the elastin gene. Elastin is the main component of the extracellular matrix of arteries, and affected patients develop an arteriopathy with intimal thickening. It is plausible, therefore, that this pathology affects pressure transduction at the level of baroreceptor afferents resulting in the observed reduction in BRS. However, in humans it is not feasible to test this hypothesis by measuring afferent firing rates from the carotid sinus in response to pressure changes. The same is true for other individual components of the baroreflex arc; a gene polymorphism of deletion can theoretically affect the function of afferent structures, central brainstem pathways, or efferent neurovascular coupling. We are only able, however, to measure integrated baroreflex function and this approach will necessarily “dilute” any genetic influence on the individual components of the baroreflex. An additional level of complexity is introduced by the fact that the “baroreflex” is not a single entity, but has separate afferent inputs arising from high pressure (the carotid sinus, aortic arch and others) and low pressure (large veins) vascular structures. The efferent pathways are also differentiated into those modulating heart rate, which are predominately parasympathetic, and vascular tone, which are mostly sympathetic. It would be impossible to phenotype each of these components in the large number of patients required for genetic studies. The most commonly used method, therefore, is to estimate the relationship between systolic blood pressure and RR interval during spontaneous periods when parallel increases (or decreases) in these parameters occur. There is inherent variability in these measurements, which may also “dilute” a genetic effect.
167
© 2012 Elsevier Inc. All rights reserved.
168
34. GEnETIC DETERmInAnTs oF BARoREFlEx FunCTIon
Despite all these limitations, a handful of studies have described associations between discrete gene polymorphisms and BRS. Polymorphisms of KCNMB1 gene coding the β1 subunit of the calcium-sensitive potassium channel BK was associated with BRS in 298 normotensive twins [4]. In particular, AA homozygous in the polymorphism of exon 4b had greater BRS than heterozygous or CC homozygous. Potassium channels (BK) are expressed in vascular smooth muscle cells and are important to calcium-mediated relaxation. They are, however, also expressed in neural tissues and the site where this polymorphism may alter BRS could not be determined from these studies. AA homozygous also had higher heart rate variability in the high frequency range, a measure of increased vagal tone. It is possible, therefore, that the increased BRS was due to the putative increase in vagal tone. A common polymorphic variant in the promoter region of the bradykinin B2 receptor gene, T-58C, was also associated with baroreflex function; greater number of T alleles was associated with increased BRS in 129 untreated hypertensive subjects, but not in 95 normotensive controls [5]. This polymorphism could account for 12% of BRS variation even after accounting for blood pressure, BMI, age and gender. In transfected cell models the 58C allele was associated with reduced B2R expression, leading the authors to suggest that decreased bradykinin actions could contribute to the reduction in BRS. In a study of Finnish subjects, a C-344T polymorphism of the aldosterone synthase gene (CYP11B2) was associated with BRS measured from the overshoot phase of the Valsalva maneuver, with the CC allele associated with decreased BRS [6]. No comparable associations were found for BRS with an insertion/deletion (I/D) polymorphism of angiotensin-converting enzyme (ACE), or the M235T variants of angiotensinogen (AGT). The C-344T polymorphism is a common variant in the promoter region of the gene. The C allele has been found to be associated with elevated plasma levels of aldosterone. Ormezzano et al studied 17 polymorphisms of 11 genes relevant to blood pressure regulation in 146 hypertensive individuals and 105 healthy controls. Only the C 1222T polymorphism of endothelin receptor A, EDNRA, correlated with BRS in both populations after adjustment for age, gender, blood pressure and BMI [7]. Importantly, the association remained significant after accounting for the multiple number of genes tested. No other polymorphism was significantly correlated with BRS, including the CYP11B2 previously reported by Ylitalo [6]. Similarly, the C allele of the A1166C polymorphism in the AT1 receptor gene was associated with reduced BRS in 135 normotensive individuals [8]. Of note, this variant occurs in an untranslated region of the gene and is not associated with a functional change in the AT1 receptor but could be in linkage disequilibrium with other sites. Also, this appears to be one of the polymorphisms previously reported not to be associated with BRS [7].
Recently, Xing-Sheng et al evaluated the influence of nine polymorphisms in six genes, in 182 normotensive Chinese men, and found that carriers of the TT genotype of the T-786C polymorphism of the endothelial nitric oxide synthase gene had lower BRS than subjects carrying either the TC or the CC genotype [9]. It is believed that the C allele is associated with reduced expression of eNOS. The finding that subjects carrying the C allele had higher BRS would imply that eNOS-generated NO normally depresses baroreflex function. They also found that subjects with the TT genotype of the C-344T polymorphism in the aldosterone gene had higher BRS as compared to those with CC confirming the results from Ylitalo et al. [6]. Finally, subjects with the CC genotype of the T-58C polymorphism of the B2R gene had lower BRS compared to subjects with TT. These results are similar to those reported by Milan et al. in hypertensive subjects, even though the latter group of investigators found no association in normotensive subjects. Multivariable regression indicated that the three polymorphisms reported by XingSheng could explain 16% of BRS variability [9]. The measurement of BRS in virtually all of the studies described above relies on spontaneous reciprocal changes in blood pressure and heart rate analyzed with spectral analysis techniques from non-invasive measurements. This parameter estimates only the vagal modulation of heart rate by the baroreflex. Cardiovagal BRS has consistently shown to be reduced in hypertensive populations, but it is reassuring that none of the polymorphisms associated with reduced cardiovagal BRS were found to correlate with blood pressure itself, suggesting that differences in BRS reported were not secondary to blood pressure changes. It is known that the hypertensive trait has a significant genetic component, but most attempts to identify relevant genes have been disappointing; in most cases, the genes that have been identified account for only a few mmHg in blood pressure. There is less information about the hereditability of the sympathetic limb of the baroreflex modulating vascular tone. Yamada et al. studied three groups of adolescents: normotensives with a positive family history of hypertension, borderline hypertensives with a positive family history, and normotensives with a negative family history [10]. “Sympathovascular” BRS was estimated by the slope of the percent decrease in muscle sympathetic nerve activity in response to increases in systolic blood pressure induced by phenylephrine. “Sympathovascular” BRS was significantly smaller in the groups with a family history of hypertension ( 8 1 %/mm Hg for both the borderline and normotensive offspring) compared to the normotensive controls ( 16 1 %/mm Hg). The sympathetic contribution to blood pressure, as determined by baseline MSNA and the fall in blood pressure induced by the ganglionic blocker trimethaphan, was greater in in borderline hypertensive offspring than in normotensives with a positive family history or normotensive controls. These results indicate an impaired baroreflex capacity to dampen
III. AUTONOMIC PHYSIOLOGY
GEnETIC DETERmInAnTs oF BARoREFlEx FunCTIon
sympathetic activity resulting in greater “sympathetically driven” blood pressure in adolescents with a family history of hypertension, even before they develop hypertension. We should note that cardiovagal BRS is consistently reduced in hypertensive subjects, but baroreflex control of sympathetic tone in most studies has not been different than normotensive controls. Whereas these studies evaluated arterial high-pressure baroreceptors, Ookuwa et al. studied the function of low pressure baroreceptors located in the venous side of the circulation. Cardiopulmonary baroreflex control of forearm vascular resistance was evaluated in 12 normotensive young subjects with a family history of hypertension and compared with normotensives without a family history of hypertension [11]. Low-pressure cardiopulmonary baroreceptors were preferentially unloaded using low levels ( 20 mmHg) of lower body negative pressure (LBNP). It should be noted, however, that even these low levels of LBNP can unload high-pressure baroreceptors. The reflex increase in forearm vascular resistance in response to LBNP was significantly lower in normotensive with a family history of hypertension (38 8%) than in normotensives with a negative family history (86 19%). These results suggest that cardiopulmonary baroreflexes are also impaired in subjects with a genetic predisposition to hypertension, even during the normotensive stage. In summary, there is substantial evidence indicating that a significant component of baroreflex function is genetically determined. Furthermore, reduced BRS is found in offspring of hypertensive parents, and predicts the development of hypertension. It is not clear whether reduced baroreflex buffering contributes to the development of hypertension or is mostly a trait of an underlying abnormality in autonomic regulation of blood pressure. A few polymorphisms have been associated with reduced baroreflex function, but it is not clear where in the baroreflex arc those genes are operative, nor whether there is a
169
causal relationship. This, perhaps, is not surprising given the complex nature of baroreflex pathways and inherent limitations in clinical measures of its function.
References [1] Ducher M, Fauvel JP, Cerutti C. Risk profile in hypertension genesis: A five-year follow-up study. Am J Hypertens 2006;19:775–80. [2] Tank J, Jordan J, Diedrich A, Stoffels M, Franke G, Faulhaber HD, et al. Genetic influences on baroreflex function in normal twins. Hypertension 2001;37:907–10. [3] Girard A, Sidi D, Aggoun Y, Laude D, Bonnet D, Elghozi JL. Elastin mutation is associated with a reduced gain of the baroreceptor-heart rate reflex in patients with Williams syndrome. Clin Auton Res 2002;12:72–7. [4] Gollasch M, Tank J, Luft FC, Jordan J, Maass P, Krasko C, et al. The BK channel beta1 subunit gene is associated with human baroreflex and blood pressure regulation. J Hypertens 2002;20:927–33. [5] Milan A, Mulatero P, Williams TA, Carra R, Schiavone D, Martuzzi R, et al. Bradykinin B2 receptor gene (-58T/C) polymorphism influences baroreflex sensitivity in never-treated hypertensive patients. J Hypertens 2005;23:63–9. [6] Ylitalo A, Airaksinen KE, Hautanen A, Kupari M, Carson M, Virolainen J, et al. Baroreflex sensitivity and variants of the renin angiotensin system genes. J Am Coll Cardiol 2000;35:194–200. [7] Ormezzano O, Poirier O, Mallion JM, Nicaud V, Amar J, Chamontin B, et al. A polymorphism in the endothelin-A receptor gene is linked to baroreflex sensitivity. J Hypertens 2005;23:2019–26. [8] Jira M, Zavodna E, Honzikova N, Novakova Z, Vasku A, Izakovicova HL, et al. Association of A1166C polymorphism in AT(1) receptor gene with baroreflex sensitivity. Physiol Res 2010;59:517–28. [9] Xing-Sheng Y, Yong-Zhi L, Jie-Xin L, Yu-Qing G, Zhang-Huang C, Chong-Fa Z, et al. Genetic influence on baroreflex sensitivity in normotensive young men. Am J Hypertens 2010;23:655–9. [10] Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Shionoiri H, Ishii M, et al. Impaired baroreflex changes in muscle sympathetic nerve activity in adolescents who have a family history of essential hypertension. J Hypertens 1988;6:S525–8. [11] Ookuwa H, Takata S, Ogawa J, Iwase N, Ikeda T, Hattori N. Abnormal cardiopulmonary baroreflexes in normotensive young subjects with a family history of essential hypertension. J Clin Hypertens 1987;3:596–604.
III. AUTONOMIC PHYSIOLOGY
C H A P T E R
35 Cardiac and Other Visceral Afferents John C. Longhurst, Liang-Wu Fu INTRODUCTION Visceral afferents convey information to the central nervous system about local changes in chemical and mechanical environments of a number of organ systems. Physiologically, the autonomic sensory nervous system provides information about the function of abdominal and thoracic organ systems, allowing for reflex responses that typically aid in the normal function of these systems. Pathophysiologically, these sensory nerves provide a warning system to alert the organism to the presence of injury or conditions that can lead to injury and cell death. Thus, they assist both in normal function and maintain homeostasis in adverse conditions. The reflex arc includes the afferent or sensory limb, central neural processing and efferent motor system innervating effector organs. This chapter focuses on afferent fibers present in vagus and sympathetic (spinal) pathways that respond to mechanical and chemical alterations in the environment, and the resulting reflex responses, using ischemia as the stimulus paradigm. Ischemia constitutes an important condition associated with cardiovascular disease. Stimulation of visceral sensory nerves leads to important cardiovascular reflex responses mediated by the autonomic nervous and humoral systems.
ANATOMICAL FRAMEWORK Finely myelinated (Aβ, Aδ) and unmyelinated (C fibers) afferent pathways innervating either unspecialized dense, diffuse or bare nerve endings, form the afferent pathway of visceral cardiovascular reflexes, Table 35.1 [1]. The nerve endings typically are located within the interstitial space and respond to mechanical and/or chemical events. Afferents ascend to the central nervous system (CNS) through mixed nerves, including the vagus or sympathetic (spinal, e.g., spinothalamic and spinoreticular) pathways. A number of nuclei in the thalamus, hypothalamus, midbrain, pons and medulla, including the nucleus tractus solitarii, caudal and rostral ventral lateral medulla, parabrachial nucleus, paraventricular nucleus, periaqueductal gray, lateral tegmental field, medullary raphé, and nucleus ambiguus, among others, process input from visceral afferents ultimately regulating sympathetic and
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00035-4
vagal autonomic motor fiber discharge activity directed to cardiovascular effector organs. These reflex arcs form the pathways for visceral reflexes concerned with regulation of autonomic outflow to the cardiovascular system.
AFFERENT STIMULI Visceral afferent fibers responsive to mechanical stimuli are either high or low threshold with the high threshold endings frequently serving as nociceptors [2–4]. Low threshold mechanosensitive receptors respond to changes in stress or strain and provide information relevant to digestion (gut), cardiac filling or function (cardiac venoatrial, atrial and ventricular). For example, cardiac atrial receptors, located mainly in the veno-atrial junctions, that are innervated by myelinated afferents that course through the vagus, respond to changes in balloon distension involving modest changes in volume but high tensions [5]. Many ventricular mechanosensitive C-fibers respond to changes in end-diastolic volume, and hence stretch, rather than systolic pressure, i.e., compression [6]. Sensory nerves that respond to changes in stress or strain in the gastrointestinal tract largely course through the vagus nerves and likely are concerned with transmission of information related to digestion rather than cardiovascular function [2].
ISCHEMIA Many high threshold mechanosensitive endings are triggered by chemical events and hence are bimodal in their sensitivity. Chemical stimuli activating these endings depend on the organ in which they are situated and the condition imposed [4]. Ischemia, for example, leads to the production and release of protons, kinins, serotonin, histamine, cyclooxygenase products like thromboxane, endothelin and reactive oxygen species, including hydroxyl radicals, among others (Fig. 35.1). These mediators stimulate afferent endings and frequently sensitize them to the action of other chemical mediators [7]. Other ischemia-related chemical changes associated with activation of peripheral chemoreceptors, such as hypoxia and hypercapnia, are not important stimuli of chemosensitive
171
© 2012 Elsevier Inc. All rights reserved.
172
35. CARdIAC And OTHER VIsCERAl AffEREnTs
TABLE 35.1 Classification of Afferent fibers from Abdominal Viscera CrossSectional Diameter (µm)
Conduction Velocity (m/sec)
Aβ (myelinated)
6–12
Aδ (finely myelinated)
C (unmyelinated)
Fiber Type
Terminal Ending
Effective Stimulus
20–84
Pacinian corpuscle
Vibration
2–6
3–30
Unknown, bare nerve endings
Vibration, pulse pressure, contraction, distension, chemicals, noxious stimuli
0.3–1.5
0.3–2.5
Unknown, bare nerve endings
Strong mechanical stimuli, chemicals, noxious stimuli
visceral sensory nerve endings [8,9]. This differential sensitivity has led to the use of the term “chemosensitive” visceral receptors to distinguish them from the arterial chemoreceptors. It is clear that visceral organs, such as the heart, are selectively responsive to chemical events related to altered metabolism associated with deprivation of blood flow and oxygen. The sources of many mediators are parenchymal cells in the organ, for example cardiac myocytes and endothelium [10]. Reactive oxygen species likely are derived from cardiac myocytes, while the endothelium is a major source for endothelin [11,12]. Circulating precursors or enzymes activated by ischemia initiate a cascade of events leading to the production of mediators like kinins, serve as an important source along with activated blood elements, such as platelets, which release several mediators during ischemia and reperfusion. Platelets aggregate at the site of injury of arterial endothelium following rupture of an atherosclerotic plaque or following occlusion of a coronary artery [13]. Activated platelets release serotonin, histamine and
FIGURE 35.1 Diagram of mediators, their receptors and cellular messaging mechanisms involved in activation of cardiac afferents during ischemia and reperfusion. Coronary artery occlusion, for example following plaque rupture induces myocardial ischemia leading to production and release of a number of mediators including 5-hydroxytryptamine (5-HT), histamine, bradykinin (BK), endothelin (ET), reactive oxygen species (ROS), lactic acid, ATP and COX pathway products, including thromboxane A2 (TxA2) and prostaglandins (PG) from various cells. Other abbreviations: adenosine 5'-triphosphate (ATP), purinergic 2X receptor (P2X), purinergic 2Y receptor (P2Y), TxA2/prostaglandin H2 receptor (TP), histamine 1 receptor (H1), 5-HT3 receptor (5-HT3), BK2 receptor (BK2), endothelin A receptor (ETA), transient receptor potential A1 (TRPA1), protons (H), phospholipase A2 (PLA2), phospholipase C (PLC), adenyl cyclase (AC), cyclic adenosine monophosphate (cAMP), phosphatidylinositol-4,5-bisphosphate (PIP2), inositol-1,4,5triphosphate (IP3), 1,2-diacylglycerol (DAG), protein kinase A (PKA), protein kinase C (PKC), arachidonic acid (AA) and cyclooxygenase (COX).
III. AUTONOMIC PHYSIOLOGY
173
Nerve Activity (impulses/5 s)
2.5
A
Control Ischemia
*
2.0
Nerve Activity (impulses/s)
Nerve Activity (impulses/s)
AuTOnOmIC REflEx REsPOnsEs TO VIsCERAl AffEREnT ACTIVATIOn
*
1.5 1.0 0.5 0.0
-Rabbit serum
+Rabbit serum
C
225 a 200 175 150 125 100 75 50 25 0 -5 -3 -1
225 200 175 150 125 100 75 50 25 0 1
3
5
7
9
2.5
B
*
2.0
*†
1.5 1.0 0.5 0.0
-Antiplatelet Ab
D
b
Anterior view
•∇•• •• •
∇ -5 -3 -1
Time (min)
1
3
5
7
9
+Antiplatelet Ab
Posterior view
•• ∇ • • ∇
FIGURE 35.2 Responses of cardiac ventricular afferents to repeated ischemia before and after treatment with control rabbit serum (A), exposure to a polyclonal rabbit antiplatelet antibody (B) and composite histogram of responses of eight afferents to five minutes of regional ischemia induced by occlusion of a left coronary artery branch before (a) and after (b) treatment with the antiplatelet antibody (C). Means and standard errors are shown. Panel D shows locations of the receptive fields of ischemically sensitive cardiac afferents on epicardial surface of left ventricle. Receptive fields of afferents included in this study: , Aδ afferents (n 4) and •, C-fiber afferents (n 10). * indicates nerve activity during ischemia was higher than during control (P 0.05) and † indicates response to ischemia after treatment with antibody was less than before (P 0.05). Modified from Fu, L-W and Longhurst, JC (2002) Role of activated platelets in excitation of cardiac afferents during myocardial ischemia in cats. Am J Physiol 282:H100–H109. Reproduced by permission.
thromboxane A2, each of which independently or in combination activate cardiac sympathetic afferent endings (Fig. 35.2). The action of each mediator is receptor mediated, with many, if not all of the receptors located on afferent endings. For example, bradykinin exerts its action through BK2, thromboxane through TP, histamine through H1, serotonin through 5-HT3 and endothelin through ETA receptors. Some mediators, like adenosine, remain controversial with regard to their role in stimulating afferent endings during ischemia [7,10]. Some reports, consisting mainly of reflex studies in the dog suggest that adenosine in the heart mediates autonomic reflexes that influence renal function. Other studies in cats suggest that adenosine does not stimulate ischemically sensitive cardiac afferents during ischemia [14].
AUTONOMIC REFLEX RESPONSES TO VISCERAL AFFERENT ACTIVATION Cardiovascular reflex responses to visceral afferent stimulation are either excitatory or inhibitory (Fig. 35.3). In this respect, stimulation of vagal afferents causes reflex
cardiovascular inhibition, including decreased heart rate, blood pressure, and myocardial contractility, consequent to reduced sympathetic outflow to the heart and blood vessels and increased vagal motor output to the heart [15]. Conversely, stimulation of sympathetic afferents that project centrally through sympathetic nerves and spinal pathways evokes reflex cardiovascular excitation, including increases in heart rate, blood pressure and myocardial performance, through increased sympathetic motor activity and, possibly, withdrawal of parasympathetic tone to the heart. Cardiovascular reflex responses originating from the heart consist of either reflex inhibitory or excitatory responses, or, more often, a combination of the two [16]. Thus, stimulation of the posterior-inferior and inner regions of the wall of the left ventricle leads to reflex bradyarrhythmias and hypotension, while stimulation of the anterior and superficial regions of the wall of the left ventricle leads to reflex tachyarrhythmias and hypertensive responses [5]. More commonly both vagal and sympathetic afferent pathways are stimulated concomitantly with a resulting reflex reflecting a mixed response consisting often of a small increase in blood pressure (Fig. 35.3) due to processing in the CNS, for example in the tractus solitarii and possibly the parabrachial nuclei [17].
III. AUTONOMIC PHYSIOLOGY
174
35. CARdIAC And OTHER VIsCERAl AffEREnTs
FIGURE 35.3 Dose-dependent responses of mean arterial pressure (MAP), heart rate (HR), and left ventricular dP/dt at 40 mmHg developed pressure (LV dP/dt40) to application of graded doses of hydrogen peroxide (H2O2) to the anterior surface of the ventricle in intact (vagal and sympathetic cardiac afferents intact, n 8), bilateral cervical vagotomized (sympathetic afferents intact, n 6) or bilateral T1–T4 ganglionectomized (vagal afferents intact, n 6) cats. Circles and brackets represent means and standard errors, respectively. * denotes significant difference comparing saline control to H2O2 (P 0.05). Modified with permission from Longhurst, JC. (2011) Regulation of autonomic function by visceral and somatic afferents. In: Central Regulation of Autonomic Functions. I. Llewellyn-Smith and A. Verberne, eds. New York: Oxford University Press.
Although stimulation of cardiac afferents can lead to reflex cardiovascular depression or excitation or a mixture of responses due to simultaneous stimulation of sensory fibers in both vagal and sympathetic pathways, stimulation of abdominal visceral afferents more commonly leads to reflex excitation since activation of afferents ascending through spinal pathways predominates. Thus, stimulation of chemosensitive, mechanosensitive and polymodal sensory endings in a number of abdominal organs activate spinal pathways that increase heart rate, myocardial contractility and arteriolar constriction in several regional circulations, including the coronary system [1,18]. Vagal afferent pathways from the abdominal region typically regulate digestive organ function, although recent studies suggest that during hypercapnic acidosis both spinal and vagal afferent activation by gastric distension leads to reflex cardiovascular depression as a result of sympathetic withdrawal and vagal activation [19]. Hence, the normal sympathoexcitatory responses evoked by abdominal visceral organ stimulation is converted to sympathoinhibition and vagal excitation by the altered baseline arterial blood gas status. These new findings may have important implications for patients undergoing abdominal surgery, when visceral afferents are stimulated either during vascular
compromise or mechanical traction. Either increases or decreases in blood pressure potentially can occur depending on the arterial blood gas and pH status. In addition to cardiovascular regulation, stimulation of visceral afferents can cause a number of other important reflex events. For example, stimulation of cardiac vagal afferents during myocardial ischemia can lead to relaxation of the stomach, the antecedent of nausea and vomiting that frequently accompanies inferior myocardial infarctions [5,10]. Stimulation of sympathetic afferents in the heart or abdominal region frequently leads to pain, e.g., angina pectoris [7]. Hence many high threshold visceral sympathetic afferents function as nociceptors [3].
PATHOLOGICAL ALTERATIONS OF VISCERAL AFFERENTS In addition to ischemia, a number of other conditions activate visceral afferents. For example, inflammation typically is associated with the production of chemical (and sometimes mechanical) changes, including increases in kinins, activation of the cyclooxygenase system and enhanced formation of reactive oxygen species. Interestingly,
III. AUTONOMIC PHYSIOLOGY
175
PATHOlOgICAl AlTERATIOns Of VIsCERAl AffEREnTs
Control Stimuli Actual BK+TxA2
5
Nerve Activity (imp/s)
4
Predicted BK+TxA2
*#
3 2
*
*
1
1400
Stimuli Actual BK+TxA2
1200
Predicted BK+TxA2
#†
1000 800 600 400 200
0
TxA2
100
Nerve Activity (imp/2 s)
(B)
Total Response (imp)
(A)
BK
C1
100
90
90
80
80
70
70
TxA2
60
0
TxA2+BK
TxA2
C2
100
70 60
50
50
40
40
40
30
30
30
20
20
20
10
10
10
0
0
200
300
400
500
600 700
BK+TxA2
80
BK
50
100
C3
90
60
0
0
100
TxA2+BK
BK
200
300
400
500
600 700
0
0
100
200
300
400
500
600 700
Time (s)
FIGURE 35.4 Bar graph summarizing average discharge activity (A) and total response over time (B) of 15 ischemically sensitive cardiac sympathetic afferents to injection of BK (1 μg), U46619 (5 μg), a thromboxane A2 (TxA2) mimetic or BK (1 μg) U46619 (5 μg) into the left atrium (LA). Neurohistograms provide summed 2 s impulse activity of 15 cardiac afferents during administration of U46619 (C1), BK (C2) or BK U46619 (C3). The total responses of afferent to the mediators were calculated by counting all spikes that occurred during the entire period of response when activity exceeded baseline rates by 20%. Columns and error bars represent means standard errors. *Indicates significant difference comparing stimuli to controls (P 0.05), # significantly different from either BK or U46619 alone (P 0.05) and †denotes significant difference comparing actual BK U46619 to predicted BK U46619 (P 0.05). Modified from Fu L-W and Longhurst JC (2009) Bradykinin and thromboxane A2 reciprocally interact to synergistically stimulate cardiac spinal afferents during myocardial ischemia. Am J Physiol 298:H235–H244. Reproduced by permission.
some chemical mediators appear to act as primary stimuli while others may sensitize in either an additive or synergistic fashion (e.g., TxA2, Fig. 35.4) or modulate (e.g., histamine) sensory nerve endings to the action of the primary stimulus (bradykinin) [7]. Other clinical conditions, like hypertension or heart failure modify the responsiveness of nerve endings in the atria or ventricles [5]. Hypertension may do this by altering the parenchymal substrate in which the endings are located. Heart failure may do this by altering the sensitivity of the nerve ending to mechanical or chemical events.
Acknowledgments Research cited was supported by NIH grants HL066217.
References [1] Longhurst JC. Cardiovascular reflexes of gastrointestinal origin. In: Shepherd AP, Granger DN, editors. Physiology of the intestinal circulation raven. New York; 1984. p. 165–78.
[2] Longhurst J. Reflex effects from abdominal visceral afferents. In: Zucker IH, Gillmore JP, editors. Reflex control of the circulation. Caldwell, NJ: Telford Press; 1991. p. 551–77. [3] Pan H-L, Longhurst JC. Ischaemia-sensitive sympathetic afferents innervating the gastrointestinal tract function as nociceptors in cats. J Physiol (Lond) 1996;492:841–50. [4] Longhurst JC. Regulation of autonomic function by visceral and somatic afferents. In: Llewellyn-Smith I, Verberne AJM, editors. Central regulation of autonomic function (Second ed.). New York: Oxford University; 2011. [5] Longhurst JC. Cardiac receptors: Their function in health and disease. Prog Cardiovasc Dis 1984;XXVII:201–22. [6] Thoren PN. Characteristics of left ventricular receptors with nonmedullated vagal afferents. Circ Res 1977;40:415–21. [7] Fu L-W, Longhurst JC. Regulation of cardiac afferent excitability in ischemia. Handb Exp Pharmacol 2009:185–225. [8] Fu L-W, Pan H-L, Pitsillides K, Longhurst J. Hypoxia does not directly stimulate ischemically sensitive abdominal visceral afferents during ischemia. Am J Physiol 1996;271:H261–6. [9] Mark AL, Abboud FM, Heistad DD, Schmid PG, Johannsen UJ. Evidence against the presence of ventricular chemoreceptors activated by hypoxia and hypercapnia. Am J Physiol 1974;227: 273–9.
III. AUTONOMIC PHYSIOLOGY
176
35. CARdIAC And OTHER VIsCERAl AffEREnTs
[10] Longhurst J, Tjen-A-Looi S, Fu L-W. Cardiac sympathetic afferent activation provoked by myocardial ischemia and reperfusion: mechanisms and reflexes. Ann N Y Acad Sci 2001;940:74–95. [11] Grill HP, Zweier JL, Kuppusamy P, Weisfeldt ML, Flaherty JT. Direct measurement of myocardial free radical generation in an in vivo model: effects of postischemic reperfusion and treatment with human recombinant superoxide dismutase. J Am Coll Cardiol 1992;20:1604–11. [12] Hans G, Schmidt BL, Strichartz G. Nociceptive sensitization by endothelin-1. Brain Res Rev 2009;60:36–42. [13] Flores NA, Sheridan DJ. The pathophysiological role of platelets during myocardial ischemia. Cardiovasc Res 1994;28:295–302. [14] Pan H-L, Longhurst J. Lack of a role of adenosine in activation of ischemically sensitive cardiac sympathetic afferents in cats. Am J Physiol 1995;269:H106–13. [15] Fu L-W, Longhurst JC. Reflex pressor response to arterial phenylbiguanide; role of abdominal sympathetic visceral afferents. Am J Physiol 1998;275:H2025–H2035.
[16] Huang H-S, Stahl G, Longhurst J. Cardiac-cardiovascular reflexes induced by hydrogen peroxide in cats. Am J Physiol 1995;268:H2114–H2124. [17] Tjen-A-Looi S, Bonham A, Longhurst J. Interactions between sympathetic and vagal cardiac afferents in nucleus tractus solitarii. Am J Physiol 1997;272:H2843–H2851. [18] Longhurst JC. Chemosensitive abdominal visceral afferents. In: Gebhart GF, editor. Proceedings: visceral pain symposium. Seattle: IASP Press; 1995. p. 99–132. [19] Tjen-A-Looi SC, Hsiao AF, Longhurst JC. Central and peripheral mechanisms underlying gastric distension inhibitory reflex responses in hypercapnic-acidotic rats. Am J Physiol 2011;300:H1003–12.
III. AUTONOMIC PHYSIOLOGY
C H A P T E R
36 Autonomic Control of the Heart Rachel C. Drew, Lawrence I. Sinoway INTRODUCTION The cardiovascular system consists of the heart and a network of blood vessels that circulate blood to tissues and organs within the body. The heart works as a pump by forcing blood into the arterial circulation in order to deliver oxygen and nutrients to tissues, and remove carbon dioxide and waste products from these tissues in the venous circulation that carries blood back to the heart. This circulatory system is essential for normal homeostatic function, as well as regulation of body temperature, fluid maintenance and adjusting to altered physiological states such as exercise, and is dependent on the heart’s ability to operate properly.
THE HEART The heart is a powerful muscle that comprises of four chambers; right atrium, right ventricle, left atrium and
left ventricle (see Fig. 36.1). Blood enters the right atrium via the superior vena cava from the upper body and the inferior vena cava from the lower body. The right atrium contracts to push blood down into the right ventricle. When the right ventricle contracts, blood is forced out of the heart through the right and left pulmonary arteries towards the lungs. Oxygen-depleted blood entering this pulmonary circulation exchanges carbon dioxide for oxygen, and so oxygen-rich blood returns to the heart via the right and left pulmonary veins and into the left atrium. Contraction of the left atrium pushes blood down into the left ventricle, and left ventricular contraction forces blood out of the heart again via the aorta to the systemic circulation. Blood flow through the heart is unidirectional, which is achieved by valves positioned between the chambers and within the vessels. Blood entering the heart will pass the tricuspid valve between the right atrium and right
Aorta (to body) Pulmonary artery
Superior vena cava (from upper body)
Left pulmonary arteries (to left lung)
Right pulmonary arteries (to right lung)
Left pulmonary veins (from left lung)
Aortic valve Right pulmonary veins (from right lung)
Left atrium Mitral valve
Right atrium
Left ventricle Tricuspid valve Inferior vena cava (from lower body) Pulmonary valve Direction of blood flow Septum
Right ventricle
FIGURE 36.1 Internal structure and blood flow within the human heart. From Diseases and Conditions Index – Heart and Blood Vessel Diseases; How the Heart Works; Anatomy; http://www.nhlbi.nih.gov/health/dci/Diseases/hhw/hhw_anatomy.html; National Heart Lung Blood Institute, National Institutes of Health, US Department of Health and Human Services, 2010. Permission granted.
Primer on the Autonomic Nervous System. DOI: 10.1016/B978-0-12-386525-0.00036-6
177
© 2012 Elsevier Inc. All rights reserved.
178
36. AuTonomIC ConTRol of THE HEART
ventricle, and then the pulmonary valve when being pumped out of the right ventricle and towards the lungs. When re-entering the heart, blood will pass the mitral valve between the left atrium and left ventricle, and finally the aortic valve when being forced out of the heart through the aorta to the rest of the body. The heart contracts in a repeated, rhythmic manner, yet blood is continuously delivered to tissues and organs due to the innate properties of arterial blood vessels. During ventricular contraction, the aorta and its branches distend and then during ventricular relaxation, the walls of the large arteries recoil elastically, which forces blood through the circulation continually.
the SA and AV nodes and activate them by releasing acetylcholine. This action decreases heart rate (negative chronotropy), force of atrial contraction (negative inotropy), rate of relaxation (negative lusitropy), and conduction velocity of the SA and AV nodes (negative dromotropy). As the parasympathetic nervous system is responsible for regulating functions primarily when the body is at rest, this increased vagal tone results in low heart rates of ~70 beats per minute in humans. As such, the parasympathetic nervous system is said to induce the “rest and digest” state. Sympathetic nervous control of the heart arises from the upper thoracic region of the spinal cord. Short preganglionic efferent nerve fibers, compared to long preganglionic vagal efferent fibers, enter the paravertebral chains of ganglia that are located on either side of the spinal column. These preganglionic fibers synapse with postganglionic sympathetic fibers and release acetylcholine, which binds to nicotinic receptors on the postganglionic fibers. From here, relatively long sympathetic adrenergic efferent fibers extend to the SA and AV nodes in the heart where they release the neurotransmitter norepinephrine at synapses with beta-adrenergic receptors. In contrast to parasympathetic effects, this action increases heart rate (positive chronotropy), force of ventricular contraction (positive inotropy), rate of relaxation (positive lusitropy), and conduction velocity of the SA and AV nodes (positive dromotropy). These responses are indicative of the “fight or flight” state that the sympathetic nervous system is said to elicit, and are capable of increasing heart rate up to ~200 beats per minute in humans.
AUTONOMIC NERVOUS CONTROL The autonomic nervous system can be divided into two sub-divisions, the parasympathetic nervous system and the sympathetic nervous system (see Fig. 36.2). Parasympathetic nervous control of the heart arises from vagal nuclei within the medulla oblongata in the brainstem, and efferent nervous outflow occurs via the tenth cranial nerve, known as the Vagus nerve. These long preganglionic efferent nerve fibers extend down to the heart where they synapse with small ganglia located near the sinoatrial (SA) and atrioventricular (AV) nodes in the heart. At this target organ, the neurotransmitter acetylcholine is released, which binds to nicotinic receptors and activates short postganglionic efferent nerve fibers. These postganglionic fibers synapse with muscarinic receptors in
Parasympathetic (vagus)
Hypothalamus Paravertebral Ganglia
Medulla
Heart Postganglionic Sympathetic Efferents Spinal Cord
Prevertebral Ganglia
Preganglionic Sympathetic Efferents
Blood Vessels
FIGURE 36.2 Anatomy of the autonomic nervous system and its control of the heart. From Cardiovascular Pharmacology Concepts – Autonomic Ganglia; http://cvpharmacology.com/autonomic_ganglia.htm; Richard E. Klabunde, 2010. Permission granted.
III. AUTONOMIC PHYSIOLOGY
AlTEREd AuTonomIC ConTRol
The actions of the parasympathetic and sympathetic nervous systems are opposed to each other, yet they work reciprocally to bring about the necessary responses to internal and external stimuli. At rest, parasympathetic tone is predominant, which can be illustrated by observing the effects of inhibiting parasympathetic and sympathetic activation [2] (see Fig. 36.3). Atropine is a muscarinic receptor antagonist that inhibits parasympathetic activity and when administered in humans at rest, heart rate increases to ~110 beats per minute. In contrast, when propranolol, which is a beta-adrenergic receptor antagonist that inhibits sympathetic activity, is given at rest, heart rate decreases only slightly to ~50 beats per minute. When both nervous systems are blocked, heart rate remains ~100 beats per minute, which is known as the intrinsic heart rate. When an increase in heart rate from resting levels is necessary, for example during exercise, parasympathetic tone is initially withdrawn and then sympathetic tone is enhanced. Conversely, when heart rate recovers following a bout of exercise or other physiologically stressful event, sympathetic activity is first reduced and then parasympathetic activation is augmented [1].
CONTROL OF THE HEARTBEAT The heart itself is capable of generating its own electrical impulses to cause coordinated and rhythmic contractions of its chambers. The SA node, a specialized group of cardiac myocytes located in the right atrium, generates action potentials that spread throughout the atria. This causes depolarization and consequent contraction of atrial
120
HEART RATE (BEATS/MIN)
110 PROPRANOLOL
100 90
ATROPINE
80
ATROPINE
70 60
NONATHLETES (N = 10) PROPRANOLOL
50 40 CONTROL 1
DOSAGE NUMBER
2 DRUG # 1
3
4
1
2
3
4
179
muscle. This produces the normal sinus rhythm, thus the SA node is known as the “pacemaker”. These electrical impulses travel from the atria to the ventricles via the AV node, another specialized group of cardiac myocytes located in the posterior inferior region of the interatrial septum. From here, these impulses are transmitted through the bundle of His, specialized cardiac myocytes that conduct electrical activity, at the base of the ventricles along the left and right bundle branches in the interventricular septum down to the apex of the heart. These branches then divide into an extensive network called Purkinje fibers that cover the inner ventricular walls, and these impulses travel throughout this system of fibers causing depolarization and contraction of ventricular muscle. This complex yet highly coordinated sequence results in one cardiac cycle, which lasts for ~0.8 seconds. Within each cycle, there are periods of relaxation, known as diastole, and contraction, known as systole. When the whole heart is in diastole, the atria fill with blood, which then contract during atrial systole and force blood into the ventricles. The ventricles then contract during ventricular systole and eject blood into the aorta and pulmonary arteries while the atria are in diastole. The ventricles then return to diastole and the cycle begins again. In addition to the heart’s intrinsic ability to regulate its electrical activity, autonomic nervous mechanisms can also directly influence the conduction of electrical impulses throughout the heart. This action is primarily mediated via the AV node. Parasympathetic activation releases acetylcholine that binds to muscarinic receptors in the AV node, which causes slower depolarization of cardiac myocytes. This results in negative dromotropy and decreased ventricular contractility. Acetylcholine release from parasympathetic nerve fibers can also inhibit the release of norepinephrine from sympathetic nerve fibers. This neurotransmitter antagonism can also cause reduced ventricular contraction. Sympathetic activation releases norepinephrine that binds to beta-adrenergic receptors in the AV node, which causes faster depolarization of cardiac myocytes. This results in positive dromotropy and increased ventricular contractility, as the time between atrial and ventricular contraction is reduced. It is possible for the conduction velocity of action potentials to be slowed to such an extent that they completely stop, leading to AV block. In the treatment of certain medical conditions, giving drugs to induce AV block can be an effective method of stabilizing heart rate. For example, patients prone to cardiac arrhythmias can be given medication to block beta-adre